

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number  
**WO 00/50639 A3**

(51) International Patent Classification: C12Q 1/68 (81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.

(21) International Application Number: PCT/US00/01392

(22) International Filing Date: 20 January 2000 (20.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/121,047	22 February 1999 (22.02.1999)	US
60/139,440	15 June 1999 (15.06.1999)	US
09/357,743	20 July 1999 (20.07.1999)	US

(71) Applicant (*for all designated States except US*): VARIGENICS, INC. [US/US]; 60 Hampshire Street, Cambridge, MA 02139-1562 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): STANTON, Vincent, Jr. [US/US]; 32 Royal Road, Belmont, MA 02173 (US).

(74) Agent: AMES, Wesley, B.; Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
10 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/50639 A3

(54) Title: GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

(57) Abstract: The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/01392

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q/168

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARSHALL ET AL.: "Getting the right drug into the right patient" NATURE BIOTECHNOLOGY, vol. 15, November 1997 (1997-11), pages 1249-1252, XP002178096 page 1249, middle column -page 1250, left-hand column ---	1
X	VUORISTO ET AL.: "Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis" JOURNAL OF HEPATOLOGY, vol. 27, no. 1, July 1997 (1997-07), pages 136-142, XP001024390 page 139, right-hand column -page 141, left-hand column --- -/-	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but contributing to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

24 September 2001

Date of mailing of the international search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 00/01392

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation or document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARRANZ ET AL.: "Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine" MOLCECULAR PSYCHIATRY, vol. 3, no. 1, January 1998 (1998-01), pages 61-66, XP001024470 abstract; tables 1-3 page 64, right-hand column -page 65, right-hand column page 61, left-hand column -page 62, left-hand column	1
X	STEEN ET AL.: "The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness" PHARMACOGENETICS, vol. 8, no. 3, June 1998 (1998-06), pages 259-268, XP001024444 abstract; tables 1-3	1

FURTHER INFORMATION CONTINUED FROM PCT/USA/ 210

Continuation of Box I.1

Claims Nos.: 145-149

Claims 145-149 relate to methods for providing contract research and methods for recruiting a clinical trial or study population which are considered as methods for doing business under the provisions of Article 17(2)(a)(i) and Rule 39.1(iii), PCT. These methods are therefore excluded from search.

Continuation of Box I.2

Claims Nos.: 1-149

The present application relates to gene sequence variations which are useful in selecting suitable treatments of various diseases. The application provides extensive listings and tables relating to human genes, gene sequence variations, diseases and compounds. No individual links are provided between the gene sequence variations and the suitable compound for treating the corresponding disease.

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible.

Additionally, present claims 1-149 relate to an extremely large number of possible compounds and methods. In fact, the claims contain so many options and possible combinations of elements from the different tables, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Independently from the above, because of the large number of elements raising from the various tables, non-unity objections will almost certainly be made when in a later EP regional stage a search is required.

Present claims 58-66 also lack clarity (Article 6 PCT), since they relate to pharmaceutical compositions defined by reference to a desirable characteristic or property, namely having a differential effect in patients having at least one copy of a particular form of an identified gene.

An attempt is made to define the pharmaceutical compositions by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search of the claimed scope impossible.

Claims 89-110,123,124,131,132,135,136,139,141-144 relate to methods of treatment of the human body. Normally the search would be based and

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

performed on the alleged effects of the compounds. However, considering the shortcomings, especially the lack of conciseness and clarity mentioned above, no search could be performed.

Since for the reasons stated above a complete search was impossible, a limited search for the general principle underlying the first independent claim (claim 1), i.e. a method of selecting a treatment on basis of gene variance, was performed. The many documents retrieved also feature some of the genes mentioned in the many tables of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

synthetase mRNA, complete cds			
Human glutathione synthetase mRNA, complete cds	601002	U34683	ARG283CYS
Human glutathione synthetase mRNA, complete cds	601002	U34683	ARG125CYS
Human glutathione synthetase mRNA, complete cds	601002	U34683	PRO314LEU
Human glutathione synthetase mRNA, complete cds	601002	U34683	6-BP DEL VAL-GLN del
Human glutathione synthetase mRNA, complete cds	601002	U34683	ASP219GLY
Human glutathione synthetase mRNA, complete cds	601002	U34683	IVS4, G-A, +5
Human kidney mRNA for catalase	115500	X04076	A to T -21
Human kidney mRNA for catalase	115500	X04076	C to A -20
Human kidney mRNA for catalase	115500	X04076	C to T -18
Human kidney mRNA for catalase	115500	X04076	T to C 4
Human kidney mRNA for catalase	115500	X04076	T to C 44
Human kidney mRNA for catalase	115500	X04076	T to C 49

Human kidney mRNA for catalase	115000	X04076	C to T 12
Human kidney mRNA for catalase	115000	X04076	C to A 27
Human kidney mRNA for catalase	115000	X04076	358 T->del
Human kidney mRNA for catalase	115000	X04076	MspI
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-2HIS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-1GLN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-1PRO
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP1VAL
Human messenger RNA for serum albumin (HSA)	103600	V00494	HIS3GLN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG114GLY
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU119LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP269GLY

albumin (HSA)	103600	V00494	LYS313ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ALA320THR
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-2CYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU321LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU354LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU358LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP365HIS
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS372GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP375ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU376LYS

Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU382LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU501LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS541GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP550GLY
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP563ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU565LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU570LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS573GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS574ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	IVS6, A-G, -2
Human messenger RNA for serum albumin (HSA)	103600	V00494	EX14DEL

RNA for serum albumin (HSA)	103600	V00494	LYS336GLU
Human messenger albumin (HSA)	103600	V00494	ARG-2CYS
RNA for serum albumin (HSA)	103600	V00494	ARG-1LEU
Human messenger albumin (HSA)	103600	V00494	GLN580LYS
RNA for serum albumin (HSA)	103600	V00494	GLU60LYS
Human messenger albumin (HSA)	103600	V00494	GLU82LYS
RNA for serum albumin (HSA)	103600	V00494	ASP494ASN
Human messenger albumin (HSA)	103600	V00494	HIS128ARG
RNA for serum albumin (HSA)	103600	V00494	IVS13DS, G-C, +1
Human messenger RNA for serum	103600	V00494	

albumin (HSA)	103600	V00494		LYS240GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	AAT267AAA1 frameshift	
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG218HS	
Human messenger RNA for serum albumin (HSA)	103600	V00494	HIS3TYR	
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS225GLN	
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS276ASN	
Human messenger RNA for serum albumin (HSA)	103600	V00494	TGC567GC frameshift	
Human messenger RNA for serum albumin (HSA)	103600	V00494	TYR140CYS	
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP63ASN	
Human messenger RNA for serum albumin (HSA)	103600	V00494	CYS177PHE	

Human messenger RNA for serum albumin (HSA)	103600	V00494	GLN268ARG
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASN318LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU331LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU376ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU479LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU505LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG218PRO
Human messenger RNA for serum albumin (HSA)	103600	V00494	LEU66PRO
Human messenger RNA for serum albumin (HSA)	103600	V00494	Arg218His
Human messenger RNA for serum albumin (HSA)	103600	V00494	HaeII intron 7
Human mitochondrial	600125	L13286	none found

1,25-dihydroxyvitamin D3 24-hydroxylase mRNA, complete cds	312170	X52709	4-BP DEL
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	7-BP DEL
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG378HIS
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	LYS313DEL
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	2-BP DEL, frameshift
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	20-BP DEL, EX11DEL
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	21-BP INS

Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG234GLY
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG302CYS
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	4-BP INS frameshift
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ASP258ALA
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	PHE205LEU
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	TYR243ASN
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ASP315ASN
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	MET282LEU

1.2.4.1)	Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	-BP INS FS14ITER
	Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG10PRO
	Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	13-BP INS, EX10
	Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	36-BP INS
	Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	179780	D13138	none found
	Human mRNA for dipeptidase	138300	X15722	none found
	Human mRNA for glutathione reductase (EC 1.6.4.2)	231950	X60069	none found
	Human mRNA for pancreatic gamma- glutamyltransferase	CMOAT2	U83659	none found
	Human multidrug resistance-associated protein homolog (MRP3)	Human	L21893	none found
	Nataurocholate			

cotransporting polypeptide mRNA, complete cds	309850	M69226	23-bp VNTR
Monoamine Oxidase A; MAOA	309850	M69226	3rd base of codon 941 941 G>T
Monoamine Oxidase A; MAOA	309850	M69226	A1026T ProlineProline
Monoamine Oxidase A; MAOA	309850	M69226	A1559G LysineArginine
Monoamine Oxidase A; MAOA	309850	M69226	A385C ArginineArginin
Monoamine Oxidase A; MAOA	309850	M69226	C1410T Aspartic Aspartic Acid
Monoamine Oxidase A; MAOA	309850	M69226	C886T GlutamineTermination codon
Monoamine Oxidase A; MAOA	309850	M69226	C886T Glutamine296T termination codon
Monoamine Oxidase A; MAOA	309850	M69226	exon 14 ... RFLP (EcoRV enzyme) length of (CA) <sub>n</sub> repeat
Monoamine Oxidase A; MAOA	309850	M69226	RFLP (EcoRV enzyme)
Monoamine Oxidase A; MAOA	309850	M69226	RFLP (Pst I)
Monoamine Oxidase A; MAOA	309850	M69226	T891G

Monoamine Oxidase A; MAOA	309830	M69226	T891G ArginineArginin e
Monoamine Oxidase B; MAOB	309860	M69177	(GT)n repeat
Monoamine Oxidase B; MAOB	309860	M69177	36 bases upstream from intron 13-exon 14 boundary
Monoamine Oxidase B; MAOB	309860	M69177	A at position 644 of intron 13
Monoamine Oxidase B; MAOB	309860	M69177	G at position 644 of intron 13
Monoamine Oxidase B; MAOB	309860	M69177	RFIP (MaelII enzyme)
multidrug resistance associated protein MRP1	158343	L05628	none found
multidrug resistance associated protein MRP2	601107	U83659	none found
multidrug resistance protein MDR1	171050	X96395	HindIII
multidrug resistance protein MDR1	171050	X96395	Ser893Ala
multidrug resistance protein MDR1	171050	X96395	GLY185VAL
multidrug resistance protein MDR3/p-glycoprotein 3/PGY3	602347	X06181	none found
myeloperoxidase/MPO	254600		ARG569TRP
myeloperoxidase/MPO	254600		TYR173CYS
myeloperoxidase/MPO	254600		MET251THR

myeloperoxidase/MPO	254600		G to A in the pronoter
myeloperoxidase/MPO	254600	-463 G/A	
myeloperoxidase/MPO	254600	Dinucleotide repeat	
myeloperoxidase/MPO	254600	EcoRV RFLP	
N-acetyltransferase	1083345	NM_00066	POLYADENYLATION SITE
I/arylamide acetylase		_2	ON SIGNAL
I/NAT1			VARIANT
N-acetyltransferase	1083345	NM_00066	VAL149LE
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	C1095A
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	T1088A
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	C1095A
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	9 bp deletion
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	G560A
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	C559T
I/arylamide acetylase	_2		
I/NAT1			
N-acetyltransferase	1083345	NM_00066	C190T

V/arylamide acetylase I/NATI	2		
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	350-351 (GG to CC)
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	497-499 (GGG to CCC)
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	C97T
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	C190T
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	T402C
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	G445A
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	T640G
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	C559T
N-acetyltransferase V/arylamide acetylase I/NATI	108345	NM_00066	G560A

I/NAT1	108345	NM_00066 2	A613G
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	A752T
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	T77C
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	G781A
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	A787G
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	Arg187 to a stop codon
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	Arg187 to Gln
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	-344 (C->T)
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	108345	NM_00066 2	640 T->G Ser-->Ala
N-acetyltransferase 1/arylamide acetylase			
I/NAT1	243400	NM_00001 5	ARG197GLN
2/arylamide acetylase			
2/NAT2			

N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	ILE114THR
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	LYS268ARG
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	857G-A GLY-GLU
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	191G-A Arg64-->Gln
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	C282T (silent)
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	T341C Ile114-->Thr
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	481C-->T silent
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	590 G-->A Arg197-->Gln
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	803 A-->G Lys268-->Arg
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	857 G-->A Gly286-->Glu
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 <i>s</i>	C759T

2/arylamide acetylase	5		
2/NAT2			
NAD(P)H menadione oxidoreductase 1, dioxin-inducible/NMOR1/diaphorase 4/DIA4	123860	NM_00090	609C>T pro187ser
NAD(P)H menadione oxidoreductase 2, dioxin-inducible/NMOR2	160998	NM_00090	none found
NEUROPATHY	603197		none found
TARGET ESTERASE			
nicotinamide N-methyltransferase/NNMT	600008	NM_00616	eight SNPs within intron 1
O6 alkylguanine-DNA alkyltransferase	156569	M60761	GGA to AGA gly160arg
O6 alkylguanine-DNA alkyltransferase	156569	M60761	1034A>G
O6 alkylguanine-DNA alkyltransferase	156569	M60761	1099C>T
O6 alkylguanine-DNA alkyltransferase	156569	M60761	79G>T
paraoxonase 1/PON1 (arylesterase)	168820	AH004193	GLN192ARG
paraoxonase 1/PON1 (arylesterase)	168820	AH004193	MET54LEU
paraoxonase 1/PON1 (arylesterase)	168820	AH004193	Leu55Met
paraoxonase 1/PON1	168820	AH004193	CA repeat intron 4.

(arylesterase)	PEPTIDE	601250	none found
METHIONINE			
SULFOXIDE			
REDUCTASE			
Peroxisome	170998	NM_00503 6	none found
proliferative activated receptor, alpha <sub>1</sub> PARA			
Peroxisome	600409	NM_00623 8	none found
proliferative activated receptor, delta <sub>1</sub> PARD			
Peroxisome	601487	NM_00503 7	PRO115GLN
proliferative activated receptor, gamma <sub>1</sub> PARG			
Peroxisome	601487	NM_00503 7	PRO12ALA
proliferative activated receptor, gamma <sub>1</sub> PARG			
Peroxisome	601487	NM_00503 7	1-BP DEL, 472A Frameshift
proliferative activated receptor, gamma <sub>1</sub> PARG			
Peroxisome	601487	NM_00503 7	GLN286PRO
proliferative activated receptor, gamma <sub>1</sub> PARG			
Peroxisome	601487	NM_00503 7	LYS319TER

Peroxisome proliferative activated receptor, gamma/PPARG	601487	NM_00503	Arg288His
Phenol-prefering sulfotransferase, family IA, member 1/SULT1A1	171150	NM_00105	Arg213His
Phenol-prefering sulfotransferase, family IA, member 2/SULT1A2	601292	NM_00105	none found
Phenol-prefering sulfotransferase, family IA, member 3/SULT1A3	600641	L19956	none found
phenylethanolamine N-methyltransferase/PNMT	171190	NM_00268	BAN1
PHOSPHOADEENOSI	601262	6	none found
NE-PHOSPHOSULFATE SYNTHETASE 1	179060	M34479	none found
Pyruvate dehydrogenase (lipoamide) beta RAR related orphan receptor A/RORA	600825	NM_00294	none found
RAR related orphan receptor C/RORC reduced folate carrier	602943	NM_00506	none found
	600424	U19720	none found

RFC]				
renal microsomal dipeptidase/DPEP1 (beta-lactam ring hydrolysis)	179780	NM_00441 3	none found	
retinal transport of beta-amino acids/AABT	109660		none found	
retinoic acid receptor alpha/RARA	180240	NM_00096 4	7-base deletion frameshift	
retinoic acid receptor alpha/RARA	180240	NM_00096 4	codon 411 C to T	
retinoic acid receptor alpha/RARA	180240	NM_00096 4	Arg272Gln	
retinoic acid receptor alpha/RARA	180240	NM_00096 4	Met297Leu	
retinoic acid receptor alpha/RARA	180220	NM_00096 5	none found	
retinoic acid receptor beta/RARB	180190	M57707	none found	
retinoic acid receptor gamma/RARG	180245	NM_00295 7	none found	
retinoid X receptor alpha/RXRA	180246	X66424	none found	
retinoid X receptor beta/RXRΒ	180247	U38480	none found	
retinoid X receptor gamma/RXRG	182138	X70697	PstI promoter 44-bp ins/del	
serotonin transporter	182138	X70697	tandem repeat close to the promoter	
serotonin transporter	182138	X70697	two polyadenylation sites	

serotonin transporter	182138	X70697	VNTR intron 2	
serotonin transporter	182138	X70697	silent polymorphism	
Solute Carrier Family 1, Member 1; Slc1a1	133550	U08989	none found	
Solute Carrier Family 1, Member 2; Slc1a2	600300	U03505	none found	
Solute Carrier Family 1, Member 3; Slc1a3	600111	U03504	none found	
Solute carrier family 1, member 4/SLC1A4 (Glutamate)	600229	NM_00303	none found	
Solute carrier family 1, member 5/SLC1A5 (neutral AA)	109190	AF105230	none found	
Solute carrier family 1, member 6 (GABA/GLU)/SLC1A 6	600637	NM_00507	none found	
Solute carrier family 10, member 1/SLC10A1 (taurocholate)	182396	NM_00304	none found	
Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_00045	LEU243PRO	
Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_00045	THR262MET	

Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295 <u>2</u>	NM_00045	A171S
Solute carrier family 12, member 2/SLC12A2 (dicarboxylic acids)	604148 <u>4</u>	NM_00398	none found
Solute carrier family 15, member 1/SLC15A1 (peptides)	600544	UJ13173	none found
Solute carrier family 15, member 2/SLC15A2 (peptides)	602339	S78203	none found
Solute carrier family 16, member 1/SLC16A1 (monocarboxylic acids)	600682 <u>1</u>	NM_00305	none found
Solute carrier family 16, member 2/SLC16A2 (monocarboxylic acids)	300095 <u>7</u>	NM_00651	none found
Solute carrier family 16, member 3/SLC16A3 (monocarboxylic acids)	603877 <u>7</u>	NM_00420	none found
Solute carrier family 16, member 4/SLC16A4 (monocarboxylic acids)	603878 <u>7</u>	*****	none found
Solute carrier family	603879	NM_00469	none found

16, member 5/SLC16A5 (monocarboxylic acids)			5
Solute carrier family 16, member 6/SLC16A6 (monocarboxylic acids)	603880	NM_00469	none found
Solute carrier family 16, member 7/SLC16A7 (monocarboxylic acids)	603654	AF049608	none found
Solute carrier family 21, member 2/SLC21A2 (prostaglandin)	601460	NM_00563	none found
Solute carrier family 21, member 3/SLC21A3 (organic anion)	602883	NM_00507	none found
Solute carrier family 22, member 1- like/SLC22A1 (organic cation)	602631	AF037064	111-BP INS
Solute carrier family 22, member 1- like/SLC22A1 (organic cation)	602631	AF037064	688G-A
Solute carrier family 22, member 1- like/SLC22A2 (organic cation)	602607	NM_00305	none found
		8	

Solute carrier family 22, member 2/SLC22A2 (organic cation)	602608	NM_00305 8	
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		113-BP DEL
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		1-BP INS, 226C
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		TRP132TER
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		G-to-A transition in the last nucleotide of intron 8 1394-BP DEL
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		19-BP INS
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		171-BP DEL
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		ARG282TER
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		TYR401TER

Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	I-BP DEL, 1345G
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	PRO478LEU
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	TYR211CYS
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	Arg169Gln
Solute carrier family 22, member 5/SLC22A5 (carnitine)	190315	X96924
Solute carrier family 25, member 1/SLC25A1 (tricarboxylic acids)		none found
Solute carrier family 29 (nucleosides), member 1/SLC29A1/ENT1	602193	NM_00495 5
Solute carrier family 29 (nucleosides), member 2/SLC29A2/ENT2	602110	X86681
Solute carrier family 3 member 1/SLC3A1 (aa transporter)	104614	*****
Solute carrier family 5 member 6/SLC5A6 (folate, biotin, lipote)	604024	*****
Solute carrier family 6 (GABA), member 1/SLC6A1	137165	X54673

Solute carrier family 6 (betaine/GABA), member 12	603080	U27699	none found
Solute carrier family 6, member 5/SLC6A2(NAT1)/NET 1 (glycine)	163970	NM_001043	none found
Solute carrier family 6, member 5/SLC6A5 (glycine)	604159	NM_004211	none found
Solute carrier family 6, member 6/SLC6A6 (taurine)	186854	U116120	Dinucleotide repeat
Solute carrier family 6, Member 9; SLC6A9 (glycine)	601019	S70612	none found
Solute carrier family 7, member 1/SLC7A1 (cationic AA)	104615	*****	TaqI
Solute carrier family 7, member 2/SLC7A2 (cationic AA)	601872	D29990	none found
Solute carrier family 7, member 4/SLC7A4 (cationic AA)	603752	*****	none found
Solute carrier family 7, member 5/SLC7A5 (neutral AA)	600182	M80244	none found
Solute carrier family 7, member 7/SLC7A7 (dibasic AA)	603593	Y18474	1181,A-T,-2-A->T

Solute carrier family 7, member 7/SLC7A7 (dibasic AA)	603593	Y18474	543-BP DEL
Solute carrier family 7, member 7/SLC7A7 (dibasic AA)	603593	Y18474	4-BP INS
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	VAL170MET
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	GLY105ARG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	ALA182THR
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	GLY195ARG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	GLY259ARG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	2-BP DEL, 596TG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	1-BP INS, 520T
sterol-O-acyl transferase 1/SOAT1	102642	L21934	none found
sterol-O-acyl transferase 2/SOAT2	601311	*****	none found

Succinic semialdehyde dehydrogenase	271980	L34820	IVS9, G-T, +1
Succinic semialdehyde dehydrogenase	271980	L34820	IVS5, G-A, +1
SULFONYLUREA RECEPTOR 2	601439		none found
Sulfotransferase, family 1C, member 3/SULT1C1	602385	U66036	none found
Sulfotransferase, family 2B, member 1/SULT2B1			none found
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00460 5	none found
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLY37ARG
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	LEU38VAL
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLY41SER
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLY41ASP
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	HIS43ARG
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLY85ARG
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLY93CYS
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLY93ALA
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	GLU100GLY
Superoxide Dismutase ISOD1 (soluble)	147450	NM_00465 4	LEU106VAL

I/SOD1 (soluble)	14/7450	NM_00045	4	ILE113THR
Superoxide Dismutase				ALA4VAL
I/SOD1 (soluble)	14/7450	NM_00045	4	HIS46ARG
Superoxide Dismutase				ALA4THR
I/SOD1 (soluble)	14/7450	NM_00045	4	ASP90ALA
Superoxide Dismutase				ILE104THE
I/SOD1 (soluble)	14/7450	NM_00045	4	LEU144SER
Superoxide Dismutase				ALA145THR
I/SOD1 (soluble)	14/7450	NM_00045	4	T-G,-10,9-BP INS
Superoxide Dismutase				CYS6PHE
I/SOD1 (soluble)	14/7450	NM_00045	4	THR151ILE
Superoxide Dismutase				GLU21LYS
I/SOD1 (soluble)	14/7450	NM_00045	4	SER134ASN
Superoxide Dismutase				LEU84VAL
I/SOD1 (soluble)	14/7450	NM_00045	4	GLY16SER
Superoxide Dismutase				I/SOD1 (soluble)

Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045		LEU126TER
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045	VS4AS, A-G, -11	
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045		GLY72SER
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045		Val7->Glu
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045		ALA16VAL
Superoxide Dismutase 2/SOD2 (mitochondrial)	147460	XG5965		
Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_00310		ARG213GLY
Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_00310		A241G
Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_00310		C280T
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387		ALA80PRO
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387		ALA154THR
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387		TYR240CYS
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	IVS9AS, G-A, -1	

mercaptopurine detoxification)			
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	ALA154THR
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	TYR240CYS
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	ARG215HIS
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	G460 to A
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	A719 to G
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	VNTR promoter
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	G644A
Thiopurine	187680	U12387	G238C

methyltransferase (6-mercaptopurine detoxification)				
Thiopurine methyltransferase (6-mercaptopurine detoxification)	187680	UJ12387	T681G	
Thiopurine methyltransferase (6-mercaptopurine detoxification)	187680	UJ12387	C->T at nucleotide 178	
Thiopurine methyltransferase (6-mercaptopurine detoxification)	187680	UJ12387	T->G681	
Thiopurine methyltransferase (6-mercaptopurine detoxification)	164014	L19067	494, Glu-Asp	
TRANSCRIPTION FACTOR P65				
UDP	191740	NM_001072	13-BP DEL	
glycosyltransferase I/UGT1				
UDP	191740	NM_001072	SER-PHE	
glycosyltransferase I/UGT1				
UDP	191740	NM_001072	GLN331TER	
glycosyltransferase I/UGT1				
UDP	191740	NM_001072	ARG341TER	
glycosyltransferase I/UGT1				
UDP	191740	NM_001072	GLN331ARG	

I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	PHE170DEL
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	SER376PHE
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	GLY309GLU
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	CYS-TER
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	PRO229GLN
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	2-BP INS, TA, TATAA ELEMENT
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	1-BP INS, 470T
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	IVS1, G-C,+1
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	145C-T
glycosyltransferase				
I/UGT1	UDP	191740	NM_00107 <sub>2</sub>	IVS3, A-G,-2
glycosyltransferase				
I/UGT1				

UDP	601291	U30930	none found
glycosyltransferase 8/UGT8			
UDP	600070	NM_00107 5	none found
glycosyltransferase family 2, member B10/UGT2B10			
UDP	600069	U06641	asp85lyr
glycosyltransferase family 2, member B15/UGT2B15			
UDP	601903	NM_00107 7	none found
glycosyltransferase family 2, member B17/UGT2B17			
UDP	600067	NM_00107 3	asp458glu
glycosyltransferase family 2, member B4/UGT2B4			
UDP	600067	NM_00107 3	leu109phe
glycosyltransferase family 2, member B4/UGT2B4			
UDP	600067	NM_00107 4	leu39phe
glycosyltransferase family 2, member B7/UGT2B7			
			none found

glucuronosyltransferases	UDP-	218800	AJ005162	none found
Vesicular acetylcholine transporter	e	600336	NM_00305	none found
Vesicular Amine Transporter 1; VAT1	transporter	193002	*****	none found
Vesicular Amine Transporter 2; VAT2	Transporter 1; VAT1	193001	L09118	TaqI XX
3,5 cyclic nucleotide phosphodiesterase (HSPDE1A3A)	3,5 cyclic nucleotide phosphodiesterase (HSPDE1A3A)	171890	U40370	none found
activated leucocyte cell adhesion molecule/CD6 ligand/ALCAM	activated leucocyte cell adhesion molecule/CD6 ligand/ALCAM	601662	L38608	none found
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	VAL1000ILE
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	CYS972TYR
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	deletion of the intron
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	ARG681HIS
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	EX18DEL
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	5-BP DEL
alpha-2-macroglobulin	alpha-2-macroglobulin	103950	M11313	intronic

Table 21. Identified Variances in Genes or Related Pathways involved in Inflammation and Immune Disease

alpha-2-macroglobulin antigen peptide transporter 1/MHC 1/TAP1	103950 170260	M11313 X57522	polymorphism EcoRI	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522		ILE333VAL
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	ASP637GLY	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	ARG659GLN	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	518 (GTC->ATC) Val->Ile	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	G->T substitution in the promoter region	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	10-bp insert in intron 9	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	G->T 80bp' 3' of termination codon	
antigen peptide transporter 2/MHC 2/TAP1	170261	222935	Ala665Thr	
antigen peptide transporter 2/MHC 2/TAP2	170261	222935	Gln687Stop	
antigen peptide transporter 2/MHC 2/TAP2	170261	222935	ILE379VAL	

2/TAP2 apoptosis-related cysteine protease /Interleukin 1-beta converting enzyme/ICE/caspase I/CASP1	147678	X65019	none found
Beta-1-adrenergic receptor; Adrb1	109630	J03019	C1165G ARG389GLY
Beta-1-adrenergic receptor; Adrb1	109630	J03019	Bgl I.
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	val 34 met
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	A->G -1343
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	C->G -468
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	G->A -1023
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	T->A -1429
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	G->A -654
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	T->C -367
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	Fnu4HII
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	T->C -20
Beta-2-Adrenergic Receptor; Adrb2	109690	M15169	T->C -47

Beta-3-Adrenergic Receptor; Adrb3	109691	X70811		TRP64ARG
Beta-3-Adrenergic Receptor; Adrb3	109691	X70811	intron 1 g1856t	
Beta-Adrenergic Receptor Kinase 2; Adrbk2	109636	X69117	none found	
bradykinin receptor B1/BDKRB1 G protein-coupled	600337	U12512	9-base pair deletion	
bradykinin receptor B1/BDKRB1 G protein-coupled	600337	U12512	A1098-->G	
bradykinin receptor B1/BDKRB1 G protein-coupled	600337	U12512	C181-->T	
bradykinin receptor B1/BDKRB1 G Protein-coupled	600337	U12512	G-699-->C	
bradykinin receptor B1/BDKRB1 G protein-coupled	113503	X86164	-845C/T	
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86165	-704C/T	
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86166	-649insG	
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86167	-640T/C	

bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86168	-536C/T
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86169	-412C/G
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86170	-143C/T
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86171	-78C/T
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86172	T21M
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86173	9 bp de (-)21-29
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86174	C>T promoter 54
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86175	tandem repeat near promoter
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86176	R14C
bradykinin receptor B2/BDKRB2 G protein-coupled	113503	X86177	repeat 3'UTR
Ca Channel alpha 1a	601011	AF004884	ARG192GLN

(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	THR666MET
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	VAL714ALA
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	ILE1811LEU
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	I-BP DEL, 4073C frameshift
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	G-to-A first nucleotide of intron 24
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	(CAG)n
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	GLY293ARG
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	ASP715GLU
(alt. splice) L-Type Ca Channel alpha Ia	601011	AF004884	C4914T premature stop
(alt. splice) L-Type Ca Channel gamma L-Type	114209	L07738	none found
Ca2+-dependent phospholipase A2	601192	U03090	none found
CD3E antigen, epsilon polypeptide (TiT3 complex)	186830	X03844	T-to-C splice change
CD3E antigen, epsilon polypeptide (TiT3 complex)	186830	X03844	TRP59TER
CD3E antigen, epsilon polypeptide (TiT3 complex)	186830	X03844	TaqI

polypeptide (T/T3 complex)			METIVAL
CD3G antigen, gamma polypeptide (T/T3 complex)	186740	X04145	
CD3G antigen, gamma polypeptide (T/T3 complex)	186740	X04145	17-BP DEL
CD3G antigen, gamma polypeptide (T/T3 complex)	186740	X04145	MspI
Complement C1S component precursor (C1 esterase)	120580	J04080	4-BP DEL
Cyclooxygenase 1 COX1	176805	M59979	none found
Cyclooxygenase 2 COX2	600262	M90100	none found
H.sapiens ACTH-R	None	X65633	none found
gene for adrenocorticotrophic hormone receptor			
Histamine receptor H1	600167	AF026261	none found
Histamine receptor H2	142703	M64799	A649G
Histamine receptor H3	None	U31332	none found
Human DP prostanoid receptor (PTGDR)			
gene, 5 region and partial cds			
Human IP gene for prostacyclin receptor,	600022	D38128	none found

Human leukotriene-C4 synthase mRNA, complete cds	246530	U11552	promoter polymorphism
Human mRNA for prostanycin synthase, complete cds	601699	D38145	none found
Human prostaglandin receptor ep 1 subtype mRNA, complete cds	176802	L22647	none found
Intercellular adhesion molecule 1	147840	M24283	K/E 469
Intercellular adhesion molecule 1	147840	M24283	Dimucleotide repeat 3'
Intercellular adhesion molecule 1	146630	X15606	none found
Intercellular adhesion molecule 2	146631	X69819	LYS29MET
Intercellular adhesion molecule 3	147569	U03875	Gln64Arg
interferon-gamma receptor 2/IFNGR2	147569		2-BP DEL, AG, NT278-279
interferon-gamma receptor 2/IFNGR2	107470	J03143	395C-A SER-TER
interferon-gamma receptor 1/IFNGR1	107470		1-BP DEL frameshift
interferon-gamma receptor 1/IFNGR1	107470		ILE87THR
interferon-gamma receptor 1/IFNGR1	107470		4-BP INS, I07TTAC
interferon-gamma receptor 1/IFNGR1	107470		G-A, +1

receptor 1/IFNGR1	107470		4-BP DEL, NT818
interferon-gamma			
receptor 1/IFNGR1	107470		
interferon-gamma			
receptor 1/IFNGR1	107470		
interferon-gamma			
interleukin 1 beta	147720	K02770	Val14Met
(IL1b)			
interleukin 1 beta	147720	K02770	TaqI
(IL1b)			
interleukin 1 beta	147720	K02770	TaqI
(IL1b)			
interleukin 1 beta	147720	K02770	+587 C -> T
(IL1b)			
interleukin 1 beta	147720	K02770	exon 5 (position +3953)
(IL1b)			position -511
interleukin 1 beta	147720	K02770	
(IL1b)			
interleukin 1 receptor	147720	K02770	Asp106Asn
(IL1b)			
Interleukin 1 receptor	147679	X52015	86-bp tandem repeat
antagonist			
Kallikrein Inhibitor	147935	L19684	none found
Kallikrein KLK1	147910	X13561	A1166->C
Kallikrein KLK1	147910	X13561	TaqI
Kallikrein KLK2	147960	S39329	C to T at base 792
L-Type Ca Channel	114204	228613	none found
alpha 2/delta			
L-Type Ca Channel	114206	Z26289	none found
alpha 1d			
L-type voltage	114205	M92269	none found
dependent calcium			
channel alpha 1C			
subunit/CACNA1C			

L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	1.33798	ARG1086HIS
L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	1.33798	ARG1239GLY
L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	1.33798	ARG1239HIS
L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	1.33798	ARG528HIS
Leukocyte integrin alpha-4	192975	L12002	none found
Leukocyte integrin alpha-d	602453	U40274	none found
Leukocyte integrin alpha-l	153370	Y00796	none found
Leukocyte integrin alpha-m	120980	J04145	none found
Leukocyte integrin alpha-x	151510	M81695	none found
Leukocyte integrin beta-1	135630	U28252	none found
Leukocyte integrin beta-2	600065	M15395	ARG593CYS
Leukocyte integrin	600065	M15395	LYS196THR

Leukocyte integrin beta-2	600065	M15395	LEU149PRO
Leukocyte integrin beta-2	600065	M15395	GLY169ARG
Leukocyte integrin beta-2	600065	M15395	ATG-to-AAG initiation codon
Leukocyte integrin beta-2	600065	M15395	ARG586TRP
Leukocyte integrin beta-2	600065	M15395	12-bp insertion pro-ser-ser-gln
Leukocyte integrin beta-2	600065	M15395	ASN351SER
Leukocyte integrin beta-2	600065	M15395	PRO178LEU
Leukocyte integrin beta-2	600065	M15395	ASP128ASN
Leukocyte integrin beta-2	600065	M15395	G-A, splice/donor site
Leukocyte integrin beta-2	600065	M15395	GLY284SER
Leukocyte integrin beta-2	600065	M15395	SER138PRO
Leukocyte integrin beta-2	600065	M15395	GLY273ARG
Leukocyte integrin beta-2	600065	M15395	S138P
Leukocyte integrin beta-3	173470	M35999	ARG214GLN
Leukocyte integrin beta-3	173470	M35999	ASP119TYR

Leukocyte integrin beta-3	173470	M35999	ARG214TRP
Leukocyte integrin beta-3	173470	M35999	SER752PRO
Leukocyte integrin beta-3	173470	M35999	ARG143GLN
Leukocyte integrin beta-3	173470	M35999	LEU33PRO
Leukocyte integrin beta-3	173470	M35999	PRO407ALA
Leukocyte integrin beta-3	173470	M35999	G-T, EXiDEL
Leukocyte integrin beta-3	173470	M35999	ARG489GLN
Leukocyte integrin beta-3	173470	M35999	CYS574TYR
Leukocyte integrin beta-3	173470	M35999	11.2-KB DEL
Leukocyte integrin beta-3	173470	M35999	ARG724TER
Leukocyte integrin beta-3	173470	M35999	GLU616TER
Leukocyte integrin beta-4	147557	X5184I	1-BP INS, 3801T
Leukocyte integrin beta-4	147557	X5184I	1-BP DEL, 1150G
Leukocyte integrin beta-4	147557	X5184I	LEU156PRO
Leukocyte integrin beta-4	147557	X5184I	ARG554TER
Leukocyte integrin	147557	X5184I	CYS61TYR

beta-4				
Leukocyte integrin	147557	X51841	CYS562ARG	
beta-4				
Leukocyte integrin	147557	X51841	IVS30DS, G-A, +1	
beta-4				
Leukocyte integrin	147557	X51841	TRP1478TER	
beta-4				
Leukocyte integrin	147557	X51841	CYS38ARG	
beta-4				
Leukocyte integrin	147557	X51841	1-BP DEL, 4776G	
beta-4				
Leukocyte integrin	147557	X51841	3434delT	
beta-4				
Leukocyte integrin	147557	X51841	8-bp deletion	
beta-4				
Leukocyte integrin	147559	M68892	none found	
beta-7				
Leukotriene A4	151570	J03459	none found	
hydrolase				
Leukotriene C4			none found	
receptor				
Leukotriene D4/E4			none found	
receptor				
lipocortin 1/annexin 1	151690	X05908	none found	
lipocortin 2/annexin 2	151740	D00017	none found	
lipocortin 3/annexin 3	106490	M20560	BgII	
lipocortin 3/annexin 3	106490	M20560	Sall	
lipocortin 3/annexin 3	106490	M20560	tandem repeat	
Lipoxygenases: 12-	152391	M62982	TAAA	
lipoxygenase (platelet)			none found	

Lipoxygenases: $\delta$ -lipoxygenase (leukocytes)	152390	J03571	none found
lymphotoxin beta receptor (TNFR superfamily, member 3/LTBR)	600979	L04270	none found
N-acylanino acid aminohydrolase	104620	L07548	none found
D2Y7 purinoreceptor/leukotriene B4 receptor/G protein-coupled	601531	D89078	none found
Phospholipase A-2 (PLA-2) lung	172410	M21054	none found
Phospholipase C beta-3	600230	Z26649	none found
Phospholipase C delta-1	602142	U09117	none found
Phospholipase C epsilon	600597	D42108	none found
Phospholipase C gamma-1	172420	M34667	none found
Phospholipase C gamma-2	600220	M37238	none found
Phospholipase C, beta 4	600810	L41349	none found
Platelet-activating factor receptor	173393	M76674	none found
Prostaglandin 15-OH dehydrogenase (PGDH)	601688	J05594	none found

Prostaglandin E receptor 2 (subtype EP2), 53kD	601586	L28175	none found
Prostaglandin E receptor 3 (subtype EP3) [alternative products]	176806	X83861	none found
PROSTAGLANDIN E2 RECEPTOR, EP2 SUBTYPE	176804	U19487	none found
PROSTAGLANDIN F RECEPTOR	600563	L24470	none found
PROSTAGLANDIN F2 ALPHA RECEPTOR	U26664		none found
prostaglandin transporter hPGT recombinant activating gene /RAG1 recombination activating gene /RAG1 recombination activating gene /RAG1 recombination activating gene /RAG1	601460	U70867	none found
	179615	M29474	GLU722LYS
	179615	M29474	GLU774TER
	179615	M29474	TYR938TER
	179615	M29474	ALA156VAL
	179615	M29474	ARG561HIS

<i>1/RAG1</i> recombination activating gene	179615	M29474	ARG396CYS
<i>1/RAG1</i> recombination activating gene	179615	M29474	TYR912CYS
<i>1/RAG1</i> recombination activating gene	179615	M29474	ARG396HIS
<i>1/RAG1</i> recombination activating gene	179615	M29474	ASP429GLY
<i>1/RAG1</i> recombination activating gene	179615	M29474	ARG361CYS
<i>1/RAG1</i> recombination activating gene	179615	M29474	ARG737HIS
<i>1/RAG1</i> recombination activating gene	179615	M29474	13-BP DEL, NT1723
<i>1/RAG1</i> recombination activating gene	179615	M29474	2-BP DEL, NT368
<i>2/RAG2</i> recombination activating gene	179616	CYS476TYR	
<i>2/RAG2</i> recombination activating gene	179616	ARG220GLN	

recombination activating gene 2/RAG2	179616	CYS41TRP
recombination activating gene 2/RAG2	179616	MET285ARG
regulator of G-protein signalling 1/RGS1	600323	X73427
Retinoic acid receptor, alpha/RARA	180240	X06538
Retinoic acid receptor, alpha/RARA	180240	X06538
Retinoic acid receptor, alpha/RARA	180240	X06538
Retinoic acid receptor, alpha/RARA	180240	X06538
Retinoic acid receptor, beta/RARB	180220	X07282
Retinoic acid receptor, gamma/RARG	180190	M24857
serotonin 5-HT receptors 5-HT3, gated ion channel	182139	D49394
signaling lymphocytic activation molecule/SLAM	603492	U33017
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemoattractant protein	158105	M28226

1/MCP1/SCYA2 small inducible cytokine subfamily A (Cys-Cys), member 2/macrophage chemotactic protein 1/MCP1/SCYA2	158105	M28226	-2076 (A or T)
small inducible cytokine subfamily A (Cys-Cys), member 2/macrophage inflammatory protein 1A/MIP1A/SCYA3	182283	M25315	none found
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	LYS56GLU
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	24-BP DEL CODONS 400- 408
Solute carrier family 4, anion exchanger,	109270	M27819	PRO327ARG

member 1  
(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)  
Solute carrier family 4,  
anion exchanger,  
member 1

GLU40LYS

109270 M27819

(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)  
Solute carrier family 4,  
anion exchanger,  
member 1

10-BP DUP

109270 M27819

(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)  
Solute carrier family 4,  
anion exchanger,  
member 1  
(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)  
Solute carrier family 4,

GLU658LYS

109270 M27819

SD-144141.1

anion exchanger,

member 1

(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)

Solute carrier family 4,

anion exchanger,  
member 1

(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)

Solute carrier family 4,

anion exchanger,  
member 1

(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)

Solute carrier family 4,

anion exchanger,  
member 1

(MEDIATES  
EXCHANGE OF  
INORGANIC  
ANIONS ACROSS  
THE MEMBRANE)

GLN330TER

ARG150TER

89G-A

Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	VAL55/MET
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG589HIS
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG589CYS
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	SER613PHE
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	

THE MEMBRANE)	109270	M27819	
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG589SER
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	GLY701ASP
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	PRO854LEU
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	GLY130ARG
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC			

ANIONS ACROSS THE MEMBRANE) Solute carrier family 4, anion exchanger, member 1	109270	M27819	THR837ALA
(MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)			
T cell receptor- associated protein tyrosine kinase ZAP- 70/ZAP70	176947	L05148	GG-AG, -11
T cell receptor- associated protein tyrosine kinase ZAP- 70/ZAP70	176947	L05148	G-A, -9
T cell receptor- associated protein tyrosine kinase ZAP- 70/ZAP70	176947	L05148	SERS518ARG
T cell receptor- associated protein tyrosine kinase ZAP- 70/ZAP70	176947	L05148	13-BP DEL frameshift
Thromboxane A2 TP receptor, platelet and non-platelet	188070	U27325	ARG60LEU
Thromboxane Synthase transforming growth	274180 190181	M80646 L11695	(CA)n intron 9 S387Y

factor, beta receptor I (activin A receptor type II-like kinase, 53kD)/TGFBR1	190182	M85079	2-BP INS frameshift
transforming growth factor, beta receptor II (70-80kD)/TGFBR2	190182	M85079	THR315MET
transforming growth factor, beta receptor II (70-80kD)/TGFBR2	190182	M85079	GG to TT Stop codon
transforming growth factor, beta receptor II (70-80kD)/TGFBR2	190182	M85079	a7g intron 2
transforming growth factor, beta receptor II (70-80kD)/TGFBR2	190182	M85079	a-4t intron 3
transforming growth factor, beta receptor II (70-80kD)/TGFBR2	190182	M85079	ACA to GCA Thr to Ala codon 128
transforming growth factor, beta receptor II (70-80kD)/TGFBR2	190182	M85079	polyadenine tract of exon 3 base in the none found
transforming growth factor, beta receptor III (betaglycan,	600742	L07594	

300kD/TGIFR3				
tumor necrosis factor alpha (TNFa)	191160	X01394	C-850T	
tumor necrosis factor alpha (TNFa)	191160	X01394	C-ins 5'UTR of exon 1	
tumor necrosis factor alpha (TNFa)	191160	X01394	G-238 A	
tumor necrosis factor alpha (TNFa)	191160	X01394	G-376 A	
tumor necrosis factor alpha (TNFa)	191160	X01394	-1,031 T->C	
tumor necrosis factor alpha (TNFa)	191160	X01394	-863 C->A	
tumor necrosis factor alpha (TNFa)	191160	X01394	-308 G/A	
tumor necrosis factor alpha (TNFa)	191160	X01394	ARG32TRP	
tumor necrosis factor alpha (TNFa)	191160	X01394	LEU29SER	
tumor necrosis factor alpha (TNFa)	191160	X01394	G-376A	
tumor necrosis factor alpha (TNFa)	191160	X01394	Ncol	
tumor necrosis factor alpha (TNFa)	191160	X01394	C to T, -857T	
TUMOR NECROSIS FACTOR RECEPTOR I PRECURSOR	191190	M58286	CYS33TYR	
TUMOR NECROSIS FACTOR RECEPTOR I PRECURSOR	191190	M58286	THR50MET	

TUMOR NECROSIS FACTOR RECEPTOR	191190	M58286	CYS30ARG
1 PRECURSOR			
TUMOR NECROSIS FACTOR RECEPTOR	191190	M58286	CYS2PHE
1 PRECURSOR			
TUMOR NECROSIS FACTOR RECEPTOR	191190	M58286	CYS88ARG
1 PRECURSOR			
TUMOR NECROSIS FACTOR RECEPTOR	191190	M58286	CYS88TYR
1 PRECURSOR			
Tumor necrosis factor receptor 2 (75kD)	191191	M32315	M196R
type 1 receptor associated protein (TRAP1)	None	U12595	none found
type 2 receptor associated protein (TRAP2)	601895	U12597	none found
Vascular cell adhesion molecule 1	192225	M60335	none found
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03238	GLY30ASP
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03238	ARG-GLY
vitamin D (1,25-			

receptor/VDR dihydroxyvitamin D3)	601769	J03258	ARG77GLN
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	ARG47GLN
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	GLN149TER
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	ARG271LEU
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	GLY46ASP
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	HIS305GLN
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	ILE314SER
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	ARG391CYS
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	ARG30TER
vitamin D (1,25-dihydroxyvitamin D3)			
receptor/VDR dihydroxyvitamin D3)	601769	J03258	BsmI

receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	ATG to ACG initiation codon
receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	Apa I
receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	Taq I
receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	codon 79 silent
receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	base change in intron 3
receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	EcoRV xx
receptor/VDR vitamin D (1,25-dihydroxyvitamin D3)	601769	J03258	none found
2,3-cyclic nucleotide 3'-phosphodiesterase	M19650	123830	none found
3beta hydroxysteroid dehydrogenase	M27137	109715	none found
alpha-glucosidase	Y00839	232300	EX18DEL

Table 22. Identified Variances in Genes or Related Pathways involved in Endocrine and Metabolic Disease

				frameshift
a-glucosidase	Y00839	232300	1-BP DEL	
a-glucosidase	Y00839	232300	T-G, -13 intron 1	
a-glucosidase	Y00839	232300		ARG725TRP
a-glucosidase	Y00839	232300		PRO545LEU
a-glucosidase	Y00839	232300		SER529VAL
a-glucosidase	Y00839	232300		GLY643ARG
a-glucosidase	Y00839	232300		GLU521LYS
a-glucosidase	Y00839	232300		GLU689LYS
a-glucosidase	Y00839	232300		ARG854TER
a-glucosidase	Y00839	232300		LEU299ARG
a-glucosidase	Y00839	232300		LYS903DEL
a-glucosidase	Y00839	232300		MET318THR
a-glucosidase	Y00839	232300		ASP91ASN
a-glucosidase	Y00839	232300		ASP645GLU
a-glucosidase AB	D2041	None	none found	
ACAT1	D90228	203750	1-BP INS, 1083A	
ACAT1	D90228	203750		1163 + 2
ACAT1	D90228	203750		4-BP INS
ACAT1	D90228	203750		828 + 1
ACAT1	D90228	203750	IVS10, A-C, -2	
ACAT1	D90228	203750	IVS10, G-C, -1	
ACAT1	D90228	203750	IVS8, G-T, +1	
ACAT1	D90228	203750		ALA347THR
ACAT1	D90228	203750		GLY150ARG
ACAT1	D90228	203750		MET1LYS
ACAT1	D90228	203750		GLN379VAL
ACAT1	D90228	203750		GLU345DEL
ACAT1	D90228	203750		ASN93SER
ACAT1	D90228	203750		ILE312THR
ACAT1	D90228	203750		ALA333PRO

ACAT1	D90228	203750		N158D
ACAT2	S70154	100678	1163 + 2	
ACAT2	S70154	100678	828 + 1	
ACAT2	S70154	100678	TaqI	N158D
ACAT2	S70154	100678		Q272X
Adrenocorticotropic hormone (ACTH)	ACAT2	100678		
Adrenocorticotropic hormone (ACTH)	M28636	176830	3804C-A	
Adrenocorticotropic hormone (ACTH)	M28636	176830	7013G-T	
Adrenocorticotropic hormone (ACTH)	M28636	176830	7133C DEL	
Alpha Amylase 2A; pancreatic	M28443	103880	(AC)n	
androgen receptor	M20132	104650	none found	
androgen receptor	M20132	313700	Hind II	
androgen receptor	M20132	313700	(CAA)n	
androgen receptor	M20132	313700	(CAG)n	
androgen receptor	M20132	313700	(GGN)n	
androgen receptor	M20132	313700	5-KB DEI, EX F G	
androgen receptor	M20132	313700	5-KB DEI, EX E	
androgen receptor	M20132	313700	C>T within exon B	silent
androgen receptor	M20132	313700	CAG340TAG	Gln>Ter
androgen receptor	M20132	313700	Del T at 3286	frameshift
androgen receptor	M20132	313700	del1893	frameshift
androgen receptor	M20132	313700	G Codon 210 A	
androgen receptor	M20132	313700	G Codon 211 A	
androgen receptor	M20132	313700	G2314A	ala>thr
androgen receptor	M20132	313700	G2677A	glu629arg
androgen receptor	M20132	313700	Hhal	
androgen receptor	M20132	313700	Hpall	

Page 1424

		Insert of 69 nucleotides	
		Maeilli	Stu I
M20132	313700	PARTIAL DEL	VAL730MET
androgen receptor	313700		ALA721THR
M20132	313700		GLN902ARG
androgen receptor	313700		HIS874TYR
M20132	313700		SER647ASN
androgen receptor	313700		THR877SER
M20132	313700		ARG607GLN
androgen receptor	313700		VAL865LEU
M20132	313700		VAL865MET
androgen receptor	313700		LYS587TER
M20132	313700		CYS579PHE
androgen receptor	313700		PHE582TYR
M20132	313700		pro892ser
androgen receptor	313700		PRO546SER
M20132	313700		ILE869MET
androgen receptor	313700		GLU2LYS
M20132	313700		ARG839CYS
androgen receptor	313700		ARG839HIS
M20132	313700		GLN607TER
androgen receptor	313700		TRP794TER
M20132	313700		LEU172TER
androgen receptor	313700		LEU707ARG
M20132	313700		MET786VAL
androgen receptor	313700		TYR772CYS
M20132	313700		ARG772CYS
androgen receptor	313700		S98 or S99 ter
M20132	313700		

androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
androgen receptor	M20132	313700					
Arginine Vasopressin Receptor 1A/AVPR1A	AF030625	600821	none found				
Arginine Vasopressin Receptor 1B/AVPR1B	AF030512	600264	none found				
Arginine vasopressin receptor 2	AF030626	304800	1-BP DEL				
Arginine vasopressin receptor 2	AF030626	304800	1-BP DEL, 102G				
Arginine vasopressin receptor 2	AF030626	304800	1-BP INS frameshift				
Arginine vasopressin receptor 2	AF030626	304800	1-BP INS 804 frameshift				

Arginine vasopressin receptor 2	AF030626	304800	15delC
Arginine vasopressin receptor 2	AF030626	304800	28-bp del
Arginine vasopressin receptor 2	AF030626	304800	78delG frameshift
Arginine vasopressin receptor 2	AF030626	304800	CpG dinucleotides
Arginine vasopressin receptor 2	AF030626	304800	TYR280CYS
Arginine vasopressin receptor 2	AF030626	304800	P322H
Arginine vasopressin receptor 2	AF030626	304800	P322S
Arginine vasopressin receptor 2	AF030626	304800	ARG113TRP
Arginine vasopressin receptor 2	AF030626	304800	TRP71TER
Arginine vasopressin receptor 2	AF030626	304800	ALA132ASP
Arginine vasopressin receptor 2	AF030626	304800	ARG203CYS
Arginine vasopressin receptor 2	AF030626	304800	GLY185CYS
Arginine vasopressin receptor 2	AF030626	304800	TYR205CYS
Arginine vasopressin receptor 2	AF030626	304800	ASP85ASN
Arginine vasopressin receptor 2	AF030626	304800	GLY201ASP

Arginine vasopressin receptor 2	AF030626	304800	ARG337TER
Arginine vasopressin receptor 2	AF030626	304800	G107E
Arginine vasopressin receptor 2	AF030626	304800	L43P
Arginine vasopressin receptor 2	AF030626	304800	W193X
Arginine vasopressin receptor 2	AF030626	304800	ARG181CYS
Arginine vasopressin receptor 2	AF030626	304800	R137H
Arginine vasopressin receptor 2	AF030626	304800	none found
ATP-sensitive inwardly rectifying K-channel Receptor; Adrb3	X70811	109691	intron 1 g1856t
Beta-3-Adrenergic Receptor; Adrb3	X70811	109691	TRP64ARG
BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE IB; BMPR1B		603248	none found
Calcitonin Receptor	U26553	114131	PRO463LEU
Calcitonin Receptor	U26553	114131	pro447eu
Calcitonin Related Peptide Receptor	U17473	114190	none found
Calcitonin Related Polypeptide Alpha	M26095	114130	1-BP INS, IVS4
Calcium-activated	U02632	600130	none found

potassium channel	NM_00000 70	114240	ARG572GLN
calpain, large polypeptide L3/CAPN3	NM_00000 70	114240	ARG110TER
calpain, large polypeptide L3/CAPN3	NM_00000 70	114240	ARG769GLN
calpain, large polypeptide L3/CAPN3	NM_00000 70	114240	PRO319LEU
calpain, large polypeptide L3/CAPN3	NM_00000 70	114240	SER86PHE
calpain, large polypeptide L3/CAPN3	NM_00000 70	114240	ASP454GLY
Acetyltransferase Carnitine X78706 600184 none found			
Carnitine D87812 600528			
Palmityltransferase I (muscle) Carnitine U09648 600650 413 delAG			
Palmityltransferase II Carnitine U09648 600650 ARQ631 CY5			
Palmityltransferase II Carnitine U09648 600650 E174K			
Palmityltransferase II Carnitine U09648 600650 F352C			
Palmityltransferase II Carnitine U09648 600650 M647V			

Carnitine	U09648	600650	V368I
Palmityltransferase II			
Carnitine	U09648	600650	SER113LEU
Palmityltransferase II			R124SOp
Carnitine	U09648	600650	ASP553ASN
Palmityltransferase II			PRO50HIS
Carnitine	U09648	600650	GLU174LYS
Palmityltransferase II			PHE383TYR
Carnitine	U09648	600650	
Palmityltransferase II			F448L
Carnitine	U09648	600650	G549D
Palmityltransferase II			ARG503CYS
Carnitine	U09648	600650	
Palmityltransferase II			TYR628SER
Carnitine	U09648	600650	
Palmityltransferase II			none found
Carnitine	U09648	600650	
Palmityltransferase II			EX35, G-A
CCCCAAAT/ENHANCER-BINDING PROTEIN, GAMMA, CEBPG	L78207	600509	
Cell surface receptor for sulfonylureas on pancreatic b cells			G-A, -9 EXON ALPHA DEL
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	

Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	3-BP DEL	PHE1388DEL
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	ACC-->ACT	Thr759Thr
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	BRANCH POINT, A-G,-20	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	Exon 16 -3c-->t	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	G-A,-1	splice change
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	G-A,-1 exon 5	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	ARG1353PRO	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	ARG1421CY S	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	ARG1494TRP	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	R275Q	
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	V560M	

for sulfonylureas on pancreatic b cells	L78207	600509	F591L
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	G1382S
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	H125Q
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	N188S
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	R1215Q
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	R1394H
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	T1139M
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	S1370A
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	GLY716VAL
Cell surface receptor for sulfonylureas on pancreatic b cells cytochrome P450 aromatase (CYP19)	X13589	107910	(TTTA)n in intron 5

				frameshift
cytochrome P450	X13589	107910	I-BP DEL, 408C	
aromatase (CYP19)			G-->A at Val80	silent
cytochrome P450	X13589	107910	G-to-A	Val370-to-Met
aromatase (CYP19)				
cytochrome P450	X13589	107910	G-1094-A	ARG365GLN
aromatase (CYP19)				
cytochrome P450	X13589	107910	G-to-A	Val370-to-Met
aromatase (CYP19)				
cytochrome P450	X13589	107910	GT to AT exon and intron 3	
aromatase (CYP19)			splice donor	29 extra amino acids
cytochrome P450	X13589	107910	(GT>GC) of intron 6	ARG435CY5
aromatase (CYP19)				
cytochrome P450	X13589	107910	CYS437TYR	
aromatase (CYP19)				
cytochrome P450	X13589	107910	Arg264cys	
aromatase (CYP19)				
cytochrome P450	X13589	107910	ARG375CY5	
aromatase (CYP19)				
cytochrome P450	X13589	107910	none found	
aromatase (CYP19)				
Cytochrome P450	S90469	124015	none found	
reductase				
Cytochrome P450, subfamily 1IB (phenobarbital- inducible), polypeptide	M29874	None	none found	
Cytochrome P450, subfamily XIA (cholesterol side chain cleavage)	M14565	118485	6	5'UTR pentanucleotide repeat

Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	1-BP DEL	frameshift
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	1-bp C del codon 131	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	1-BP DEL	frameshift
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	4-BP DUP, EX8	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	469-BP INS	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	518-BP DEL	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	7-BP DUP, EX2	

subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	IWS2, G-T,+5
subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	IVS7+5G to A
subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	T->C promoter
subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	ARG347HIS
subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	ARG358GLN
subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	TRP17TER

(steroid 17-alpha-hydroxylase), adrenal hyperplasia			PHE417CYS
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	PHE53/54 DEL
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	ARG239TER
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	SER106PRO
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	PHE33DEL
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	

hydroxylase), adrenal hyperplasia	M14564	202110	his373leu
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	Arg496Cys
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	Gln461Stop
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	ARG96TRP
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	none found
DOLICHOL- PHOSPHATE MANNOSYLTRANSF ERASE 1	603503		none found
DOLICHOL- PHOSPHATE MANNOSYLTRANSF ERASE 2 REGULATORY	603564		

SUBUNIT				
Endothelin Receptor	D90348	131243	none found	
Type A				
Endothelin Receptor	L06623	131244	1-BP INS, 878T	
Type B				
Endothelin Receptor	L06623	131244	TRP275TER	
Type B				
Endothelin Receptor	L06623	131244	ALA183GLY	
Type B				
Endothelin Receptor	L06623	131244	TRP276CYS	
Type B				
Endothelin Receptor	L06623	131244	SER305ASN	
Type B				
Endothelin Receptor	L06623	131244	GLY57SER	
Type B				
estrogen receptor 1	X01635	133430	RFLP (PssI enzyme)	
(ESR1)				
estrogen receptor 1	X03635	133430	RFLP (PvuII enzyme)	
(ESR1)			none found	
Estrogen-pre-fering sulfotransferase STE_20	NM_005420	600043	none found	
FATTY ACID COENZYME A LIGASE, LONG-CHAIN 2		152426	none found	
Folic Acid (Folate Receptor)	M28099	136430	none found	
follicle stimulating hormone-beta (FSH)	M16646	136530	CYS31GLY	
follicle stimulating hormone-beta (FSH)	M16646	136530	FS87TER	
hormone-beta (FSH)				

FSH receptor	M65085	136435	566C->T	
FSH receptor	M65085	136435	BsmI	
FSH receptor	M65085	136435	HindIII	
FSH receptor	M65085	136435	PstI	
FSH receptor	M65085	136435		ARG573CYSS
FSH receptor	M65085	136435		ILE160THR
FSH receptor	M65085	136435		PHE591SER
FSH receptor	M65085	136435		Thr307Ala
FSH receptor	M65085	136435		Asp567Gly
FSH receptor	M65085	136435		Ser680Asn
FSH receptor	M65085	136435		Asp334Gly
FSH receptor	M65085	136435		ALA189VAL
G PROTEIN-COUPLED RECEPTOR 24;		601751	none found	
GPR24				
glucagon	Glucagon	J04040	138030	Dinucleotide repeat
receptor/GCGR		NM_00001	138033	Alu-repeat
glucagon	glucagon	60	138033	
receptor/GCGR		60		
glucagon-like peptide 1	U01156	138032	silent substitution in exon 6	
receptor/GLP1R			simple tandem repeat DNA polymorphism	
glucagon-like peptide 1	U01156	138032	none found	
receptor/GLP1R				
glucagon-like peptide 2	*****	603659		
receptor/GLP2R				
glucocorticoid receptor	M11050	138040	4-BP DEL	2 bases of the exon and the first 2

glucocorticoid receptor	M11050	138040	A to G 3'-splice junction of intron G	intron 6 frameshift
glucocorticoid receptor	M11050	138040	Base-pair deletion in exon 9	32 amino acid deletion
glucocorticoid receptor	M11050	138040	T insertion 1188 and Bc11	frameshift
glucocorticoid receptor	M11050	138040	1189	
glucocorticoid receptor	M11050	138040	Arg453	
glucocorticoid receptor	M11050	138040	trinucleotide insertion Th1111	
glucocorticoid receptor	M11050	138040	LEU753PHE	
glucocorticoid receptor	M11050	138040	CYS736SER	
glucocorticoid receptor	M11050	138040	CYS736THR	
glucocorticoid receptor	M11050	138040	ILE747THR	
glucocorticoid receptor	M11050	138040	ASP641VAL	
glucocorticoid receptor	M11050	138040	L753F	
glucocorticoid receptor	M11050	138040	Q710X	
glucocorticoid receptor	M11050	138040	ASN363SER	
glucocorticoid receptor	U25029	138040	none found	
glucocorticoid receptor alpha	X03348	138040	none found	
glucocorticoid receptor beta		601993	none found	
GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1	S70004	138571	IVS6, G-C, +1 [human, liver, mRNA, 2912 nt]	

glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ALA339PRO
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ARG246TER
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ASN39SER
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	HIS446ASP
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	MET49IARG
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	SER483PRO
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	PRO479GLN
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ARG262GLN
gonadotropin releasing hormone receptor/G protein-coupled/LHRHR/GNR HR	NM_000406	138830	GLN106ARG

gonadotropin releasing hormone receptor/G protein-coupled/LHRHR/GNR HR	NM_000406	138850	TYR284CYS
gonadotropin releasing hormone receptor/G protein-coupled/LHRHR/GNR HR	NM_000406	138850	Mae III
Gonadotropin-releasing hormone (leutinizing-releasing hormone) GROWTH FACTOR RECEPTOR-BOUNDED PROTEIN 2; GRB2	M12578	152760	none found
Growth hormone I	V00519	139250	G-T, +1 intron 4
Growth hormone I	V00519	139250	1-BP DEL, 371C
Growth hormone I	V00519	139250	18-BP DEL, +28-45
Growth hormone I	V00519	139250	intron 3
Growth hormone I	V00519	139250	FSI132TER
Growth hormone I	V00519	139250	2-BP DEL
Growth hormone I	V00519	139250	6.7-KB DEL
Growth hormone I	V00519	139250	BgII
Growth hormone I	V00519	139250	G-A, +1 intron 3
Growth hormone I	V00519	139250	G-A, +28
Growth hormone I	V00519	139250	G-C, +1 intron 3
Growth hormone I	V00519	139250	G-C, +1 intron 4
Growth hormone I	V00519	139250	HincII
Growth hormone I	V00519	139250	MspI
Growth hormone I	V00519	139250	T-C, +6 intron 3
Growth hormone I	V00519	139250	ARG77CYS

Growth hormone 1	V00519	139250	ASPI112GLY
Growth hormone 1	V00519	139250	TRP20TER
Growth hormone receptor	X06562	600946	none found
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	IVSSDS, G-C,-1 alternative splice
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	1-BP DEL frameshift
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	2-BP DEL frameshift
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	C to T codon 236, silent
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	EX4,6DEL
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	GAA180GAG silent
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	IVS4DS, G-A,+1 alternative splice

coupled/GHRHR growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	IVS6AS, G-T, -1
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	IVS8AS, G-C, -1
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	IVS9DS, G-A, +1 frameshift
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	ARG161CYS
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	GLU224ASP
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	GLU441LYS
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	PHE96SER
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	ASP152HIS

receptor/G protein-coupled/GHRHR	U34195	139191	GLN154PRO
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	ILE153THR
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	VAL155GLY
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	VAL155ILE
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	PRO131GLN
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	GLU224TER
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	P561T
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	ARG217TER

releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191		ARG43TER
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191		CYS38TER
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	L29177		none found	
growth hormone releasing factor (GRF)	X62282	601244	none found	
Guanylate cyclase 1, soluble, alpha 2	X66534	139396	none found	
Guanylate cyclase soluble, alpia-3 chain	X66533	139397	none found	
Guanylate cyclase soluble, beta-1 chain	H.sapiens ACTH-R X65633	202200		C818A
gene for adrenocorticotropic hormone receptor	H.sapiens ACTH-R X65633	202200		Ser74Ile
gene for adrenocorticotropic hormone receptor	H.sapiens ALK-3 mRNA	Z22535	601299	none found
H.sapiens encoding PC1/PC3	X64810	162150	IVSS5DS, A-C, +4	

<i>H.sapiens</i> encoding PC1/PC3	X64810	162150		GLY483ARG
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	1-BP DEL	PHE75T
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281		GLN268TER
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281		ARG154TER
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281		ARG127TRP
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281		VAL393ILE
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281		Val/Met255
<i>H.sapiens</i> HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281		
<i>H.sapiens</i> IL-1R2 mRNA for type II interleukin-1 receptor, (cell line CB23)	X59770	147811	none found	
<i>H.sapiens</i> mRNA for beta subunit of epithelial amiloride- sensitive sodium channel	X87159	600760	1-BP INS, 592C	
<i>H.sapiens</i> mRNA for beta subunit of	X87159	600760	32-BP DEL	

epithelial amiloride-sensitive sodium channel	X87159	600760	ARG564TER
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel			
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	PRO616LEU
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	GLY37SER
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	TYR618HS
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	PRO615SER
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	1-BP INS frameshift
H.sapiens mRNA for carnitine carrier	Y10319	212138	
H.sapiens mRNA for	Y10319	212138	110-BP DEL

carnitine carrier	H.sapiens mRNA for carnitine carrier	Y10319	212138	128-BP DEL	
carnitine carrier	H.sapiens mRNA for carnitine carrier	Y10319	212138		ARG166TER
carnitine carrier	H.sapiens mRNA for cathepsin O	X82153	601105		TER330TRP
carnitine carrier	H.sapiens mRNA for cathepsin O	X82153	601105		GLY146ARG
carnitine carrier	H.sapiens mRNA for cathepsin O	X82153	601105		ARG241TER
carnitine carrier	H.sapiens mRNA for cathepsin O	X82153	601105		ALA277VAL
carnitine carrier	H.sapiens mRNA for cathepsin O	X82153	601105		none found
carnitine carrier	H.sapiens mRNA for cathepsin-O	X77383	600550		none found
carnitine carrier	H.sapiens mRNA for CCAAT/enhancer binding protein alpha	Y11525	116897		none found
carnitine carrier	H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047		1389 (A/G)
carnitine carrier	H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	dinucleotide repeat introns 12	
carnitine carrier	H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	dinucleotide repeat introns 5	
carnitine carrier	H.sapiens mRNA for gamma subunit of epithelial amiloride-sensitive sodium	X87160	600761		none found

H.sapiens mRNA for channel	Z82022	191350	none found
GlcNac-1-P transferase			539G del
H.sapiens mRNA for glucose-dependant insulinotropic polypeptide receptor gene	X81832	147940	
H.sapiens mRNA for glucose-dependant insulinotropic polypeptide receptor gene	X81832	147940	A>230C
H.sapiens mRNA for growth factor receptor tyrosine kinase	X61656	191306	none found
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	-164 T->C
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	-400 A->T
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	-493T/G
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	1-BP DEL, 215C

H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	IVS, G-A, +5
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	IVSSAS, G-A, -1
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	ARG215TER
H.sapiens mRNA for microsomal triglyceride transfer protein	X68596	168468	33-BP DEL
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468	HIS223ARG
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468	THR410PRO
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468	ARG383GLN
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468	PRO132LEU
H.sapiens mRNA for phosphoenolpyruvate carboxykinase	X92720	261650	none found

<i>H.sapiens</i>	M77844	106210	IVS12DS, G-C, -1
oculorhombin (aniridia) mRNA, complete cds			
<i>H.sapiens</i>	M77844	106210	2-BP INS
oculorhombin (aniridia) mRNA, complete cds			
<i>H.sapiens</i>	M77844	106210	dinucleotide repeat promoter
oculorhombin (aniridia) mRNA, complete cds			
<i>H.sapiens</i>	M77844	106210	EXON G DEL
oculorhombin (aniridia) mRNA, complete cds			
<i>H.sapiens</i>	M77844	106210	IVS10AS, A-T, -2
oculorhombin (aniridia) mRNA, complete cds			
<i>H.sapiens</i>	M77844	106210	IVS11DS, A,G, -2
oculorhombin (aniridia) mRNA, complete cds			ARG103TER
<i>H.sapiens</i>	M77844	106210	SER353TER
oculorhombin (aniridia) mRNA, complete cds			

complete cds					
H.sapiens	M77844	106210			ARG26GLY
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			I29V
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			N17S
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			Q178I
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			R44Q
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			Q422R
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			ARG203TER
oculorhombin					
(aniridia) mRNA,					
complete cds					
H.sapiens	M77844	106210			ARG224OTER
oculorhombin					

(aniridia) mRNA, complete cds H.sapiens	M77844	106210	GLY64VAL
oculohombin (aniridia) mRNA, complete cds H.sapiens	M77844	106210	VAL126ASP
oculohombin (aniridia) mRNA, complete cds H.sapiens	M77844	106210	GLN116TER
oculohombin (aniridia) mRNA, complete cds H.sapiens	M77844	106210	187R
oculohombin (aniridia) mRNA, complete cds H.sapiens	M77844	106210	ARG125CYS
oculohombin (aniridia) mRNA, complete cds H.sapiens	M77844	106210	VAL54ASP
oculohombin (aniridia) mRNA, complete cds H.sapiens PPP1R3 mRNA for protein phosphatase 1, glycogen-binding regulatory subunit	X78578	600917	5-BP INS/DEL 3'UTR

H.sapiens PP1R3	X78578	600917					ASP90STYR
mRNA for protein phosphatase 1, glycogen-binding regulatory subunit			600288		none found		
HEPATOCYTE							
NUCLEAR FACTOR							
3-BETA-HNF3B							
HEPATOCYTE			602295		none found		
NUCLEAR FACTOR							
3-GAMMA-HNF3G							
HEPATOCYTE							
NUCLEAR FACTOR			604164		none found		
HMG CoA synthase (HSH1) mitochondrial	U12789	600234			none found		
HMG CoA synthase soluble	X66435	142940			none found		
HMGCoA reductase/HMGR	NM_0008	142910				HgIAI	
HMGCoA reductase/HMGR	NM_0008	142910			ScfI polymorphism in the 2nd intron		
Homo sapiens (clone L05144)	L05144	261680			none found		
lambda-nEC-3)							
phosphoenolpyruvate carboxykinase (PCK1)							
mRNA, complete cds Homo sapiens (clone L40992)	L40992	600211				16-BP INS	
PEBP2aa1) core-binding factor, runt domain, alpha subunit							

1 (CBFA1) mRNA, 3'				
end of cds				
Homo sapiens (clone L40992	600211	ALA REPEAT		
PEBP2AA1) core-				
binding factor, runt				
domain, alpha subunit				
1 (CBFA1) mRNA, 3'				
end of cds				
Homo sapiens (clone L40992	600211	MET175ARG		
PEBP2AA1) core-				
binding factor, runt				
domain, alpha subunit				
1 (CBFA1) mRNA, 3'				
end of cds				
Homo sapiens (clone L40992	600211	SER191ASN		
PEBP2AA1) core-				
binding factor, runt				
domain, alpha subunit				
1 (CBFA1) mRNA, 3'				
end of cds				
Homo sapiens (clone L40992	600211	TRP283TER		
PEBP2AA1) core-				
binding factor, runt				
domain, alpha subunit				
1 (CBFA1) mRNA, 3'				
end of cds				
Homo sapiens (clone L40992	600211	none found		
PEBP2AA1) core-				
binding factor, runt				
domain, alpha subunit				
1 (CBFA1) mRNA, 3'				
end of cds				
Homo sapiens acyl-CoA synthetase 4	AF030555	300157		
(ACS4) mRNA,				
complete cds				
Homo sapiens low	M28219	143890	ATn	

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-6DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	-19(CGG)n
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1-BP DEL, 197G
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1061-8T->C
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1650delG frameshift

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	163delG
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	18-BP DUP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	1846-1G-->A
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	2-BP DEL, 694AC
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	2199delCA

causing familial hypercholesterolemia mRNA, 3 end	M28219	143890	2201delCA
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	313 + 1G->A
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	335del10 frameshift
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	347delGCC frameshift
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	4-BP INS, EX8 frameshift

hypercholesterolemia) mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	7-BP DEL	frameshift
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	785insG	
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	9-BP DEL	
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	AGG450AGA	silent
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	C766T	

mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX13-14DEL
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX13-15DEL
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX13-15DUP
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX15DEL
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX15DEL
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX16-17DEL

Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX16-18DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX16DEL
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX17-18DEL
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX17DEL
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX17DEL
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX2-12DEL
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX2-3DEL
mRNA, 3' end			

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-5DUP
density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-8DUP
density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX3-8DEL
density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX4-6DEL
density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX5DEL

receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX7-14DEL
receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX7-8DEL
receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX7DEL
receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX9-10DEL
receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	EX9DUP

causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	HhaI intron 9
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	HincII
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	IVS3, G-A, +1
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	IVS4, T-C, +2
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	null allele

hypercholesterolemia mRNA, 3' end	M28219	143890	PvuII
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)			
mRNA, 3' end	M28219	143890	SstI
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)			
mRNA, 3' end	M28219	143890	T -> A28
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)			
mRNA, 3' end	M28219	143890	ALA410THR
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)			
mRNA, 3' end	M28219	143890	VAL302MET
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)			

mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	ASP283ASN
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	GLY27DEL
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	GLU207LYS
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	D154N
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	D206F
mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	

Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890		V408M
mRNA, 3' end				
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	GLY197DEL	
mRNA, 3' end				
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	C127W	
mRNA, 3' end				
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	C139G	
mRNA, 3' end				
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	E397X	
mRNA, 3' end				
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	GLN12TER	
mRNA, 3' end				
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890		

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY525ASP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY528ASP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS163TYR
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASP206GLU
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS646TYR

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	TRP66GLY
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	SER156LEU
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY544VAL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	R329X
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASN543HIS

causing familial hypercholesterolemia	mRNA, 3 end	M28219	143890	ASP154ASN
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	N543H
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	Glu119-Lys
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	C152R
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	T705I
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial				SD-144141.1

hypercholesterolemia	mRNA, 3' end	M28219	143890	Cys297-->Phe
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	asp147his
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	Trp469Stop
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	ASP412HIS
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3' end	M28219	143890	PRO664LEU

mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	Ala370-->Thr
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	C356-->Y
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	CYS240PHE
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	Asp200-->Gly
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	C122X
mRNA, 3' end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	

Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	Pro84-->Ser
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	pro664leu
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	Cys646-->Tyr
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	Glu207-->Lys
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	Trp66-->Gly
mRNA, 3' end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	CYS660TER
mRNA, 3' end			
Homo sapiens low	M28219	143890	

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	TYR807CYS
mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	TRP792TER
mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	CYS210TER
mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	GLY823ASP
mRNA, 3 end	Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	M28219	143890	LEU380HIS

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	TYR167TER
receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	VAL408MET
receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	C331C
receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	E119K
receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3' end	M28219	143890	N494 N

causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	T383P
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	T705I
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	W23X
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	W556S
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia)	mRNA, 3 end	M28219	143890	W66G

hypercholesterolemia)				
mRNA, 3 end				
Homo sapiens mRNA for Acyl-CoA synthetase 3, complete cds	D89053	602371	none found	
Homo sapiens mRNA AB006590 for estrogen receptor beta, complete cds		601663	none found	
Homo sapiens mRNA AB005293 for perilipin, complete cds		170290	none found	
Homo sapiens mRNA AJ006276 for transient receptor potential protein TRP6 Homo sapiens mRNA for very-long-chain acyl-CoA synthetase, complete cds	D88308	603247	none found	
Homo sapiens muscle AF066859 glycogen phosphorylase (PYGM) mRNA, complete cds		232600	IVS14, G-A,+1,67- BP DEL	ARG49TER
Homo sapiens muscle AF066859 glycogen phosphorylase (PYGM) mRNA, complete cds		232600		GLY204SER
Homo sapiens muscle AF066859 glycogen		232600		

phosphorylase (PYGM) mRNA, complete cds			
Homo sapiens muscle AF066859	232600	LYS542THR	
glycogen phosphorylase (PYGM) mRNA, complete cds			
Homo sapiens muscle AF066859	232600	MET1GLY	
glycogen phosphorylase (PYGM) mRNA, complete cds			
Homo sapiens muscle AF066859	232600	GLU654LYS	
glycogen phosphorylase (PYGM) mRNA, complete cds			
Homo sapiens muscle AF066859	232600	LEU396PRO	
glycogen phosphorylase (PYGM) mRNA, complete cds			
Homo sapiens muscle AF066859	232600	GLY685ARG	
glycogen phosphorylase (PYGM) mRNA, complete cds			
Homo sapiens muscle AF066859	232600	ARG575TER	
glycogen phosphorylase			

(PYGM) mRNA, complete cds			
Homo sapiens muscle	AF066859	232600	GLN665GLU
glycogen phosphorylase			
(PYGM) mRNA, complete cds			
Homo sapiens muscle	AF066859	232600	LYS753, DEL A
glycogen phosphorylase			
(PYGM) mRNA, complete cds			METIVAL
Homo sapiens muscle	AF066859	232600	GLU540TER
glycogen phosphorylase			
(PYGM) mRNA, complete cds			
Homo sapiens muscle	AF066859	232600	none found
glycogen phosphorylase			
(PYGM) mRNA, complete cds			
Homo sapiens	L07833	182454	none found
somatostatin receptor (SSTR4) gene, complete cds			
Homo sapiens sorbitol dehydrogenase gene, complete cds	U07361	182500	GLY31ARG
HOMOLOG OF SONIC HEDGEHOG	600725		

HOMOLOG OF SONIC HEDGEHOG		600725	GLN100TER
HOMOLOG OF SONIC HEDGEHOG		600725	LYS105TER
HOMOLOG OF SONIC HEDGEHOG		600725	TRP117GLY
HOMOLOG OF SONIC HEDGEHOG		600725	TRP117ARG
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195	138140	silent
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195	138140	XbaI
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195	138140	DEL
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195	138140	LYS456TER
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195	138140	TYR449TER
Human activin receptor-like kinase (ALK-5) mRNA, cds	L11695	190181	S387Y

complete cds			
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	ALU INS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	CYS342TYR
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	CYS342ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	CYS342SER
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TYR340HIS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER354CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	ALA344ALA
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	ALA344GLY
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TYR328CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER347CYS

Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER232TRP
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	PRO253ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	THR341PRO
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	CYS342TRP
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	GLN289PRO
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TYR375CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER372CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER252PHE
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	PRO253SER
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290CYS
Human bek mRNA for			LYS292GLU

fibroblast growth factor receptor-BEK			
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290GLY
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	LYS292GLU
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290GLY
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	VAL-VAL DEL
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER351CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER252PHE
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	ILE15THR
Human beta-LH gene (luteinizing hormone gene beta subunit)	X00264	152780	TRP8ARG
Human beta-LH gene (luteinizing hormone)	X00264	152780	

gene beta subunit)	X00264	152780		GLN54ARG
Human beta-LH gene (luteinizing hormone gene beta subunit)				
Human brain glycogen phosphorylase mRNA, complete cds	J03544	138550	none found	
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	1-BP INS, CODON 443	frameshift
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160		1305G-C
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	C1644i	frameshift
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	EX4-10DEL	
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	HindII	
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160		VAL458ALA
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160		R338L
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160		GLY340ARG

Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ALA229THR
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	THR332DEL
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG383HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	LYS438GLU
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	GLY340SER
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG320LEU
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG311HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG438HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG320CYS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG338TRP
Human c-erb-A mRNA	X04707	190160	ALA312THR

for thyroid hormone receptor	X04707	190160	GLY327ARG
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	GLY340VAL
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	GLY342GLU
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	MET437VAL
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	PRO448THR
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	PRO448HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	THR337ALA
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	CYS344TER
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	CYS346ARG
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	LEU445HIS

Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	GLY340ASP
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	GLN335HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	pro453ser
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	R316H
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	met313thre
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	L346V
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	MET310THR
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	LEU325PHE
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG243GLN
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG243TRP

Human c-erbA mRNA for thyroid hormone receptor	X04707	190160	ASP317HIS
Human c-erbA mRNA for thyroid hormone receptor	X04707	190160	PHE454CYS
Human c-erbA mRNA for thyroid hormone receptor	X04707	190160	ARG315HIS
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	X55005	190120	LYS370ASN
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	X55005	190120	SER377LEU
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	X55005	190120	SER451LE
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	M91667	123805	none found
Human cGMP- inhibited cAMP phosphodiesterase mRNA, complete cds	J02883	120105	none found
Human collagen type XVII alpha 1 (COL18A1) mRNA, partial cds	L22548	120328	none found
Human CYP11B2 gene for steroid 18- hydroxylase, complete	D13752	124080	-344C/T

			5-BP DEL	frameshift
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080		
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	T4986C	
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	GLU198ASP	
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	GLU255TER	
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	LYS173ARG	
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	THR185ILE	
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	LEU461PRO	
Human CYP11B2 gene for steroid 18- hydroxylase, complete	cds D13752	124080	ARG181TRP	

hydroxylase, complete	cds		VAL386ALA
Human CYP1B2 gene for steroid 18-hydroxylase, complete	D13752	I24080	
Human CYP1B2 gene for steroid 18-hydroxylase, complete	D13752	I24080	T318M
Human CYP1B2 gene for steroid 18-hydroxylase, complete	cds		
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	1761Tins
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	C-G intron 2
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	DEL
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	PvuII
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	TGC to AC
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	3'-BP INS
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	LEU10INS
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	656 A->G
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	8-BP DEL
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	ClusterE6
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	F306+t
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	G-T exon 7

P450c21 mRNA, 3' end Human cytochrome	M17252	201910	GG dinucleotide to a C in exon 10 HaeIII
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	IVS2AS A/C-G, -13
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	IVS7DS, G-C, +1
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	Ncol
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	Rsa I
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	T-A exon 4
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	ILE172ASN
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	VAL281LEU
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	PRO301LEU
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	SER268THR
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	GLY292SER
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	TYR102ARG
P450c21 mRNA, 3' end Human cytochrome	M17252	201910	ILE235ASN

Human cytochrome P450c21 mRNA, 3' end	M17252	201910	VAL236GLU
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	MEI238LYS
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	GLN318TER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	ARG339HIS
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	TRP406TER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	GLU380ASP
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Q318X
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	R356W
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	I236N
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	V237E
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	M239K
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	GLY324SER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	R356Q
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Y97X
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Arg357Ter
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	D183E

P450c21 mRNA, 3' end Human cytochrome P450c21 mRNA, 3' end	M17252	201910		W23X
Human fatty acid synthase (fas) mRNA, complete cds	U266944	600212	none found	
Human gene for nuclear factor NF-IL6	X52560	189965	none found	
Human glucagon-like peptide-1 receptor mRNA with CA dinucleotide repeat, complete cds	U01157	138032	none found	
Human hepatin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds	M32977	192240	none found	
Human hepatic lipase mRNA, complete cds	J03540	151670	SER267PHE	
Human hepatic lipase mRNA, complete cds	J03540	151670	THR383MET	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	A-C, -58	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds,	M57732	142410	1-BP DEL frameshift	

clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	1-BP INS	frameshift
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	Real promoter	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	PRO447LEU	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	E619K	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	RS37T	

HCL12, HCL17, and HCL20	Human hepatic nuclear factor 1 (TCF1)	M57732	142410	Ala/Val98
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20				
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	TYR122CYS	
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20				
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	THR62ILE	
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20				
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	Gly574Ser	
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20				
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	Cys241Gly	
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20				

Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	HCL20	M57732	142410	Glu48Lys
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	HCL20	M57732	142410	Pro291fsdelA
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	HCL20	M57732	142410	ARG272HS
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	HCL20	M57732	142410	ARG583GLY
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	HCL20	M57732	142410	K205Q

Human hepatic nuclear factor 1 (TCF1)	M57732	142410	R131Q
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20			
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	T392fsdelA
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20			
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	L12H
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20			
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	L584S585fsinsT C
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20			
Human hepatic nuclear factor 1 (TCF1)	M57732	142410	P379fsdelCT
mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20			
Human hepatic nuclear	M57732	142410	R263C

factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL2, HCL17, and HCL20	M57732	142410	G191D
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	GLY319SER
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	U39840	602294	none found
Human hepatocyte nuclear factor-3 alpha (HNF-3 alpha) mRNA, complete cds	U40002	151750	dinucleotide repeat
Human hormone- sensitive lipase testicular isoform mRNA, complete cds	U40002	151750	Arg309Cys
Human hormone- sensitive lipase testicular isoform mRNA, complete cds	D83260	601125	none found
Human HXC-26 mRNA, complete cds			

Human insulin promoter factor 1 (IPF1) mRNA, complete cds	U30329	600733	I-BP DEL	frameshift
Human insulin-degrading enzyme (IDE) mRNA, complete cds	M21188	146680	none found	
Human insulin-responsive glucose transporter (GLUT4) mRNA, complete cds	M20747	138190	VAL383ILE	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	IVS13DS, G-A, +I	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	IVS14DS, G-A, +I	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	IVS4AS, G-C, -I	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	ASN338SER	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	ASN376LYS	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	VAL221ILE	
Human long-chain L09229	152425		A-->T	new initiation

acyl-coenzyme A synthetase (FACL) mRNA, complete cds	M63108	152790	6-BP DEI, NT1822	codon +18 amino acids
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	LEU-GLN INS, CODON 19-20	
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	SER616TYR	
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		ARG554TER
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		ALA593PRO
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		ASP578GLY

receptor mRNA, complete cds			
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ILE625LYS
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ILE342LEU
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ALA373VAL
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	GLU354LYS
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ARG133CYS
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ASP578GLY
Human luteinizing hormone- choriogonadotropin receptor mRNA,			

complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	ALA572VAL
complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	THR577ILE
complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	ASP582GLY
complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	MET575ILE
complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	MET398THR
complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	CYS545TER
complete cds	Human luteinizing hormone-choriogonadotropin receptor mRNA, complete cds	M63108	152790	

Human	U60475	307800	2-BP DEL	frameshift
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	A-G, NT-429	
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	IVS1AS, G-A, -I	
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	IVS1AS, G-C, -I	
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	LEU555PRO	
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	CYS82TYR	
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	LEU274TER	
metalloendopeptidase homolog (PEX)				
mRNA, partial cds				
Human	U60475	307800	MET250ILE	
metalloendopeptidase homolog (PEX)				

mRNA, partial cds Human	U60475	307800	PHE249SER
metalloendopeptidase homolog (PEX)			
mRNA, partial cds Human molecular marker (EPIC-1) gene, complete cds	M90439	172860	G to A 5
Human molecular marker (EPIC-1) gene, complete cds	M90439	172860	Met727Irr
Human molecular marker (EPIC-1) gene, complete cds	M90439	172860	Thr130Thr
Human molecular marker (EPIC-1) gene, complete cds	M90439	172860	Tyr321Tyr
Human molecular marker (EPIC-1) gene, complete cds	M90439	172860	
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	1-BP DEL 744
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	1-BP DEL, 485T
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	frameshift
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	2-BP INS, 513TT
Human mRNA for alpha-tocopherol	D49488	600415	SS2G-A

transfer protein, complete cds	D49488	600415	HIS101GLN
Human mRNA for alpha-tocophero transfer protein, complete cds	D49488	600415	ARG192HIS
Human mRNA for alpha-tocophero transfer protein, complete cds	D49488	600415	ARG134TER
Human mRNA for alpha-tocophero transfer protein, complete cds	D49488	600415	none found
Human mRNA for carboxypeptidase E (EC 3.4.17.10)	X51405	114855	none found
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	2-BP INS, CODON 394
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	28bp deletion
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	5 bp duplication
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	CHIMERA
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	MspI

Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	Pfull
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	ARG448HS
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	TRP116TER
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	N133H
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	P42S
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	Y423X
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	arg384gly
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	ARG374GLN
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	THR318MET
Beta)	Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	C494F

Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	G267D
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	G267R
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	Q356X
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	R427H
Human mRNA for cytochrome P-450 (11 Beta)	Y00083	190220	none found
T-cell suppressor factor G-TsF (transforming growth factor-beta2, TGF-beta2)			
Human mRNA for plasminogen	X05199	173350	IVS17, 1-BP DEL, G,+1 TaqI
Human mRNA for plasminogen	X05199	173350	GLU460TER
Human mRNA for plasminogen	X05199	173350	ALA600THR
Human mRNA for plasminogen	X05199	173350	ARG216HIS
Human mRNA for plasminogen	X05199	173350	GLY732ARG
Human mRNA for plasminogen	X05199	173350	LYS19GLU

plasminogen	X05199	173350	LYS212DEL
Human mRNA for plasminogen	X05199	173350	SER572PRO
Human mRNA for plasminogen	X05199	173350	TRP597TER
Human mRNA for plasminogen	X05199	173350	VAL355PHE
Human mRNA for plasminogen	X05199	173350	D676N
Human mRNA for plasminogen	X05199	173350	Ala675Thr
Human mRNA for plasminogen	X02812	190180	713-8delC
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	713-8delC
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	Leu10->Pro
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	Arg25->Pro
Human mRNA for transforming growth factor-beta 3 (TGF-beta 3)	X14149	190230	none found
Human mRNA for variant hepatic nuclear factor 1 (vHNF1)	X58840	189907	75-BP DEL, NT409
Human mRNA for variant hepatic nuclear	X58840	189907	ARG177TER

factor 1 (VHNF1)				
Human mRNA	X02404	114160	none found	
fragment for second calcitonin gene related peptide (CGRP) from medullary thyroid carcinoma (MTC)	X12451	116880	none found	
Human mRNA for pro-cathepsin L (major excreted protein MEP)	J04501	138570	TTC342TTT	
Human muscle glycogen synthase mRNA, complete cds				Gln71His
Human muscle glycogen synthase mRNA, complete cds	J04501	138570		Gly464Ser
Human muscle glycogen synthase mRNA, complete cds	J04501	138570		Met416Val
Human muscle glycogen synthase mRNA, complete cds	J04501	138570		U80982
Human myeloid-specific C/EBP-epsilon transcription factor (CEBPE) gene, complete cds		600749	none found	
Human neurokinin A receptor (NK-2R) mRNA, complete cds	M57414	162321	none found	
Human NF-IL6-beta	M83667	116898	none found	

protein mRNA, complete cds				
Human obese (ob) mRNA, complete cds	U18915	164160	-1387 G/A	
Human obese (ob) mRNA, complete cds	U18915	164160	1-BP DEL	frameshift
Human obese (ob) mRNA, complete cds	U18915	164160	A -> G + 19 exon 1	
Human obese (ob) mRNA, complete cds	U18915	164160	C(-188)A	
Human obese (ob) mRNA, complete cds	U18915	164160	ARG105TRP	
Human obese (ob) mRNA, complete cds	U18915	164160	Glu-126-Gln	
Human obese (ob) mRNA, complete cds	U18915	164160	Ser-91-Ser	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	CCC[Pro]- >CCG[Pro] at codon 145	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	intron 1 a variant (C->T)	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	(258) G-to-A	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	(TAC->TAT) in codon 215	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	-120 (G->T)	

Human pancreatic beta-cell glucokinase	M88011	138079	-194 (A-->G)
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	-282 (C-->T)
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	-30 G/A
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	10-bp (base pair) deletion in exon 3;
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	33-bp deletion at the exon 5/intron 5 junction
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	403 (C-->G)
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	603 (G-->T)
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	A--> G 244
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	C--> T 8 bp 3' to the exon 9
mRNA, complete cds			
Human pancreatic beta-cell glucokinase	M88011	138079	compound imperfect dinucleotide repeat
mRNA, complete cds			
Human pancreatic	M88011	138079	G--> A 13

beta-cell glucokinase mRNA, complete cds	M88011	138079	IVS4DS, 15-BP DEL
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	TGG257->CGG257
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	ARG18TER
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	GLU265TER
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	GLU279TER
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	GLY261ARG
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	GLY299ARG
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	SER131PRO
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	THR228MET
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	VAL455MET

mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Val62Ala
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Thr209-->Met209
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Gly261-->Glu261
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Arg36-->Trp36
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Glu70-->Lys
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Ser131-->Pro
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Ala188-->Thr
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Trp257-->Arg
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Lys414-->Glu
mRNA, complete cds Human pancreatic beta-cell glucokinase	M88011	138079	Asp4-->Asn

Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		Ala11Thr
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	(CA) <sub>n</sub>	
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	2-BP DEL/1-BP INS	
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ALU INS, CODON 877	
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	T/C fifth intron	
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG796TRP	
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU298LYS	
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG185GLN	

Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU128ALA
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG227LEU
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	CYS82TYR
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU681HIS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ALA116THR
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE806SER
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	THR151MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ASN118LYS

complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE128LEU
complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	THR151MET
complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU191LYS
complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE612SER
complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	LEU773ARG
complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG185TER
complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLY670GLU
complete cds Human parathyroid cell calcium-sensing receptor mRNA	U20759	601199	PRO40ALA

receptor mRNA, complete cds			
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG22GLN
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	THR139MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLY144GLU
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG63MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG67CYS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE78CYS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	LYS47ASN
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	A986S

calcium-sensing receptor mRNA, complete cds				
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		1148G-A
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		1-BP DEL
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		1-BP INS
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		frameshift
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		2-BP INS
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		3340A-T
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		37-BP DEL
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	451C-T	Pro-Ser
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	9-BP INS	CODON 815, PRO-ASN-ILE INS
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		nonsense

homolog (PTC) mRNA, complete cds			codon 361
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	Gln816Leu
Human PTH2	U25128	601469	none found
parathyroid hormone receptor mRNA, complete cds	U47050	602345	none found
Human putative calcium influx channel (htp3) mRNA, complete cds	M91211	600214	none found
Human receptor for advanced glycosylation end products (RAGE) mRNA, partial cds	M12654	139200	HaeIII
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	(TAAA)n
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	MspI

complete cds	M12654	139200	StyI
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	T to C at Cys283
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	THR420LYS
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	J00306	182450	BamHI intron
Human somatostatin 1 gene and flanks	J00306	182450	EcoRI 3'
Human somatostatin 1 gene and flanks	U00968	184756	none found
Human SREBP-1 mRNA, complete cds	U46768	601185	none found
Human stanniocalcin mRNA, complete cds	M74047	264600	1-BP DEL, PRO251DEL
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	null allele
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	ARG246TRP
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	GLY115ASP

reductase 2 (SRD5A2)			
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	GLY183SER
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	GLY196SER
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	HIS231ARG
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	LEU55GLN
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	MET157DEL
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	THR228ALA
mRNA, complete cds			
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	ARG227TER
mRNA, complete cds			
Human steroidogenic acute regulatory protein (STAR) mRNA, complete cds	U17280	600617	840delA
Human steroidogenic acute regulatory protein (STAR) mRNA, complete cds	U17280	600617	IVS4AS.T-A.-11

Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	GLN258TER
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	ARG182LEU
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	1-BP DEL, 261T
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS2, 1-BP INS, T, +3
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	D203A
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U02031	600481	none found
Human sterol regulatory element binding protein-2 mRNA, complete cds	L07594	600742	none found
Human transforming growth factor-beta type III receptor (TGF-beta)	U53506	601413	none found
Human type II iodothyronine deiodinase mRNA,			

complete cds Human type II serine/threonine kinase receptor mRNA, complete cds	U20165	600799	none found
Human vascular endothelial growth factor related protein VEGF mRNA, complete cds	U43142	601528	none found
Human VEGF related factor isoform VRF186 precursor (VRF)	U43368	601398	none found
mRNA, complete cds Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	1-BP INS
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	Dinucleotide repeat
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	ARG249TER
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	VAL248ASN
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	TRP171TER

steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2		M21023	none found
IGF-2 receptor	Y00285	147280	17 bp deletion
IGF-2 receptor	Y00285	147280	CA repeat polymorphisms
IGF-2 receptor	Y00285	147280	SacI
IGF-2 receptor	Y00285	147280	Asn2020Ser
IGF-2 receptor	Y00285	147280	GLY1449VAL
IGF-2 receptor	Y00285	147280	GLY1464GLU
Insulin receptor	M10051	147670	10 base pair deletion
Insulin receptor	M10051	147670	1058 CAC->CAT
Insulin receptor	M10051	147670	12 additional base
Insulin receptor	M10051	147670	pairs in exon 3
Insulin receptor	M10051	147670	3' flanking intron (T- ->G at position 74)
Insulin receptor	M10051	147670	400-bp insertion
			intron
Insulin receptor	M10051	147670	8-BP DEL
Insulin receptor	M10051	147670	A-G,-2 inton 4
Insulin receptor	M10051	147670	Alu
Insulin receptor	M10051	147670	codon 1058 (CAC-- ->CAT)
			deletion of the gene
Insulin receptor	M10051	147670	EcoRI
Insulin receptor	M10051	147670	EX14DEL
Insulin receptor	M10051	147670	Four RSAI
Insulin receptor	M10051	147670	G->T at position 13, 5' intron

Insulin receptor	M10051	147670	Gln276 (CAA->CAG)	silent
Insulin receptor	M10051	147670	Gly8 (GGA-->GGG)	silent
Insulin receptor	M10051	147670	His1068 (CAC->CAT)	silent
Insulin receptor	M10051	147670	Insertion intron 9, Nsil	
Insulin receptor	M10051	147670	Nsil	
Insulin receptor	M10051	147670	Short repeats in intron 2	
Insulin receptor	M10051	147670	Thr789 (ACG-->ACA)	silent
Insulin receptor	M10051	147670	GLY996VAL	
Insulin receptor	M10051	147670	GLU672TER	
Insulin receptor	M10051	147670	LYS460GLU	
Insulin receptor	M10051	147670	Asn461Thr	
Insulin receptor	M10051	147670	MET1153ILE	
Insulin receptor	M10051	147670	ARG866PRO	
Insulin receptor	M10051	147670	TRP1200SER	
Insulin receptor	M10051	147670	TRP737SER	
Insulin receptor	M10051	147670	ALA1134THR	
Insulin receptor	M10051	147670	LYS121TER	
Insulin receptor	M10051	147670	ILE119MET	
Insulin receptor	M10051	147670	ARG735SER	
Insulin receptor	M10051	147670	ARG981GLN	
Insulin receptor	M10051	147670	ARG988TER	
Insulin receptor	M10051	147670	TRP412SER	
Insulin receptor	M10051	147670	ALA1135GLU	
Insulin receptor	M10051	147670	ARG1000TER	
Insulin receptor	M10051	147670	ASN462SER	
Insulin receptor	M10051	147670	CODON 897	

		nonsense		
Insulin receptor	M10051	147670	HIS209ARG	
Insulin receptor	M10051	147670	TRP133TER	
Insulin receptor	M10051	147670	Asn281del	
Insulin receptor	M10051	147670	his252arg	
Insulin receptor	M10051	147670	Leu999del	
Insulin receptor	M10051	147670	glyc1008val	
Insulin receptor	M10051	147670	glu1131arg	
Insulin receptor	M10051	147670	Leu193Pro	
Insulin receptor	M10051	147670	ser462asp	
Insulin receptor	M10051	147670	GLY31ARG	
Insulin receptor	M10051	147670	PHE382VAL	
Insulin receptor	M10051	147670	LEU233PRO	
Insulin receptor	M10051	147670	Arg86ter	
Insulin receptor	M10051	147670	Ter1193Leu	
Insulin receptor	M10051	147670	Leu1178Pro	
Insulin receptor	M10051	147670	ARG1174GLN	
Insulin receptor	M10051	147670	VAL985MET	
Insulin receptor	M10051	147670	GLY366ARG	
Insulin receptor	M10051	147670	VAL28ALA	
Insulin receptor	M10051	147670	Asp59Gly	
Insulin receptor	M10051	147670	Leu62Pro	
Insulin receptor	M10051	147670	ARG372TER	
Insulin receptor	M10051	147670	ASN15LYS	
Insulin receptor	M10051	147670	ARG1152GLN	
Insulin-like growth factor 1 receptor	X04434	147370	none found	
Insulin-like growth factor 2	J03242	147470	(CA) <sub>n</sub>	
Insulin-like growth factor 2	J03242	147470	Apal 3'UTR	

Insulin-like growth factor 2	J03242	147470		Avall
Insulin-like growth factor 2	J03242	147470		BamHI
Insulin-like growth factor 2	J03242	147470		Eco RI
Insulin-like growth factor 2	J03242	147470	Sst I	
Insulin-like growth factor 2	J03242	147470	VNTR upstream	
insulin-like growth protein 1	NM_000596	146730	none found	
Insulin-like growth factor 1	M29644	147440	(CA) <sub>n</sub>	
Insulin-like growth factor 1	M29644	147440	EcoRV	
Insulin-like growth factor 1	M29644	147440	EX4,5 DEL	
Insulin-like growth factor 1	M29644	147440	HindIII	
Insulin-like growth factor 1	M29644	147440	PvuII	
interleukin 1 receptor	M27492	147810	PstI	
(IL-1R)	M20566	147880	dinucleotide (CA)	
interleukin 6 receptor (IL-6R) (20)	D50582		none found	
inward rectifier K channel	NM_002303	601007	(CTTTA) <sub>n</sub>	
leptin receptor/LEPR	NM_002303	601007	3'-UTR	

leptin receptor/LEPR	NM_0023 03	601007	insertion/deletion
leptin receptor/LEPR	NM_0023 03	601007	CA microsatellite repeat in intron 3, IVS16, G-A, +1
leptin receptor/LEPR	NM_0023 03	601007	K109R
leptin receptor/LEPR	NM_0023 03	601007	K656N
leptin receptor/LEPR	NM_0023 03	601007	Ala976Asp
leptin receptor/LEPR	NM_0023 03	601007	Gln223Arg
leptin receptor/LEPR	NM_0023 03	601007	Lys109Arg
leptin receptor/LEPR	NM_0023 03	601007	Lys656Asn
leptin receptor/LEPR	NM_0023 03	601007	Pro1019Pro
leptin receptor/LEPR	NM_0023 03	601007	Ser343Ser
leptin receptor/LEPR	NM_0023 03	601007	Ser492Thr
leptin receptor/LEPR	NM_0023 03	601007	GLN23ARG
Leukocyte integrin alpha-J	Y0796	153370	none found
Leukocyte integrin alpha-X	M81695	151510	none found
Lipoprotein lipase	M15856	238600	INS
Lipoprotein lipase	M15856	238600	(TTTA)n

Lipoprotein lipase	M15856	238600	-39T-C
Lipoprotein lipase	M15856	238600	-93T-G
Lipoprotein lipase	M15856	238600	1-BP DEL
Lipoprotein lipase	M15856	238600	1-BP DEL, 221G
Lipoprotein lipase	M15856	238600	2-KB DUP
Lipoprotein lipase	M15856	238600	6-KB DEL
Lipoprotein lipase	M15856	238600	C->A -3 nitron 6
Lipoprotein lipase	M15856	238600	C-10-T -480
Lipoprotein lipase	M15856	238600	C1338->A
Lipoprotein lipase	M15856	238600	C1595->G
Lipoprotein lipase	M15856	238600	G579->A
Lipoprotein lipase	M15856	238600	HindIII
Lipoprotein lipase	M15856	238600	IVS1, G-C, +1
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1
Lipoprotein lipase	M15856	238600	ALA176THR
Lipoprotein lipase	M15856	238600	GLY Y188GLU
Lipoprotein lipase	M15856	238600	TRP64TER
Lipoprotein lipase	M15856	238600	ARG75SER
Lipoprotein lipase	M15856	238600	TYR73TER
Lipoprotein lipase	M15856	238600	SER172CYS
Lipoprotein lipase	M15856	238600	TRP382TER
Lipoprotein lipase	M15856	238600	TYR61TER
Lipoprotein lipase	M15856	238600	ASP204GLU
Lipoprotein lipase	M15856	238600	GLY142GLU
Lipoprotein lipase	M15856	238600	GLY195GLU
Lipoprotein lipase	M15856	238600	ILE194THR
Lipoprotein lipase	M15856	238600	ARG243HIS
Lipoprotein lipase	M15856	238600	ASP156GLY
Lipoprotein lipase	M15856	238600	SER447TER
Lipoprotein lipase	M15856	238600	Cys239-->stop

Lipoprotein lipase	M15856	238600	His183->Gln
Lipoprotein lipase	M15856	238600	ARG243CYS
Lipoprotein lipase	M15856	238600	ASN291SER
Lipoprotein lipase	M15856	238600	E163G
Lipoprotein lipase	M15856	238600	E410K
Lipoprotein lipase	M15856	238600	ASP180GLU
Lipoprotein lipase	M15856	238600	ASP250ASN
Lipoprotein lipase	M15856	238600	Pro157 Arg
Lipoprotein lipase	M15856	238600	Glu118 Glu
Lipoprotein lipase	M15856	238600	Glu421Lys
Lipoprotein lipase	M15856	238600	CYS418TYR
Lipoprotein lipase	M15856	238600	LEU365VAL
Lipoprotein lipase	M15856	238600	ALA334THR
Lipoprotein lipase	M15856	238600	ASP9 ASN
Lipoprotein lipase	M15856	238600	ILE225THR
Lipoprotein lipase	M15856	238600	TRP86ARG
Lipoprotein lipase	M15856	238600	SER244THR
Lipoprotein lipase	M15856	238600	GLN106TER
Lipoprotein lipase	M15856	238600	PRO207LEU
Lipoprotein lipase	M15856	238600	Tyr262->His
MELANOCORTIN 4 RECEPTOR	155541	4-BP DEL NT631	
MELANOCORTIN 4 RECEPTOR	155541	4-BP INS, NT732	
MELANOCORTIN 4 RECEPTOR	155541	TYR35TER	
MELANOCORTIN 4 RECEPTOR	155541	ASP37VAL	
MELANOCORTIN 4 RECEPTOR	155541	Thr112Met	
MELANOCORTIN 4	155541	Ile137Thr	

RECEPTOR Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	I-BP DEL	frameshift at codon 337
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	I-BP DEL	frameshift at codon 459
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	760->G760	Ile180->Val180
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	A DEL,+3 intron 5	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	C944->T944	Ala241->Val241
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983		ARG537TER
natriuretic peptide receptor B/guanylylate cyclase B	L13436	108961	none found	
NEUROMEDIN K	M89473	162332	none found	
RECEPTOR Neuropeptide Y receptor Y5	U94320	602001	none found	
Nicotinic, Cholinergic receptor alpha 2	118502	U62431	none found	
Norepinephrine transporter	M65105	163970	none found	
Opioid Receptor,	U17298	165196	none found	

Kappa-1; Oprk1	X64878	167035	C to T exon 3
Oxytocin receptor	X64878	167035	CA repeat
Oxytocin receptor		167413	none found
PAIRRED BOX GENE			
Pancreatic lipase (PNLIP) (Dietary supplement)	M93285	246600	C-to-T promoter
Pancreatic lipase (PNLIP) (Dietary supplement)	M93285	246600	Ser267Phe
Pancreatic lipase (PNLIP) (Dietary supplement)	M93285	246600	Thr383Met
Parathyroid hormone V00597	168450	DraII	
Parathyroid hormone V00597	168450	G-C, +1	
Parathyroid hormone V00597	168450	EX2DEL	
Parathyroid hormone V00597	168450	(AAA)n intron 1	
Parathyroid hormone V00597	168450	BstB I	
Parathyroid hormone V00597	168450	Pst I	
Parathyroid hormone V00597	168450	Tag I	
Parathyroid hormone V00597	168450	XmnI	
Peroxidase (thyroid) Y00406	274500	CYS18ARG	
Peroxidase (thyroid) Y00406	274500	1-BP INS	
Peroxidase (thyroid) Y00406	274500	1-BP INS, 2505C	
Peroxidase (thyroid) Y00406	274500	20-BP DUP	
Peroxidase (thyroid) Y00406	274500	frameshift	
Peroxidase (thyroid) Y00406	274500	Val->Ala	
Peroxidase (thyroid) Y00406	274500	frameshift	
Peroxidase (thyroid) Y00406	274500	4-BP INS	
Peroxidase (thyroid) Y00406	274500	50 bp repeat in	
Peroxidase (thyroid) Y00406	274500	intron 10	
Peroxidase (thyroid) Y00406	274500	Acyl intron 8	
Peroxidase (thyroid) Y00406	274500	Eco RI	

Peroxidase (thyroid)	Y00406	274500		
Peroxidase (thyroid)	Y00406	274500	ARG648GLN	
Peroxidase (thyroid)	Y00406	274500	GLU799LYS	
Peroxidase (thyroid)	Y00406	274500	GLY590SER	
Peroxidase (thyroid)	Y00406	274500	ILE447PHE	
Peroxidase (thyroid)	Y00406	274500	TYR453ASP	
Peroxidase (thyroid)	Y00406	274500	ARG540TER	
Peroxosome NM_00500	601487	1-BP DEL, 472A	Frameshift	
proliferative activated receptor, gamma/PPARG				
Peroxosome NM_00500	601487		PRO115GLN	
proliferative activated receptor, gamma/PPARG	37			
Peroxosome NM_00500	601487		ARG288HIS	
proliferative activated receptor, gamma/PPARG	37			
Peroxosome NM_00500	601487		GLN286PRO	
proliferative activated receptor, gamma/PPARG	37			
Peroxosome NM_00500	601487		LYS319TER	
proliferative activated receptor, gamma/PPARG	37			
Peroxosome NM_00500	601487		PRO12ALA	
proliferative activated receptor, gamma/PPARG	37			
Peroxosome NM_0062	172425		TaqIB	
phospholipid transfer				

protein/PLTP	27	118470	A1503G
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G-A splice junction alternative splice
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G-A splice junction alternative splice
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G1696A
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	C-T transition in intron 12
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	EconNI
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G->A intron 14
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G-A transition in intron 15
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G1533A
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	INS T alternative (intron/exon14) splice
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	StuI

plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	T->G tyr57stop
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	TaqI A
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	TaqIB in intron 1
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	268 Arg->STOP
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G181X
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	Asp 442 to Gly
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	1405V
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	Lys309-Stop
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	Val421-Ile
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	R451Q
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	ASPA442GLY

ester transfer protein/CETP	78			
potassium channel beta subunit	U25138	603951	none found	
POTASSIUM CHANNEL INWARDLY RECTIFYING SUBFAMILY J MEMBER 11; KCNJ11	X83582	600734	none found	LEU147PRO
Potassium channel K13.4		176795	none found	
PRO-MELANIN-CONCENTRATING HORMONE				
progesterone receptor	M15716	264080	none found	
Prolactin receptor	V00566	176760	BglII	
Prolactin receptor	M31661	176761	none found	
protein kinase C beta 1	X06318	176970	none found	
Pyridoxine (Pyridoxal Kinase)	U89606	179020	none found	
RAR related orphan receptor A/RORA	NM_002943	600825	none found	
RAR related orphan receptor B/RORB	43*****	601972	none found	
RAR related orphan receptor C/RORC	NM_005060	602943	none found	
REGUCALCIN		300212	none found	
retinoic acid receptor alpha/RARA	NM_000964	180240	7-base deletion frameshift	

retinoic acid receptor alpha/RARA	NM_0009 64	180240	codon 411 C to T
retinoic acid receptor alpha/RARA	NM_0009 64	180240	Arg272Gln
retinoic acid receptor alpha/RARA	NM_0009 64	180240	Met297Leu
RETINOIC ACID RECEPTOR BETA-2	X07282	180220	none found
retinoic acid receptor gamma/RARG	M57707	180190	none found
Retinoic acid receptor, gamma I	M38258	180190	none found
retinoid X receptor alpha/RXRA	NM_0029 57	180245	none found
retinoid X receptor gamma/RXRG	U38480	180247	none found
Retinoid X receptor- gamma	U38480	180247	none found
serotonin 5-HT receptors 5-HT1C, G protein-coupled	U49516	312861	2831T > G in the 3'
serotonin 5-HT receptors 5-HT1C, G protein-coupled	U49516	312861	CYS23SER
SODIUM-IODIDE SYMPORTER		601843	THR354PRO
SODIUM-IODIDE SYMPORTER		601843	CYS272TER
SODIUM-IODIDE SYMPORTER		601843	GLN267GLU
SODIUM-IODIDE		601843	TYR531TER

SYMPORTER		GLY93ARG
SODIUM-IODIDE SYMPORTER	601843	
SODIUM-IODIDE SYMPORTER	601843	
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na <sup>+</sup> /H <sup>+</sup> , anilinide sensitive)	X76180	600228
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na <sup>+</sup> /H <sup>+</sup> , anilinide sensitive)	X76180	600228
Somatostatin receptor 1/G protein-coupled	M81829	182451
Somatostatin receptor 2	M81830	182452
Somatostatin receptor 3/adenylyl cyclase coupled	M96738	182453
Somatostatin receptor 5 subtype 2	D16827 L05521	182455
Steroid 5 alpha reductase 1	M32313	184753
STEROID HORMONE RECEPTOR ERR1	X51416	601998
Steroid receptor coactivator (SRC-1)	U40396	602691

Sucrase-isomaltase	X61597	222900		GLN1098PRO
Tachykinin NK1 receptor/TACR1	M81797	162323	none found	
thyroid stimulating hormone receptor	NM_0003 69	603372	18-BP DEL, 4-BP frameshift INS	
thyroid stimulating hormone receptor	NM_0003 69	603372	1953-1957 deletion Asp at 619 deleted	
thyroid stimulating hormone receptor	NM_0003 69	603372	2 bases deleted of codon 655	
thyroid stimulating hormone receptor	NM_0003 69	603372	C233A	
thyroid stimulating hormone receptor	NM_0003 69	603372	duplication of nucleotides -346 to -330	
thyroid stimulating hormone receptor	NM_0003 69	603372	G to C +3 intron 6	
thyroid stimulating hormone receptor	NM_0003 69	603372	G-A -4 intron	
thyroid stimulating hormone receptor	NM_0003 69	603372	TaqI	
thyroid stimulating hormone receptor	NM_0003 69	603372	[leu677va]	
thyroid stimulating hormone receptor	NM_0003 69	603372	Astn715Asp	
thyroid stimulating hormone receptor	NM_0003 69	603372	Asp219Glu	
thyroid stimulating hormone receptor	NM_0003 69	603372	Asp727Glu	
thyroid stimulating hormone receptor	NM_0003	603372	Lys723 Met	

hormone receptor	69	NM_0003	603372	Phe197Ile
thyroid stimulating		NM_0003		
hormone receptor	69			
thyroid stimulating				
hormone receptor	69	NM_0003	603372	LYS183ARG
thyroid stimulating				
hormone receptor	69	NM_0003	603372	ILE167ASN
thyroid stimulating				
hormone receptor	69	NM_0003	603372	PRO162ALA
thyroid stimulating				
hormone receptor	69	NM_0003	603372	PHE63ILEU
thyroid stimulating				
hormone receptor	69	NM_0003	603372	CYS67TYR
thyroid stimulating				
hormone receptor	69	NM_0003	603372	VAL509ALA
thyroid stimulating				
hormone receptor	69	NM_0003	603372	ALA623ILE
thyroid stimulating				
hormone receptor	69	NM_0003	603372	ASP619GLY
thyroid stimulating				
hormone receptor	69	NM_0003	603372	ALA553THR
thyroid stimulating				
hormone receptor	69	NM_0003	603372	SER281ILE
thyroid stimulating				
hormone receptor	69	NM_0003	603372	SER281ASN
thyroid stimulating				
hormone receptor	69	NM_0003	603372	ASP633HIS
thyroid stimulating				
hormone receptor	69	NM_0003	603372	LEU629PHE
thyroid stimulating				
hormone receptor	69	NM_0003	603372	SER505ASN
thyroid stimulating				
hormone receptor	69			

thyroid stimulating hormone receptor	NM_0003 69	603372	TRP546TER
thyroid stimulating hormone receptor	NM_0003 69	603372	MET453THR
thyroid stimulating hormone receptor	NM_0003 69	603372	ASP36HIS
thyroid stimulating hormone receptor	NM_0003 69	603372	alanine 623 to valine
thyroid stimulating hormone receptor	NM_0003 69	603372	asp727glu
thyroid stimulating hormone receptor	NM_0003 69	603372	CAG
thyroid stimulating hormone receptor	NM_0003 69	603372	[Glu]227CAT
thyroid stimulating hormone receptor	NM_0003 69	603372	[His]
thyroid stimulating hormone receptor	NM_0003 69	603372	GCG
thyroid stimulating hormone receptor	NM_0003 69	603372	[Ala]460GCA
thyroid stimulating hormone receptor	NM_0003 69	603372	[Ala]
thyroid stimulating hormone receptor	NM_0003 69	603372	GGT[Arg]201C
thyroid stimulating hormone receptor	NM_0003 69	603372	AT[His]
thyroid stimulating hormone receptor	NM_0003 69	603372	ARG109GLN
thyroid stimulating hormone receptor	NM_0003 69	603372	CYS41SER
thyroid stimulating hormone receptor	NM_0003 69	603372	ASP410ASN
thyroid stimulating hormone receptor	NM_0003 69	603372	CYS390TRP
thyroid stimulating hormone receptor	NM_0003 69	603372	GLN324TER
thyroid stimulating hormone receptor	NM_0003 69	603372	PHE325LEU
Transferin receptor	X01060	190010	Bcll

(p90, CD71)	Transferrin receptor	X01060	190010	RsaI
(p90, CD71)	Transferrin receptor	X01060	190010	Ser142-->Gly
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	2-BP INS frameshift
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	a-4t intron 3
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	a7g intron 2
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	ACA to GCA Thr to Ala
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	base in the polyadenine tract of exon 3
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	GG to TT Stop codon
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	THR315MET
(p90, CD71)	transforming growth factor, beta receptor II (70-80kD)/TGFBR2	M85079	190182	codon 128
(p90, CD71)	TUBBY, MOUSE, HOMOLOG		601197	none found

type I 5 iodothyronine deiodinase [human, mRNA, 2222 nt]	S48220	147892	none found
Type V cyclic nucleotide phosphodiesterase receptor/VDR	AJ004865	603310	none found
vitamin D receptor/VDR	NM_000376	601769	A(T/C)G putative translation start site
vitamin D receptor/VDR	NM_76	601769	Apal
vitamin D receptor/VDR	NM_000376	601769	BsmI
vitamin D receptor/VDR	NM_000376	601769	FokI
vitamin D receptor/VDR	NM_000376	601769	PvuII
vitamin D receptor/VDR	NM_000376	601769	TaqI
vitamin D receptor/VDR	NM_000376	601769	XbaI
vitamin D receptor/VDR	NM_000376	601769	ARG-GLY
vitamin D receptor/VDR	NM_000376	601769	GLY30ASP
vitamin D receptor/VDR	NM_000376	601769	TYR292TER
vitamin D receptor/VDR	NM_000376	601769	ARG77GLN
vitamin D receptor/VDR	NM_000376	601769	ARG39ICYS

vitamin D receptor/VDR	NM_000376	601769	ILE14SER
vitamin D receptor/VDR	NM_000376	601769	ARG27ILEU
vitamin D receptor/VDR	NM_000376	601769	GLN149TER
vitamin D receptor/VDR	NM_000376	601769	ARG30TER
vitamin D receptor/VDR	NM_000376	601769	GLY46ASP
vitamin D receptor/VDR	NM_000376	601769	codon 352
vitamin D receptor/VDR	NM_000376	601769	HIS305GLN
vitamin D receptor/VDR	NM_000376	601769	ARG47GLN
vitamin D receptor/VDR	NM_000376	601769	
3beta hydroxysteroid dehydrogenase	M27137	109715	none found
METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1027T-G
	U09806	236250	1084C-T

Table 23. Identified Variances in Genes or Related Pathways involved in Cardiovascular and Renal Disease

METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1298A-C
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1711C-T
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	677C-T ala-->val
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	983A-G
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	exon 7 Ala-->Glu
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	A225V
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	ARG158GLN

5,10-	U09806	236250		ARG184TER
METHYLENETETRA				
HYDROFOLATE				
REDUCTASE	L22214	102775		
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	1777C/A	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	1827C/T	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	1904C/T	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2126G/T	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2294insT	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	267 + 275C/T	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2776C/T	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2777del36	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2819T/G	

Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	805T/G
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	48T/A
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	716T/G
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	1083C/T
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	405C/T
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	432C/T
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	Gly-340-Ser
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	none found
Adenosine A2b Receptor; Adora2b/G protein-coupled	X68487	600446	none found
Adenosine A3 Receptor; Adora3/G protein-coupled	L20463	600445	none found
alpha-1b-adrenergic receptor; ADRA1B	L31773	104220	none found
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	-1291

alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	DraI
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	HhaI
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	MspI promoter
alpha-2a-adrenergic receptor; ADRA2A	AF005900	104260	none found
alpha-2b-adrenergic receptor; ADRA2B	J03853	104250	(CA)n
alpha-2c-adrenergic receptor; ADRA2C			
androgen receptor	M20132	313700	Hind III
androgen receptor	M20132	313700	(CAA)n
androgen receptor	M20132	313700	(CAG)n
androgen receptor	M20132	313700	(GGN)n
androgen receptor	M20132	313700	5-KB DEL, EX F,G
androgen receptor	M20132	313700	5-KB DEL,EX E
androgen receptor	M20132	313700	C>T within exon B
androgen receptor	M20132	313700	silent
androgen receptor	M20132	313700	CAG340TAG
androgen receptor	M20132	313700	Del T at 326
androgen receptor	M20132	313700	del1893
androgen receptor	M20132	313700	G Codon 210 A
androgen receptor	M20132	313700	G Codon 211 A
androgen receptor	M20132	313700	G2314A
androgen receptor	M20132	313700	ala>thr
androgen receptor	M20132	313700	G2677A
androgen receptor	M20132	313700	HhaI
androgen receptor	M20132	313700	HpaII
androgen receptor	M20132	313700	Insert of 69 nucleotides
androgen receptor	M20132	313700	MaeII
androgen receptor	M20132	313700	PARTIAL DEL
androgen receptor	M20132	313700	Stu I



androgen receptor	M20132	313700	MET786VAL
androgen receptor	M20132	313700	PHE82TYR
androgen receptor	M20132	313700	PRO546SER
androgen receptor	M20132	313700	pro892ser
androgen receptor	M20132	313700	SER647ASN
androgen receptor	M20132	313700	THR877ALA
androgen receptor	M20132	313700	THR877SER
androgen receptor	M20132	313700	TRP717TER
androgen receptor	M20132	313700	TRP794TER
androgen receptor	M20132	313700	TYR761CTS
androgen receptor	M20132	313700	val 581 phe
androgen receptor	M20132	313700	VAL730MET
androgen receptor	M20132	313700	VAL865LEU
androgen receptor	M20132	313700	VAL865MET
angiotensin converting enzyme dipeptidyl carboxypeptidase	NM_000789	106180	250-bp in/del
angiotensin converting enzyme dipeptidyl carboxypeptidase	NM_000789	106180	3 in the 3' UTR
angiotensin converting enzyme dipeptidyl carboxypeptidase	NM_000789	106180	5 in the 5' region
angiotensin converting enzyme dipeptidyl carboxypeptidase	NM_000789	106180	Pst I RFLP
angiotensin receptor 1A/GTR1A	M87290	106165	1166A-C
Anticoagulant Protein C (inactivator of	X02750	176860	-1641 A/G

coagulation factors Va and VIIIa)				
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	(6376 GT) in intron 7	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	-1654 C/T	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	1-BP DEL 42AA	frameshift
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	1432 C->T	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	2-BP INS, TT, NT6139	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	3350insA	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	3351del4	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	40 T->G	

C (inactivator of coagulation factors Va and VIIa)	X02750	176860	5-bp deletion nucleotides 3455 to 3459
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	6128 T->C
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	6216 C->T
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	6246 G->A
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	7253 C->T
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	8589 G->A
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	8631 C->T

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/G at -641
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/T at -1476
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/T at -476
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	C insertion: CAT->CCAT
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	C/T at -654
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	CCT to CCC
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Pro-21 Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	deletion of 5 nucleotides (nt) (CCCCG) in the end of exon VI G3079A
Anticoagulant Protein C (inactivator of coagulation factors Va			

and VIIIa)	X02750	176860	G8857 deletion
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	IVS G, C-T, +9
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	MspI
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	T-C, -14
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	230 Arg-Lys
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	254 Thr-Ile
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	325 Val-Ala
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	359 Asp-Asn

coagulation factors Va and VIIa)			
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	364 Met>Trp, 378 Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Ala136->Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ALA259VAL
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ALA267THR
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Arg 157>Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ARG12TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ARG169TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ARG178GLN

C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ARG178TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ARG230CYS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Arg286His
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ARG306TER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	arg352try
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Asn102-->Lys
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Asn1329-->Thr

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Asp359Asn
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Asp359Asn
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Cys-331 to Arg
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Cys78-->Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	GLN184HIS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	GLU20ALA
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Gly-376 Asp
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Gly232Ser
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	

and VIIa) Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	GLY292SER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	GLY301SER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Gly350Arg
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	HIS107PRO
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	ILE403MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	LEU223PHE
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Lys150 deletion
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	
Anticoagulant Protein C (inactivator of			Met365Ile

coagulation factors Va and VIIa)	X02750	176860	Phe139Val
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	PRO168LEU
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	PRO247LEU
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Pro279Leu
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Pro327Leu
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Q132X
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Ser270Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Thr298-->Met

C (inactivator of coagulation factors Va and VIIa)	X02750	176860	TRP402CYS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Tyr399His
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	VAL297MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	VAL34MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	X02750	176860	Y124C
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIa)	Y00692	176880	G to T at codon Cys598
Anticoagulant protein S	Y00692	176880	IVS11, A-G, -9
Anticoagulant protein S	Y00692	176880	+1 G to A in intron d
Anticoagulant protein S	Y00692	176880	+3 A to C in intron j

Anticoagulant protein	Y00692	176880	1 nt (T) insertion at codon 265
Anticoagulant protein	S	176880	delete T 635
Anticoagulant protein	S	176880	G to A at codon Tp465
Anticoagulant protein	S	176880	IVS10, G-A, +5
Anticoagulant protein	S	176880	Arg410 (CGA)->Stop
Anticoagulant protein	S	176880	Lys368stop
Anticoagulant protein	S	176880	Ala 484->Pro
Anticoagulant protein	S	176880	Arg506->Gln
Anticoagulant protein	S	176880	ARG520GLY
Anticoagulant protein	S	176880	ASN217SER
Anticoagulant protein	S	176880	Cys145Tyr
Anticoagulant protein	S	176880	Cys200Ser
Anticoagulant protein	S	176880	Cys408Ser
Anticoagulant protein	S	176880	Cys625Arg
Anticoagulant protein	S	176880	GLN238TER
Anticoagulant protein	S	176880	Glu26Ala

Anticoagulant protein S	Y00692	176880	Gly340Asp
Anticoagulant protein S	Y00692	176880	Gly54Glu
Anticoagulant protein S	Y00692	176880	LYS155GLU
Anticoagulant protein S	Y00692	176880	Lys155Glu
Anticoagulant protein S	Y00692	176880	Lys9Glu
Anticoagulant protein S	Y00692	176880	Ser283Pro
Anticoagulant protein S	Y00692	176880	SER406PRO
Anticoagulant protein S	Y00692	176880	Ser460Pro
Anticoagulant protein S	Y00692	176880	TER636TYR, 649TER
Anticoagulant protein S	Y00692	176880	Tyr595stop
Anticoagulant protein S	Y00692	176880	Val703-->Ile
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C2316-->A
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	(TG)n
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	1-BP DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	frameshift
			1-BP DEL

(including Ag(x) antigen)			
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	1-BP DEL, FS1425TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	3'-VNTR
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	A---G second intron +722
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ApalI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Avall
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	BalI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C to T -516
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C-->T change at nucleotide 7064,
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	CTT3517..>CTG
Apolipoprotein B (including Ag(x)	J02610	107730	EcoRI

Apolipoprotein B (including Ag(x) antigen)	J02610	107730	EX21DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GCC3527-->GCT
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	HincII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	INS AND DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ins/Del
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	intron 20 Alu repeat
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	MspI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	PvuII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	SstI second intron
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	T-to-C 1981

Apolipoprotein B (including Ag(x) antigen)	J02610	107730	XbaI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	A3371V
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Arg----Glu3611
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ARG1306TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ARG2058TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ARG2495TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ARG3500GLN
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ARG3531CYS
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ASN1728THR
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Asn4311----Ser
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Cys646-->Tyr

(including Ag(x) antigen)			
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Gln 3405 Glu
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLN1450TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLN2252TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Glu207->Lys
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLU4034ARG
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Glu4154
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Leu 3350 Leu
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Leu-Ala-Leu signal peptide (SP) insertion/delete D
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	LEU304TER

Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Q3405E
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ser 3252 Gl	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ser 3455 Arg	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	SER(729)TER	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Thr71->Ile	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Trp66-->Gly	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Val 3396 Met	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	VAL1829CYS	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Val591-->Ala	
apolipoprotein EAPOE	NM_0000 41	107741	7 AA insertion; tandem repeat of residues 121-127	
apolipoprotein	NM_0000	107741	A178G Threonine42Ala	

E/APOE apolipoprotein E/APOE	NM_00000 41	107741		A490C Lysine146Gluta mine
apolipoprotein E/APOE	NM_00000 41	107741		A490G Lysine146Gluta mine
apolipoprotein E/APOE	NM_00000 41	107741		A490C Lysine146Gluta mic Acid
apolipoprotein E/APOE	NM_00000 41	107741		A940C Sérine296Argini ne
apolipoprotein E/APOE	NM_00000 41	107741	Aintron3G substitution creates 2 abnormally spliced mRNA forms	Aintron3G substitution creates 2 abnormally spliced mRNA forms
apolipoprotein E/APOE	NM_00000 41	107741	C305G Proline84Argini ne	C305G Proline84Argini ne
apolipoprotein E/APOE	NM_00000 41	107741	C460A Arginine136Ser ine	C460A Arginine136Ser ine
apolipoprotein E/APOE	NM_00000 41	107741	C478T Arg142142Cysl 42	C478T Arg142142Cysl 42
apolipoprotein E/APOE	NM_00000 41	107741	C487T Arginine145Cys teine	C487T Arginine145Cys teine
apolipoprotein E/APOE	NM_00000 41	107741	C526T Arginine158Cys teine	C526T Arginine158Cys teine
apolipoprotein E/APOE	NM_00000 41	107741	C736T Arginine228Cys teine	C736T Arginine228Cys teine
apolipoprotein E/APOE	NM_00000 41	107741	C805G Arg251251Gly2 51	C805G Arg251251Gly2 51
apolipoprotein E/APOE	NM_00000 41	107741	G144deletion Leucine60Termination Codon (frameshift)	G144deletion Leucine60Termination Codon (frameshift)
apolipoprotein E/APOE	NM_00000 41	107741	G349A Ala9999Thr99	G349A Ala9999Thr99

apolipoprotein E/APOE	NM_00000 41	107741	G434A Gly127127Asp 27
apolipoprotein E/APOE	NM_00000 41	107741	G455A Arginine134Glu amine
apolipoprotein E/APOE	NM_00000 41	107741	G488A Arginine145His tidine
apolipoprotein E/APOE	NM_00000 41	107741	G568C Ala152Proline
apolipoprotein E/APOE	NM_00000 41	107741	G61A Glutamic Acid33Lysine
apolipoprotein E/APOE	NM_00000 41	107741	G683A Tryptophan210 Termination Codon
apolipoprotein E/APOE	NM_00000 41	107741	G725A Arg224224Gln2 24
apolipoprotein E/APOE	NM_00000 41	107741	G875A Arginine274His tidine
apolipoprotein E/APOE	NM_00000 41	107741	G91A Glutamic Acid131lysine
apolipoprotein E/APOE	NM_00000 41	107741	GAG-GAG844- Glu244/Glu245 849AAAG-AAG 244- 245Lys244/Lys 245
apolipoprotein E/APOE	NM_00000 41	107741	T137C Leucine287Trolin e
apolipoprotein E/APOE	NM_00000 41	107741	T388C Cysteine112Arg inine
apolipoprotein E/APOE	NM_00000 41	152200	T761A Valine236Glu/a mic Acid -773G,+93T, +121G
APOLOPOPROTEIN <sup>a</sup> ); LPA			

APOLIPOPROTEIN(a ); LPA	152200	C/T(+93)
APOLIPOPROTEIN(a ); LPA	152200	-773A, +93C, +121A
APOLIPOPROTEIN(a ); LPA	152200	C/T at -49
APOLIPOPROTEIN(a ); LPA	152200	G/A at -21
APOLIPOPROTEIN(a ); LPA	152200	G/A at -914
APOLIPOPROTEIN(a ); LPA	152200	IVS K4 TYPE 8 DS, G-A, +1
APOLIPOPROTEIN(a ); LPA	152200	TTTA repeat
APOLIPOPROTEIN(a ); LPA	152200	Met-->Thr 66
APOLIPOPROTEIN(a ); LPA	152200	Met/Thr 4168
APOLIPOPROTEIN(a ); LPA	152200	Thr12-->Pro
arachidonate 5- lipoxygenase- activating protein/FLAP/ALOX5	NM_0016 29	none found
AP		
Arginine Vasopressin	AF030512	600264 none found
Receptor 1/B/AVPR1B		
Arginine vasopressin receptor 2	AF030626	304800 1-BP DEL
Arginine vasopressin receptor 2	AF030626	304800 1-BP DEL, 102G

Arginine vasopressin receptor 2	AF030626	304800	1-BP INS frameshift
Arginine vasopressin receptor 2	AF030626	304800	1-BP INS 804 frameshift
Arginine vasopressin receptor 2	AF030626	304800	15delC
Arginine vasopressin receptor 2	AF030626	304800	28-bp del
Arginine vasopressin receptor 2	AF030626	304800	786delG frameshift
Arginine vasopressin receptor 2	AF030626	304800	CpG dinucleotides
Arginine vasopressin receptor 2	AF030626	304800	ALA132ASP
Arginine vasopressin receptor 2	AF030626	304800	ARG181CYS
Arginine vasopressin receptor 2	AF030626	304800	ARG113TRP
Arginine vasopressin receptor 2	AF030626	304800	ARG203CYS
Arginine vasopressin receptor 2	AF030626	304800	ARG337TER
Arginine vasopressin receptor 2	AF030626	304800	ASP85ASN
Arginine vasopressin receptor 2	AF030626	304800	G107E
Arginine vasopressin receptor 2	AF030626	304800	GLY185CYS
Arginine vasopressin receptor 2	AF030626	304800	GLY201ASP
Arginine vasopressin	AF030626	304800	L43P

receptor 2	Arginine vasopressin	AF030626	304800	P322H
receptor 2	Arginine vasopressin	AF030626	304800	P322S
receptor 2	Arginine vasopressin	AF030626	304800	R137H
receptor 2	Arginine vasopressin	AF030626	304800	TRP71TER
receptor 2	Arginine vasopressin	AF030626	304800	TYR205CYS
receptor 2	Arginine vasopressin	AF030626	304800	TYR280CYS
receptor 2	Arginine vasopressin	AF030626	304800	W193X
receptor 2	Arginine vasopressin	AF030626	304800	437C DEL
ATPase, Ca++ transporting, cardiac muscle, fast twitch I	U96781	108730	IVS3DS G-C, -2	
ATPase, Ca++ transporting, cardiac muscle, fast twitch I	U96781	108730	ARG198TER	
ATPase, Ca++ transporting, cardiac muscle, fast twitch I	U96781	108730	CYS675TER	
ATPase, Ca++ transporting, cardiac muscle, fast twitch I	U96781	108730	Bgl I.	
beta-1-adrenergic receptor; Adrb1	J03019	109630		
beta-1-adrenergic receptor; Adrb1	J03019	109630	C1165G ARG389GLY	

Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	Fnu4H1
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	A-->G -1343
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	C-->G -468
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	G-->A -1023
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	G-->A -654
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->A -1429
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -20
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -367
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -47
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	ARG16GLY
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	GLN27GLU
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	Thr164Ile
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	val 34 met
Beta-2-Adrenergic Receptor; Adrb2	X69117	109636	none found
Beta-Adrenergic Receptor Kinase 2; Adrbk2	NM_00116	109635	none found
beta-adrenergic receptor kinase	19		

1/BARK1	bradykinin receptor B1/BDKRB1 G protein-coupled bradykinin receptor B1/BDKRB1 G protein-coupled bradykinin receptor B1/BDKRB1 G protein-coupled bradykinin receptor B1/BDKRB1 G protein-coupled bradykinin receptor B2/BDKRB2 G protein-coupled bradykinin receptor B2/BDKRB2 G protein-coupled bradykinin receptor B2/BDKRB2 G protein-coupled bradykinin receptor B2/BDKRB2 G protein-coupled bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0007 10 NM_0007 10 NM_0007 10 NM_0007 10 NM_0006 23 NM_0006 23 NM_0006 23 NM_0006 23 NM_0006 23 NM_0006 23 NM_0006 23 NM_0006 23	600337 600337 600337 600337 600337 113503 113503 113503 113503 113503 113503 113503 113503 113503 113503	9-base pair deletion A1098-->G C181-->T G-699-->C -143C/T -412C/G -536C/T -640T/C -649insG -704C/T
---------	---	--	--	---

bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	-	-78C/T
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	9 bp de (-)21-29	-845C/T
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	C>T promoter 54	
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	repeat 3'UTR	
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	tandem repeat near promoter	R14C
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503		T21M
Ca2+-dependent phospholipase A2	U01090	601192	none found	
Carbonic anhydrase II	J03037	259730	BstNI	
Carbonic anhydrase II	J03037	259730	gt-->t splice donor site at the 5' end of intron 6	
Carbonic anhydrase II	J03037	259730	IVS2, G-A, +1	

Carboxic anhydrase II	J03037	259730	IWS5, G-C,-I
Carboxic anhydrase II	J03037	259730	TAQI
Carboxic anhydrase II	J03037	259730	TYR40TER
Carboxic anhydrase II	J03037	259730	ASN252ASP
Carboxic anhydrase II	J03037	259730	HIS107TYR
Carboxic anhydrase II	J03037	259730	Ile31Val
Carboxic anhydrase II	J03037	259730	LYS17GLU
Carboxic anhydrase II	J03037	259730	PRO237HIS
Carbonic anhydrase IV	M83670	114760	none found
Chloride channel 5	X91906	300008	1-BP DEL, 2085C
Chloride channel 5	X91906	300008	Igcag --> tgaag
Chloride channel 5	X91906	300008	Arg704Stop
Chloride channel 5	X91906	300008	GLY57VAL
Chloride channel 5	X91906	300008	ARC280PRO
Chloride channel 5	X91906	300008	Arg34Stop
Chloride channel 5	X91906	300008	ARG648TER
Chloride channel 5	X91906	300008	ARG704TER
Chloride channel 5	X91906	300008	GLY506GLU
Chloride channel 5	X91906	300008	LEU200ARG
Chloride channel 5	X91906	300008	SER244I EU
Chloride channel 5	X91906	300008	SER520PRO
Chloride channel 5	X91906	300008	TRP279TER
Chloride channel 5	X91906	300008	TRP343TER
Cholecystokinin A receptor/CCKAR	L13605	118444	GLY21ARG
Cholecystokinin A receptor/CCKAR	L13605	118444	VAL1365ILE
Cholecystokinin B receptor/CCKBR	L08112	118445	I550 G-->A Val1125-->Ile
Cholecystokinin B receptor/CCKBR	L08112	118445	CAT 207 CAC His207His

Cholecystokinin B receptor/CCKBR	L08112	118445	Arg215His
Cholecystokinin B receptor/CCKBR	L08112	118445	Val138Met
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE I; CHRNA1	100690		Hae III
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE I; CHRNA1	100690		ASN217LYS
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE I; CHRNA1	100690		GLY153SER
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE I; CHRNA1	100690		SER269ILE
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE I; CHRNA1	100690		THR254ILE
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE I; CHRNA1	100690		VAL156MET

NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1		11838 120580		none found 4-BP DEL
CHYMASE 1; CMAL Complement C1S	J04080	602270		none found
component precursor (C1 esterase) Copper Transport Protein HAH1	U70660	603602 118485		none found 5' UTR pentanucleotide repeat
CPLA2-GAMMA Cytochrome P450, subfamily XIA (cholesterol side chain cleavage)	M14565	222360		
dopamine beta hydroxylase	Y00996			
Dopamine Receptor D1	X58987	126449	C/T Isoleucine49	
Dopamine Receptor D2	X51362	126450	I41 C ins/del	
Dopamine Receptor D2	X51362	126450	A241G	
Dopamine Receptor D2	X51362	126450	Neol RFLP	
Dopamine Receptor D2	X51362	126450	TaqI A, TaqI B, TaqI D, and (CA)n	
Dopamine Receptor D2	X51362	126450	STRP	Serine 311Cysteine
Endopeptidase Endothelin 1	X07166 Y00749	120520 131240	none found A at position 138	
Endothelin 1	Y00749	131240	C at position 121	5'UTR 5'UTR
Endothelin 1	Y00749	131240	Dinucleotide repeat	
Endothelin 1	Y00749	131240	A985G	Lys198Asn 3'UTR
Endothelin 2	M65199	131241		

Endothelin 3	X52001	131242	1-BP INS	
Endothelin 3	X52001	131242	1-BP INS, 262G	
Endothelin 3	X52001	131242	262GC-T	
Endothelin 3	X52001	131242	ALA17THR	
Endothelin 3	X52001	131242	ALA22THR	
Endothelin 3	X52001	131242	CYS15PHE	
Endothelin 3	X52001	131242	ARG742CYS	
Endothelin Converting Enzyme 1	Z35307	600423	none found	
Endothelin Receptor Type A	D90348	131243		
Endothelin Receptor Type B	L06623	131244	1-BP INS, 878T	
Endothelin Receptor Type B	L06623	131244	ALA183GLY	
Endothelin Receptor Type B	L06623	131244	GLY57SER	
Endothelin Receptor Type B	L06623	131244	SER305ASN	
Endothelin Receptor Type B	L06623	131244	TRP275TER	
Endothelin Receptor Type B	L06623	131244	TRP276CYS	
endothophil peroxidase/EPX eosinophil		131399	INS G, NT1537	
endothophil peroxidase/EPX		131399	ARG286HIS	
Erythropoietin receptor	M34986	133171	7-BP DEL	
Erythropoietin receptor	M34986	133171	1-BP INS	frameshift
Erythropoietin receptor	M34986	133171	1-BP INS, 5967T	FS444TER
Erythropoietin receptor	M34986	133171	BamHI	frameshift
Erythropoietin receptor	M34986	133171	Bgl II	[REDACTED]

Erythropoietin receptor	M34986	133171	C to T [REDACTED] -->I35stop
Erythropoietin receptor	M34986	133171	C6148T
Erythropoietin receptor	M34986	133171	HindIII
Erythropoietin receptor	M34986	133171	SacI [REDACTED]
Erythropoietin receptor	M34986	133171	ASN487SER
Erythropoietin receptor	M34986	133171	TRP439TER
Erythropoietin receptor	M34986	133171	TYR426TER
estrogen receptor 1 (ESR1)	M12674	133430	RFLP (PstI enzyme)
estrogen receptor 1 (ESR1)	M12674	133430	RFLP (PvuII enzyme)
estrogen receptor 2 (ESR2)	X99101	601663	none found
Estrogen-preferring sulfotransferaseSTE	NM_0054	600043	none found
G protein coupled potassium channel, subfamily J, member	NM_0022	20	
39		601534	(CA)n
3KCN3/GIRK1		121013	none found
GAP JUNCTION PROTEIN, ALPHA-5		231200	(39-base pair)n
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	92-BP DUP SER399.
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	THR411 DUP
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	Arg342(A-->G) silent
GLYCOPROTEIN Ib,		231200	T-->C 2nd

PLATELET, ALPHA POLYPEPTIDE	231200	nucleotide exon 2
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	Tyr492 (TAT->T)
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	ALA156VAL
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	GLY233VAL
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	LEU57PHE
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	MET239VAL
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	TRP126TER
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	TRP343TER
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	TRP498TER
Granulocyte colony- stimulating factor Guanine nucleotide binding protein (G protein), alpha	M64592 J03004	none found PHE200LEU

inhibiting activity polypeptide 2	J03004	139360	ARG179CYSS
Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2	J03004	139360	ARG179GLY
Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2	J03004	139360	ARG179HIS
Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2	M31328	139130	C825T
Guanine nucleotide binding protein (G protein), beta polypeptide 3	U40038	600998	none found
Guanine nucleotide binding protein (G protein), q polypeptide GLANINE NUCLEOTIDE- BINDING PROTEIN ALPHA-	139311		none found
ACTIVATING ACTIVITY POLYPEPTIDE O;			

GNAO1	Guanylate cyclase I, soluble, alpha 2	X63282	601244	none found
GUANYLATE CYCLASE 1, SOLUBLE, BETA-2	Guanylate cyclase soluble, alpha-3 chain	X66534	603695	none found
	Guanylate cyclase soluble, beta-1 chain	X66533	139396	none found
	H.sapiens 40 kDa protein kinase related to rat ERK2	Z11695	139397	none found
	H.sapiens 44kDa protein kinase related to rat ERK1	Z11696	176948	none found
	H.sapiens encoding CLA-1 mRNA	Z22555	601040	none found
	H.sapiens gene for antithrombin III	X68793	107300	AAAG----AAA transition at Lys 176 Ddel
	H.sapiens gene for antithrombin III	X68793	107300	Hae III
	H.sapiens gene for antithrombin III	X68793	107300	NheI
	H.sapiens gene for antithrombin III	X68793	107300	Pst I
	H.sapiens gene for antithrombin III	X68793	107300	Trinucleotide repeat
	H.sapiens gene for	X68793	107300	GLU245FS

antithrombin III H.sapiens gene for	X68793	107300	ILE7ASN
antithrombin III H.sapiens gene for	X68793	107300	ALA382THR
antithrombin III H.sapiens gene for	X68793	107300	ala382thr
antithrombin III H.sapiens gene for	X68793	107300	ALA384PRO
antithrombin III H.sapiens gene for	X68793	107300	ALA384SER
antithrombin III H.sapiens gene for	X68793	107300	ALA387VAL
antithrombin III H.sapiens gene for	X68793	107300	ALA404THR
antithrombin III H.sapiens gene for	X68793	107300	ARG129TER
antithrombin III H.sapiens gene for	X68793	107300	ARG24CY S
antithrombin III H.sapiens gene for	X68793	107300	ARG393CY S
antithrombin III H.sapiens gene for	X68793	107300	ARG393HIS
antithrombin III H.sapiens gene for	X68793	107300	ARG393PRO
antithrombin III H.sapiens gene for	X68793	107300	arg406met
antithrombin III H.sapiens gene for	X68793	107300	ARG47CY S
antithrombin III H.sapiens gene for	X68793	107300	ARG47HIS

H.sapiens gene for antithrombin III	X68793	107300	ARG47SER
H.sapiens gene for antithrombin III	X68793	107300	ASN208LYS
H.sapiens gene for antithrombin III	X68793	107300	ASP309LYS
H.sapiens gene for antithrombin III	X68793	107300	GLY392ASP
H.sapiens gene for antithrombin III	X68793	107300	His120->Tyr
H.sapiens gene for antithrombin III	X68793	107300	LEU-10PRO
H.sapiens gene for antithrombin III	X68793	107300	LEU99PHE
H.sapiens gene for antithrombin III	X68793	107300	LYS228FS
H.sapiens gene for antithrombin III	X68793	107300	LYS370ARG
H.sapiens gene for antithrombin III	X68793	107300	PRO407LEU
H.sapiens gene for antithrombin III	X68793	107300	PRO411LEU
H.sapiens gene for antithrombin III	X68793	107300	PRO429LEU
H.sapiens gene for antithrombin III	X68793	107300	Pro80->Thr
H.sapiens gene for antithrombin III	X68793	107300	SER291PRO
H.sapiens gene for antithrombin III	X68793	107300	SER349PRO
H.sapiens gene for antithrombin III	X68793	107300	SER394LEU

antithrombin III H.sapiens gene for antithrombin III	X68793	107300	Tyr158-->Cys
H.sapiens gene for antithrombin III	X68793	107300	VAL-3GLU
H.sapiens gene for antithrombin III	X68793	107300	VAL48CYSS
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	IVS15, G-A, +1
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	Arg102Leu
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	ARG278CYSS
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	ARG92GLN
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	ILE79ASN
H.sapiens mRNA for adenosine triphosphatase, calcium H.sapiens mRNA for cyclic nucleotide phosphodiesterase	Z69881	601929	none found
H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	1389 (A/G)
H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	dinucleotide repeat intron 12

H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	di nucleotide repeat introns 5
H.sapiens mRNA for delta-sarcoglycan	X95191	601411	I-BP DEL, 656C
H.sapiens mRNA for delta-sarcoglycan	X95191	601411	ARG165TER
H.sapiens mRNA for delta-sarcoglycan	X95191	601411	GLU262LYS
H.sapiens mRNA for delta-sarcoglycan	X95191	601411	TRP30TER
H.sapiens mRNA for growth factor receptor tyrosine kinase	X61656	191306	none found
H.sapiens mRNA for nitric oxide synthase	X73029	163730	(CCTTT)n
H.sapiens mRNA for platelet derived growth factor alpha receptor	X76079	173490	none found
H.sapiens mRNA for ryanodine receptor 2	X98330	180902	none found
H.sapiens mRNA for thrombospondin-4	Z19585	600715	none found
H.sapiens tropomyosin isoform mRNA, complete CDS	Z24727	191010	ASP175ASN
H.sapiens tropomyosin isoform mRNA, complete CDS	Z24727	191010	GLU180GLY
Histidine receptor H1	AF026261	600167	none found
HMGC-CoA	NM_00088	142910	HgIA

reductase/HMGCR HMGCoA reductase/HMGCR	NM_59 NM_59	142910 137167	Scrf1 polymorphism in the 2nd intron	LEU394ARG
Homo sapiens (clone H4/H16) gamma- glutamic carboxylase mRNA, complete cds	L17128			
Homo sapiens ADDL mRNA for adducin- like protein, complete cds	D67031	601568	none found	
Homo sapiens beta- arrestin 1A mRNA, complete cds	AF084040	107940	none found	
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	2.4-KB DEL	
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG249GLN	
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG403GLN	
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG403LEU	
Homo sapiens beta- myosin heavy chain (MYH7) mRNA,	M58018	160760	ARG453CYS	

myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	ARG719TRP
Homo sapiens beta- myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	ARG723CYSS
Homo sapiens beta- myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	ASP778GLY
Homo sapiens beta- myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	GLU924LYS
Homo sapiens beta- myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	GLU949LYS
Homo sapiens beta- myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	GLY256GLU
Homo sapiens beta- myosin heavy chain (MYHT) mRNA, complete cds	M58018	160760	GLY584ARG

Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY741ARG
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	LEU908VAL
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	PHE513CYS
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	VAL606MET
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M23114	108740	18-BP INS, IVS2,+12
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	IVS6DS, G-A,+1
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	ASN754 DEL
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	ASN767SER
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	CYS268PHE

Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	CYS560ARG
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	GLN108TER
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	GLY23GLU
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	AFO64594	603604	none found
Homo sapiens calcium- independent phospholipase A2 mRNA, complete cds			
Homo sapiens carbonic anhydrase precursor (CA 12) mRNA, complete cds	AF037335	603263	none found
Homo sapiens focal adhesion kinase mRNA, complete cds	L05186	600758	none found
Homo sapiens GATA- 4 mRNA, complete cds	L34357	600576	none found
Homo sapiens integrin alpha 8 subunit mRNA, 3' end	L36531	604063	none found
Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	1-bp frameshift deletion at cDNA nucleotide 1204 21-BP INS
Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	

Homo sapiens integrin	AF032108	600536	98-BP DEL
alpha-7 mRNA, complete cds			
Homo sapiens mRNA	AB005289	300135	ILE400MET
for ABC transporter 7 protein, complete cds			
Homo sapiens mRNA	AB022017	602739	none found
for AMP-activated protein kinase alpha-1, complete cds			
Homo sapiens mRNA	AJ224515	602740	none found
for AMP-activated protein kinase beta 1			
Homo sapiens mRNA	AJ224538	602741	none found
for AMP-activated protein kinase beta 2 subunit			
Homo sapiens mRNA	AB010125	180903	none found
for brain tyrosine receptor, complete cds			
Homo sapiens p21- activated kinase 3 (PAK3) mRNA, complete cds			
Homo sapiens	L48513	602447	ALA148GLY
paraoxonase 2 (PON2) mRNA, complete cds			
Homo sapiens	L48513	602447	CYS311SER
paraoxonase 2 (PON2) mRNA, complete cds			
Homo sapiens	L48516	602720	none found

paraoxonase 3 (PON3)				
mRNA, 5' end of cds				
Homo sapiens	M95678	604114		none found
phospholipase C-beta-2				
mRNA, complete cds				
Homo sapiens	AF033850	602384		none found
phospholipase D2				
(PLD2)mRNA,				
complete cds				
Homo sapiens receptor	L06139	600221		
protein-tyrosine kinase				
(PTK) mRNA,				
complete cds				
Human 47-kD	M55067	233700	1-BP DEL, 502G	frameshift
autosomal chronic				
granulomatous disease				
protein mRNA,				
complete cds				
Human 47-kD	M55067	233700	2-BP DEL, EX2,-2, GT	frameshift
autosomal chronic				
granulomatous disease				
protein mRNA,				
complete cds				
Human 47-kD	M55067	233700	2-BP INS	frameshift
autosomal chronic				
granulomatous disease				
protein mRNA,				
complete cds				
Human 47-kD	M55067	233700		ASPI61VAL
autosomal chronic				
granulomatous disease				

protein mRNA, complete cds				
Human 47-kD autosomal chronic granulomatous disease	M5067	233700	LYS160GLU	
protein mRNA, complete cds				
Human 5'-AMP- activated protein kinase, gamma-1 subunit mRNA, complete cds	U42412	602742	none found	
Human activin receptor-like kinase (ALK-5) mRNA, complete cds	L11695	190181	S387Y	
Human alpha adducin mRNA, partial cds including alternate exons A and B	L07261	102680	G460W	
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	1-BP DEL, CODON 202	
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	1-BP INS	
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	1121 C/T in intron 3	
Human apolipoprotein A-I mRNA, complete	M27875	107680	12-BP DEL AND 2- BP INS	

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	A/G at position 78 bp upstream
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	DELETION OF APOA1/APOC3/AP OA4 GENE COMPLEX EX4/IVS1
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	G-to-A -75 bp
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	IVS2, G-C, +1
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Msp I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Pst I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Sst I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Xmn I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Lys-107 deletion

Human apolipoprotein A-I mRNA, complete	M27875	107680	Ala-95-->Asp
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	ARG10LEU
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	ARG173CYS
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	Asp[103----Asn]
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	GLN-2TER
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	GLN32TER
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	GLN84TER
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	GLU136LYS
	cds		
Human apolipoprotein A-I mRNA, complete	M27875	107680	GLU198LYS
	cds		

Human apolipoprotein A-I mRNA, complete	M27875	107680	GLY26ARG
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	LEU60ARG
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	LEU90PRO
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	LYS107DEL
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	PRO143ARG
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	Pro165-->Arg
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	PRO165ARG
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	PRO3ARG
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	PRO4ARG
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	Ter-108-->Arg
cds			
Human apolipoprotein A-I mRNA, complete	M27875	107680	TRP50ARG
cds			

A-1 mRNA, complete cds			
Human apolipoprotein A-1 mRNA, complete cds	M27875	107680	VAL156GLU
Human ARF-activated phosphatidylcholine-specific phospholipase D1 (hPLD1) mRNA, complete cds	U38545	602382	none found
Human beta $\alpha$ adducin mRNA, alternatively spliced partial cds	U43959	102681	none found
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839	ASP648ASN
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839	TRP625TER
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839	VAL272PHE
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U30246	600840	none found
Human c-sis/platelet-derived growth factor 2 mRNA, complete cds	M12783	190040	135-BP DEL, IVSS

(SIS/PDGFR) mRNA, complete cds	M12783	190040	FUSION WITH COLIA
Human c-sis/platelet- derived growth factor 2 (SIS/PDGFR) mRNA, complete cds	U95301	603603	none found
Human calcium- dependent group X phospholipase A2			
mRNA, complete cds	M33336	188830	none found
Human cAMP- dependent protein kinase type I alpha subunit (PRKAR1A)	L10844	116952	none found
mRNA, complete cds	M91667	123805	none found
Human cellular growth-regulating protein mRNA, complete cds	M14058	216950	none found
Human cGMP- inhibited cAMP phosphodiesterase	U59167	125660	21-BP DEL
mRNA, complete cds	U59167	125660	EcoRV
Human complement C1r mRNA, complete cds	U59167	125660	ALA337PRO
Human desmin mRNA, complete cds	U59167	125660	
Human desmin mRNA, complete cds	U59167	125660	
Human desmin mRNA,			

complete cds				
Human desmin mRNA, complete cds	U59167	125660		ALA360PRO
Human desmin mRNA, complete cds	U59167	125660		ASN393IUE
Human desmin mRNA, complete cds	U59167	125660		ILE451MET
Human desmin mRNA, complete cds	U59167	125660		none found
Human DNA sequence AL023653	300145			
from clone 753P9 on chromosome Xq25.				
26.1. Contains the gene coding for				
Aminopeptidase P (EC 3.4.11.9, XAA-Pro-X- Pro/Proline/Aminoacyl proline				
Aminopeptidase and a novel gene. Contains EST's, STSs, GSSs and a gaaa repeat				
Human ERK5 mRNA, complete cds	U25278	602521	none found	
Human ferritin H chain mRNA, complete cds	M11146	134770	none found	
Human ferritin L chain mRNA, complete cds	M11147	134790	22T-G	
Human ferritin L chain mRNA, complete cds	M11147	134790	146A-G	
Human ferritin L chain mRNA, complete cds	M11147	134790	147G-C	

Human ferritin L chain mRNA, complete cds	M11147	134790	18C-T
Human ferritin L chain mRNA, complete cds	M11147	134790	29-BP DEL IRE DEL
Human ferritin L chain mRNA, complete cds	M11147	134790	32G-A
Human ferritin L chain mRNA, complete cds	M11147	134790	32G-T
Human ferritin L chain mRNA, complete cds	M11147	134790	36C-A
Human ferritin L chain mRNA, complete cds	M11147	134790	39C-T
Human ferritin L chain mRNA, complete cds	M11147	134790	Dinucleotide repeat
Human flt mRNA for receptor-related tyrosine kinase	X51602	165070	
Human heparin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds	M32977	192240	none found
Human hepatic lipase mRNA, complete cds	J03540	151670	SER267PHF
Human hepatic lipase mRNA, complete cds	J03540	151670	THR383MET
Human hormone-sensitive lipase testicular isoform mRNA, complete cds	U40002	151750	dinucleotide repeat
Human hormone-sensitive lipase testicular isoform mRNA, complete cds	U40002	151750	Arg309Cys

mRNA, complete cds	L24158	603963	none found
Human integrin alpha 9 protein mRNA, 3'end			none found
Human IP gene for prostanacyclin receptor, exon 3	D38128	600022	none found
Human kidney mRNA fragment for retin (aa 105-401)	X00063	179320	ARG387TER
Human lipid-activated, protein kinase PRK2 mRNA, complete cds	U33052	602349	none found
Human mRNA for adrenomedullin, complete cds	D14874	103275	none found
Human mRNA for cardiac gap junction protein	X52947	121014	GCG->GTG
Human mRNA for LIMK (LIM kinase), complete cds	D26309	601329	Ala253Val
Human mRNA for LIMK-2, complete cds	D45906	601988	none found
Human mRNA for natriuretic peptide receptor (ANP-A receptor)	X15557	108960	none found
Human mRNA for plasminogen	X05199	173350	IVS17, 1-BP DEL, G,+1 TaqI
Human mRNA for plasminogen	X05199	173350	

Human mRNA for plasminogen	X05199	173350	GLU460TER
Human mRNA for plasminogen	X05199	173350	ALA600THR
Human mRNA for plasminogen	X05199	173350	Ala675Thr
Human mRNA for plasminogen	X05199	173350	ARG216HIS
Human mRNA for plasminogen	X05199	173350	D676N
Human mRNA for plasminogen	X05199	173350	GLY732ARG
Human mRNA for plasminogen	X05199	173350	LYS19GLU
Human mRNA for plasminogen	X05199	173350	LYS212DEL
Human mRNA for plasminogen	X05199	173350	SER572PRO
Human mRNA for plasminogen	X05199	173350	TRP597TER
Human mRNA for plasminogen	X05199	173350	VAL355PHE
Human mRNA for plasminogen	X05199	173350	none found
Human mRNA for platelet-derived growth factor PDGF-A	X06374	173430	none found
Human mRNA for thrombospondin	X04665	188060	none found
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	72
Human mRNA for	X02812	190180	-509

transforming growth factor-beta (TGF-beta)				
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	-800	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	-988	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	713-8delC intron 4	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	C788-T	thr263iso
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180		Arg25-->Pro
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180		Leu10-->Pro
Human mRNA for transforming growth factor-beta (TGF-beta)	Y07512	176894	none found	
I beta cGMP-dependent protein kinase (EC 2.7.1.37)	M60092	102770	C143-->T	PRO48LEU
Human myoadenylate deaminase (AMPD1) mRNA, complete cds	M60092	102770	C34-T	Gln-->Stop
Human myoadenylate deaminase (AMPD1) mRNA, complete cds	U17327	163731	none found	

oxide synthase(NOS1) mRNA, complete cds			
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	1-BP DEL, 272C
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	10-KB DEL
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	IVS4DS, G-A, +1
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	ARG90GLN
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	HIS77TYR
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	HIS94ARG

complete cds			PRO156GLN
Human neutrophil cytochrome b light chain p22 phagocyte b-cytochrome mRNA, complete cds	M21186	233690	
Human neutrophil cytochrome b light chain p22 phagocyte b-cytochrome mRNA, complete cds	M21186	233690	SER118ARG
Human neutrophil cytochrome b light chain p22 phagocyte b-cytochrome mRNA, complete cds	M32011	233710	5-nucleotide del nt 1169-1173
Human neutrophil oxidase factor (p67-phox) mRNA, complete cds	M32011	233710	9-nt in-frame deletion in exon 2 (nts 55-63)
Human neutrophil oxidase factor (p67-phox) mRNA, complete cds	M32011	233710	C(304) --> T
Human neutrophil oxidase factor (p67-phox) mRNA, complete cds	M32011	233710	del A(728)
Human neutrophil oxidase factor (p67-phox) mRNA, complete cds	M32011	233710	intron 4 (G --> A)

Human p21-activated protein kinase (Pak 1) gene, complete cds	U24152	602590	none found
Human M63603	172405		
phospholamban mRNA, complete cds	M25827	173515	
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515	Ala139(ACC) >Thr(GCC)
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515	ASN45SER
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515	ASP21GLY
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515	LEU40PRO
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515	PHE55SER
Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds	M21616	173410	none found
Human protein kinase C iota isoform (PRKCH) mRNA, complete cds	L18964	300094	none found
Human RASF-A PLA2 mRNA, complete cds	M22430	172411	2-BP DEL frameshift

Human receptor for advanced glycosylation end products (RAGE)	M91211	600214	none found
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	1-BP DEL
mRNA, partial cds			PRO251DEL
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	null allele
mRNA, complete cds			GLY196SER
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			LEU55GLN
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			ARG227TER
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			ARG246TRP
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			GLY115ASP
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			GLY183SER
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			HIS231ARG
Human steroid 5-alpha-reductase 2 (SRD5A2)	M74047	264600	
mRNA, complete cds			

Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	MET157DEL
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	THR228ALA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	840delA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS4AS, T-A, -11
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS2, 1-BP INS, T, +3
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	1-BP DEL, 261T
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	ARG182LEU
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	D203A
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	GLN258TER

acute regulatory protein (S1AR) mRNA, complete cds	M85079	190182	2-BP INS	Frameshift
Human TGF-beta type II receptor mRNA, complete cds				
Human TGF-beta type II receptor mRNA, complete cds	M85079	190182	THR315MET	
Human thiazide-sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	3-BP DEL	
Human thiazide-sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	119-bp insertion between exons 3 and 4	
Human thiazide-sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	exon 24 was deleted	
Human thiazide-sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	intron 24, GGT --> GTT	
Human thiazide-sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	intron 3, CAG --> CAA	
Human thiazide-sensitive Na-Cl	U44128	600968	IVS15AS, G-T, -1	

cotransporter (hTSC) mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	IVS23DS, G-T, +1
mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	ALA588VAL
mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	ARG209TRP
mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	ARG653LEU
mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	CYS421ARG
mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	GLY630VAL
mRNA, complete cds			
Human thiazide- sensitive Na-Cl cotransporter (hTSC)	U44128	600968	LEU623PRO

sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	LEU850PR0
Human thiiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	PRO349LEU
Human thiiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U68162	159330	none found
Human thrombopoietin receptor (MPL) gene Human thrombospondin mRNA	M31339	188061	none found
Human tie mRNA for putative receptor tyrosine kinase	X60957	600222	none found
Human transferrin mRNA, complete cds	M12530	190000	Aval
Human transferrin mRNA, complete cds	M12530	190000	ASP277GLY
Human transferrin mRNA, complete cds	M12530	190000	GLY652GLU
Human transferrin mRNA, complete cds	M12530	190000	HIS300ARG
Human transferrin mRNA, complete cds	M12530	190000	LYS627GLU
Human transferrin mRNA, complete cds	M12530	190000	PRO570SER

Human transforming growth factor-beta type III receptor (TGF-beta) mRNA, complete cds	L07594	600742	none found
Human urokinase gene, 3' end	K02286	191840	BamHI
Human urokinase gene, 3' end	K02286	191840	C to T change near the beginning of exon 8
Human urokinase gene, 3' end	K02286	191840	Leu residue by a Pro, in the kringle domain
Human vascular endothelial growth factor related protein VRP mRNA, complete cds	U43142	601528	none found
Human VEGF related factor isoform VRF186 precursor (VRF) mRNA, complete cds	U43368	601398	none found
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	1-BP INS
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	Dinucleotide repeat
Hydroxy-delta-5-steroid dehydrogenase,	M67466	201810	ARG249TER

3 beta- and steroid delta-isomerase 2	M67466	201810		TRP171TER
Hydroxy-delta-5-steroid dehydrogenase,				
3 beta- and steroid delta-isomerase 2	M67466	201810		VAL248ASN
Hydroxy-delta-5-steroid dehydrogenase,				
3 beta- and steroid delta-isomerase 2	K02770	147720	+5887 C --> T	
interleukin 1 beta (IL1b)				
interleukin 1 beta K02770	K02770	147720	exon 5 (position +3953) position -511	
interleukin 1 beta (IL1b)				
interleukin 1 beta K02770	K02770	147720	TaqI	
interleukin 1 beta (IL1b)				
interleukin 1 beta K02770	K02770	147720	Asp106Asn	
INTERLEUKIN 1 X65019	X65019	147678	none found	
BETA CONVERTASE PRECURSOR				
interleukin 1 receptor (IL1R)	M27492	147810	PstI	
interleukin 12a (IL12a)	M65271	161560	none found	
interleukin 12b (IL12b)	M65272	161561	4.4-KB DEL -330	
interleukin 2 (IL2)	X01586	147680		
interleukin 2 (IL2)	X01586	147680	166	
interleukin 2 (IL2)	X01586	147680	AUUUA motif deleted	

interleukin 2 (IL2)	X01586	147680	Dinucleotide Repeat
interleukin 2 receptor beta (IL-2R $\beta$ )	M26062	146710	CA repeat
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	690-691 hotspot
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	9-BP DUP
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	GLN-HIS-TRP INS
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	G-to-A first position of intron 3
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	ARG222CYS
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	ARG267TER
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	ARG285GLN
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	CYS115ARG
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	CYS62TER
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	GLY114ASP
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	ILE153ASN
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	LEU271GLN
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	LYS97TER
interleukin 2 receptor gamma (IL-2R $\gamma$ )	D11086	308380	SER286TER
interleukin 4 (IL4)	M13982	147780	-285 C-T
interleukin 4 (IL4)	M13982	147780	-81 A-G

interleukin 4 (IL-4)	M13982	147780	C-589T
interleukin 4 (IL-4)	M13982	147780	Dinucleotide Repeat
interleukin 4 receptor (IL-4R)	X52425	147781	intron 2
interleukin 4 receptor (IL-4R)	X52425	147781	GLN576ARG
interleukin 6 (IL-6)	M14584	147620	CA repeat
interleukin 6 (IL-6)	M14584	147620	174G-C
interleukin 6 (IL-6)	M14584	147620	AT repeat
interleukin 6 (IL-6)	M14584	147620	BglI
interleukin 6 (IL-6)	M14584	147620	MspI
interleukin 6 (IL-6)	M14584	147620	NheII promoter
interleukin 6 (IL-6)	M14584	147620	dinucleotide (CA)
interleukin 6 receptor (IL-6R) (20)	M20566	147880	
interleukin receptor 11	U232324	600939	none found
alpha (IL-11a)			
interleukin receptor 12	U03187	601642	none found
beta2 (IL-12b2)			
K+ channel (KvLQT1)	AF000571	192500	7-BP DEL AND 8-
K+ channel (KvLQT1)	AF000571	192500	BP INS
K+ channel (KvLQT1)	AF000571	192500	1-BP INS, 282G
K+ channel (KvLQT1)	AF000571	192500	3-BP DEL
K+ channel (KvLQT1)	AF000571	192500	9-BP DEL, NT373
K+ channel (KvLQT1)	AF000571	192500	ALA300THR
K+ channel (KvLQT1)	AF000571	192500	ALA341GLU
K+ channel (KvLQT1)	AF000571	192500	ALA341VAL
K+ channel (KvLQT1)	AF000571	192500	ALA529THR

K+ channel (KvLQT1)	AF000571	192500	
K+ channel (KvLQT1)	AF000571	192500	ALA83PRO
K+ channel (KvLQT1)	AF000571	192500	ARG518TER
K+ channel (KvLQT1)	AF000571	192500	ARG555CYS
K+ channel (KvLQT1)	AF000571	192500	ARG595GLN
K+ channel (KvLQT1)	AF000571	192500	GLY189ARG
K+ channel (KvLQT1)	AF000571	192500	GLY211ARG
K+ channel (KvLQT1)	AF000571	192500	GLY219SER
K+ channel (KvLQT1)	AF000571	192500	GLY250GLU
K+ channel (KvLQT1)	AF000571	192500	LEU178PHE
K+ channel (KvLQT1)	AF000571	192500	PHE339DEL
K+ channel (KvLQT1)	AF000571	192500	THR217ILE
K+ channel (KvLQT1)	AF000571	192500	TRP305SER
K+ channel (KvLQT1)	AF000571	192500	VAL159MET
	NM_0007	114205	none found
L-type voltage dependent calcium channel alpha 1C subunit/CACNA1C	U28252	135630	none found
Leukocyte integrin beta-1	M35999	173470	11.2-KB DEL
Leukocyte integrin beta-3	M35999	173470	G-T, EXIDEL
Leukocyte integrin beta-3	M35999	173470	ARG142GLN
Leukocyte integrin beta-3	M35999	173470	ARG214GLN
Leukocyte integrin beta-3	M35999	173470	ARG214TRP
Leukocyte integrin beta-3	M35999	173470	ARG489GLN
	19		

Leukocyte integrin beta-3	M35999	173470		ARG724TER
Leukocyte integrin beta-3	M35999	173470		ASP119TYR
Leukocyte integrin beta-3	M35999	173470		CYS374TYR
Leukocyte integrin beta-3	M35999	173470		GLU616TER
Leukocyte integrin beta-3	M35999	173470		LEU33PRO
Leukocyte integrin beta-3	M35999	173470		PRO407ALA
Leukocyte integrin beta-3	M35999	173470		SER752PRO
Lipoprotein lipase	M15856	238600	INS	
Lipoprotein lipase	M15856	238600	(TTTA)n	
Lipoprotein lipase	M15856	238600	-39T-C	
Lipoprotein lipase	M15856	238600	-93T-G	
Lipoprotein lipase	M15856	238600	1-BP DEL	
Lipoprotein lipase	M15856	238600	1-BP DEL, 221G	
Lipoprotein lipase	M15856	238600	2-KB DUP	
Lipoprotein lipase	M15856	238600	6-KB DEL	
Lipoprotein lipase	M15856	238600	C->A -3 intron 6	
Lipoprotein lipase	M15856	238600	C-16-T -480	
Lipoprotein lipase	M15856	238600	C1338->A	
Lipoprotein lipase	M15856	238600	C1595->G	
Lipoprotein lipase	M15856	238600	G579->A	
Lipoprotein lipase	M15856	238600	HindIII	
Lipoprotein lipase	M15856	238600	IVS1, G-C, +1	
Lipoprotein lipase	M15856	238600	IVS2DS, G-A	
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1	

Lipoprotein lipase	M15856	238600	ILE194THR
Lipoprotein lipase	M15856	238600	ILE225THR
Lipoprotein lipase	M15856	238600	TRP382TER
Lipoprotein lipase	M15856	238600	TYR61TER
Lipoprotein lipase	M15856	238600	ALA176THR
Lipoprotein lipase	M15856	238600	ALA334THR
Lipoprotein lipase	M15856	238600	ARG243CYS
Lipoprotein lipase	M15856	238600	ARG243HIS
Lipoprotein lipase	M15856	238600	ARG75SER
Lipoprotein lipase	M15856	238600	ASN291SER
Lipoprotein lipase	M15856	238600	ASP156GLY
Lipoprotein lipase	M15856	238600	ASP180GLU
Lipoprotein lipase	M15856	238600	ASP204GLU
Lipoprotein lipase	M15856	238600	ASP250ASN
Lipoprotein lipase	M15856	238600	ASP9 ASN
Lipoprotein lipase	M15856	238600	Cys239->stop
Lipoprotein lipase	M15856	238600	CYS418TYR
Lipoprotein lipase	M15856	238600	E163G
Lipoprotein lipase	M15856	238600	E410K
Lipoprotein lipase	M15856	238600	GLN106TER
Lipoprotein lipase	M15856	238600	Glu118Glu
Lipoprotein lipase	M15856	238600	Glu421Lys
Lipoprotein lipase	M15856	238600	GLY142GLU
Lipoprotein lipase	M15856	238600	GLY188GLU
Lipoprotein lipase	M15856	238600	GLY195GLU
Lipoprotein lipase	M15856	238600	His183->Gln
Lipoprotein lipase	M15856	238600	LEU365VAL
Lipoprotein lipase	M15856	238600	Pro157 Arg
Lipoprotein lipase	M15856	238600	PRO207LEU
Lipoprotein lipase	M15856	238600	SER172CYS
Lipoprotein lipase	M15856	238600	SER244THR

Lipoprotein lipase	M15836	238600	SER447TER
Lipoprotein lipase	M15836	238600	TRP64TER
Lipoprotein lipase	M15836	238600	TRP86ARG
Lipoprotein lipase	M15836	238600	Tyr262-->His
Lipoprotein lipase	M15836	238600	TYR73TER
Lipoxygenases: 5-lipoxygenase (leukocytes)	J03571	152390	none found
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL frameshift at codon 337
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL frameshift at codon 459
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	Ileu180-->Val180
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	A'DEL,+3 intron 5
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	C944-->T944 Ala241-->Val241
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	ARG537TER
myeloperoxidase	X04876	254600	C8089T
myeloperoxidase	X04876	254600	Dinucleotide Repeat
myeloperoxidase	X04876	254600	EcoRV
myeloperoxidase	X04876	254600	G to A (promoter) KpnI
myeloperoxidase	X04876	254600	

myeloperoxidase	X04876	254600	PstI	
myeloperoxidase	X04876	254600		MET251THR
myeloperoxidase	X04876	254600		TYR173CYS
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	5-BP DEL, EX25		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	IVS, G-A, +1		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	12-BP DUP/4-BP DEL		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	18-BP DUP		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	BRANCH POINT, IVS23, A-G, TGAT- TGGT		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	IVS, A-G		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	IVS, G-C, +5		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	IVS23, G-A, +1		
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	IVS7, G-A, +5		
MYOSIN-BINDING	600958	Arg654His		

PROTEIN C, CARDIAC	600958	Glu1096 termination codon GLU542GLN
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	
MYOSIN-BINDING PROTEIN C, CARDIAC	600958	
NEPHRIN	602716	1-BP INS, 3250G
NEPHRIN	602716	2-BP DEL, 121CT
NEPHRIN	602716	2-BP INS, 1306AC
NEPHRIN	602716	none found
Neuropeptide Y	M84755	ARG1109TER
receptor Y1/NPY1R		
Nicotinic, Cholinergic	X14830	LEU263MET
receptor beta 1	100710	
Nicotinic, Cholinergic	X14830	VAL266MET
receptor beta 1	100710	
Nicotinic, Cholinergic	X66403	ARG147LEU
receptor epsilon		
polypeptide		ARG64TER
Nicotinic, Cholinergic	X66403	
receptor epsilon		
polypeptide		
Nicotinic, Cholinergic	X66403	LEU269PHE
receptor epsilon		
polypeptide		
Nicotinic, Cholinergic	X66403	PRR011LEU
receptor epsilon		
polypeptide		
Nicotinic, Cholinergic	X66403	THR264PRO

receptor epsilon polypeptide				
NITRIC OXIDE SYNTHASE 3	163729		GLU298ASP	
NITRIC OXIDE SYNTHASE, MACROPHAGE, TYPE 2B	600719		none found	
NITRIC OXIDE SYNTHASE, MACROPHAGE, TYPE 2C; NOS2C	600720		none found	
Paraoxonase 1/PON1 (arylesterase) 3	AH00419	168820	CA repeat intron 4.	
Paraoxonase 1/PON1 (arylesterase) 3	AH00419	168820		GLN192ARG
Paraoxonase 1/PON1 (arylesterase) 3	AH00419	168820		Leu55Met
Paraoxonase 1/PON1 (arylesterase) 3	AH00419	168820		MET54LEU
Paraoxonase 1/PON1 (arylesterase) 3	AH00419	168820		BANI
phenylethanolamine N- methyltransferase/PN 86				
MT				
Phospholipase A-2 (PLA-2) lung	M21054	172410	none found	
Phospholipase A2, Group IV	M6874	600522	none found	
Phospholipase C beta-3	Z26649	600230	none found	
Phospholipase C, beta	L41349	600810	none found	
plasma cholesterol	NM_0000	118470		A1503G
	4			

ester transfer protein/CETP	78	NM_00000 78	118470	G-A splice junction alternative splice
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	G1696A
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	C-T transition in intron 12
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	EcoNI
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	G->A intron 14
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	G-A transition in intron 15
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	G1533A
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	INST alternative (intron/exon 4) splice
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	StuI
plasma cholesterol ester transfer protein/CETP	78	NM_00000 78	118470	T->G ty57stop

protein/CETP	NM_00000 78	118470	TaqI A
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	TaqIB in intron 1
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	268 Arg->STOP
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	Asp 442 to Gly
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	ASP442GLY
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	G181X
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	I405V
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	Lys309-Stop
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	R451Q
plasma cholesterol ester transfer protein/CETP	NM_00000 78	118470	Val421-Ile

Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	11-BP DEL, EX12
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	13-BP DEL AT INTRON-EXON BOUNDARY OF EXON 4
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	4.5-KB DEL, EX2-9
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	IVS15DS, G-A, +1
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	IVS2AS, C-G, -3
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ARG327HIS
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ARG584TER
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ASP426DEL
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	GLU324LYS
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	GLY273ASP

Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	GLY418ASP
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ILE565THR
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ILE843SER
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	LEU214PRO
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	VAL425DEL
Platelet-activating factor receptor	M76674	173393	none found
Potassium channel subunit (h-erg)	U04270	152427	1-BP DEL
Potassium channel subunit (h-erg)	U04270	152427	27-BP DEL
Potassium channel subunit (h-erg)	U04270	152427	IVS3, G-C, +1
Potassium channel subunit (h-erg)	U04270	152427	VAL822MET
Potassium channel subunit (h-erg)	U04270	152427	ALA561VAL
Potassium channel subunit (h-erg)	U04270	152427	ARG582CYS
Potassium channel subunit (h-erg)	U04270	152427	ASN470ASP

Potassium channel subunit (1-erg)	U04270	152427		GLY628SER
Potassium channel subunit (1-erg) POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2	U04270	152427		ILE593ARG
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796		GLN9GLU
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796		ILE57THR
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796		MET54THR
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796		
progesterone receptor PROTEIN KINASE C, EPSILON	M15716	264080	none found	
PROTEIN KINASE, AMP-ACTIVATED, CATALYTIC, ALPHA-2		176975	none found	
PROTEIN KINASE, AMP-ACTIVATED,		600497	none found	
			none found	

NONCATALYTIC,				
GAMMA-2; PRKAG2	M61831	180960	none found	
Sadenosyl homocysteine hydrolase	X57829	109760	RsaI	
serotonin 5-HT receptors 5-HT1A, G protein-coupled	Y08756	602164	none found	
serotonin 5-HT receptors 5-HT4, G protein-coupled	M28226	158105	-2076 (A or T)	
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemoattract protein 1/MCP1/SCYA2	M28226	158105	-2518 (G or A)	
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemoattract protein 1/MCP1/SCYA2	Solute carrier family 9 (sodium/hydrogen exchanger)	M81768	107310	none found
Steroid 5 alpha reductase 1	M32313	184753	none found	
Superoxide dismutase 1 (Cu/Zn)	X02317	147430		
Superoxide Dismutase NM_0004	147450	T-G, -10, 9-BP INS		

I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	VS4AS, A-G, -11	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	ALA145THR	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	ALA4THR	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	ALA4VAL	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	ASP90ALA	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	CYS9PHE	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLU100GLY	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLU21LYS	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY16SER	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY37ARG	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY41ASP	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY41SER	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY72SER	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY85ARG	
I/SOD1 (soluble)	54			
Superoxide Dismutase	NM_0004	147450	GLY93ALA	
I/SOD1 (soluble)	54			

Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	GLY93CYS
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	HIS43ARG
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	HIS46ARG
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	ILE104THE
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	ILE113THR
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	LEU106VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	LEU126TER
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	LEU144SER
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	LEU38VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	LEU84VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	SER134ASN
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	THR151E
Superoxide Dismutase 1/SOD1 (soluble)	NM_000454	147450	Val7->Glu
Superoxide Dismutase 2/SOD2 (mitochondrial)	X65965	147460	ALA16VAL
Tafazzin	Z50115	300069	none found
Thimet oligopeptidase	601117	601117	none found

Thrombopoietin	U70136	600044	1-BP DEL, 3252G
Thrombopoietin	U70136	600044	IVS3, G-C, +1
THROMBOSPONDIN	II	188062	none found
Thromboxane synthase	M80046	274180	(CA)n intron 9
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	BgIII
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	EcoRI
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	HincII
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	polymorphic dinucleotide intron 1
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	PstI
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	TaqI
Tissue Plasminogen activator, tissue type (t-PA)	M18182	173370	XmnI
Transferin receptor (p90, CD71)	X01060	190010	BclI
Transferin receptor (p90, CD71) tRNA-LEU,	X01060	190010	RsaI
		590050	3243A-G

MITOCHONDRIAL tRNA-LEU,	590050	3250T-C
MITOCHONDRIAL tRNA-LEU,	590050	3251A-G
MITOCHONDRIAL tRNA-LEU,	590050	3252T-C
MITOCHONDRIAL tRNA-LEU,	590050	3256C-T
MITOCHONDRIAL tRNA-LEU,	590050	3260A-G
MITOCHONDRIAL tRNA-LEU,	590050	3271T-C
MITOCHONDRIAL tRNA-LEU,	590050	3303C-T
MITOCHONDRIAL tRNA-LEU,	590050	A3288G
MITOCHONDRIAL tRNA-LEU,	590050	G->A 12301
MITOCHONDRIAL Type V cyclic nucleotide phosphodiesterase	AJ004865	none found
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_000335	600163
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_000335	600163
type V voltage	NM_000335	600163

dependent sodium channel alpha subunit/SCN5A type V voltage dependent sodium channel alpha subunit/SCN5A Vascular cell adhesion molecule 1 vitamin B12 receptor/cubilin/CUBN vitamin B12 receptor/cubilin/CUBN	35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0003 35 NM_0010 81 NM_0010 81	600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 600163 192225 NM_0010 602997 NM_0010 602997	LYS1505/PRO1 506/GLN1507D EL ARG1232TRP ARG1623GLN ARG1644HIS] GLU1784LYS THR1620MET none found IVS6, C-G PRO1297LEU
--	---	--	--

Table 24. Current Candidate Therapeutic Interventions for the Treatment of Cancer

Product Name	Latest Phase	Chemical Name	Action	Indication
2-chloro-2'-fluoro-vidarabine; 2-chloro-2'-fluoro-araA A 007	Phase I	bis(4-hydroxyphenyl)-(2,4-dinitrophenyl)-methanone, hydrazone		cancer
acemannan derivatives, Carrington adozolesin; U 73975; ADOSAR	Preclinical			cancer
AG 7352	Phase II	(7bR)-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrol[3,2-e][indol-2(1H-yl)carbonyl]-1H-indol-5-yl]-2-benzofurancarboxamido]de		cancer
aging-related disease therapy, Chiroscience/Geron	Preclinical			atherosclerosis; cancer; osteoporosis; diabetes; eye disease

AK 2123	Phase II	<chem>N-(2-methoxyethyl)-3-nitro-1H-1,2,4-triazole-1-acetamide</chem>	cancer
adenosine	Phase II	<chem>L-2-amino-3-(hydroxynitrosoamino)-L-alanine</chem>	cancer
alkyltransferase inhibitors, National Institutes of Health	Preliminary		cancer
alretamine; hexamethylamine; hexamethylmelanine; KB 913; NSC 13875; HEXALEN; HEXASTAT; HEXINAWAS; amonafide; MFA naldimidide; MFA 142; FA 142	Marketed	<chem>N,N,N',N'',N'''-hexamethyl-1,3,5-triazine-2,4,6-triamine</chem>	cancer
ansacrine; CI 880; NSC 249992; NSC 156203; AMSIDYL; AMSIDINE; AMSEDINE; AMEKRIN ANCERT	Discontinued Marketed	<chem>5-amino-2-(2-dimethylamine)ethyl-1H-benz[de]isoquinoline-1,3(2H)-dione</chem> <chem>N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide</chem>	cancer
antonaceous acetogenins	Preliminary		cancer; leukopenia
anticancer agent, Gryphon	Preliminary		cancer

anticancer agent, Kiyowa Hakko	Precclinical	[1aS-(1alpha,8beta,8alpha, a,8beta[pha]-8- [(aminocarbonyl)oxy -methyl]-5-ethyl- 1,1a,2,3,8a,8b- hexahydro-6,8a- dimethoxyazirino[2',3' '3,4]pyrrol[1,2- a]indole-4,7-dione	cancer
anticancer agent, Paracetamol	Precclinical		cancer
anticancer agent, SOAD	Precclinical		cancer
anticancer agent, Xcyte Therapies	Precclinical		cancer
anticancer agents, Millennium	Precclinical		cancer
anticancer, Klasato University	Precclinical	7,8-dihydroxy-3-(4- hydroxyphenyl)-4H- 1-benzopyran-4-one	cancer
anticancer, New York University	Precclinical	(1- methylethyl)carbamic acid (5,6-dihydro-8- methoxypyrrrol[2,1- a]isoquinoline-1,2- diyl)bism(methylene) ester	cancer
anticancer, Sloan Kettering	Precclinical	3-[bis(2- chloroethyl)- amino]methyl]-1,8- dihydroxy-9,10- anthracenedione	cancer

anticancer, Southern Research Institute	Preclinical	(1-alpha, 3-beta, 4-alpha)-2-amino-1,9-dihydro-9-(3-hydroxy-4-(phosphonomethyl)cyclopentyl)-6H-purin-6-one	cancer
anticancer, Takeda	Discontinued	1-octadecyl-2-acetoxethyl-3-glycerol omega-trimethylammoniodecyl phosphate	cancer
anticancer, Yale University	Preclinical	1-(2-chloroethyl)-2,2'-bis(methyisulfonyl)hydrazide methanesulfonic acid	cancer
antiproliferative agents, Harvard University/Sheffield Medical	Phase I		cancer, restenosis; psoriasis; atherosclerosis
antiproliferative therapy, SIDER	Preclinical		cancer
AP 633	Discontinued		cancer
AP 656	Discontinued		cancer
aplidine	Phase I		cancer
apoptosis modulators, Devgen	Preclinical		cancer, inflammation
apoptosis regulators, Apoptosis Technology, Apoptosis regulators, ICRF	Preclinical		cancer

AQ6N	Discontinued	1-[{2-[dimethylamino-N-oxide]ethyl}amino]-4-[[2(ethylamino)ethyl]amino]-5,8-dihydroxyanthracene-9,10-dione	cancer
arginine deaminase; CX 108	Preliminary		cancer
artificial platelets, Andans; SYNTHOCYTES AT 3510	Preliminary		thrombocytopenia; cancer
atrinustine; bestraucil; busramustine; KM 2210; KREGAN	Preliminary	Discontinued (17beta)-estratrien-3,17-diol 3-benzoate 17-[[4-[bis[2-chloroethyl]amino]phenyl]-1-oxobutoxy]acetate] ester	cancer

ATX 70	Preliminary [[7,12-bis[1-(deoxyethoxyethyl]-3,8,13,17-tetramethyl-2,1H,23H-porphine-2,18-diyl-kappaN2],kappaN22,kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)bis[L-aspartato][6-)gallate(3-)trihydrogen	(SP-4-2)-[[N,N'-	depression; cancer
AV 109	Discontinued		cancer
AV 21; PM 92100	Preliminary Unspecified		cancer
azatyrosine; SF 1346	Discontinued (S)-alpha-amino-5-hydroxy-2-pyridinepropanoic acid	(S)-alpha-amino-5-hydroxy-2-pyridinepropanoic acid	cancer
azinomycin A	Discontinued	6-(3-acetoxy-4-hydroxy-1,5-methyleneptyridin-2-yldene)-2,2(oxyethylene)-5,8-diaza-4,7,10-trioxo-undecyl-3-methoxy-5-methyl-1-naphthalenesboxylate	cancer
azinomycin B	Discontinued		cancer
BCH 1184	Discontinued		cancer
BCH 1667	Discontinued		cancer
BCH 2050	Discontinued		cancer
BD 95325	Discontinued		cancer

BE 12406B	Discontinued	N-[{3-methoxy-5-(1H-pyrrrol-2-yl)-2H-pyrrrol-2-ylidene]methyl]-1-dodecanamine	cancer
BE 18591	Discontinued		
benzeneacetic acid ester	Phase I	alpha-(benzyloxy)-alpha-cyclopentyl-benzenoic acid, 1-methyl-4-piperidinyl ester	cancer
bFGF inhibitor, PharmaGenics	Discontinued		cancer; cardiovascular disease
bistratene A;	Preliminary	tetrahydro-N-[2-hydroxy-4-[[3-[8-(6-hydroxy-3,5-dimethyl-4-heptenyl)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]propyl]amino]-3-methyl-4-oxobutyl]-3-methyl-1-6-(2-oxo-3-pentenyl)-2H-pyran-2-acetamide	cancer
BMOV	Preliminary	bis(malolato)orthova nadate	cancer

BMS 181174; BMY 25067	Discontinued	[1aS-[1a[alpha,8alpha,8beta,8b[alpha]-8-[(aminocarbonyl)oxy][methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-[2-[(4-nitrophenyl)dithiolethyl]amino]azirinot[2;3,3,4]pyrrolot[1,2-a]indole-4,7-dione	cancer
BMS 181175	Discontinued		cancer
BMS 181176	Discontinued		cancer
BMS 185660; BMS 1856602	Discontinued		cancer
BMY 21577	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt	cancer
BN 52205	Discontinued	4-hydroxy-6-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt	cancer
BN 52207	Discontinued	4-hydroxy-6-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt	cancer

BN 52208	Discontinued	8-hydroxy-N,N,N-trimethyl-5-[[(methyloctadecylamino)methyl]3-oxo-4,7,9-trioxa-2-aza-8-phosphanodecan-11-aminium 8-oxide inner salt	cancer
BN 52210	Discontinued		
BN 52211	Discontinued	4-hydroxy-7-methoxy-N,N,N,9-tetramethyl-3,5-dioxa-9-azza-4-phosphahexacosan-1-aminium 4-oxide inner salt	cancer
BN 52213	Discontinued		cancer
BN 52214	Discontinued		cancer
BNP 7787, dimesna	Phase I	2,2'-dithiobisethanesulfonic acid disodium salt	cancer
brain tumor therapy, John Wayne Cancer Institute	Phase II		cancer
breast and ovarian cancer therapy, Myriad/Lilly	Preclinical		cancer
Affymax/American Home Products	Preclinical		cancer
breast cancer therapy, Taito/SRI International	Preclinical		cancer

BW 773U82; 773U82	Discontinued	2-[{(3-fluorophenyl)methyl]amino}-2-methyl-1,3-propanedioil	cancer
C 1006	Preliminary	N-hexyl-L-N'-(1-nitro-9-acridinyl)-L-3-propanediamine dihydrochloride	cancer
C 1210S	Discontinued		
C 609	Preliminary	N,N-dimethyl-N'-(1-nitro-9-anthracenyl)-1,5-pentanediamine dihydrochloride	cancer
C 835	Preliminary	2,2'[{[(1-nitro-9-acridinyl)amino]ethyl}limino]bis-ethanol	cancer
CA 102	Discontinued		
cancer therapy polymers, Cornell Research Foundation	Preliminary		cancer
cancer therapy, Agouron	Preliminary		cancer
cancer therapy, ASP 05/ASP 07	Preliminary		cancer
cancer therapy, brca 2 gene, Cancer Research Campaign	Preliminary		cancer
cancer therapy, Bristol-Myers Squibb/Lxsys	Preliminary		cancer

cancer therapy, Cambridge NeuroScience/Replig en	Preliminary			cancer
cancer therapy, Cell Pathways/Tripos/Pan abs	Preliminary			cancer
cancer therapy, CellPath/Genzyme	Preliminary			cancer
cancer therapy, Chiroscience. Cytolignans	Discontinued			cancer
cancer therapy,	Phase I			cancer
cancer therapy, Duke University/Targen	Preliminary			cancer
cancer therapy, Galenica/SuperGen	Preliminary			cancer
cancer therapy, GenQuest/AlQuie	Preliminary			cancer
cancer therapy, Genzyme	Preliminary			cancer
cancer therapy, Genzyme/Xenova	Preliminary			cancer
cancer therapy, Hughes Institute/Minnesota University	Preliminary			cancer
cancer therapy, ImClone/CombioChem	Preliminary			cancer
cancer therapy, Ku80, Lexicon Genetics	Preliminary			cancer

cancer therapy, Lilly;	Precinical			cancer
cancer therapy, Millennium	Precinical			cancer
cancer therapy, modulators of Rad 51/BrcA2 signalling pathway, Lexicon Genetics	Precinical			cancer
cancer therapy, National Cancer Institute	Precinical			cancer
cancer therapy, Neo Genesis	Precinical			cancer
cancer therapy, NOVALON	Precinical			cancer
cancer therapy, Ontogeny/Brightham & Women's Hospital	Precinical			cancer
cancer therapy, Ontogeny/University of California San Francisco	Precinical			cancer
cancer therapy, Pharmacopeia	Precinical			cancer
cancer therapy, PharmaMar	Precinical			cancer
cancer therapy, Phytera/Chiron	Precinical			cancer
cancer therapy, polymeric prodrug	Precinical			cancer
cancer therapy, Prolifix/BioFocus	Precinical			cancer

cancer therapy, reovirus, SYNSORB Biotech	Preliminary			cancer
cancer therapy, Shimpoong	Preliminary			cancer
cancer therapy, spiegelner, Noxxon	Preliminary			cancer
cancer therapy, SUGEN/Zeneca	Preliminary			cancer
cancer therapy, Toyama/Sugen	Preliminary			cancer
CaRest M3	Preliminary	5-(aziridin-1-yl)-2,4-dinitro-1-isobutylbenzoazole	cancer; contraception	cancer
CB 10200	Preliminary	4-(3,3-dimethyl-1-[(triazenyl)benzoic acid]-[6-(methylamino)-1,3,5-triazine-2,4-diy]bis(methylimino)]bismethanol		
CB 10277; CB 10-277	Phase II			cancer
CB 7646	Preliminary			cancer
CBT 1	Preliminary			malaria; cancer
CCI 779	Phase I			cancer
CD36 inhibitors, Affymax	Preliminary			
CDC 25	Discontinued			cancer
CDF inhibitor, Prolifx	Preliminary			cancer; psoriasis
cell cycle inhibitors, Cortex	Discontinued			cancer
cell cycle regulators, Janssen/Rigel	Preliminary			cancer

cell cycle regulators, Onyx; cell cycle regulators, Warner Lambert	Preliminary		cancer
CH 271	Phase I	4-amino-N-(5-chloro-2-quinoxaliny)benzenesulfonamide	cancer
chloroquinoxaline sulfonamide; chlorosulfoniquinoxaline ; NSC 339004; CQS	Discontinued		cancer
chronic myelogenous leukemia therapy, OSI/Aston Molecules; CML therapy, OSI/Aston Molecules			
CHS 828	Phase I	N-[6-(4-chlorophenoxy)hexyl]-N'-cyano-N''-4-pyridinylguanidine	cancer
CIDI	Preliminary		
CL 329753	Discontinued	alpha-(3,4-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha-[(4-methylphenyl)thio]-2(1H)-isouquinolinethiopentenitrile	cancer
clanfenur; DU 113901	Discontinued	I-(p-chlorophenyl)-3-(6-fluoro-N,N-dimethylanthraniloyl)urea	cancer

cloturin; VUJB 15686	Suspended	(2-chloroethyl)carbanion furoic acid, S-1H-purin-6-yl ester		cancer
colon cancer therapy; Onyx	Precclinical			cancer
combretastatin A4; NSC 817373; CRC 8709; CRC 87-09	Precclinical	(Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol		cancer
combretastatin A4 prodrug CP 79328	Phase I			cancer
	Precclinical	2-[(aminooiminomethyl) amino]-N-(5-fluoro- 2-benzothiazolyl)-4-thiazolecarboxamide		cancer

crambescidin 816; PM 92105	Preliminary	[2'a,alpha,4' <sup>1</sup> alpha,(R*) <sup>2</sup> ,7'.alpha.(S*) <sup>3</sup> ,8'.beta. <sup>4</sup> ,a.(R*) <sup>5</sup> ,8'a.alpha.a.]]-7'-ethyl-[1',2',2'a,3',4',4",5",6',7",8",8-a-dodecahydro-8'a-hydroxy-6"-methylidispirooxepin-2(3H),4'-[4H-5,6,8b]triazaacenaphthylylene]-7'(5'H),2"-[2H]pyran-8-carboxylic acid 16-[(4-amino-2-hydroxybutyl)(3-aminopropyl)amino]-16-oxohexadecyl ester	cancer
	CT 1537X	Discontinued	cancer
	CT 1595	Discontinued	cancer
	CT 3501	Discontinued	cancer; restenosis
	CTC 119	Preliminary	cancer
curacin A	Preliminary	2,4 dihydroxymethyl-alpha-tertiophenene 4,5-dihydro-4-(1-methoxy-8-methyl-1,5,7,13-tetradecatetraenyl)-2-(2-methylcyclopropyl)-thiazole	cancer
CYC 300	Preliminary		cancer

cyclin D inhibitor, Prolifix	Precinical			cancer
cyclopentenylcytosine ; CPEC	Precinical	4-amino-1-[ <i>(1R,4S)-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl]-2-(1H)-pyrimidinone</i>		cancer
D 20133	Discontinued	octadecyl-(2-(N-methyl(piperidino)ethyl)D-phosphate		cancer
D 20566	Discontinued			cancer
D 20567	Discontinued			cancer
D 21621	Discontinued			cancer
D 21663	Discontinued			cancer
D 21805	Discontinued	[2-[[hydroxy(octadecyloxy)phosphoryl]oxy]ethyltrimethylsilyl]arsoniium inner salt		cancer
D 23980	Discontinued			cancer
DA 3030; LEUCOSTIM	Pre-registration			leukopenia; cancer
daniquidone;	Discontinued	8-aminoisoindolo[1,2-b]quinazolin-12(1OH)-one		cancer
batracylin; BAY h 2049; NSC 320846				
datelliptium chloride; SR 95156B; NSC 311152; SR 95156	Discontinued	2-[2-(diethylaminoethyl)-9-hydroxy-5,11-dimethyl-6H-pyridol[4,3-b]carbolium chloride		cancer

decitabine; 5-aza-2'-deoxycytidine; 5-aza-2'-deoxyuridine; 5-CdR; AZA-DC; DAC; NSC 127716	Phase II 4-amino-1-(2-deoxy-beta-D-erythro-pento(furanosyl)-1,3,5-triazin-2 (1H)-one	[N]3-bis(2-chloroethyl)tetrahydrido-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide	cancer
dexifofanamide; D 4809	Discontinued		
dexverapamil; verapamil, d-; verapamil, R-(+); verapamil, (R); verapamil, (+); LU 33925	Phase II [R]-alpha-[3-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}propyl]-3,4-dimethoxy-alpha-[1-methylethyl]benzenecetonitrile		cancer
diaziquone; AZQ; CI 904; NSC 182986	Phase III [2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]bis(carbamic acid diethyl ester		cancer

diazonomide A	Precclinical	2-amino-N-[1-(2,6-dichloro-17,18,19,20-tetrahydro-12,31-dihydroxy-20-(1-methylethyl)-18-oxo-2H,16H-24,27'-epoxy-10a,6,10-(methanoxymethyo)-11,15-metheno-23,21-nitriolo]1,4]oxaazacyclotetradecinol[14,13-g]pyrrol[2,3,4-r][4]benzaazacyclopentadecin-17-yl]-3-methylbutanamide		cancer
	Discontinued			cancer; psoriasis; restenosis
differentiation-inducing compounds, Prolifix	Phase II			cancer
dihydro-5-szacyidine; DHAC	DIP C1	N,N,N',N'-tetraakis(2-chloroethyl)-4,8-di-1-piperidinylypyrimido[5,4-d]pyrimidine-2,6-diamine		cancer
diphenyl spironustine	Precclinical	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decan-2,4-dione diphenyl derivative		cancer
distamycin A derivatives, Menarini	Discontinued			cancer

DNA binding agent, Proteus International	Discontinued		bacterial infection; viral infection; cancer; cardiovascular disease
DNA methyltransferase modulators	Preclinical		cancer
docosahexaenoic acid, Heliosynthese; docosahexaenoic acid, Scotia DPPE	Discontinued		cancer
	Phase II	N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine	cancer, gastrointestinal ulcer
drug delivery system, Preclinical albumin microcapsules, cytotoxic drugs, CYTOCAPS			cancer, delivery system
drug delivery system, Preclinical aphidicolin; SPARTAJECT <sup>T</sup>			cancer
drug delivery system, Preclinical biodegradable polymer paste BMOV; BMOV biodegradable polymer paste			cancer

drug delivery system, chemotherapeutic drugs, ImRx; MRX-ONC	Preliminary		cancer
drug delivery system, colonic polyp therapy	Phase I		cancer
drug delivery system, intravenous, SPARTAJECT temozolomide; temozolomide SPARTAJECT	Preliminary		cancer
drug delivery system, mitoxantrone; mitoxantrone delivery system; HYAL CV1282	Phase II		cancer
drug delivery system, Pep Trans, cancer therapy	Preliminary		cancer
drug delivery system, Polyfunctional Molecular Modification, etoposide; etoposide Polyfunctional Molecular Modification	Preliminary		cancer
drug delivery system, SPARTAJECT busulfan; busulfan SPARTAJECT	Phase I		cancer

drug delivery system, SPARTAJECT <sup>®</sup> etoposide; etoposide SPARTAJECT <sup>®</sup>	Preclinical		cancer	
DT 5461	Discontinued	3-[2-deoxy-6-O-[2-deoxy-3-O-[1-oxododecyl]amino]acetyl]-2-[(1-oxotetradecyl)amino]-4-O-phosphono-beta-D-glucopyranosyl]-3-O-[(1-oxododecyl)amino]acetyl]-2-[(1-oxotetradecyl)amino]acetyl]-alpha-D-glucopyranosyl]oxy]pentanedioic acid e		cancer
ecomustine; NSC 609224; CY 233	Preclinical	methyl 3-[3-(2-chloroethyl)-3-nitrosureido]-2,3-dideoxy-alpha-D-arabinohexapyranosid e	cancer	

lecteinasidin 772; ET 772	Preliminary	[6R-(6alpha,6beta,7beta, 13beta,14beta,16alphi- a,20R*)]-5- (acetoxy)- 2',3',4',6'a,7',9',13,14, 16-decalydro-8,14- dihydroxy-9- methoxy-4,10- dimethylspiro[6,16- (epithiopropanoxymel- lano)-7,13-imino- 12H-1,3- dioxolo[7,8]isoquinol[ 3,2-b][3]benzazocine- 20,1'-11H]pyrido[3,4- b]indol]-19-one	cancer
------------------------------	-------------	---	--------

ecteinascidin 729; ETI [preclinical 729; E 729; NSC 638718]	<p>[6R-(6alpha,6beta,7beta, 13beta,14beta,16alpha- alpha,20R')]-5- (acetoxyloxy)- 3',4',6,7,13,14,16- octahydro-6',8,14- trihydroxy-7',9- dimethoxy-4,10- dimethylspiro[6,16- (epithiopropanoxymethyl- hano)-7,13-imino- 12H-1,3- dioxolo[7,8]isoquinol[ 3,2-b][3]benzazocine- 20,1'(2H)- isoquinolin]-19-one</p>	
---	---	--

ecteinascidin 743; ecteinascidin 743, monoacetyl; ET 743; E 743	Phase II  [6R- (6alpha,6beta,7beta, 13beta,14beta,16alpha- a,20R')]-5- (acet oxy)- 3',4',6,6a,7,13,14,16- octahydro-6',8,14- trihydroxy-7',9'- dimethoxy-4,10,23- trimethylspiro[6,16- (epithiopropanoxymethyl- hano)-7,13-imino- 12H-1,3- dioxol[b][7,8]isoquinol[ 3,2-b][3]benzazocine- 20,1'(2H)- isoquinolin]-19-one		cancer
ED 749; 1,107088	Preliminary Marketed	2-(difluoromethyl)- DL-omuritine	cancer cancer; trypanosomiasis; skin disease
EKI 785	Preliminary		
EL 532	Phase III		cancer anemia; cancer
elemene	Registered		cancer

emitefur; BOFA2; LAST-F	Pre-registration	3-[[3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H-pyrimidinyl)carbonyl]benzoic acid 6-(benzoyloxy)-3-cyano-2-pyridinyl ester	cancer
eugeniefeldin FA 15	Discontinued Preclinical	3-trifluoromethyl-9-(4-diethylamino-1-methylbutylamino)acridine	cancer cancer
FCE 26492	Preclinical	4,4'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino]b]is-1,5-naphthalenedisulfonic acid	cancer

FCE 26605	Preliminary	8,8'-[carbonylbis(imino)(1-methyl-1H-pyrrole-4,2-diy)carbonylimino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt	cancer
FCE 26752	Preliminary	3,5,7,7a-tetrahydro-3-hydroxy-5,7-di-1-propenyl-2H-furo[3,4-b]pyran-2-one	cancer
FD 211	Preliminary		cancer
EJ 776	Phase I		cancer
FK 973	Discontinued		cancer
fludarabine + pentostatin; fludarabine + flurbiprofen, (R); E 7869	Phase II	L-valine 5'-ester with 5-fluorouridine monohydrochloride	cancer
FO 152	Discontinued		cancer

FOLLIGEN	Precinical	6-D-phenylalanine-8-L-glutamine-9-(N-ethyl-L-prolinamide)-10-deglycaminide-luteinizing hormone-releasing factor (swine)	cancer
fosquidone; GR 63178A; NSC D 611615	Discontinued	benzyl 5,8,13,14-tetrahydro-14-methyl-8,13-dioxobenz[5,6]isindol[2,1-b]isoquinolin-9-yl ester	cancer
galocitabine; neofutulon; Ro 091390; Ro 91390	Phase III	5'-deoxy-5-fluoro-N-(3,4,5-trimethoxybenzoyl)cytidine	cancer
GAP 31	Precinical	N-[N-[N-[N-(N-L-lysylglycyl)-L-alanyl-L-threonyl]-L-tyrosyl]-L-isoleucyl]-L-threonine	HIV infection; cancer
GBC 590; NCCG	Phase I		
gene discovery, angiogenesis, Progenitor	Precinical		cancer, cardiovascular disease; eye disease; skin ulcer
gene discovery, breast & prostate cancer	Precinical		cancer
gene discovery, breast cancer, Amplicon	Precinical		cancer

gene discovery, cancer	Preclinical		cancer
gene discovery, cancer	Preclinical		cancer
gene discovery, cancer, AlphaGene	Preclinical		cancer
gene discovery, cancer, Chiron/Hyseq	Preclinical		cancer
gene discovery, cancer, CuraGen	Preclinical		cancer
gene discovery, cancer, deCODE genetics	Preclinical		cancer
gene discovery, cancer, Genassiance/Visible Genetics	Preclinical		cancer
gene discovery, cancer, Genetica/Mitox	Preclinical		cancer
gene discovery, cancer, Genome Pharmaceuticals	Preclinical		cancer
gene discovery, cancer, Genos Biosciences	Preclinical		cancer
gene discovery, cancer, Genzyme	Preclinical		cancer
gene discovery, cancer, Imcyte/OncorMed	Discontinued		cancer
gene discovery, cancer, LifeSpan	Preclinical		cancer

gene discovery, cancer, Micromet	Preliminary		cancer
gene discovery, cancer, Tularik/Amplicon	Preliminary		cancer
gene discovery, colorectal cancer, Myriad	Preliminary		cancer
gene discovery, connective tissue disorders	Preliminary		cancer; diabetes; obesity; autoimmune disease
gene discovery, growth factors, CuraGen	Preliminary		cancer
gene discovery, head and neck cancer	Preliminary		cancer
gene discovery, immunomodulatory genes, asthma, Genelabs	Preliminary		asthma; cancer
gene discovery, liver cancer, GeneCore	Preliminary		cancer
gene discovery, lymphoma, Myriad	Preliminary		cancer
gene discovery, p21 ras signalling pathway, Exelixis	Preliminary		cancer
gene discovery, pancreatic cancer	Preliminary		cancer
gene discovery, prostate and colon cancer, Millennium	Preliminary		cancer

gene discovery, prostate cancer, Amplicon	Preliminary			cancer
gene discovery, prostate cancer, Gene Logic	Preliminary			cancer
gene discovery, prostate cancer, GenSel/Sanofi- Synthelabo	Preliminary			cancer
gene discovery, prostate cancer, Myriad/Schering Plough	Preliminary			cancer
gene discovery, prostate cancer, Progenitor	Preliminary			cancer
genetic suppressor elements, cancer	Preliminary			cancer
GM 1603	Preliminary			cancer
granulocyte colony- stimulating factor mimetic; G-CSF mimetic	Discontinued			cancer
GRB2 antagonist	Preliminary			cancer
growth factor inhibitor, GlycoTech	Preliminary			cancer
growth hormone releasing hormone antagonists; GHRH antagonists	Preliminary			cancer

guanine derivatives, National Cancer Institute	Phase I		cancer
GW 278884; BW 668W95	Preliminary		cancer
halomon; NSC 650893	Suspended	(3S,6R)-6-bromo-3-(bromomethyl)-2,3,7-trichloro-7-methyl-1-octene	cancer
hatomarubigin A; CE 33A	Preliminary	(S)-3,4-dihydro-6-hydroxy-8-methoxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione	cancer
hatomarubigin B; CE 33B	Preliminary	(S)-3,4-dihydro-11-hydroxy-8-methoxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione	cancer
hatomarubigin C; CE 33C	Preliminary	(1S-cis)-1,2,3,4-tetrahydro-1,11-dihydroxy-8-methoxy-3-methylbenz[a]anthracene-7,12-dione	cancer

halomarubigin D; CE 33D	Preliminary	[1S-[1alpha,3alpha,10(1'R ,3R*)]10,10'- methylenebis[1,2,3,4- tetrahydro-1,11- dihydroxy-3- methoxy-3- methylbenz[a]anthrac- ene-7,12-dione	cancer
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer	Preliminary		stroke; ischemia; reperfusion injury; cancer
hepsulfam; NSC 329680	Discontinued	1,7-heptanediol-bis- sulfamate	cancer
HO 221	Discontinued	N-[{4-[{5-(5-pyrimidinyl)oxy}-3- chlorophenyl]amino}-2- nitrobenzamide	cancer
holmium 166 chitosan; DW 166HC	Phase II		cancer; rheumatoid arthritis
HPV E2 inhibitor, Signal	Preliminary		viral infection;
HPV E6 inhibitors, PharmaGenics	Discontinued		cancer
HRP monomer	Preliminary		cancer
human fetal alpha fetoprotein; alpha fetoprotein; DDS- DEA	Marketed		cancer

human papilloma virus 16 inhibitor, Xenova	Discontinued		cancer; viral infection
[CC 03	Discontinued		cancer
[CI 198583	Suspended	2-desamino-2-methyl-N[10-propargyl]-5,8-dideazafolic acid	cancer
[CO 15	Discontinued		cancer
sifofamide + methylene blue; methylene blue + sifofamide; D 7991	Discontinued		cancer
[KP 104	Preliminary	1-(2-chloro-3,5-dimethoxyphenyl)-2-(4-fluorophenyl)-3-methyl-6-phenyl-4(1H)-pyridinone	cancer
[L 101	Preliminary		cancer
IL-6 production inhibitors, Signal IndH (RuiInd2Cl4)	Preliminary	trans-indazolium-bisindazoletetrachlororuthenate III	osteoporosis; cancer
inhibitor of mevalonate incorporation into cholesterol: IMIC	Discontinued		cancer; hyperlipidemia
ipomeanol, 4-; 4-ipomeanol; IPo; NSC 349438	Phase I	1-(3-furyl)-4-hydroxy-1-pentanone	cancer
isobengazole	Discontinued		cancer

[isohomohalicondrin B] Discontinued	51-decarboxymethyl-12,13-dideoxy-51-(4-hydroxy-2-oxobutyl)norhalichondrin A		cancer
[ZP 94002; PHOSPHONATE]	Precclinical		cancer
[JP 7]	Precclinical		cancer; surgery; heart ischemia; stroke
[kalatalide F; PM 92102]	Precclinical	N-(5-methyl-1-oxohexyl)valylthreonylvalylvalyl-D-prolyl-L-ornithyl-D-alloisoleucylthreonyl-D-alloisoleucylvalyl-L-phenylalanyl-(Z)-2,3-dihydro-2-aminobutanoyl-valine rho-lactone	cancer; viral infection
[Kaposi's sarcoma-associated herpes virus (KSHV) infection therapy]	Precclinical		herpes; cancer
[KI 414]	Precclinical	S'-O-(N-acetyl-1,4,7,9-tetra-O-acetyl-1-methylneuraminosy)-5-fluoro-2'-3'-O-(1-methylethylidene)juridine	cancer

kinesin modulator, Cytokinetics KNK 41	Preliminary	(all-E)-5-hydroxy- 4-(8-phenyl-1,3,5,7- octatetraenyl)-2(5H)- furanone	cancer
KT 6124	Discontinued	(9alpha,10alpha,12alpha)- 2-amino-9,10,11,12- tetrahydro-10- (hydroxymethyl)-9- methyl-9,12-epoxy- 1H-dindolo[1,2,3- fg;3'2',1'- k]pyrrol[3,4- i][1,6]benzodiazocine -1,3(2H)-dione	cancer
KW 2149, KT 6149	Phase I	7-N-[2-[[2-(gamma- L- glutanylamino)ethyl] dithio]ethyl]imidomyci- n C	cancer
KW 2170	Phase I		
KYN 54	Discontinued	5-hydroxy-4-(2- phenyl-(E)-ethenyl)- 2(5H)-furanone	cancer
LAC 83	Preliminary		cancer

lanellarin-N tracetate	Discontinued (+)-3,11- bis(acetoxy)-14-[3- (acetoxy)-4- methoxyphenyl]- 2,12-dimethoxy-6H- [1]benzopyran[4',3'; 4,5]pyrrolo[2,1- a]isoquinolin-6-one		cancer
LDI 200 lissoclinamide 7	Phase III Preclinical [3R- (3R*,4S*,7R*,11R*, 4R*,18R*,21S*,26S *)]- 6,7,12,13,14,17,18,20 [2],24,25,26,26a- decahydro-3-methyl- 7-(1-methylethyl)- 16,21- bis(phenylmethyl)- 3H,1OH- 4,1:1,8:18:15- trinitro-1H- pyrrole[2,1- c][1,11,18,4,7,14,21]o- xadilinatetraazacyclo- etracosine- 5,12,19,22(4H,11H)- tetrone	[3R- (3R*,4S*,7R*,11R*, 4R*,18R*,21S*,26S *)]- 6,7,12,13,14,17,18,20 [2],24,25,26,26a- decahydro-3-methyl- 7-(1-methylethyl)- 16,21- bis(phenylmethyl)- 3H,1OH- 4,1:1,8:18:15- trinitro-1H- pyrrole[2,1- c][1,11,18,4,7,14,21]o- xadilinatetraazacyclo- etracosine- 5,12,19,22(4H,11H)- tetrone	cancer

lonidamine; diclondazolic acid; AF 1890; KN 228; DORADAMINA LY 195448	Marketed Discontinued	I-(2,4-dichlorobenzyl)- 1H-indazole-3-carboxylic acid (R)-4-[3-(2-hydroxy- 2-phenylethyl)amino]- 3-methylbutyl]benzamide monohydrochloride	cancer cancer
LY 296329; 296329 LY 320236	Preliminary Phase I	(4aR-trans)-8-[(4- ethyl-1-2-benzothiazolyl)thio]- 1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[1]quinolin-3(2H)-one	cancer benign prostate hyper trophy; cancer
lysolecithin; lysolecithin; T 680 mammastatin	Discontinued Phase 1	Unspecified	cancer cancer

MC 77	Preliminary	[1aS-(1aalpha,8beta,8aaalpha,8balpha)-8-[(aminocarbonyl)oxy]-1,1a,2,3,8a,8b-hexahydro-8a-methoxy-5-methyl-6-[[4-[[(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)oxy]phenyl]amino]azinol[2',3':3,4]pyrrolo[1,2-alindole-4,7-dione	cancer
MDL 27048	Suspended	(E)-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylaminophenyl)-2-methyl-2-propen-1-one	cancer
Ventana Genetics	Preliminary		cancer
melarsoprol; RP 3854	Marketed	2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiar solane-4-methanol	cough; cancer
MEN 10710	Discontinued		cancer
merbarone; V 1235; NSC 336628; NSC 336028	Phase II	hexahydro-4,6-dioxo-N-phenyl-2-thioxo-5-pyrimidinecarboxamide	cancer
METCYCLOR	Preliminary		cancer

MGI 222	Discontinued			cancer
MGI 650	Discontinued			hyperammonemia, cancer
MF inhibitor, NIH; macrophage migration inhibitory factor inhibitor, NIH	Preclinical			cancer
mitoflaxone; flavone acetic acid; FAA; LM 975; NSC 347512	Discontinued	4-oxo-2-phenyl-4H-1- benzopyran-8-acetic acid		cancer
mitomycin analogues; Discontinued Georgetown University				cancer
mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHA Q; DHAD; NOVANTRONE; NOVATRON	Marketed	1,4-dihydroxy-5,8- bis[2-[2-[2- hydroxyethyl]amino]e- thyl]amino]9,10- anthracenedione		cancer; multiple sclerosis
MM-COOK	Preclinical	4-(3-methyl-1- triazenyl)benzoic acid, monopotassium salt		cancer
molarotene; Ro 408757	Discontinued	(E)-4-[2-[4-(2- [5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2- naphthalenyl)-1- propenyl]phenoxy]eth- yl]morpholine		cancer

monophosphoryl lipid A + trehalose dimycolate; trehalose dimycolate + monophosphoryl lipid A; MPL + THD; OVAMID	Discontinued		cancer
moipidamol; RA 233; OLX 102; AR 102; RAPENTON	Withdrawn	2,2'2",2""-[{4-piperidinopyrimidol[5,4-d]pyrimidine-2,6-diyl]dinitriolo}tetraethanol]	cancer
MPC 467	Preliminary		cancer
MS 247	Preliminary	[3-[[5-[{[4-[bis(2-chloroethyl)amino]phenyl}amino]carbonyl]-1H-benzimidazol-2-yl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxopropylidinemethylsulfonium mono(4-methylbenzenesulfonate) salt with 4-methylbenzene sulfonic acid (1:1)	cancer
MSI 1290	Discontinued		cancer
MSI 130	Discontinued		cancer, gastrointestinal disorder
MSI 1436	Discontinued		viral infection; restenosis; diabetes; cancer
MSI 511	Discontinued		cancer

MSI 58	Discontinued		cancer
MSI 782	Discontinued		cancer
MSI 99	Discontinued		cancer
MT 1	Suspended		cancer
MT 2	Preclinical		cancer
multiple drug resistance gene inhibitor, Immunex	Preclinical		cancer
mustard anticancer agent; NORPRAN MX 6; MX6	Preclinical		cancer
mycaperoxide B; PM 92104	Phase III	[1R-[1alpha, [13S*(S*),6S *]-2alpha,4alpha,8ab eta]]-6-[2-(decahydro-1-hydroxy-2,5,5,8a-tetramethyl-1-naphthalenyl)ethyl]-alpha,6-dimethyl-1,2-dioxane-3-acetic acid	cancer
mycobacterial cell wall extract; MCWE; REGRESSIN myriaporone	Phase II		cancer
N 1554	Discontinued	(all-E)-3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracontanonaen-1-ol dihydrogen phosphate	cancer

N-acetyldinaline; acetyldinaline; Cl 994; GOE 5549; PD I23654	Phase II  4-(acetylamino)-N-(2- aminophenyl)benzani- de	cancer
NC 381	Preliminary	
NC 383	Preliminary	cancer
NC 384	Preliminary	cancer
NC 407	Preliminary	cancer
melarabine; melazarabine; 506U78; BW 506U; MAY; 506U	Phase III  9-beta-D- arabinofuranosyl-6- methoxy-9H-purin-2- amine	cancer
NIK 264	Phase I  Preclinical	cancer
NK 242	4-(5,6-dihydro-1,4- dioxin-2-yl)-1,4- dihydro-2,6-dimethyl- 3,5- pyridinedicarboxylic acid bis[3-(3- pyridinyl)propyl] ester	cancer
NK 250	Preclinical  4-(5,6-dihydro-3- methyl-1,4-dithiin-2- yl)-1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid bis(4- pyridinylmethyl) ester	cancer

NR 252	Preliminary	4-(5,6-dihydro-1,4-dioxin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis[5-ethyl-2-pyridinylmethyl]ester		cancer
NM 324	Phase I	2-[[(hydroxy[[12-[[3-(iodo-[125]I)phenyl]dodecyl]oxy]phosphoryloxy]N,N,N-trimethyllethanaminium inner salt		cancer
	Marketed	noscapine; narcosine; methoxyhydrastine; opian; opianine; NSC 5366; COSCOPIN; COSCOTABS; CAPVAL; KEY-TUSSCAPINE; NOSCAPAL; TERBENOL		cough; cancer
	Preliminary	notch signalling pathway modulators, Exelixis		stroke; cognitive defect; cancer
NSC 242557	Preliminary	[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]propanedi nitrile		cancer

NSC 303861	Discontinued	S-(N-methylcarbanate)-L-cysteine, ethyl ester, monohydrochloride		cancer
NSC 361456	Phase I	N-nitrosoprazinamine, sodium salt		cancer
NSC 639829	Preliminary	dimethyl amino benzoylphenylurea		cancer
NSC 650573	Preliminary	(Z)-2-methyl-9-(phenylinino)aphthal[2,3-d]oxazol-4(9H)-one		cancer
NSC 686288	Preliminary	5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one		cancer
OC 144093	Preliminary			
OCT 1001	Preliminary	6-amino-1,2-benzopyrone		viral infection; cancer
okicenone	Preliminary	3,4-dihydro-4,6,9-trihydroxy-8-methyl-1(2H)-anthracenone		cancer
OLX 516	Discontinued			septic shock; cancer; vascular leakage
ONO FS045	Discontinued			
oracitin; VUFB 16956	Phase I	6-[2-[(2-hydroxyethyl)amino]ethyl]-5H-indeno[1,2-c]isoquinoline-5,1(6H)-dione		cancer

oral cytokine inducer, Phase I immunex	Phase I		cancer, leukopenia
P 154	Preliminary		cancer
p185 inhibitors, University of Pennsylvania	Preliminary		cancer
p53 function activators, Genzyme	Preliminary		cancer
p53 mimetic, BioNumerik	Preliminary		cancer
p53/MDM2 interaction inhibitor, Genzyme	Preliminary		cancer
PA 8	Preliminary	2,2'[(1,1,3,3- tetrabutyl-1,3- distanoxane-4,4'- oxy carbonyl)bis[ methoxyphenol]]bis[4-	cancer
palauamine	Discontinued	[3aa]beta,[0aa]alpha,[1] beta,12beta,13beta(S*) )13aa[alpha,13bR*]-{ )2,2'-diamino-11- (aminomethyl)-12- chloro- 1,1',3a,5,10a,11,12,1 3a-octahydro-5'- hydroxyspiro[8H- cyclopenta[3,4]pyrrol o[1,2-d]imidazo[4,5- b]pyrrole[1,2- d]pyrazine- 13(10H),4'- [4H]imidazol]-8-one	cancer

154]	palmitoylrrizoxin; RS	Preliminary 2,3,11,12-diepoxy- 8,12-dimethyl-7,13- dihydroxy-15[3- methoxy-4,8- dimethyl-9-(2- methyl-4- oxazolyl)octa:4,6- dien-2-yl]-9- pentadecenolide-5- acetic acid gamma- lactone	cancer
	panaxytriol	Preliminary 1-heptadecene-4,6- diyne-3,9,10-triol	cancer
	pazelliptine; BD 40; SR 95225A; SR 95225	Discontinued N,N-diethyl-N'-(6- methyl-1H- pyrido[3',4':4,5]- pyrrololo[2,3- g]isoquinolin-10-yl)- 1,3-propanediamine	cancer
	PEPTIDYL MIM	Preliminary	cancer, bacterial infection
PG 2		Phase I	
PG 266		Preliminary	
PG 278		Discontinued	
PG 349		Discontinued	
PG 356		Discontinued	
PG 36		Discontinued	
PG 4336		Discontinued	

PG 488 phenetyl isothiocyanate	Discontinued Phase I		cancer; anemia
picibanil; OK 432; OK 5; PCB 45; PICIBANIL; PICIVANYL	Marketed		cancer
piroxantrone; oxathiazole; oxantrazole; CI 942; PD 111815; NSC 349174; DUP 942	Discontinued	5-[3-(3- aminopropyl)amino]- 7,10-dihydroxy-2-[2- [(2- hydroxyethyl)amino]e- thy]anthra[1,9- cd]pyrazol-6(2H)-one	cancer
PKH 135	Discontinued		cancer; ischemia; reperfusion injury
platinum compounds, BioNumerik	Preliminary		cancer
PM 14	Preliminary	hepta-mu-oxo-mu6- oxodioxo(penta-mu- oxotetraoxotetratungs- tate)divanadate(4-) tetraplatinum	cancer
PM 24	Preliminary	polyoxotungstate	
PM 40; JM 1490	Preliminary	(guaniniclate)(mu12 -orthosilicate)(4-) O:O-O':O":O":O' O":O":O":O":O":O": sa-mu- oxoundecaoxoundecat- ungstate(6-) hexaplatinum	cancer
PM 90001	Preliminary		cancer

PM 91101	Preclinical		cancer
PM 91102	Preclinical		cancer
PM 92127	Preclinical		cancer
PM 92130	Preclinical		cancer
PM 93100	Preclinical		cancer
PM 93107	Discontinued		cancer
PM 93113	Preclinical		cancer
PM 94103	Preclinical		cancer
PM 94127	Preclinical		cancer
PM 94132	Preclinical		cancer
PNU 153429	Phase I 2,2'-[carbonylbis(imino)(1-methyl-1H-pyrrole-4,2-diy)carbonylimino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino]bisc-1,5-naphthalenedisulfonic acid tetrasodium salt		cancer
PNU 157911	Preclinical		cancer
PNU 166196	Preclinical		cancer
podophyllotoxin analogues, IGT	Preclinical		cancer
Pharma	Poly ADP-ribose polymerase inhibitor; PARP inhibitor	Preclinical	cancer
	protein kinase RNA-activated based therapeutics, RiboGene	Preclinical	cancer; viral infection

PX 12 pyrazoloacridine; pyrazoloacridine hydrochloride; PD 115934; NSC 366140	Precinical Phase I	9-methoxy-N,N- dimethyl-5- nitropyrazolo[3,4,5- k]lactidine-2(6H)- propanamine	cancer cancer
RA 700; RA VII; TPC-B	Suspended	5-(N-methyl-L- tyrosine)-6-(3- hydroxy-N,O- dimethyl-L- tyrosine)heptyavadin	cancer
raf antagonists, SUGEN	Precinical		cancer
ras geranylgeranylation inhibitors	Precinical		cancer
ras inhibitors, ProScript	Precinical		cancer
ras-GAP inhibitor, Xenova	Discontinued		cancer
retellipine; SR 95325; SR 95325B	Discontinued	1-[3- (dimethylamino)prop- yl]amino]-9-methoxy- 5,11-dimethyl-6H- pyrido[4,3- b]carbazole	cancer
retellipine demethylated rice-bran saccharide;	Discontinued		cancer
RBS, SPR 901 RL 344007;	Discontinued	(1-3),(1-6)-alpha-D- glucan	cancer
NORPRAM	Preclinical		cancer

RSR 4	Preclinical	2-[4-[2-[3-(5-dichlorophenyl)amino]-2-oxethyl]phenoxy]-2-methylpropanoic acid	cancer; surgery; heart ischemia; stroke
RSR 46	Preclinical	2-[4-[2-[2-(2,3-dihydro-1H-inden-5-yl)amino]-2-oxethyl]phenoxy]-2-methylpropanoic acid	cancer; surgery; heart ischemia; stroke
salvinolic acid A	Preclinical		
sarcodictyins	Preclinical		cancer
SC 101; SC 101c; EPAKEX	Phase III	1-(Z,Z,Z,Z-eicos-5,8,11,14,17-pentaenoyloxy)-3-(Z,Z,Z,Z-eicos-5,8,11,14,17-pentaenoyloxy)propane	cancer; cachexia
SC 101g; GLAMEPA	Preclinical	1-(Z,Z,Z-octadeca-6,9,12-trienoyloxy)-3-(Z,Z,Z,Z-eicos-5,8,11,14,17-pentaenoyloxy)-3-(Z,Z,Z,Z-eicos-5,8,11,14,17-pentaenoyloxy)propane	cancer
MEGLUMINE-GLA	Phase I	meglumine-2,Z-	
SC 101i	Preclinical	6,9,12-octadecatrienoate meglumine-6,9,12,octadecatrienoate	cancer

SCHAL 3	Phase I			skin disease; cancer; psoriasis
Sdi 1 mimetics, SENNES	Discontinued			cancer
SDK 110	Preliminary	3-[3-(trimethylsilyl)propyl]thio]-1-propanamine		cancer
SDZ MKT 077; MKT 077; FJ 776	Phase I	1-ethyl-2-[3-ethyl-5-(3-methyl-2-(3H)-benzothiazolylidene)-4-oxo-2-thiazoolidinylidene]methyl[pyridinium chloride]		cancer
SE 12363	Preliminary			cancer
selenium thiosemicarbazone; NEOSTAT	Preliminary			cancer
SF 2698	Preliminary	(6S)-iminoazacyclohexa-3-ene-6-carboxylic acid		cancer
sialyl transferase inhibitor, Biota	Preliminary			cancer
SJ 3249	Preliminary	4-(3,5-dimethylphenyl)-N-(2-methoxy-5,6-dimethyl-3-pyridinyl)-1-piperazinecarboxamid e		cancer
sodium phenylacetate; EL 530	Phase III	sodium phenylacetate		cancer

spirodiam 3; diam 3; PE 1001	Discontinued	[2,2,4,4,-tetakis(1-aziridinyl)-2,2,4,4-tetrahydro-1,3,5,7,11-pentaza-2,4,6-ambda,5-triphosphorotri[5.5]undeca-1,3,5-triene	cancer
spongistatin 1  SR 26050	Discontinued Discontinued	(1-(3-diethylaminopropylamino)-9-hydroxyellipticine dihydrochloride	cancer cancer
SR 271425  SR 45023a; SR 45023	Phase I Phase I	[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-phosphonic acid tetraakis(1-methylethyl) ester	cancer
ST 30	Preliminary	(E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid	cancer
ST 40	Preliminary	(E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid	cancer

stipamide; fenalamid A1; phenalamide A1	Precinical [[12R- [1(S*)-2E,4E,6Z,8E]- [0E,12R*,13R*,14E]- [6S*]-]13-hydroxy-N- (2-hydroxy-1- methyl ethyl)- 2,10,12,14,16- pentanethyl-18- phenyl-2,4,6,8,10,14- octadecahexaenamide]	cancer
SU 201	Discontinued	cancer
SU 65591	Precinical	cancer
SUN 4599	Discontinued 2-alpha-L- arabinopyranosyl-9- hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbazolium bromide	cancer
superfibronectin suranin; CI 1003; METARET	Precinical 8,8'- [carbonyl]bis[imino- 3,1- phenylene carbonylimi- no(4-methyl-3,1- phenylene carbonyli- mino)]bis-1,3,5- naphthalenetrisulfonic acid	cancer parasitic infection; cancer

swainsonine; (-)-swainsonine; hydrochloride; GD 0039	Phase II	[1S-(1alpha,2alpha,8beta,8beta)-octahydro-1,2,8-indolizinetriol]	cancer; viral infection
T4GEN	Phase I		HIV infection; cancer
TAC 903	Preliminary	chrome-8-acetic acid	cancer
tamoxifen methiodide; PA 50300	Preliminary		cancer
TBC 1635	Preliminary	4-tert-butyl-[3-(2-chloroethyl)ureido]benzene	retinopathy; cancer
BCEU	Preliminary		cancer
TER 286	Preliminary	(2R)-L-gamma-glutamyl-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethyl]suifonyl-L-alanyl-2-phenyl-glycine	cancer

thaliblastine; thaliblastine; thalicarpine; (+)- thalicarpine; TBL; thalicarpin; NSC 68075	Phase III  [(1,2,3,4-tetrahydro- 6,7-dimethoxy-2- methyl-1- isoquinoliny)methyl] phenoxyl-5,6,6a,7- tetrahydro-1,2,10- trimethoxy-6-methyl- 4H-dibenzo[de,g]quinolin e	[S-(R*,R*)]-9-[4,5- dimethoxy-2- [(1,2,3,4-tetrahydro- 6,7-dimethoxy-2- methyl-1- isoquinoliny)methyl]]	cancer
thrombopoietin mimetic, Arys	Discontinued		cancer; thrombocytopenia
TJ 14026	Discontinued		cancer
transforming growth factor beta receptor inhibitors, Affymax	Preliminary		cancer
tracytelyuridine	Phase I		HIV infection;
triciridine; NSC 154020; TCN	Preliminary	1,5-dihydro-5- methyl-1-beta-D- ribofuranosyl- 1,4,5,6,8- pentazaacenaphthylc n-3-amine	cancer
TRIFENS	Preliminary		diarrhea; gastrointestinal disorder; sickle cell anemia; cancer
TT 62	Discontinued	5-fluoro-2'- deoxyuridine 5'- tetradecylphosphate	cancer

tucaresol; BW A 589C; BW 589C80; BW 589C; 589C	Phase II	4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
tumor suppressor genes, oncology; Onyx	Preliminary		cancer
tumor suppressor genes, Onyx U77863	Preliminary		cancer
	Discontinued	trans-3-(2-methylphenyl)-2-propene-1-carboxamide	cancer
UBC 10 inhibitors, cancer, ProScript UK 21	Preliminary		cancer
V 489	Phase I	N-(1-oxo-2-propylpentyl)glycine ester with 5-fluouridine	cancer
VA 5	Preliminary	6-(2,5-dimethoxyphenyl)-2,3-dihydroimidazo[2,1-b]thiazole	heart failure; cancer
variolin B	Discontinued		cancer; viral infection
VDacac	Preliminary		cancer; contraception
WDDTC	Preliminary		cancer; contraception
Velaresol; BW 12C79; 12C	Suspended	5-(2-formyl-3-hydroxyphenoxy)-pentanoic acid	cancer; sickle cell anemia
VG 18563	Preliminary		anemia; cancer

vitamin B12 growth blockers; Receptigen. WIN 33377	Precinical Discontinued	N-[1-[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-y[methyl]-methanesulfonamide	cancer cancer
XX 469 Y 25510	Precinical Discontinued	(+,-)-3-[4-[2-(dimethylamino)-1-methyl[ethoxy]phenyl]-1H-pyrazolo[3,4-b]pyridine-1-acetic acid	cancer cancer
YM 534	Phase I	6-[4-[5-(1H-imidazol-1-yl)pentyloxy]phenoxy]-2,2-dimethylhexanoic acid ethyl ester monohydrochloride	cancer
YW 200 YW 213 ZD 2767P	Precinical Precinical Phase I	N-[4-[bis(2-iodoethyl)amino]phenoxycarbonyl]-L-glutamic acid	cancer cancer cancer
ZD 9063P zilascorb; ZOXXXZ	Precinical Suspended	5,6-O-(RS)-benzylidene-alpha-L-L-ascorbic acid	cancer cancer

zinostatin stimalamer; drug delivery system; neocarzinostatin; neocarzinostatin delivery system; YM 881; SMANCS	Marketed	zinostatin stimalamer		cancer
ZK 119010	Preliminary	2-(4-hydroxyphenyl)- 3-methyl-1-[6-(1- pyrroldinyl)hexyl]- 1H-indol-5-ol		cancer
ZYN176	Suspended Preliminary			cancer cancer
ZYN-LINKER conjugated thiocochicine analogues	Discontinued	17beta-[(1,1- dimethyl ethyl)amino] carbonyl]androsta- 3,5-diene-3- carboxylic acid	5 alpha reductase inhibitor	benign prostate hypertrophy; cancer; alopecia; acne
epiristeride; SKF 105657; ONO 9302	Marketed	(5alpha,17beta)-N- (1,1-dimethyl ethyl)- 3-oxo-4-azandrost-1- ene-17-carboxamide	5 alpha reductase inhibitor	cancer; benign prostate hypertrophy; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO- PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA [23]	Discontinued		5 alpha reductase inhibitor	cancer; acne; hirsutism

A 63162	Precinical	N-hydroxy-N-[1-[4-(phenylmethoxy)phenyl]ethyl]lactamide	5 lipoxygenase inhibitor	cancer
masaprocol; CHX 100; ACTINEX	Marketed	(R*,S*)-4,4'-[2,3-dimethyl-1,4-butanediyl]bis-1,2-benzenediol	5 lipoxygenase inhibitor	skin disease; cancer; psoriasis
SC 41661A	Discontinued		5 lipoxygenase inhibitor	cancer
KBR 8498	Precinical	(1alpha,2alpha,4beta)-4-[[2-(1-piperazinyl)-4-quinazolinyl]oxy]-1,2-cyclopentanediol	5HT agonist	cancer
EF 7412	Precinical	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrrol[1,2-c]imidazol-2(3H)-yl]butyl]-1-piperazinyl]phenyl]jetranesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
adecyepenol; OM 3223	Precinical	5-(7,8-dihydro-8-hydroxymidazo[4,5-d] [1,3]diazepin-3(4H)-yl)-3-(hydroxymethyl)-3-cyclopentene-1,2-diol	adenosine deaminase inhibitor	cancer

pentostatin; 2'-deoxycoformycin; covtarabine; Cl 825; NSC 218321; PD 81565; Cl 67310465; YK 176; NIPENT; COFORIN	Marketed	(R)-3-(2-deoxy-beta-D-erythro-pento furanoyl)-3,4,7,g-tetrahydromimidazo[4,5-d][1,3]diazepin-8-ol	adenosine deaminase inhibitor	adenosine deaminase inhibitor	cancer
adenosine allosteric modulators; Medeo	Preliminary		adenosine regulating agent	cardiovascular disease; cancer; stroke	
OCT 1003	Preliminary	3-nitrobenzamide	ADPRT ligand	cancer	
OCT 1004	Preliminary	6-nitroso-1,2-benzoxazine	ADPRT ligand	cancer	
forfenimex; forphenicinol; BF 121	Discontinued	(S)-alpha-amino-3-hydroxy-4-(hydroxymethyl)benzenoic acid	alkaline phosphatase inhibitor; immunostimulant	bacterial infection; cancer	
sambamustine; PTT 119; BLASTOP	Phase III	N-[3-[bis(2-chloroethyl)amino]-N-(4-fluoro-L-phenylalanyl)-L-phenylalanyl]-L-methionine, ethyl ester	alkylating agent	cancer	
bistrizenes, NIH bistrizesin; U 7779; NSC 615291	Preliminary		alkylating agent	cancer	
	Phase I	S-(R*-R*)]-6,6'-[carbonylbis(imino-1H-indole-5,2-diyl carbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methylbenzo[1,2-b:4,3-b']dipyrrol-4-ol]	alkylating agent	cancer	

carzelesin; U 80244	Phase II	N-[2-[[1-(chloromethyl)-1,6-dihydro-8-methyl-5-[[[phenylamino]carboxy]oxy]benzoi[1,2-b:4,3-b]dipyrrol-3(2H,7H)[carbonyl]-1H-indol-5-yl]-6-(diethylamino)-2-benzofurancarboxamidine	alkylating agent	cancer
CBS 5	Discontinued	4-[3-(2-chloroethyl)-1-(benzyl)-2-triazenyl]-1,4-dioxobutyl-beta-alanyl-tryptophyl-methionyl-aspartyl-phenylalaninamide	alkylating agent	cancer
DABIS maleate; NSC/Precinical 262666		1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane ((Z)-2-butenedioate (1:2)	alkylating agent	cancer

drug delivery system, carbustine biodegradable implant; drug delivery system, sustained release BCNU; BIODEL BCNU implant; carbustine delivery system; prolifeprasan 20, carbustine implant; GLIADEL, GLIADEL WAFER	Marketed		alkylating agent	cancer
electrophilic alkylating agents, BioNumerik	Preliminary		alkylating agent	cancer
EO 9; NSC 382459	Phase II	(E)-5-(1-aziridinyl)-3-alkylating agent (hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-[1H-indole]-4,7-dione		cancer
estramustine analogue glufoxanamide; D 19575	Phase I	1-[N,N'-bis(2-chloroethyl)phosphodiimidate]-beta-D-glucopyranose	alkylating agent alkylating agent	cancer cancer
glutathione S-transferase-activated toxins, Telik	Discontinued		alkylating agent	cancer
isopropyl pyrrolizine derivative; IPP	Discontinued		alkylating agent	cancer
KF 22678	Preliminary		alkylating agent	cancer

mebastamine; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	Discontinued mebastamine; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	cis-(+,-)-2-[{2-[bis(2- chlorethylamino)tetrahydronaphthalenyl]oxy}-2H-1,3,2- oxazaphosphorin-4- ylthio]ethanesulfonic acid P-oxide	cis-(+,-)-2-[{2-[bis(2- chlorethylamino)tetrahydronaphthalenyl]oxy}-2H-1,3,2- oxazaphosphorin-4- ylthio]ethanesulfonic acid P-oxide	alkylating agent cancer
melphalan + A-MSH; F1K	Discontinued melphalan + L-amino oxidase			alkylating agent cancer
OCX 177; OCX 0177	Preliminary Phase III			alkylating agent cancer
porfimycin; N- methylimidoycin C; ENT 50825; NSC 56410; U 14743; PROMYCIN		[1As- [1a.alpha.,8.beta.,8a.a [8b.alpha.]-6- amino-8- [(aminocarbonyl)oxy [methyl]- 1,1a,2,8a,8b- hexahydro-8a- methoxy-1,5- dimethyl- azirino[2,3';3,4]pyrro lo[1,2-a]indole-4,7- dione		alkylating agent cancer
SBR 11170; SBR 170	Preliminary Marketed			alkylating agent cancer
tenozolamide; methazolastone; SCH 52365; CCRG 81045; NSC 362856; M&B 39831; TEMODAL		3,4-dihydro-3- methyl-1-imidazo[5,1- d]-1,2,3,5-tetrazine-8- carboxamide		alkylating agent cancer
treosulfan; OVASTAT; TREOSULFAN	Marketed	L-threitol 1,4- dimethanesulfonate		alkylating agent cancer

PNU 159548	Phase I	(7S-cis)-9-acetyl-7-[3-(1-azindinyl)-2,3,6-trideoxy-4-O-(methylsulfonyl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	alkylating agent; DNA intercalator	cancer
	Marketed	1,6-dibromo-1,6-dideoxygalactitol	alkylating agent; peptide	cancer
mitolectol; bromoalcohol; dibromodulcidol; DBD; NSC 104800; MITOLACTOL; METHOLACTOLE; ELOBROMOL				
bisaziridinylsperrmine; BAS	Preliminary	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
diaziridinylsperrmine; DASPM	Preliminary	N,N'-bis[3-(1-aziridinyl)propyl]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
O6-benzylguanine	Phase I		alkyltransferase inhibitor, chemosensitizer	cancer
samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium CYT 424; QUADRAMET	Marketed	(OC-6-21)-[[1,2-ethanediylibis(nitrilotriakis(methylene))tetraakis(phosphonato)][8-], N,N',O,P,O',O'',O''-]-samarate(5-)] 1.535m	analgesic; NSAID; antiinflammatory/radiotherapeutic	cancer; pain; rheumatoid arthritis

abiraterone; piraterone; CB 7630; CB 7598	Phase I Preclinical	(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol	androgen synthesis inhibitor	cancer
cancer therapy, Institute of Cancer Research Saarbrücken University GI 111924	Preclinical Suspended		androgen synthesis inhibitor	cancer
VN 851	Preclinical		androgen synthesis inhibitor	cancer
VN 871	Preclinical		androgen synthesis inhibitor	cancer
YM 116	Phase I	2-(1H-imidazol-4-ylmethyl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 53789	Preclinical	2-(6,7-dihydro-5H-pyrrrol[1,2-c]imidazol-7-yl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 55208	Preclinical	2-[1-(1H-imidazol-1-yl)ethyl]-9H-carbazole	androgen synthesis inhibitor	cancer
gene therapy, cancer, Genetix	Preclinical		angiogenesis inducer; biotechnology; gene therapy	cancer
2-methyl-2-phthalimidino-glutaric acid	Preclinical		angiogenesis inhibitor	cancer

9alpha-fluoromethoxyprogesterone acetate; FMPA	Preclinical	(6-alpha)-17-(acetoxy)-9-fluoro-6-methyl-pregn-4-ene-3,20-dione	angiogenesis inhibitor	cancer
ANG 453; ZD 6126	Preclinical		angiogenesis inhibitor	cancer
angio genesis inhibitor, Boston Life Sciences	Preclinical		angiogenesis inhibitor	cancer
angio genesis inhibitor, Merck KGaA; EMD 121974	Phase I		angiogenesis inhibitor	cancer
angio genesis inhibitors, AstraZeneca	Preclinical		angiogenesis inhibitor	cancer
angio genesis inhibitors, Nanodesign	Preclinical		angiogenesis inhibitor	cancer
angio genesis inhibitors, Novartis/Schering AG	Preclinical		angiogenesis inhibitor	cancer
angio genesis inhibitors, Repligen CT 3577	Discontinued		angiogenesis inhibitor	cancer

FCE 26644; PNU 151484	Preliminary	7,7'-[carbonylbis(imino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino)]bis-1,3-naphthalenedisulfonic acid tetrasodium salt	angiogenesis inhibitor	cancer
FCE 27164; PNU 163897	Preliminary	7,7'-[carbonylbis(imino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino(1-methyl-1H-pyrrole-4,2-diy)carbonylimino)]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt	angiogenesis inhibitor	cancer
gene discovery, tumor epithelium	Preliminary		angiogenesis inhibitor	cancer
greenstatin	Preliminary		angiogenesis inhibitor	cancer
Isogladine; Isogladine maleate; Isaglidole; MN 1695; GASLON; GASLON-N	Marketed	2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine	angiogenesis inhibitor	gastrointestinal ulcer; cancer
RG 8803; RG 8803B11; RG 1009	Preliminary		angiogenesis inhibitor	cancer

squalamine	Phase 1 SR 25989	(3beta,5alpha,7alpha,24R)angio genesis inhibitor 3-[3-[4-(aminobutyyl)amino]propyl]aminocholestan e-7-24-diol 24-(hydrogen sulfate)	viral infection; cancer; retinopathy
SU 301	Discontinued	angio genesis inhibitor	cancer
SU 302	Discontinued	angio genesis inhibitor	cancer
suradista	Discontinued	angio genesis inhibitor	cancer
TAN 1120	Phase I Preclinical	angio genesis inhibitor 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[octahydro-5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethylpyranol[3,4-d]-1,3,6-dioxazocin-8-y]oxy]-5,12-naphthacenedione	cancer
TZ 93	Discontinued Preclinical	angio genesis inhibitor angio genesis inhibitor	cancer cancer
VE-cadherin-2 antagonists, ImClone Systems	Prec clinical		
VEGF receptor modulators, Pharmacopeia	Prec clinical	angio genesis inhibitor	cancer
INGN 401	Prec clinical		angio genesis inhibitor; cancer
soluble Tie-2	Prec clinical		angiogenesis inhibitor; antiproliferative agent angiogenesis inhibitor; cancer biotechnology

angiogenesis inhibitor; Bio-Technology General; plasminogen-related peptide Bio-Technology General	Precinical		angiogenesis inhibitor; biotechnology; peptide	cancer
SU 6668	Phase I		angiogenesis inhibitor; cancer growth factor modulator	
AE 941; NEOVASTAT <sup>®</sup> ; NEORETNA; PSOVASCAR; ARTHROVAS	Phase III		angiogenesis inhibitor; cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy	NSAID
FR 111142; WF 2015A	Discontinued	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butene)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester	angiogenesis inhibitor; cancer; rheumatoid arthritis; retinopathy	NSAID
InSight heparanase inhibitors, Preclinical			angiogenesis inhibitor; cancer; inflammation	NSAID
Itronopin 1; cartilage derived inhibitor	Precinical		angiogenesis inhibitor; cancer; rheumatoid arthritis; biotechnology; eye disease	NSAID
antiangenesis agent, Ixsys	Discontinued		angiogenesis inhibitor; cancer; restenosis	peptide
XMP 300	Precinical		angiogenesis inhibitor; peptide	inflammation; cancer
ENDOSTATIN	Precinical		angiogenesis inhibitor; peptide	cancer
				peptide; biotechnology

thrombospondin 1 inhibitor; Inkine; TSP-1 inhibitor, Inkine	Preliminary		angiogenesis inhibitor; cancer; diagnosis; platelet antaggregant; thrombosis
tegocalan sodium; DS/Phase I 4152; SP PG	Phase II	sulfated polysaccharide peptidoglycan	angiogenesis inhibitor; cancer polysaccharide sulfate
SU 5416		3-[{4,5-dimethyl-1H-pyrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one	angiogenesis inhibitor; cancer tyrosine kinase inhibitor; signal transduction inhibitor
rubiginone B1	Discontinued		anguicycline; antibiotic
aclarubicin;	Marketed	methyl[(R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl}oxy]-1-naphthacenecarboxylate	cancer; anthracycline; antibiotic; DNA intercalator
aclarubicin hydrochloride;			
aclacinomycin A; NSC 208734; MA 144A1; JAACLACIN; ACLAPLASTIN; ACLACINOMYCIN; ACLACINON			

drug delivery system, liposome anthracycline;	Phase II		anthracycline; antibiotic; DNA intercalator	cancer
liposome; AR 522; ANNAMYCIN	IT 62B	Discontinued	anthracycline; antibiotic; DNA intercalator	cancer; bacterial infection
	SO 075R1	Preliminary	anthracycline; antibiotic; DNA intercalator	bacterial infection; cancer
bisanitrene; bisanitrene hydrochloride; CL 216942; NSC 337766; ADCA; CYABIN	bisanitrene	Phase III	bis[4,5-dihydro-1H-imidazol[2-yl]hydrazone]-9,10-anthracenedicarboxaldehyde	anthracycline; DNA intercalator; antibiotic
daunoform		Preliminary		anthracycline; DNA intercalator; antibiotic
doxoform		Preliminary		anthracycline; DNA intercalator; antibiotic
drug delivery system, micellar doxorubicin; doxorubicin micelles epidoxoform		Preliminary		anthracycline; DNA intercalator; antibiotic

doxorubicin; FCE 23762	Phase II [8S-[8alpha,10alpha(R*)]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-{(2-methoxy-4-nmorpholinyl)-alpha-L-lyxo-hexopyranosyl}oxy]-5,12-naphthacenedione]	[8S-[8alpha,10alpha(R*)]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-{(2-methoxy-4-nmorpholinyl)-alpha-L-lyxo-hexopyranosyl}oxy]-5,12-naphthacenedione]	anthracycline; DNA intercalator; antibiotic cancer
ZYN 191	Suspended	[2S-cis]-6-[N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[2,3-dihydro-1H-pyrol-1-yl]-alpha-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl]-1,5-dioxopentyl]-D-lysine]-luteinizing hormone-releasing factor (swine)	anthracycline; DNA intercalator; antibiotic cancer
D 26232; AN 207	Preliminary	[2S-cis]-6-[N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[2,3-dihydro-1H-pyrol-1-yl]-alpha-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl]-1,5-dioxopentyl]-D-lysine]-luteinizing hormone-releasing factor (swine)	anthracycline; DNA intercalator; antibiotic gonadorelin agonist; peptide
AN 1006	Discontinued		anthraquinone cancer

anthraquinone products, De Montfort University antiandrogen, prostatic carcinoma	Discontinued Discontinued		anthraquinone; radiosensitizer	cancer
bicalutamide; Zeneca I76334; ICI 176334; CASODEX	Marketed	(+,-)N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[4-(4-fluorophenyl)sulfonyl]l-2-hydroxy-2-methylpropanamide	antiandrogen	benign prostate hypertrophy; cancer
ICI 192779 LGD 1331	Suspended Preclinical		antiandrogen	cancer
miltamide; RU 23908; RU 23908-10; ANANDRON; NILANDRON	Marketed	5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione	antiandrogen	cancer
osaterone; osaterone acetate; TZP 4238; HIPROS zanoterone; WIN 49596	Pre-registration Phase II	17-(acetyl oxy)-6-chloro-2-oxapregna-4,6-diene-3,20-dione (Salpha,7alpha)-1'-(methylsulfonyl)-1'H-pregn-20-ynol[3,2-c]pyrazol-17-ol	antiandrogen	benign prostate hypertrophy; cancer; osteoporosis
albacarin; virenonycin M, V	Discontinued		antibiotic	benign prostate hypertrophy; cancer

ankinomycin	Discontinued	2-(4,4-anhydro-1,6-dideoxy-alpha-L-sorbo-2,3-oxiranosyl)-11-hydroxy-5-methyl-10-[2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl-alpha-L-lyxo-hexopyranosyl]-4H-anthra[1,2,b]pyran-4,7,12-trione	antibiotic	cancer
antibiotic, Sagami	Preclinical	(7S-cis)-7-[(2,6-dideoxy-alpha-L-lyxo-hexopyranosyloxy)-9-(fluoracetyl)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	antibiotic	cancer
anticancer, Chugai	Discontinued	3'-deoxyxalopericidin A1 (DTPA)	antibiotic	cancer
AT 2433 A1	Discontinued	1-chloro-13-[6-O-[2,4-dideoxy-4-(methylamino)-alpha-D-threo-pento pyranosyl]-4-O-methyl-beta-D-glucopyranosyl]-12,13-dihydro-6-SH-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	antibiotic	cancer

azamitoseses BE 12406A	Preliminary Discontinued	[2-[((6-deoxy-alpha-L-mannopyranosyl)oxy]-1-hydroxy-10-methoxy-8-methyl-6H-benzo[d]naphtho[1,2-b]pyran-6-one	antibiotic antibiotic	cancer cancer
betaclanycin B; BCMA CC 1065	Preliminary Discontinued	(7BR)-7-[1,6-dihydro-4-hydroxy-5-methoxy-7-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrol[3,2-e]indol-2(1H)-y])carbonyl]benzo[1,2-b:4,3-b']dipyrrrol-3(2H)-yl]cabonyl-1,6-dihydro-4-hydroxy-5-methoxybenzo[1,2-b:4,3-b']dipyrrrole-3(2H)-carboxamide	antibiotic	bacterial infection; cancer
collismycin A, SF 2738A	Discontinued	(E)-4-anethoxy-5-(methylthio)-1-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer

collismycin B; SF 2738B	Discontinued	(Z)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer
collismycin C; SF 2738C	Discontinued	N,N-dimethyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-prolyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-prolyl-(E)-2,3-didehydro-2-aminobutanoyl-L-valyl-L-alanyl-L-glutaminy-L-phenylalanyl-L-isoleucyl-L-glutaminyglycyl-L-seryl-(E)-2,3-didehydro-2-aminobutanoyl-L-isoleucyl-L-cysteinyl-L-leucyl-N-(2-mercaptophenyl)-L-leucinamide cyclic (19,21)-sulfide	antibiotic	bacterial infection; cancer

dioxamycin; BE 16493	Preclinical	[2alpha,3alpha,4alpha,9]2-antibiotic R*,3S*[1E(2S*,4S*,5S*),3E,5E],6R*,1,12a- [fa]-(+)-2,4-dimethyl- 5-[7-oxo-7- [tetrahydro-2- methyl-6- (1,2,3,4,4a,7,12,12b- octahydro- 2,3,4a,8,12b- pentahydroxy-3- methyl-1,7,12- trioxobenz[a]anthracene n-9-yl)-2H-pyran-3- yloxy]-1,3,5- heptatrienyl]-1,3- dioxolane-2- carboxylic acid	cancer; bacterial infection
eponemycin; BMY 28647; BU13862T	Discontinued	[2R-[2R*[S*(S*)]]]- N-[1- (hydroxymethyl)-2- [[1-[2-( (hydroxymethyl)oxira- nyl)carbonyl]-3- methyl-3- butenyl]amino]-2- oxoethyl]-6- methylheptanamide	antibiotic cancer
epoxomicin	Discontinued		antibiotic cancer

esperatruclin; esperamicin A1; esperamycin; esperamicin; BMY 28175; BBM 1675A1; BBM 1675	Discontinued  [1R*-(47,8S*)-12S*-1,13 E]-4,5-dimethoxy-2- [2-methoxy-1-oxo-2- propenyl]amino]benz ic acid 3'[(2'-ester with methyl [8-[14,6- dideoxy2-O-[2',4- dideoxy-3-O-methyl- 4-[(1- methyl)ethyl]amino]- alpha-L- thiopentopyranosyl]- 4-[(2',6-dideoxy-4-S- methyl-1-thio-beta-D- ribo- hexopyranosyloxy]a mino]beta-D- glucopyranosyloxy] 12-[(2',6-dideoxy-alpha- L-lyxo- hexopyranosyloxy]oxy] 1-hydroxy-13-[2- (methylthio)ethylid ene]-1-L- oxobicyclo[7.3.1]tride ca-4,9-diene-2,6- dien-10-ylcarbamate	antibiotic	cancer
---	--	------------	--------

FCE 21424	Preliminary	8-acetyl-10-[[5-(hexahydro-2,4,6-trioxa-5-pyrimidinyl)octahydro- o-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazocin-8-yloxy]-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FCE 24366	Preliminary	8-acetyl-10-[[5-(hexahydro-1,3-dimethyl-2,4,6-trioxa- 5-pyrimidinyl)octahydro- o-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazocin-8-yloxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

FCF 24367	Precinical	g-acetyl-10-[[5-(hexahydro-4,6-dioxo-2-thioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyranol[3,4-d]-1,3,6-dioxaazocin-8-yloxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FK 317	Phase I	10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-8-(fluoroacetyl)]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

batomamicin; YL 0358MA	Precinical	[2R-[2a $\alpha$ ,3a $\alpha$ ,6a $\beta$ ]IR* (S*)]2Z,4E(1a $\alpha$ S*,7- a $\alpha$ R*)]]-6-[{[4-(2,3- dihydrocyclopent[b]o- xireno[c]pyridin- 7(1aH)-ylidene)-1-(1- hydroxypropyl)-3- methyl-2- butenyl]oxy}tetrahyd- ro-2-methyl-2H-pyran- 3-ol]	antibiotic	cancer
himastatin; BMY 40800	Discontinued		antibiotic	bacterial infection; cancer
hydramycin	Discontinued	[4S-[4a $\beta$ , 4a $\alpha$ ,5a $\beta$ ,5a $\alpha$ , 1 $\alpha$ ,6a $\beta$ ,12a $\alpha$ ]-4- dimethylamino]- 1,4,4a,5,5a,6,11,12a- octahydro- 3,5,10,12,12a- pentahydroxy-6- methyl-1,11-dioxo-2- naphthalacencarboxam- ide]	antibiotic	cancer; bacterial infection
K 818B	Discontinued		antibiotic	cancer
kedarcidin	Discontinued		antibiotic	bacterial infection; cancer
KT 5432	Discontinued		antibiotic	cancer

KW 2189	Phase II leinamycin, leinomycin; DC 107	(S)-8-(bromomethyl)-3,6,7,8-tetrahydro-2-methyl-4-[(4-methyl-1-piperazinyl)carbonyl]-oxy]-6-[(5,6,7-trimethoxy-1H-indol-2-y)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid, methyl ester	antibiotic	cancer; bacterial infection
lactimidomycin	Discontinued leinamycin; DC 107	[2R-[2R*,6R*(R*)]9E,11R*,13E,15Z]-4,11'-dihydroxy-2',4',9'-trimethylspiro[1,2-dithiolane-3,6-[1,9]thia[3,2]diazabicyclo[15.2.1]eicosal[120,9,13,15,17]pentadec]-4',5,12'-trione 2-oxide	antibiotic	cancer cancer
lepolistatin	Preliminary bleomycin; NK 313	N1-[3-[3-[bis[3-phenylmethoxy]phenyl]methyl]amino]propylbleomycinamide	antibiotic	cancer cancer; bacterial infection

nisamycin; antibiotic 106B	Preliminary	[1S-[1alpha,2beta,2'(2E,4E, 6E),4(2E,4E),(gaffal)]- 7-[4-[(5-cyclohexyl- 1-oxo-2,4- pentadienyl)amino]- 2-hydroxy-5-oxo-7- oxabicyclo[4.1.0]hept- 3-en-2-yl]-2,4,6- heptatrienoic acid	antibiotic	bacterial infection; cancer
oligonycin E, MCI 2225	Discontinued	26-hydroxy-28- oxooligomycin A	antibiotic	cancer
oxazinomycin; D 788; Preliminary R 20X2	Preliminary	[7R-(7alpha,8beta,10beta)]- 10-[{3-amino-2,3,6- trideoxy-alpha-L-lyxo- hexopyranosyl)oxy}- 8-ethyl-7,8,9,10- tetrahydro-1,6,7,8,11- pentahydroxy-5,12- naphthacenedione	antibiotic	cancer
phenazinomycin; (-)- phenazinomycin	Preliminary	[R-(E)]-5-[5-(2,2- dimethyl-6- methylene cyclohexyl)- 3-methyl-2-pent- enyl]-1(5H)- phenazinone	antibiotic	bacterial infection; cancer

pyridamycin A	Discontinued (2R-trans)-8-(chlorononyl)-1,2,3,6,7,8-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-y)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, methyl ester	antibiotic	cancer
pyridamycin B	Discontinued 8-chloro-2,3,6,7,8,9-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-y)carbonyl]-1H-pyrido[3,2-f]quinoline-2-carboxylic acid, methyl ester	antibiotic	cancer
saintopin	Discontinued 1,3,8,10,11-pentahydroxy-5,12-naphthacenedione	antibiotic	bacterial infection; cancer

saptomycin D	Discontinued	[2alpha,3beta(Z)]-10-[4-O-acetyl-2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl-alpha-L-lyxo-hexopyranosyl]-11-hydroxy-5-methyl-2-[2-methyl-3-{(1-propenyl)oxiranyl}-4H-anthral-1,2-b]pyran-4,7,12-trione	antibiotic	cancer; bacterial infection
SPM VIII	Discontinued	4-deoxy-4-[[[(1-oxododecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycer-beta-D-manno-heptopyranosylamine	antibiotic	cancer
tetrazomine; Y 09194L-B	Preliminary	3-hydroxy-N-[2a,3,4,5,6,6a,7,11b-octahydro-5-(hydroxymethyl)-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11c-azanaphth[1,2,3-c]azulen-10-yl]-2-piperidinocarboxamidine	antibiotic	bacterial infection; cancer
UCA 1064B vicenistatin	Discontinued Discontinued		antibiotic antibiotic	cancer cancer

Y 05460MA	Precinical  drug delivery system, miomycin; Therapeutic Implant; MPI 5016	[4-amino-4,5,6-trideoxy-N-[1-(3,4-dihydro-8-hydroxy-1H-2-benzopyran-3-yl)-3-methylbutyl]-5-methylhexanamide	antibiotic antibiotic; alkylating agent	bacterial infection; cancer
MGI 114; HMAF	Phase II	(R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclop propane-1,5'-[5H]inden]-7'(6'H)-one	antibiotic; alkylating agent; terpene	cancer
AGM 1470; TNP 470	Phase II	[3R-[3alpha, 4alpha-(2R*,3R*),5beta, 6beta]-5-methoxy-4-[2-methyl-3-(3-methyl-1-2-butene)oxiranyl]-1-oxaspiro[2.5]oct-6-yl carbanic acid chloroacetyl ester	antibiotic; angiogenesis inhibitor	cancer

AD 143	Precinical	hexanedioic acid (2S-cis)-mono[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)aminο]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthalenyl]-2-oxoethyl] ester	antibiotic; anthracycline; DNA intercalator	cancer
AD 198	Precinical	Pentanoic acid (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(phenylmethyl)aminο]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthalenyl]-2-oxoethyl] ester	antibiotic; anthracycline; DNA intercalator	cancer
anthracycline analogue, BioChem Pharma	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
B 880308	Suspended	7-O-(3-N-methyl-3-N-(R)-glycidyl-α-L-daunosaminyl)-β-D-homocycinone	antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, ATRIGEL sustained release doxorubicin; doxorubicin ATRIGEL	Preliminary		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system; AD 70; ADM OXD; GC 1004	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin-tumor homing peptide; THP-doxorubicin	Preliminary		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin Therapeutic Implant; MPI 5015	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, HPMA polymer-bound doxorubicin; doxorubicin HPMA polymer-bound; PK 1	Phase I		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, liposome daunorubicin; daunorubicin liposome; VS 103; DaunoXome	Marketed		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome; DOXOME	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome; TLC D99; TLC DOX 99; DOX 99; EVACET; LIPODOX	Pre- registration		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome	Clinicals		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome	Phase III		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome micellar doxorubicin; doxorubicin micelles	Preliminary		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, Phase I nanosphere doxorubicin; doxorubicin nanosphere			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued ONCHOLAB aclanubicin; aclanubicin ONCHOLAB			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued ONCHOLAB AD 32; AD 32 ONCHOLAB			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Marketed STEALTH liposome doxorubicin; doxorubicin STEALTH; DOXIL; DOX-SL; S-DOX; CAELYX			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Preclinical tetrapeptide doxorubicin; doxorubicin tetrapeptide; Super- Leu-Dox			antibiotic; anthracycline; DNA intercalator	cancer

epirubicin; idarubicin; 4-epi- doxorubicin; IMI 28; MSC 256942; FI 7701; PHARMORUBICIN; FARMORUBICIN; FARMORUBICINE FCE 27726	Marketed	(8S-cis)-10-[(3- amino-2,3,6-trideoxy- alpha-L-arabino- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
	Discontinued	(7S-cis)-9-acetyl-7- [[3-[bis(2- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-Jyo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
galarubicin; DA 125	Phase II	2-[(2S,4S)-4-[(2,6- dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthaenyl]-2- oxoethyl ester beta- alanine hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer

GPX 100	Phase I		antibiotic; anthracycline; DNA intercalator	cancer
I-DOX	Phase I	4'-iodo-4'-deoxydoxorubicin	antibiotic; anthracycline; DNA intercalator	cancer
idarubicin; IMI 30; NSC 256439; IMI 22; ZAVEDOS; ZAVEDOSE; ZAVIDOS; IDAMYCIN; DAUNOBLASTINA; CERUBIDINE	Marketed	9-acetyl-7-[3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
iododoxorubicin; FCE 21954; IODODOX	Phase II	[2R-[2alpha[8S*,10S*],4beta]-10-a,5beta,6beta]-10-[[4-aminotetrahydro-5-iodo-6-methyl-2H-pyran-2-yloxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyaceyl)-1-methoxy-5,12-naphthacenedione	antibiotic; [2alpha[8S*,10S*],4beta]-10-[[4-aminotetrahydro-5-iodo-6-methyl-2H-pyran-2-yloxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyaceyl)-1-methoxy-5,12-naphthacenedione	cancer

KRN 8602; MX 2	Phase II	[7R-[7alpha,8beta,10beta]-[8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentaihydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione hydrochloride]	antibiotic; anthracycline; DNA intercalator	cancer
ME 2303; FAD 104	Discontinued	heptanedioic acid, mono[2-[4-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-tritydroxy-7-methoxy-6,11-dioxo-2-naphthacetyl]-2-oxoethyl] ester, (2S -cis)-	antibiotic; anthracycline; DNA intercalator	cancer

menogaril; 7-OHEN; NSC 269148; TUT 7; U 52047; TOMOSAR; TAMOSAR	Phase III (2R,3S,4R,5R,6R,11R,13R)-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthalenol[1,2-b]oxocin-9,16-dione	antibiotic; anthracycline; DNA intercalator	cancer
piranubicin; tiranubicin; theprubicin; THP-doxorubicin; THP-ADM; theprubicin; THERARUBICIN; PINORUBIN; BERIRUBIN; THEPRUBICINE	Marketed 8S-[8alpha,10alpha(S*)]-10-[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-9,8,11-trihydroxy-8-(hydroxycetyl)-1-methoxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer

ruboxyl	Phase II	(2S-cis)-4-[[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)oxy]1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacetyl]ethylidene]hydrazono-2,2,6,6-tetramethyl-1-piperidinyloxy]	antibiotic; anthracycline; DNA intercalator	cancer
	Marketed	Pentanoic acid, (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyloxy]-2-naphthacetyl]-2-oxoetyl ester	antibiotic; anthracycline; DNA intercalator	cancer
ZYN 198	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
ZYN-LINKER conjugated doxorubicin	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
	Marketed		antibiotic; anthracycline; DNA intercalator; estrogen	cancer

annubicin; SM 5887	Phase II	(7S-cis)-9-acetyl-9-aminoo-7-[(2-deoxy-beta-D-erythropentopyranosyloxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
MEN 10755; BMS 195615	Phase I	(7S-cis)-7-[4-O-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxycetyl)-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
BU 4704	Discontinued	1-(4-methoxyphenyl)-antibiotic; antifungal	mycosis; cancer	
NK 8602791	Discontinued	44-homooligomycin B	antibiotic; antifungal	mycosis; cancer
NK 8602791	Discontinued	44-homooligomycin A	antibiotic; antifungal	mycosis; cancer

reveromycin A	Preclinical	10-[9-butyl-8-[4-carboxy-3-methyl-1-(E),3(E)-butadienyl]-9-(hydroxysuccinyl oxy)-3-methyl-1,7-dioxaspiro-[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyl-2(E),6(E),8(E)-decanoic acid	antibiotic; antifungal	bacterial infection; cancer; mycosis
sulfurecin	Discontinued	5,6-dihydro-5-hydroxy-6-(6-hydroxy-5-methyl-4-hydroxysulfonyl oxyheptadec-1,7,9,11-tetraenyl)-2H-pyron-2-one	antibiotic; antifungal	cancer; mycosis
JSM ASB001	Preclinical		antibiotic; antioxidant; citicatrant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BCYL001	Preclinical		antibiotic; antioxidant; citicatrant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BIAS001	Preclinical		antibiotic; antioxidant; citicatrant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
beta lactam derivatives, Pliva	Preclinical		antibiotic; beta lactam	cancer

clavulanine; SYN 1931; Ro 22-5417	Preliminary [3S-[3alpha(R*),5alpha]-alpha-amino-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid]	antibiotic; beta lactam cancer
SYN 1127	Preliminary [3-(hydroxymethyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one]	antibiotic; beta lactam cancer
SYN 1932	Preliminary [3R-[3alpha(alphaS*,betaR*),5alpha]-alpha-amino-7-oxo-beta-(phenylmethoxy)-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid]	antibiotic; beta lactam cancer
MAb, doxorubicin conjugate	Preliminary antibiotic; biotechnology, monoclonal antibody, anthracycline; DNA intercalator	cancer
MAb, drug delivery system, liposome doxorubicin conjugate; MAb, STeALTH doxorubicin conjugate; SPI 49	Preliminary antibiotic; biotechnology, monoclonal antibody, anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelle	Preliminary antibiotic; DNA intercalator; anthracycline	cancer

[ST 622; A 132; NSC 639830]	Phase II	3-ethoxypropanoic acid (S)-10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl-alpha-D-galactopyranosyl)-3,4-O-(phenylmethylene)-beta-D-galactopyranosy]oxy]-5,12-dihydro-1-methyl-5,12-dioxobenzol[h][1]benzopyran[5,4,3-cde][1]benzopyran-6-yl ester	antibiotic; DNA topoisomerase inhibitor	cancer
NSC 655649; BMY 27557	Phase I	I,11-dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-5H-indol[2,3-ajpyrrol[3,4-c]carbazol e-5,7(6H)]-dione	antibiotic; DNA topoisomerase inhibitor; DNA intercalator	cancer
WIN 58161	Preliminary	(S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid	antibiotic; DNA topoisomerase inhibitor; quinolone	cancer
MI 4337F11; MI 43	Preliminary		immunostimulant	cancer

gludapepin; FK 565; FK 41565	Discontinued	heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine	antibiotic; immunostimulant; peptide	cancer; HIV infection
feldanycin; BMY 28565	Discontinued	(S)-N-methyl-L-histidyl-N3-[1-carboxy-2-(1H-imidazol-4-yl)ethyl]-L-threo-2,3-diaminobutanic acid	antibiotic; melanin synthesis inhibitor	cancer
cordycepin; NSC 63984	Phase I		antibiotic; nucleoside; antimetabolite	cancer
C 1027	Preliminary	Antibiotic C	antibiotic; peptide	cancer; bacterial infection
ecropin B	Discontinued		antibiotic; peptide	bacterial infection; cancer
lytic peptides; Proteus International	Discontinued		antibiotic; peptide	bacterial infection; cancer
verucopepin; BU 3983T; BMY 28782	Discontinued		antibiotic; peptide	cancer
placelin A	Preliminary		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
placelin B	Preliminary		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
MS 073	Preliminary	5-(3-(40(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-yl)piperazin-1-yl)12-hydroxypropoxy)quinoline	antibiotic; quinoline	cancer

A 74932	Discontinued	6-[2-[(2-amino-1-oxepentyl)amino]-1-pyridinyl]-5-fluoro-3-oxo-3H-pyrido[3,2,1-R]phenoxazine-2-carboxylic acid monohydrochloride	antibiotic; quinolone	cancer
E 7010	Discontinued	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
E 7070	Phase I Preclinical	N-(0,1,1-dihydro-2-fluoro-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
ER 34410				
ER 35744	Precclinical	N-(3-chloro-1H-indol-7-yl)-1,4-benzene-disulfonamide	antibiotic; sulfonamide	cancer
HMN 214	Precclinical	(E)-N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridinyl)ethenyl]phenyl]acetamide	antibiotic; sulfonamide	cancer
Andrographolide PN 271; PN 271; AndroCar	Precclinical Phase II		antibiotic; terpene antibiotic; terpene	cancer cancer; restenosis

PN 272	Precinical		antibiotic; terpene	cancer
PN 273	Precinical		antibiotic; terpene	cancer
PN 274	Precinical		antibiotic; terpene	cancer
PN 275	Precinical		antibiotic; terpene	cancer
giracodazole; girodazole; girolline; (+)-giroline; RP 49532; RP 49532A; NSC 627434	Discontinued	[S-(R*,R*)]-2-amino- alpha-(2-amino-1- chloroethyl)-1H- imidazole-4-methanol	antibiotic; tRNA synthetase inhibitor	cancer
glycopine;	Marketed	N2-[N-[N-acetyl-4-O- [2-(acetylaminio)-2- deoxy-beta-D- glucopyranosyl]mura- moyl]-L-alanyl]-D- alpha-glutamine	-antibiotic; vaccine adjuvant; immunostimulant; glycopeptide	psoriasis; cancer; leukopenia; septic shock; infectious disease; eye disease
antiestrogens, AVAX Technologies	Precinical			
antiestrogens, BioNumerik	Preclinical		antiestrogen	cancer
clomifene analogues, Ligand	Precinical		antiestrogen	cancer
droloxifene; droloxifene citrate; 3'- hydroxytamoxifen; K 21060E citrate	Suspended Pre- registration	(E)-alpha-[p-[2- (dimethylamino)ethoxy- y]phenyl]-alpha- ethyl-3-stilbenol	antiestrogen	cancer; endometriosis
drug delivery system, controlled release GEMOMATRIX	Discontinued		antiestrogen	cancer
tamoxifen; tamoxifen GEMOMATRIX				

EM 139	Preliminary	(7alpha,16alpha,17beta)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestr-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 170	Preliminary	(7alpha,16alpha,17beta)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestr-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 800	Phase III	2,2-dimethylpropanoic acid (S)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2H-1-benzopyran-3-yl]phenyl ester	antiestrogen	cancer
estrogen antagonists, Telik	Discontinued		antiestrogen	cancer
fulvestrant; ZD 182780; ZM 182780; Zeneca 182780; ICI 182780; FASLODEX	Phase III	(7alpha,17beta)-7-[9-((4,4,5,5,5-pentafluoropentyl)sulphonyl)onyl]estr-1,3,5(10)-triene-3,17-beta-diol	antiestrogen	cancer; gynecological

iproxifene; TAT 59	Phase III	(E)-4-[1-[4-(2-dimethylamino)ethoxy]phenyl]-2-[4-(1-methylethyl)phenyl]-1-butyl]phenol dihydrogen phosphate (ester)	antiestrogen	cancer
MDL 103323	Suspended	(E)-4-[4-(2-chloro-1,2-diphenylethoxy)phenoxyl]-N,N-diethylbutanamine	antiestrogen	cancer
panomifene; EGIS 5650; GYKI 13504	Discontinued	(E)-2-[[(2-[p-(3,3,3-trifluoro-1,2-diphenylpropenyl)phenoxy]ethyl)amino]ethanol]	antiestrogen	cancer
R 1128B	Discontinued	1,3,6-trihydroxy-8-n-butylanthraquinone	antiestrogen	cancer
RU 53637	Discontinued	(11beta,17alpha)-3,17-dihydroxy-N-methyl-N-(methylethyl)-19-norpregna-1,3,5(10)-trien-20-yne-11-undecanamide	antiestrogen	cancer
RU 58668; RU 59428	Discontinued			
SH 646	Phase I			
lormefifene; tolemifene; FC 1157a; NK 622; FARESTON; TREMIFEN	Marketed	2-(p-((Z)-4-chloro-1,2-diphenyl-1-butene)phenoxy)-N,N-dimethyl ethylamine	antiestrogen	cancer

Zindoxyfene; D 16726	Discontinued	2-[4-(acetoxy)phenyl]-1-ethyl-3-methyl-1H-indol-5-ol acetate (ester)	antiestrogen	cancer
Marzoxifene; LY 353381	Phase II	2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benz[b]thiophene-6-ol	antiestrogen; estrogen agonist	cancer
ERA 923	Preliminary		antiestrogen; estrogen agonist	cancer
Estrogen receptor modulator, Genaisance; estrogen receptor modulator, Telik	Preliminary		antiestrogen; estrogen agonist	cancer; osteoporosis
Estrogen Receptor modulators, Nanodesign	Preliminary		antiestrogen; estrogen agonist	cancer; osteoporosis
Iodoxifene; SB 223030; CB 7432	Phase II	(E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butene]phenoxy]ethyl]pyrrolidine	antiestrogen; estrogen agonist	cancer
LY 326315	Preliminary	6-(4-hydroxyphenyl)-5-[[(4-[2-(1-piperidinyl)ethoxy]phenoxy)methyl]-2-naphthalenol hydrochloride	antiestrogen; estrogen agonist	cancer

raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	Marketed	[6-hydroxy-2-(4-hydroxyphenyl)benzo[ <i>b</i> ]thien-3-yl][4-[2-(1-ethoxy)phenyl]metha none]	antiestrogen; estrogen receptor antagonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
aminopterin; aminopterine; pteramina; NSC 739; APGA	Phase II	N-[4-[(2,4-diamino-6-pteridinyl)methyl]benzoyl]-L-glutamic acid	antifolate	cancer
anticancer agent; Eisai	Discontinued	N-[4-[3-(2,4-diamino-6,7-dihydro-7H-cyclopenta[d]pyrimidi n-5-yl)propyl]benzoyl]-L-glutamic acid	antifolate	cancer
edatrexate; aminopterin, O-ethyl-10-deaza, 10 EDAM; EDAM 10; CCP 30694	Discontinued	N-[p-[(2,4-diamino-6-pteridinyl)methyl]pro pyl]benzoyl]-L-glutamic acid	antifolate	cancer
lometsrexol; LY 249543; LY 264618	Phase I	(R)-N-[4-[2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid	antifolate	cancer

LY 254155	Phase I	$N-[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamic acid$	antifolate	cancer
LY 335580	Preliminary	$N-(2,4-diamino-3,4,5,6,7,8-hexahdropyrido[2,3-d]pyrimidine-6-yl)ethyl)-2-thienylcarbonyl]-L-glutamic acid$	antifolate	cancer
PT 523	Preliminary	$(S)-2-[[4-[4-carboxy-4-[[4-[[2,4-diamino-6-pteridinyl)methyl]amino]butyl]benzoyl]amino]butyric acid$	antifolate	cancer
TNP 351	Discontinued	$N-[4-[[3-(2,4-diamino-1H-pyrido[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid$	antifolate; antimetabolite	cancer
piritrexim; BW 301U; NSC 351521	Phase II	$6-[2,5-dimethoxyphenyl]-methyl]-5-methyl-pyrid[2,3-d]pyrimidine-2,4-diamine$	antifolate; dihydrofolate reductase inhibitor	cancer, pneumocystis, toxoplasmosis

translation inhibitor; Trega Biosciences/Ribogen e	Preliminary		antifungal	viral infection; mycosis; cancer
liarazole; liarazole hydrochloride; liarazole fumarate; R 75251; R 85246; LIAZAL	Pre- registration	5-[{(3-chlorophenyl)- 1H-imidazol-1- ylmethyl]-1H- benzimidazole	antifungal; androgen synthesis inhibitor; imidazole	cancer; psoriasis
BBR 3438	Preliminary		antifungal; anthrapyrazole	cancer
BBR 3439	Discontinued		antifungal; anthrapyrazole	cancer
DUP 942	Discontinued		antifungal; anthrapyrazole	cancer
losoxantrone; losoxantrone hydrochloride; planitazole; C 941; Dup 941; NSC 357885; PD 113785; BIANDA	Phase III	7-hydroxy-2-[2-[(2- hydroxyethyl)amino]jeanthropyrazole hydroxymethyl]-5-[2-[(2- hydroxyethyl)amino]e- thy]laminooanthra- cylpyrazol-6(2H)- one,	antifungal; anthrapyrazole	cancer
teloxantrone; teloxantrone hydrochloride; moxantrazole; DUP 937; Cl 937; PD 113309; NSC 355644	Discontinued	7,10-dihydroxy-2-[2- [(2- hydroxyethyl)amino]e- thy]-5-[2- (methylamino)ethyl]a- minoanthra[1,9- c]pyrazol-6(2H)- one, dihydrochloride, monohydrate	antifungal; anthrapyrazole	cancer

cancer therapy; Lorus Therapeutics; Ion clotrimazole; BAY 5097; CUTAMYCON; ENSCHENT; FUNGIZID; HAKUSERIN; LOTRIMIN AF; MYCO-HERMAL; MYKO CORDES; TRIGENTAX; CANESTEN; LOTRIMIN jasplakinolide; jaspamide	Precinical Marketed		antifungal; imidazole	cancer
			antifungal; imidazole	mycosis; sickle cell anemia; cancer; diarrhea
	Precinical	[2S-(2R*,4E,6S*,8R*)]-N-[2-bromo-N-(8-hydroxy-2,4,6-trimethyl-1-oxo-4-nonyl)-L-alanyl]-N-methyl-D-tryptophyl]-L-3-(4-hydroxyphenyl)-beta-alanine rho-lactone	antifungal; peptide	mycosis; cancer
aminoimidazole carboxamide ribonucleotide formyltransferase inhibitors, Agouron; AICART inhibitors, Agouron	Discontinued		antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole	cancer; inflammation

26-epibryostatin 1	Precinical	(2E,4E)-2,4-octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyl oxy)-1,11,21-trihydroxy-17-[1(S)-1-hydroxyethyl]-5-[3-[bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13.7.111,15]nona-3,10-en-12-yl ester	antimetabolite	cancer
capecitabine; Ro 091978; XELODA	Marketed	pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate	antimetabolite	cancer
doxifluridine; DFUR; Ro 219738; FURTOLON; FURTULON	Marketed	5-deoxy-5-fluorouridine	antimetabolite	cancer

drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5003; AccuSite	Marketed Discontinued		antimetabolite	cancer; psoriasis; viral infection
drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5011; INTRADOSE-FU	Precinical		antimetabolite	cancer
drug delivery system, fluorouracil; fluorouracil Therapeutic Adhesive	Discontinued		antimetabolite	cancer
drug delivery system, methotrexate; methotrexate delivery system; HYAL CV1281	Discontinued		antimetabolite	cancer
drug delivery system, sustained release methotrexate; methotrexate DepoFoam	Discontinued		antimetabolite	cancer
fazarabine; arabinosyl-5-azacytosine; ara-AC; NSC 281272	Phase II	4-amino-1-beta-D-arabinofuranosyl-1,3,5-triazin-2(1H)-one	antimetabolite	cancer
fludarabine + chlorambucil; chlorambucil + fludarabine	Discontinued		antimetabolite	cancer

folic acid analogue, Glaxo Wellcome	Discontinued	N-alpha-(5-deaza- 5,6,7,8-tetrahydropteroyl)-L- omithine	antimetabolite	cancer
levamisole + fluorouracil + levamisole	Registered		antimetabolite	cancer
T 506	Discontinued	mono[2-( trimethylammonio)ethyl ester of 2'-deoxy- 5-fluoro-5'-uridylic acid 3'(9- octadecenoate) hydroxide inner salt]	antimetabolite	cancer
TAS 102	Phase I		antimetabolite	cancer
legafur; BMS 20060401; MUF 12264; NSC 148958; DAIYALOSE; FENTAL; FTORAFUR; FTORALON; FURAFLOR; FUTRAFUL; LAMAR; NEBERK; TORAFURIN; UFT	Marketed	5-fluoro-1- (tetrahydro-2- furanyl)- 2,4(H,3H)pyrimidin edione	antimetabolite	cancer
ZYN-LINKER conjugated fluorouracil	Suspended		antimetabolite	cancer

brequinar; brequinar sodium; DUP 785; NSC 368390	Suspended	6-fluoro-2-(2'-fluor[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
ZYN-LINKER conjugated methotrexate	Suspended		antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
cytarabine octofate; phosphacaine sodium; YNK 01; C18PCA; STARASID	Marketed	4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-beta-D-arabinofuranosyl] 2(H)-pyrimidinone	antimetabolite; nucleoside analogue	cancer
drug delivery system; DepoFoam	Marketed		antimetabolite; nucleoside analogue	cancer
cytarabine; cytarabine DepoFoam; DTC 101; DepoCyt; SAVEDAR	Preliminary		antimetabolite; nucleoside analogue	cancer
nucleotide thio analogues; Oklahoma University LY 207702	Preliminary	2',2'-difluoro-2'-deoxyribofuranosyl-2,6-diaminopurine (dFdAp)	antimetabolite; ribonucleotide reductase inhibitor	cancer
antineoplaston A10	Phase II		antineoplaston; peptide	cancer
antineoplaston AS2-1	Phase II		antineoplaston; peptide	HIV infection;

nitroxide antioxidant; NIH	Preliminary		antioxidant; free radical scavenger; NSAID	respiratory distress syndrome; inflammation; cancer; reperfusion injury
antioxidants, University of California	Preliminary		antioxidant; NSAID	skin disease; inflammation; cancer
naphterpin; CL 190Y2	Preliminary	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-didihydro-2,5,9,9-tetramethyl-4H-benzo[dl]naphthol[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
OS 535	Preliminary		antiplasmin	
LG 1127	Preliminary		antiprogestogen	cancer; endometriosis
LG 1147	Preliminary		antiprogestogen	cancer; endometriosis
LG 1447	Preliminary	1,2-dihydro-2,4-trimethyl-6-phenyl-quinoline	antiprogestogen	cancer; endometriosis
mifepristone; RU 486; RU 38486; RU 38486; R 38486; MIFEGYNE	Marketed	(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogestogen	abortion; cancer; contraception

onapristone; ZK 98299; SH 549; ZK 299	Discontinued [11beta,13alpha,17alpha]-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)estra-4,9-dien-3-one	[11beta,13alpha,17alpha]-antiprogestogen	cancer; contraception
ORG 31710	Discontinued [11beta,13alpha,17beta]-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-1-spiro[estra-4,9-diene-17,2'-(3H)-furan]-3-one	[11beta,13alpha,17beta]-antiprogestogen	cancer
ORG 31806	Discontinued [11beta,13alpha,17beta]-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-7-methyl-1-spiro[estra-4,9-diene-17,2'-(3H)-furan]-3-one.	[11beta,13alpha,17beta]-antiprogestogen	cancer
ORG 33245	Discontinued [11beta,13alpha,17alpha]-11-[4-acetylphenyl]-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one	[11beta,13alpha,17alpha]-antiprogestogen	cancer; abortion
ORG 33628	Discontinued [11beta,13alpha,17alpha]-11-[4-(acetylphenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one]	[11beta,13alpha,17alpha]-antiprogestogen	cancer
ORG 33832	Discontinued RU 46556	[11beta,13alpha,17beta]-11-[4-(methylthio)phenyl]-17,2'(5H)-furan]-3-one	antiprogestogen cancer, induction
		[11beta,13alpha,17beta]-antiprogestogen	cancer, endometriosis; labor induction

RU 49295	Discontinued (11beta,17beta)-11-(4-acetylphenyl)spiro[estra-4,9-diene-17,2'(5H)-furan]-3-one	antiprogestogen cancer; endometriosis
SH 207 ZK 112993	Phase I Discontinued (11beta,17beta)-11-(4-acetylphenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogestogen cancer cancer
ZK 136798	Discontinued [[11alpha,17beta,17(Z)]-9,11-dihydro-17-hydroxy-17-(3-hydroxy-1-propenyl)-3-oxo-4'H-naphth[3',2',1':10,9,11]estra-4,9(11)-dien-6'-yl]benzonitrile	antiprogestogen cancer
21-substituted progesterone derivatives, NIH Iopsentin; Iopsentine; Iopsentin B1; Iopsentine B1	Preliminary [[6-hydroxy-1H-indol-3-yl][4-(1H-imidazol-2-yl)methanone]	antiprogestogen; hormone replacement therapy endometriosis; labor induction; hormone deficiency; cancer cancer

carboxyamidotriazole ; CAI; NSC 609974; L 651582	Phase I  5-amino-1-[[3,5-dichloro-4-(4-chlorobenzyl)phenyl]-methyl]-1H-1,2,3-triazole-4-carboxamide	antiproliferative agent; cancer imidazole
antisense oligonucleotide, BCL-X	Preclinical	antisense; oligonucleotide; biotechnology
antisense oligonucleotide, c-fos	Preclinical	antisense; oligonucleotide; biotechnology
antisense oligonucleotide, c-jun	Preclinical	antisense; oligonucleotide; biotechnology
antisense oligonucleotide, calcium binding protein in placenta;	Preclinical	antisense; oligonucleotide; biotechnology
antisense oligonucleotide, CAPL	Phase I  oligonucleotide, DNA methyltransferase; MG 98	antisense; oligonucleotide; biotechnology
antisense oligonucleotide, Epstein Barr virus;	Preclinical	antisense; oligonucleotide; biotechnology
antisense oligonucleotide, EBV		cancer

antisense oligonucleotide, jun kinase-1	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, transforming growth factor beta; antisense oligonucleotide, TGF-beta; antisense oligonucleotide, cancer	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotides, basic fibroblast growth factor	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotides, cancer, Children's Hospital of Orange County	Preclinical		antisense; oligonucleotide; biotechnology	cancer
anti-sense oligonucleotide, multiple drug resistance	Preclinical		antisense; oligonucleotide; biotechnology; mRNA translation inhibitor	cancer
anticancer agents, OSI/Pfizer	Preclinical		apoptosis inducer	cancer
apoptosis inhibitors, Oxford Asymmetry/LXR Biotechnology	Preclinical		apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder

breast cancer therapy, Temple University; breast cancer therapy, Alliance	Preliminary		apoptosis inducer	cancer
C 837	Preliminary	2-[(1-nitro-9-acridinyl)amino]ethan ol monohydrochloride	apoptosis inducer	cancer
cancer therapy, Axiom Biotechnologies/Zaiyi a	Preliminary		apoptosis inducer	cancer
cancer therapy, BioChem Pharma/ImmunoGen	Preliminary		apoptosis inducer	cancer
cancer therapy, Hitachi; cancer therapy, Nippon Chemipharm	Phase I		apoptosis inducer	cancer
cancer therapy, Idun/Abbott	Preliminary		apoptosis inducer	cancer
cancer therapy, Rigel DDE 313	Preliminary		apoptosis inducer	cancer
Fas modulators, Menatini	Preliminary		apoptosis inducer	cancer
K 22175; K22.175	Preliminary		apoptosis inducer	cancer
ONCODON	Preliminary		apoptosis inducer	cancer
small cell lung carcinoma therapy, Cadus	Preliminary		apoptosis inducer	cancer
E2F inhibitors, Prolifix	Preliminary		apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis

apoptosis inducer, IDUN CP 461	Preliminary Phase I		apoptosis inducer; caspase inhibitor cancer
exisulind; FGN 1; PREVATAC	Phase III	(1Z)-5-fluoro-2- methyl-1-[4-( methylsulfonyl)phenyl] [1-methylene]-1H- indene-3-acetic acid	apoptosis inducer; phosphodiesterase inhibitor cancer
apoptosis inhibitor, Biota	Discontinued		apoptosis inhibitor cancer
apoptosis modulators, Preclinical University of Colorado			apoptosis inhibitor; apoptosis inducer cancer; autoimmune disease; neurodegeneration
anastrozole; ZD 1033; Marketed ICI D1033; ARIMIDEX	Marketed	alpha, $\beta$ ,alpha, $\alpha_1$ p aromatase inhibitor ha'-tetramethyl-5- (1H-1,2,4-triazol-1- yimethyl)-1,3- benzenediacetonitrile	cancer
aromatase inhibitor, Menarini	Preclinical		aromatase inhibitor cancer
aromatase inhibitor, Merrell Dow	Discontinued	19-acetylenic- androstenedione	aromatase inhibitor cancer
aromatase inhibitors, Washington Research Foundation	Preclinical		aromatase inhibitor cancer
stanestane; SH 489; ZK 93639 CGP 47645	Discontinued Discontinued	1-methylandrosta-1,4- diene-3,17-dione	aromatase inhibitor cancer; benign prostate hypertrophy cancer

CGS 18320B; CGS 18320	Discontinued e; D 3967	Phase III	4,4'-(1H-imidazol-1-ylmethylene)bis[benzonitrile compound with butanedioic acid (2:1)]	aromatase inhibitor	cancer
exemestane; FCE 24304; PNU 971; ONC 0028; AROMASIN	Pre-registration	6-methyleneandrosta-1,4-diene-3,17-dione	aromatase inhibitor	cancer	
fadrozole; CGS 16949A; AFEMA 32349; AT 0931; LENTARON; LETOZOLE; CGS 20267; FEMARA	Marketed	4-(5,6,7,8-tetrahydroimidazo[1,5- <i>a</i> ]pyridin-5-yl)benzonitrile	aromatase inhibitor	cancer	
formestane; CGP 32349; AT 0931; LENTARON;	Marketed	4-hydroxyandrostene-3,17-dione	aromatase inhibitor	cancer	
minanestane; FCE 24928	Discontinued	4,4'-(1H-1,2,4-triazol-1-ylmethylene)bisbenzonitrile	aromatase inhibitor	cancer	
MPV 2213; MPV 2213ad	Phase I	4-[3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile	aromatase inhibitor	cancer; benign prostate hypertrophy	

NKS 01	Discontinued	[4alpha-hydroxy-4-androsten-3,6,17-trione]	aromatase inhibitor	cancer
ORG 30958	Discontinued	19-(ethyldithio)androst-4-ene-3,17-dione	aromatase inhibitor	cancer
ORG 33201	Discontinued	[3(alpha)-trans-1-[3(alpha)-ethyl-9-(ethyldithio)-2,3,3alpha,4,5,6-hexahydro-1H-phenalen-2-yl]-methyl]-1H-imidazole [HCl]	aromatase inhibitor	cancer; endometriosis
penetrozole; SH 582; ZK 154065	Preliminary	17-[[(1-oxohexyl)oxy]-19-norpreg-4-ene-3,20-dione]	aromatase inhibitor	cancer
rogelimide; pyridoglutelimide	Discontinued	(+,-)-3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione	aromatase inhibitor	cancer
RU 54115	Discontinued	10-[2-(methylthio)ethyl]estr-a-4,9(11)-diene-3,17-dione	aromatase inhibitor	cancer; endometriosis
SAE 9	Discontinued		aromatase inhibitor	cancer
TAN 931	Preclinical	4-(2,6-dihydroxybenzoyl)-3-formyl-5-hydroxybenzoic acid	aromatase inhibitor	cancer

Vorozole; R 76713; R 83842; JK 201; RIVIZOR	Phase III	6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]1-1-methyl-1H-benz triazole	aromatase inhibitor	cancer
YM 511	Phase II	4-[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]benzonitrile	aromatase inhibitor	cancer; endometriosis
YM 553	Preliminary	4-[(3,5-difluorophenyl)methyl]-5-pyrimidinylamino]benzonitrile	aromatase inhibitor	cancer
Sparfosic acid; Sparfosate sodium; PALA; platinum complex; CI 882; NSC 224131; Pt 268; NSC 328005	Phase III	N-(phosphonoacetyl)-L-aspartate transcarbamylase inhibitor		cancer; viral infection
AV 04	Discontinued			
AV 17	Discontinued			
AV 38	Discontinued			
AV 43	Discontinued			
AV 57	Discontinued	6,9-dihydro-4-methyl-6-(2-nitrophenyl)-pyrido[3,2-g]quinoine-2,5,10(1H)-trione		
AV 61	Discontinued			
AV 66	Discontinued			
AV 80	Discontinued			

ImuVert	Discontinued		biological response modifier	cancer
ONO 4005	Discontinued		biological response modifier	cancer
ONO 4007	Phase II	(S)-2-deoxy-2-[[1-oxo-3-[1-oxo-9-(phenylonyloxy)tetra-decyl]amino-D-glucose, 3-benzenenonanoate 4-(hydrogensulfate), monosodium salt.	biological response modifier	cancer
VIRULIZIN	Registered		biological response modifier	cancer
RS 33277	Discontinued		biological response modifier, peptide	cancer
adiposit; lipotropin alpha mutein; mutein, alpha; HT 003	Precclinical		biotechnology	obesity; cancer
anticancer oligonucleotides, MicroProbe	Precclinical		biotechnology	cancer
ATF HI 8 B 2036PEG; PEG-B 2036; TROVERT	Precclinical		biotechnology	cancer
cancer immunotherapy, Medimmune	Discontinued		biotechnology	cancer

cancer therapy, University Technologies International	Precinical		biotechnology	cancer
cell lysis factor, Texas University colon cancer therapy, Precinical Axis Genetics	Precinical		biotechnology	cancer
cystolytic factor, CF DCC tumor suppressor gene	Precinical		biotechnology	cancer
drug delivery system, Precinical HIT breast cancer	Precinical		biotechnology	cancer
drug delivery system, Precinical ONYX 015; ONYX 015, viramASC coating; ONYX 015	Precinical		biotechnology	cancer
drug delivery system, Precinical ONYX 838; ONYX 838, viramASC coating	Precinical		biotechnology	cancer
G 207	Phase I		biotechnology	cancer
gene discovery, hereditary glioma, Myriad	Precinical		biotechnology	cancer
gene discovery, leukemia, Myriad	Precinical		biotechnology	cancer
gene discovery, lung cancer, Myriad	Precinical		biotechnology	cancer
gene therapy, anti- erbB-2 single chain	Precinical		biotechnology	cancer

gene therapy, antisense insulin-like growth factor; gene therapy, antisense IGF-1	Phase I		biotechnology	cancer
gene therapy, breast cancer; gene therapy, breast, MB 200	Precclinical		biotechnology	cancer
gene therapy, interleukin-2	Precclinical		biotechnology	cancer
HER-2/neu oncogene protein	Discontinued		biotechnology	cancer
HGF/NK1	Precclinical		biotechnology	cancer
hPRL Gi29R	Precclinical		biotechnology	cancer
HSV 1716	Phase I		biotechnology	cancer
human chorionic gonadotropin; hCG; OVIDREL	Phase II		biotechnology	infertility; cancer
IL-2 analogue; INGN 301; F42K	Precclinical		biotechnology	cancer
inoplast; platelet factor 4; PF4; endostatin B; REPLISTATIN	Phase II		biotechnology	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
mismatched double stranded RNA; poly(I)poly(C)sub12) U; AMPLIGEN	Pre- registration		biotechnology	allergy; viral infection; blood clotting disorder; cancer; chronic fatigue syndrome
neu differentiation factor; NDF	Discontinued		biotechnology	cancer
NV 1020	Precclinical		biotechnology	cancer

ONYX 015 osteoprotegerin; OPG p53 gene	Phase II Phase I Preclinical		biotechnology biotechnology cancer
prostate cancer therapy, Axis Genetics	Preclinical		biotechnology cancer
protein replacement therapy, retinoblastoma protein; protein replacement therapy, Rb protein	Preclinical		biotechnology cancer
Salmonella lyphimurium, mutagenized S	Preclinical		biotechnology cancer
single chain antigen binding protein; SCA transcription factor,	Preclinical		diagnosis; cancer biotechnology cancer
urogenital sinus- derived growth inhibitory factor; UGIF; ps20	Preclinical		biotechnology cancer; benign prostate hypertrophy
vaccine, beta-human chorionic gonadotrophin, Vaxcel; vaccine, cancer	Preclinical		biotechnology cancer
vaccine, cancer, Ludwig Institute/SIGA	Preclinical		biotechnology cancer

vaccine, non-Hodgkin's B cell lymphoma	Preliminary		biotechnology	cancer
verotoxin	Preliminary		biotechnology	cancer
angiogenesis inhibitor; Genzyme	Preliminary		biotechnology;	cancer
angiopeitin 2	Preliminary		angiogenesis inhibitor;	cancer
ANGIOSTATIN	Preliminary		angiogenesis inhibitor;	cancer
BST 2001; ANGIOCOL	Preliminary		angiogenesis inhibitor;	cancer
gene therapy, endostatin	Preliminary		angiogenesis inhibitor;	cancer
Del-1 angiogenic protein based therapies	Preliminary		angiogenesis inhibitor;	cancer; ischemia; restenosis
drug delivery system, TCS, antisense oligonucleotide, VEGFR; antisense oligonucleotide, VEGFR, TCS	Preliminary		angiogenesis inhibitor;	cancer
	BST 2002		angiogenesis inducer	
antisense oligonucleotide, - myo; LR 3001, INX 3001	Phase I		biotechnology;	cancer
antisense oligonucleotide, c-kit	Preliminary		antisense;	oligonucleotide
			biotechnology;	cancer
			antisense;	oligonucleotide

antisense oligonucleotide, c- myb	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, Enzo	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, INSERM	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, climeric 2-5A, chronic myelogenous leukemia	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chronic myelogenous leukemia; RGA 1512	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; antisense oligonucleotide, EGFR	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, insulin-like growth factor-1 receptor; antisense oligonucleotide, IGF- IR; INX 4437	Phase I		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, mdm2	Precclinical		biotechnology; antisense; oligonucleotide;	cancer
antisense oligonucleotide, multi-drug resistance protein-1; antisense oligonucleotide, MDR-1	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1102	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1106	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, p120; ISIS 3466	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, phospholipase A2; antisense oligonucleotide, PLA2	Precclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase A; GEM 231	Phase II		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, protein kinase C- alpha; antisense oligonucleotide, cancer; ISIS 3521; CGP 64128A; ISI 641A	Phase II		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase type I; antisense oligonucleotide; PKA-I	Preliminary		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, tumor necrosis factor; AR 797	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; AR 639	Preliminary		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; antisense oligonucleotide; VEGF; GEM 220	Preliminary		biotechnology; antisense; oligonucleotide	retinopathy; cancer; skin disease
antisense oligonucleotides, cancer, Matricech	Discontinued		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotides, human papillomavirus 16/18; antisense oligonucleotides, HPV 16/18	Preliminary		biotechnology; antisense; oligonucleotide	cancer; viral infection
antisense oligonucleotides, multi-drug resistance protein; antisense oligonucleotides, MRP	Preliminary		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, erbB-2	Preliminary		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, p27	Preliminary		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS antisense oligonucleotide, c-myc; antisense oligonucleotide, TCS c-myc; INX 3000, TCS	Preliminary		biotechnology; antisense; oligonucleotide	cancer
Drug delivery system, TCS INX 3280; INX 3280 TCS; INXC 6295	Preliminary		biotechnology; antisense; oligonucleotide	cancer

Drug delivery system, TCS, antisense oligonucleotide, IGF-IR, antisense oligonucleotide, IGF-IR, TCS; INX 4437, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, bcl-2; G 3139	Phase II		biotechnology; antisense; oligonucleotide; chemosensitizer	cancer
antisense oligonucleotide, raf-1, Neopharm; drug delivery system, antisense oligonucleotide, raf-1, Neopharm	Preclinical		biotechnology; antisense; oligonucleotide; radiosensitizer	cancer
antisense oligonucleotide, p65 NF-kappaB	Preclinical		biotechnology; antisense; oligonucleotide; transcription factor regulator	cancer
tumor necrosis factor apoptosis inducing ligand; TRAIL, secreted apoptosis related proteins, SARP	Preclinical		biotechnology; apoptosis inducer	cancer
keratinocyte growth factor antagonist, NeXstar; KGF antagonist	Preclinical		biotechnology; apoptosis inhibitor; aptamer; oligonucleotide	cancer

PDGF antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
TGF-beta antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
NX 1838	Phase I		biotechnology; aptamer; oligonucleotide;	cancer; diabetes; retinopathy
MIG	Preclinical		angiogenesis inhibitor biotechnology; chemokine;	angiogenesis inhibitor biotechnology; cancer
somatomedin binding protein; insulin-like growth factor binding protein; IGF BP-1	Suspended		angiogenesis inhibitor biotechnology; cicatrizant	skin ulcer; cancer
interleukin-1 beta; IL-1beta	Discontinued		biotechnology; cicatrizant; cytokine; vaccine adjuvant	cancer; infectious disease
avotermin; transforming growth factor beta-3; TGF beta-3; CGF 46614	Phase II	transforming growth factor beta3 (human), dimer	biotechnology; cicatrizant; growth factor	cancer; skin ulcer; mucositis
tumor growth factor-alpha; TGF-alpha	Discontinued		biotechnology; cicatrizant; growth factor	eye disease; cancer; skin ulcer
Fibroblast ant collagenase; FBAC; ant collagenase Fibroblast	Suspended		biotechnology; cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis

tissue inhibitor of metalloproteinase 2; TIMP-2	Discontinued		biotechnology; collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; gene inhibitor	cancer
BC 1; AS 122; AngioMab	Phase I		biotechnology; contrast medium; monoclonal antibody; radiotherapeutic; radiodiagnostic; angiogenesis inhibitor	cancer; diagnosis
senescence derived inhibitor 1; Sdi 1	Discontinued		biotechnology; cyclin dependent kinase inhibitor	cancer, psoriasis; eye disease; cancer
multiple tumor suppressor 1-based therapy	Preliminary		biotechnology; cyclin dependent kinase inhibitor; gene	cancer
AR 324	Discontinued		biotechnology; cytokine	cancer
canarypox IL-2; ALVAC-hIL-2	Phase II		biotechnology; Cytokine	cancer
drug delivery system, preclinical interleukin secreting implant; interleukin secreting implant	Preclinical		biotechnology; cytokine	cancer
IL-2 conjugate, Ajinomoto; Gal3 modified IL-2	Preliminary		biotechnology; cytokine	cancer

interleukin-3/interleukin-6 mutant chimeric molecule; IL-3/IL-6 in chimeric molecule	Suspended		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6; IL-6; SDZ ILS 969; ILS 969	Discontinued		biotechnology; cytokine	cancer
interleukin-6; IL-6; SIGOSIX	Phase II		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6 mutant; IL-6 mutant; FCE 27809	Phase I		biotechnology; cytokine	cancer; thrombocytopenia
magrestip; magrestip; BB 10010; MIP-1alpha	Discontinued	(human clone pAT464 macrophage inflammatory reduced), 26-L-alanine-lymphokine MIP 1alpha	biotechnology; cytokine	cancer; HIV infection
SC 68420; MPO 1	Discontinued		biotechnology; cytokine	cancer
sonemin; tumor necrosis factor; TNF; PT 050; TIENEF; TIINEF	Discontinued	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer
sonemin; tumor necrosis factor; TNF; PAC 4D	Pre-registration	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer; psoriasis

fasenremin; tumor necrosis factor alpha; TNF-alpha; FK 516; BEROMUN	Registered		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor; Discontinued TNF			biotechnology; cytokine	cancer
tumor necrosis factor alpha; TNF-alpha	Preliminary		biotechnology; cytokine	cancer
tumor necrosis factor alpha tip mutants; TNF-alpha tip mutants	Discontinued		biotechnology; cytokine	cancer
gene therapy, IL-12; gene therapy, cancer	Preliminary		biotechnology; cytokine; gene therapy; biotechnology; immunostimulant	cancer
gene therapy, interferon-alpha; gene therapy, cancer	Phase II		biotechnology; cytokine; gene therapy; immunostimulant; interferon	cancer

danuplesin; interleukin-3 synthokine; IL-3 synthokine; SC 55494	Discontinued	14-al-a18-ile-25-his- 29-arg-32-asn-37-pro- cytokine; growth factor 55-thr-59-leu-62-val- 67-his-69-glu-73-gly- 76-al-a-79-arg-82-gln- 87-ser-93-ser-98-ile- 101-al-a-105-gln-109- glu-116-val-120-gln- 123-glu-14-125- interleukin 3 (human clone D11)	biotechnology; cytokine; growth factor; hematopoietic factor	cancer
IL-6/IL-2 fusion protein	Preliminary		biotechnology; cytokine; growth factor; hematopoietic factor	cancer
interleukin-6; IL-6; BETA TROPIN	Suspended		biotechnology; cytokine; growth factor; hematopoietic factor	cancer; thrombocytopenia
aldesleukin; interleukin-2; IL-2; PROLEUKIN cancer therapy, monkey vero cell line secretting IL-2; vero- IL-2	Marketed Phase II	125-L-serine-2-133- interleukin 2 (human reduced)	biotechnology; cytokine; immunostimulant biotechnology; cytokine; immunostimulant	cancer; HIV infection cancer

celmoleukin; interleukin-2; IL-2; TAKELEUKIN; CELEUK	Marketed	A-P-T-S-S-T-K-K- T-Q-L-Q-L-E-H-L-L- L-D-L-Q-M-LL-N-G- I-N-N-Y-K-N-P-K-L- T-R-M-L-T-F-K-F-Y- M-P-K-K-A-T-E-L- K-H-L-Q-C-L-E-E-F- L-K-P-L-E-E-V-L-N- L-A-Q-S-K-N-F-H-J- R-P-R-D-L-I-S-N-I- N-V-I-V-L-E-L-K-G- S-E-T-T-F-M-C-E-Y- A-D-E-T-A-T-I-V-E- F-L-N-R-W-I-T-F-C- Q-S-I-H-S-T-L-T	virology; biotechnology; cytokine; immunostimulant cancer
drug delivery system, adesleukin; drug delivery system, interleukin-2; adesleukin	Discontinued		cancer; HIV infection
DepoFoam	Drug delivery system, interleukin-2; interleukin-2 delivery system; drug delivery system, IL-2	Drug delivery system, interleukin-2; interleukin-2 delivery system; drug delivery system, IL-2	biotechnology; virology; cytokine; immunostimulant cancer

interferon alfa-N1; IFN alfa-N1; WELLFERON; SUMIFERON; HUMOFERON	Marketed		biotechnology; cytokine; immunostimulant	cancer; viral infection
interleukin-1; IL-1	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha; IL-1a	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha derivative; OCT 7000	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL-1 beta; OCT 43; OCTIN	Pre- registration		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2; NSC 600664; LEUFERON 2	Phase III		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-5; IL-5	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-6; IL-6	Suspended		biotechnology; cytokine; immunostimulant	cancer

interleukin-7; IL-7	Preliminary		biotechnology; cytokine; immunostimulant	cancer
mitoflaxone + interleukin-1; interleukin-1 + mitoflaxone	Discontinued		biotechnology; cytokine; immunostimulant	cancer
oprelvekin; interleukin-11; IL-11; YM 294; NEUIMEGA polyethylene glycol interleukin 2; PEG IL-2; interleukin 2 mactogol	Marketed	Phases II	biotechnology; cytokine; immunostimulant	cancer; HIV infection; mucositis; Crohn disease
SC 71858; PMP		Phase I	biotechnology; cytokine; immunostimulant	HIV infection; cancer
interleukin-1 beta; IL-1 beta	Preliminary		biotechnology; cytokine; immunostimulant	cancer
interleukin-3; IL-3; ALLEVORIN	Suspended		biotechnology; cytokine; immunostimulant; cicatrizant	cancer; skin ulcer
interleukin-3; IL-3	Discontinued		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-3; IL-3	Phase I		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; leukopenia
lenidistin; SC 70935; MPO	Phase III		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
muphestin; interleukin-3; IL-3; SDZ ILE964; ILE 964; HEMOKINE	Phase III	human interleukin 3	biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; thrombocytopenia; leukopenia
drug delivery system, ProLease interferon alfa; interferon alfa ProLease	Discontinued		biotechnology; cytokine; immunostimulant; interferon	viral infection; cancer
MAb ch14.18-IL-2 fusion protein	Preliminary		biotechnology; cytokine; immunostimulant; monoclonal antibody	cancer
interleukin-4; IL-4; SCH 39400; QUADRAKINE	Phase II		biotechnology; cytokine; immunostimulant; NSAID	cancer; viral infection; rheumatoid arthritis
interleukin-12; IL-12; natural killer cell stimulatory factor; NKSF; YM01C	Phase II		biotechnology; cytokine; immunostimulant; vaccine adjuvant	viral infection; cancer

interleukin-1 deletion mutants	Preliminary		biotechnology; cytokine; vaccine adjuvant; radioprotectant; immunostimulant	cancer; infectious disease
antisense oligonucleotide, cancer, DNA binding antisense oligonucleotide	Preliminary		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; triple helix oligonucleotide, EGFR; T 03101	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, her-2, triple helix oligonucleotide, her-2 sense oligonucleotide, NF-kappaB decoy	Discontinued		biotechnology; DNA transcription inhibitor; oligonucleotide; transcription factor regulator	cancer; viral infection
methioninase; AC 9301; ONCase	Preliminary		biotechnology; enzyme	cancer

acidic fibroblast growth factor-Pseudomonas exotoxin fusion protein; aFGF-Pseudomonas exotoxin fusion protein DWP 408	Discontinued		biotechnology; fusion toxin	cancer
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF fusion toxin; interleukin-13 fusion protein; hIL13.E13K-PE4E	Phase II		biotechnology; fusion toxin	cancer; restenosis; psoriasis
GM-CSF diphtheria toxin chimeric protein; DT388 GM-CSF	Discontinued		biotechnology; fusion toxin	cancer
heregulin-Pseudomonas exotoxin fusion protein	Preliminary		biotechnology; fusion toxin	cancer

[IL-4 fusion toxin; IL-4(38-37)-PE38KDEL; interleukin-4 fusion toxin; NBI 3001]	Phase II		biotechnology; fusion toxin	cancer
[IL-13-PE38QQR; interleukin-13/pseudomonas exotoxin derivative]	Preliminary		biotechnology; fusion toxin	cancer
[interleukin-4-pseudomonas exotoxin A; IL-4-PE]	Preliminary		biotechnology; fusion toxin	cancer
[interleukin-6-diphtheria toxin chimeric protein; IL-6-diphtheria toxin chimeric protein; IL-6-fusion protein]	Preliminary		biotechnology; fusion toxin	[HIV infection; cancer]
[interleukin-6-Pseudomonas exotoxin 40 chimeric protein; IL-6-PE40]	Preliminary		biotechnology; fusion toxin	cancer
[interleukin-6-Pseudomonas exotoxin 66(4Glu) chimeric protein; IL-6-PE66(4Glu)]	Preliminary		biotechnology; fusion toxin	cancer
[melanocyte stimulating hormone diphtheria toxin chimeric protein; MSH diphtheria toxin chimeric protein; MSH fusion protein]	Preliminary		biotechnology; fusion toxin	cancer

mitotoxin fibroblast growth factor-saponin; mitotoxin; FGF-saponin; PANTARIN	Discontinued		biotechnology; fusion toxin	cancer; restenosis; eye disease
[TGFalpha-PF38; TGFalpha PE38 fusion toxin	Preliminary		biotechnology; fusion toxin	cancer
transferrin-CRM107; transferrin-toxin; HN 66000	Phase II		biotechnology; fusion toxin	cancer
transforming growth factor alpha-Pseudomonas exotoxin 40 chimeric protein; TGF alpha-PE40; TGFa-PE40	Preclinical		biotechnology; fusion toxin	cancer
interleukin-4-diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	Preclinical		biotechnology; fusion toxin; immunosuppressant	autoimmune diseases; transplant rejection; cancer; HIV infection
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	Marketed	1-388-toxin (Corynebacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine, (388-fivdarw-2)-protein with 2-133-interleukin 2 (human clone pTIL2-21-a)	biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer

interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; DAB 486-IL-2; D-IL-2	Discontinued		biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumaloid arthritis; cancer
cancer therapy, inf6 cancer therapy, tumor suppressor, University Technologies International	Preliminary	Preliminary	biotechnology; gene therapy	cancer; diagnosis
melastatin	Preliminary		biotechnology; gene therapy	cancer
BRUSH-1 gene based therapy; cancer therapy	Preliminary		biotechnology; gene therapy	cancer
cancer therapy, modified adenovirus, Onyx; ONYX 838	Preliminary		biotechnology; gene therapy	cancer
gene therapy, adenoviral herpes simplex virus thymidine kinase; gene therapy, cancer gene therapy, anti- metastasis technology	Preliminary		biotechnology; gene therapy	cancer
gene therapy, anticancer stem cell; gene therapy, cancer	Preliminary		biotechnology; gene therapy	cancer

gene therapy, anticancer T cell; gene therapy, CC49; CC 49	Phase II	biotechnology; gene therapy	cancer
gene therapy, antisense c-myc; gene therapy, prostate cancer	Preclinical	biotechnology; gene therapy	cancer
gene therapy, Bcl-xS, Preclinical cancer, IDUN	Preclinical	biotechnology; gene therapy	cancer
gene therapy, BCR-ABL transcription inhibitor protein	Preclinical	biotechnology; gene therapy	cancer
gene therapy, brca1, Vanderbilt University	Phase II	biotechnology; gene therapy	cancer
gene therapy, breast cancer; gene therapy, brca1, MB 300	Preclinical	biotechnology; gene therapy	cancer
gene therapy, breast cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Preclinical	biotechnology; gene therapy	cancer
gene therapy, c-fos; gene therapy, cancer	Phase I	biotechnology; gene therapy	cancer
gene therapy, cancer; GENECEUTICALS	Preclinical	biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, T-body	Discontinued	biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical	biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical	biotechnology; gene therapy	cancer

gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; cationic lipid vectors	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; immunostimulatory genes	Phase II		biotechnology; gene therapy	cancer
gene therapy, cancer, Copernicus Gene Systems	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer, Vion	Preclinical		biotechnology; gene therapy	cancer
gene therapy, chronic myelogenous leukemia	Phase I		biotechnology; gene therapy	cancer
gene therapy, CIITA; gene therapy, MHC class II deficiency	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cytidine deaminase	Phase I		biotechnology; gene therapy	cancer
gene therapy, cytotoxic T cells;	Suspended		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	coronary artery disease; peripheral vascular disease;
gene therapy, del-1; gene therapy, vascular disease; del-1	Preclinical			cancer
gene therapy, delta-like protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, drug activation	Preclinical		biotechnology; gene therapy	cancer

gene therapy, E1A repressor; gene therapy, cancer; RGG 0853; RGA 0853; tgDCC-E1A	Phase II		biotechnology; gene therapy	cancer
gene therapy, Egr-1 + TNF-alpha, gene therapy, Ad5.Egr- TNF; gene therapy, radiation-controlled technology	Preclinical	biotechnology; gene therapy		cancer
gene therapy, Ebb2- R; gene therapy, cancer	Precinical	biotechnology; gene therapy		cancer
gene therapy, fas ligand; gene therapy, cancer	Precinical	biotechnology; gene therapy		cancer
gene therapy, fasdeltaTM; gene therapy, cancer	Precinical	biotechnology; gene therapy		cancer
gene therapy, G156A MGMT; gene therapy, cancer	Precinical	biotechnology; gene therapy		cancer
gene therapy, glioblastoma; G207 gene therapy, glioma	Discontinued	biotechnology; gene therapy		cancer
gene therapy, GM- CSF	Precinical	biotechnology; gene therapy		cancer
gene therapy, H-Nuc	Precinical	biotechnology; gene therapy		cancer
gene therapy, H19; gene therapy, cancer	Precinical	biotechnology; gene therapy		cancer

gene therapy, herpes simplex thymidine kinase	Phase I	biotechnology; gene therapy	cancer
gene therapy, herpes simplex tyrosine kinase; gene therapy HS-ik	Preliminary	biotechnology; gene therapy	cancer
gene therapy, HLA-B7; gene therapy, melanoma	Preliminary	biotechnology; gene therapy	cancer
gene therapy, human papillomavirus; gene therapy, HPV	Preliminary	biotechnology; gene therapy	cancer
gene therapy, IL-12 fusion protein	Preliminary	biotechnology; gene therapy	cancer; viral infection
gene therapy, interleukin-2; AdCAIL-2	Phase I	biotechnology; gene therapy	cancer
gene therapy, interleukin-7	Discontinued	biotechnology; gene therapy	cancer
gene therapy, LeIF	Discontinued	biotechnology; gene therapy	cancer.
gene therapy, leukemia, Novartis, GVH 313	Phase I	biotechnology; gene therapy	cancer
gene therapy, macrophage colony-stimulating factor	Preliminary	biotechnology; gene therapy	cancer
gene therapy, mda-7; gene therapy, melanoma	Preliminary	biotechnology; gene therapy	cancer

gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, men; gene therapy, cancer	Preliminary		biotechnology; gene therapy	cancer
gene therapy, multi-drug resistance	Preliminary		biotechnology; gene therapy	cancer
gene therapy, multiple drug resistance-1; gene therapy, MDR-1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, p16, Introgen; gene therapy, cancer, Introgen; INGN 221	Preliminary		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer, SCH 58500	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, retroviral p53; INGN 101	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, adenovirus p53; INGN 201	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; p53 TCS	Preliminary		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer	Preliminary		biotechnology; gene therapy	cancer
gene therapy, p53(MDM2)	Preliminary		biotechnology; gene therapy	cancer

gene therapy, p53/WAF1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, pancreatic cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Phase I		biotechnology; gene therapy	cancer
gene therapy, pRb2/p130; gene therapy, cancer	Preliminary		biotechnology; gene therapy	cancer
gene therapy, pro- drug activation	Preliminary		biotechnology; gene therapy	cancer
gene therapy, prostate cancer, Calydon; CN 706	Phase I		biotechnology; gene therapy	cancer
gene therapy, PTEN;	Preliminary		biotechnology; gene therapy	cancer
gene therapy, cancer				
gene therapy, RB 94; SG 94; RB 94	Preliminary		biotechnology; gene therapy	cancer
gene therapy, recombinant oncolytic HSV expressing CYP2B1; rRp450	Preliminary		biotechnology; gene therapy	cancer
gene therapy, retinoblastoma gene; gene therapy, Rb gene; ACNRB	Preliminary		biotechnology; gene therapy	cancer

gene therapy, ribozyme, cancer, City of Hope Medical Center; ribozyme, cancer, City of Hope Medical Center	Precinical		biotechnology; gene therapy	cancer
gene therapy, scFv- RAS; INGN 212	Precinical		biotechnology; gene therapy	cancer
gene therapy; solid tumors, Oxford BioMedica; Metrixia	Precinical		biotechnology; gene therapy	cancer
gene therapy, T cell chimeric receptor;	Discontinued		biotechnology; gene therapy	cancer
gene therapy, cancer gene therapy,	Phase III		biotechnology; gene therapy	cancer
thymidine kinase; gene therapy, cancer; gene therapy, HS-tk; SDZ GL1328; GLI 328				
gene therapy, thymidine kinase; gene therapy, leptomeningeal carcinomatosis; gene therapy, HS-tk gene therapy	Discontinued		biotechnology; gene therapy	cancer
thymidine kinase; gene therapy, HS-tk; gene therapy, mesothelioma	Phase I		biotechnology; gene therapy	cancer

gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, brain cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Suspended		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer	Phase I	National Institute of Neurological Disorders and Stroke; gene therapy, HS-tk, NINDS	biotechnology; gene therapy	cancer

gene therapy, TNF alpha	Preliminary		biotechnology; gene therapy	cancer
gene therapy, tumor necrosis factor alpha; gene therapy, solid tumor	Phase II		biotechnology; gene therapy	cancer
toxigenes	Preliminary		biotechnology; gene therapy	cancer
gene therapy, epithelial cell cancer, Cobra Therapeutics; CTL 302	Preliminary		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, liver cancer, Cobra Therapeutics; CTL 203	Preliminary		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, prostate cancer, Cobra Therapeutics; CTL 401	Preliminary		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, angiogenesis	Preliminary		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, antiangiogenesis genes, cancer	Preliminary		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, cancer; gene therapy, angiogenesis inhibition	Preliminary		biotechnology; gene therapy; angiogenesis inhibitor	cancer

gene therapy; antisense K-ras; antisense oligonucleotide, K- ras; INGN111	Preliminary		biotechnology; gene therapy; antisense; oligonucleotide	cancer
gene therapy, chemotherapy- resistance genes; gene therapy, MDR	Preliminary		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR; gene therapy, cancer;	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR- I; gene therapy, MDR- I; gene therapy, cancer	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, gp91 phox; gene therapy chronic granulomatous disease	Preliminary		biotechnology; gene therapy; coagulation factor	cancer
gene therapy, Sdi 1; gene therapy, cancer	Discontinued		biotechnology; gene therapy; cyclin dependent kinase inhibitor	cancer
gene therapy, cancer; gene therapy, VV- GM	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, cancer; gene therapy; cytokine; gene therapy, immunostimulatory cell surface molecules	Preliminary		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, consensus interferon; gene therapy, IFN-con1; gene therapy, cancer	Preliminary		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-2; gene therapy, IL-2; BIWB 2	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-3, IntroGene; gene therapy, cancer, IntroGene	Preliminary		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interferon beta; gene therapy, cancer	Preliminary		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12/B7-1; gene therapy, AdIL12/B7-1; gene therapy, cancer, AdIL12/B7-1	Preliminary		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; AC 9401; MetaGene	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; VCL 1102; LEUVETIN	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, breast cancer; AVECTIN	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; BIWB 1	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-2, gene therapy, neuroblastoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2, gene therapy, colon cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, IL-2, gene therapy, melanoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + interferon gamma; gene therapy, cancer	Precclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + thymidine kinase; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2, interferon gamma, thymidine kinase; gene therapy, cancer	Precclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Precclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-7; gene therapy, IL-7; gene therapy, malignant melanoma	Suspended		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-7; gene therapy, IL-7	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, TNF; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
NV 1030	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant; angiogenesis inhibitor	cancer
gene therapy, granulocyte macrophage-colony stimulating factor, Geniva, gene therapy, cancer, Geniva	Phase I		biotechnology; gene therapy; cytokine; immunostimulant; vaccine	cancer
gene therapy, MDR, GenPak; gene therapy, cancer	Phase II		biotechnology; gene therapy; hematoprotectant;	
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; hematoprotectant;	cancer

gene therapy, HLA-B7; gene therapy, cancer; gene therapy, HLA-B7/cytofectin complex; ALLOVECTIN-7	Phase III gene therapy, IL-2; gene therapy, small cell lung cancer; gene therapy, BPV vector gene therapy, suicide gene + immunotherapeutic; gene therapy, cancer gene therapy, gamma interferon; gene therapy, cancer	Phase II Preclinical Phase I	biotechnology; gene therapy; immunostimulant biotechnology; gene therapy; immunostimulant biotechnology; gene therapy; immunostimulant biotechnology; gene therapy; immunostimulant biotechnology; gene therapy; cytokine	biotechnology; gene therapy; immunostimulant cancer cancer cancer cancer
gene therapy, GM-CSF; gene therapy, cancer; vaccine, GVAX	Phase II Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	biotechnology; gene therapy; immunostimulant; cytokine
gene therapy, interleukin-10; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	biotechnology; gene therapy; immunostimulant; cytokine
gene therapy, interleukin-2; gene therapy, melanoma; gene therapy, tyrosinase promoter				cancer

gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, AdCAIL-2; AdCAIL-2	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preliminary		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, leukemia; gene therapy, immunostimulatory molecules	Preliminary		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interferon alpha	Preliminary		biotechnology; gene therapy; immunostimulant;	cancer
gene therapy, interferon gamma; gene therapy, cancer	Preliminary		cytokine; interferon biotechnology; gene therapy; immunostimulant;	cancer
gene therapy, MRP; gene therapy, cancer	Preliminary		cytokine; interferon biotechnology; gene therapy; MDR	cancer
gene therapy, multidrug resistance; gene therapy, MDR	Discontinued		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, herpes simplex thymidine kinase gene; gene therapy, cancer	Phase I		biotechnology; gene therapy; NSAID	rheumatoid arthritis; restenosis; cancer
gene therapy, transforming growth factor beta; oligonucleotide, TGF beta	Phase I		biotechnology; gene therapy; oligonucleotide	cancer
gene therapy, hammerhead ribozyme, cancer, Berlex Biosciences; ribozyme, c-erb-B2, Berlex Biosciences	Preclinical		biotechnology; gene therapy; oligonucleotide; ribozyme	cancer

gene therapy, Ad(GV)CD10; gene therapy, cytosine deaminase; gene therapy, colon cancer gene therapy, p53; vaccine, p53; gene therapy, cancer.	Phase II  Preclinical	biotechnology; gene therapy; radiosensitizer	cancer
vaccine, gene-based, B cell lymphoma vaccine, gene-based, carcinoembryonic antigen; vaccine, gene-based, pGT37; vaccine, gene-based, cancer	Phase I  Preclinical	biotechnology; gene therapy; vaccine biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, E7; vaccine, gene- based cancer	Preclinical	biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100; vaccine, gene- based, melanoma	Phase I	biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100 + MART-1; vaccine, gene-based, melanoma	Phase II	biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, MART-1; vaccine, gene-based, cancer	Phase I	biotechnology; gene therapy; vaccine	cancer

vaccine, gene-based, melanoma, Bavarian Nordic Research Institute; gene therapy, melanoma, Bavarian Nordic Research Institute; MVA TYR	Precinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, NY-ESO-1; vaccine, gene-based, cancer vaccine, gene-based, T cell cancer	Precinical		biotechnology; gene therapy; vaccine	cancer
vaccine, human papillomavirus antigens; vaccine HPV antigens; vaccine, cervical cancer	Discontinued		biotechnology; gene therapy; vaccine	cancer
anti-dorsalizing morphogenetic protein-1	Precinical		biotechnology, growth factor	cancer
heregulin; Neu differentiation factor; NDF	Discontinued		biotechnology, growth factor	cancer
megakaryocyte stimulating factor			biotechnology; growth factor	cancer
Red blood cell growth factor	Precinical		biotechnology; growth factor	cancer
transforming growth factor beta; TGF beta; BMS 196725	Precinical		biotechnology; growth factor	cancer; mucositis

transforming growth factor beta; TGF-beta keratinocyte growth factor 2; KGF 2; HG 03400	Preliminary Phase II		biotechnology; growth factor	biotechnology; growth factor; mucositis; cancer; musculoskeletal disorder
granulocyte macrophage colony stimulating factor muteins; GM-CSF muteins	Preliminary		biotechnology; growth factor; cicatrizing; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
polyethylene glycol hemoglobin; PEG-hemoglobin	Phase I		biotechnology; growth factor; hematopoietic factor	cancer
polyethylene glycol megakaryocyte growth and development factor; PEG-MGDF	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
polyethylene granulocyte macrophage colony stimulating factor glycol; PEG-GM-CSF; PolyMASC-GM-CSF	Preliminary		biotechnology; growth factor; hematopoietic factor	cancer
thrombopoietin; TPO; Phase III			biotechnology; growth factor; hematopoietic factor	thrombocytopenia

thrombopoietin; TPO	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
thrombopoietin; TPO	Preliminary		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia

cilostim; macrophage colony stimulating factor; M-CSF; MACSTIM	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	bacteremia; hyperlipidemia; bacterial infection; cancer
filgrastim; granulocyte colony stimulating factor; G-CSF; neutropoetin; KRN 8601; NEUPOGEN; GRANULOKINE; GRAN; GRUMATIN	Marketed	N-L-methionyl-colony-stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant	cancer; HIV infection; pneumonia; leukopenia; skin ulcer
filgrastim SD001; PEG-granulocyte-colony stimulating factor; PEG-GCSF; SD-NEUPOGEN	Phase II			biotechnology; growth factor; hematopoietic factor; immunostimulant
macrophage colony stimulating factor; GM-CSF; LEUCOTROPIN	Phase III			biotechnology; growth factor; hematopoietic factor; immunostimulant
macrophage inflammatory protein-alpha; MIP-1alpha	Preclinical			biotechnology; growth factor; hematopoietic factor; immunostimulant

molgramostim; granulocyte macrophage colony stimulating factor; GM-CSF; GMC 89107; SCH 39300; CSF 39300; LEUCOMAX	Marketed	colony stimulating factor 2 (human clone pHG25 protein moiety reduced)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
natograstim; marograstim; granulocyte colony stimulating factor mutein; G-CSF mutein; KW 2228; NEU-UP	Marketed	1-(N-L-methionyl-L- alanine)-3-L- threonine-4-L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
pegantratograstim; pegylated G-CSF mutein; PEG-G-Ro 256315; Ro 25-8315; Ro 25-8315/000	Suspended	Pegantratograstim	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
polyethylene glycol granulocyte colony stimulating factor; PEG-G-CSF; granulocyte colony stimulating factor macrogol progenopoietin; progenopoietin G; SD 1091	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

totipotent stem cell factor; T-SCF	Precclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
FLT3 ligand; DNAX Research Institute; FLT 3	Precclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
FLT3 ligand; Immunex; FLT 3; FLT 003; MOBIST	Phase II		biotechnology; growth factor; immunostimulant; hematopoietic factor; vaccine adjuvant	cancer
stem cell proliferation factor; SCFF	Precclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
DWP 404	Precclinical		biotechnology; hematopoietic factor; growth factor	cancer; thrombocytopenia
TPO-Rp	Precclinical		biotechnology; hematopoietic factor; growth factor; peptide hormone	thrombocytopenia; cancer
thyroid stimulating hormone; TSH; THYROGEN	Marketed	thyrotropin (human beta-subunit) complex with chorionic gonadotropin (human alpha-subunit)	biotechnology; hormone	cancer; diagnosis; hypothyroidism
polyethylene glycol arginase; PEG-arginase; arginase macrotool	Discontinued		biotechnology; hydrolase; arginase enzyme	cancer

pegaspargase; polyethylene glycol L-asparaginase; PEG- L-asparaginase; asparaginase macrogol; ONCASPAR	Marketed cervical cancer therapy. Transgene immunotherapeutic, cancer, Transgene mistletoe lectin; mistletoekin	pegaspargase	biotechnology; hydrolase; asparaginase; enzymic asparaginase	cancer
	Precinical Phase II		biotechnology; immunostimulant biotechnology;	cancer
	Precinical		immunostimulant biotechnology;	cancer
	Discontinued		immunostimulant biotechnology;	cancer
gene therapy, macrophage activated killer cells plus bispecific antibody; MAK therapy; MAK ancestini; stem cell factor; SCF; STEMGEN	Phase II		immunostimulant; biotechnology; immunostimulant; gene therapy	cancer
	Pre- registration	N-L-methionyl-1- 165-hematopoietic cell growth factor KL (human clone V19.8:hSCF162) dimer	biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
granulocyte colony- stimulating factor; BM 800001	Suspended		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-9; IL-9	Discontinued		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
lenograstim; granulocyte colony stimulating factor; G- CSF; pluripotetin; NEUTROGIN; GRANOCYTE; EUPROTIN; MYELOSTIM	Marketed	133-[O-(N-acetyl- alpha-neuraminoxy)- (2-3)-O-beta-D- galactopyranosyl-(1- 3)-2-(acetylamino)-2- deoxy-beta-D- galactopyranosyl]-L- threonine]-colonyl stimulating factor (human clone 1034)	biotechnology; immunostimulant; growth factor; hematopoietic factor	anemia; HIV infection; cancer; leukopenia
sarganostim; granulocyte macrophage colony stimulating factor; GM-CSF; Bi 61012; rhu GM-CSF; LEUKINE; PROKINE; INTERBERIN	Marketed	23-L-leucine colony- stimulating factor 2 (human clone pHG25 protein moiety)	biotechnology; immunostimulant; growth factor; hematopoietic factor; vaccine adjuvant	cancer; infectious disease; HIV infection; leukopenia
stem cell factor; SCF	Discontinued		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
ImmTher	Phase II		biotechnology; immunostimulant; peptide	cancer

vaccine, prostate cancer; JT 1001; OncoVax-P; Onco Vax-Ph	Phase II		biotechnology; immunostimulant; vaccine	cancer
cytokine cocktail; BC-IL; leukocyte interleukin injection; MULTIKINE ZYN-LINKER conjugated superantigens	Phase II Suspended		biotechnology; immunostimulant; vaccine adjuvant; cytokine	cancer; infectious disease; HIV infection
MAb, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA E 21R	Phase I Preclinical		biotechnology; immunosuppressant; NSAID	rheumatoid arthritis; cancer
G28-5 sFV-PE40	Preclinical		biotechnology; immunosuppressant; NSAID	autoimmune disease; cancer
immunotoxin, lymphoma MAb, glioma/neuroblastoma	Discontinued Phase I		biotechnology; immunotoxin	allergy
gelonin; GLIOMAB-H				cancer
immunotoxin, cancer, immunomedics/NCI	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer

MAb, epidermal growth factor receptor-DMI; MAb, EGFR-DMI	Preliminary		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, interleukin-13-PE38QQR; immunotoxin, IL-13-PE38QQR	Preliminary		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, ricin A immunotoxin; MAb, colorectal cancer; ZD 0490; ICI D0490	Discontinued		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, SS(dsFv)-PE38	Preliminary		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, venus flytrap cluster conjugate	Preliminary		biotechnology; immunotoxin; monoclonal antibody	cancer; diagnosis

nacolomab tafenatox; MAb, C242-staphylococcal enterotoxin A; FA <sub>b</sub> , C242-staphylococcal enterotoxin A; PNU 214565; LS 4565; TTMA LS 4585	Phase I	20-244-immunoglobulin G1, anti-(human colorectal tumor antigen C242) Fab fragment (mouse monoclonal r-C242Fab-SEA clone pKP941 gamma-m chain) fusion protein with enterotoxin A (Staphylococcus aureus), disulfide with mouse monoclonal r-C242Fab-SEA clone pKP941 kappa-chain	biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, doxorubicin conjugate; MA <sub>b</sub> , BR 96-doxorubicin; MAb, BR 96-DOX; BMS 182248; BMS 18224801	Phase II		biotechnology; immunotoxin; monoclonal antibody; anthracycline; antibiotic; DNA intercalator.	cancer
MAb, B43-genistein; B43-Gen immunoconjugate	Phase I		biotechnology; immunotoxin; monoclonal antibody; tyrosine kinase inhibitor	cancer

drug delivery system, pre-interferon alfa; interferon alfa drug delivery system; SUMIFERON MINIPELLET	Pre-registration	biotechnology; interferon	viral infection; cancer
drug delivery system, interferon beta; interferon beta drug delivery system; drug delivery system, IFN beta	Discontinued	biotechnology; interferon	cancer; viral infection; cancer; viral infection
drug delivery system, oral interferon alfa-2a; IFN alfa-2a, oral	Suspended	biotechnology; interferon	cancer; viral infection
interferon alfa, natural; IFN-alfa, natural; EGIFFERON	Marketed	biotechnology; interferon	cancer; viral infection
interferon alpha, hybrid; hybrid interferon alpha	Preliminary	biotechnology; interferon	viral infection; cancer
interferon alpha, natural; FPI 31 interferon beta; IFN-beta; DL 8234; FERON	Pre-registration Marketed	biotechnology; interferon	viral infection; cancer
interferon beta; IFN-beta	Discontinued	biotechnology; interferon	viral infection; cancer; retinopathy
interferon beta-1a; IFN beta; AVONEX	Marketed	biotechnology; interferon	cancer; viral infection
			viral infection; multiple sclerosis; cancer

interferon beta-1a; interferon beta; IFN-beta; REBIF	Marketed		biotechnology; interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETAFFERON	Marketed	2'-166-interferon beta I (human fibroblast reduced)	biotechnology; interferon	multiple sclerosis; cancer; viral infection
interferon omega; IFN omega	Phase II		biotechnology; interferon	viral infection; cancer
polyethylene glycol interferon alfa-2b; PEG-interferon alfa-2b; interferon alfa-2b macrogol; PEG- INTRON A	Phase III		biotechnology; interferon; cytokine	viral infection; cancer
interferon alfa-2b; IFN alfa-2b; SCH 30300; YM 1490; INTRON A; CIBIAN; VIRAFERON	Marketed		biotechnology; interferon; cytokine; immunostimulant	cancer; viral infection
tumor necrosis factor + interferon alfa-2a; interferon alfa-2a + tumor necrosis factor; TNF + IFN alfa-2a	Discontinued		biotechnology; interferon; growth factor	cancer

interferon alfa-2a; IFN alfa-2a; Ro 228181; ROFERON A; CANFERON A; ROFERON	Marketed	(human leukocyte protein moiety) interferon alpha A	biotechnology; interferon; immunostimulant	viral infection; cancer
interferon gamma-1a; SUN 4800; BIOGAMMA A	Marketed		biotechnology; interferon; immunostimulant	cancer
interferon gamma-1b; interferon gamma; IFN gamma; ACTIMMUNE, IMUKIN; IMUFOR GAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer; bacterial infection; chronic granulomatous disease; tuberculosis
interferon, consensus; consensus interferon; interferon alfacon-1; YM 643; INFERGEN	Marketed	interferon alpha 1 (human lymphoblast reduced), N-L- methionyl-22-L-arg- 76-L-alala-78-L-asp- 79-L-glu-86-L-tyr-90- L-tyr-156-L-thr-157- L-asn-158-L-leu-	biotechnology; interferon; immunostimulant	viral infection; cancer
3622WW94; BW 3622WW94	Phase II		biotechnology; monoclonal antibody	cancer
antibodies, Sdi 1	Discontinued		biotechnology; monoclonal antibody	cancer
detumomab, MAb, idiotype B cell lymphoma; MAAb, B cell lymphoma; B cell lymphoma MAAb; SPECIFICID	Discontinued		biotechnology; monoclonal antibody	cancer

drug delivery system, liposome MAb, 273- 34A; MAb, 273-34A liposome; liposome, MAb 273-34A	Preclinical		biotechnology; monoclonal antibody	cancer
edrecolomab; MAb, 17-1A; MAb, colorectal cancer; MAb, CO17-1A; 17 1A; C-1; PANOREX	Marketed	immunoglobulin G 2a biotechnology; (mouse monoclonal 17-1A gamma-chain anti-human colon cancer tumour- associated antigen), disulfide with mouse monoclonal 17-1A light chain dimer	monoclonal antibody	cancer
lintuzumab; MAb, humanized M195; MAb, humanized CD33; SMART M195; HuM195	Phase III	immunoglobulin G1 (human-mouse monoclonal HuM195, gamma-1- chain anti-human antigen CD 33), disulfide with human monoclonal HuM195 kappa- chain, dimer	biotechnology; monoclonal antibody	cancer
lintuzumab-bismuth- 213; MAb, humanized M195- 213Bi	Phase I		biotechnology; monoclonal antibody	cancer
LYM 2	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, 12G5	Preclinical		biotechnology; monoclonal antibody	cancer

MAb, 2A11; MAb, gastrin releasing peptide	Phase II		biotechnology; monoclonal antibody	cancer
MAb, 323A3; 323A3	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, 3F8; IgG3 anti-ganglioside GD 2;	Phase I		biotechnology; monoclonal antibody	cancer
MAb, neuroblastoma			biotechnology; monoclonal antibody	cancer
MAb, 42/6; MAb, transferrin receptor	Phase I		biotechnology; monoclonal antibody	cancer
MAb, 88BY9-rhenium 186	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, 977; MAb, bladder cancer	Preliminary		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, 9D9	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, adrenomedullin	Preliminary		biotechnology; monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
MAb, antiganglioside GM2; KM 966	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, antinuclear auto-antibodies; MAb, cancer	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, B cell Lymphoma; 1D10	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, B-E4; MAb, interleukin-6; MAb, IL-6; B-E4	Phase I		biotechnology; monoclonal antibody	cancer
MAb, B4-DC1	Discontinued		biotechnology; monoclonal antibody	cancer

MAb, B6.2/212 single chain antibody; MAb, B6.2/212 SCA	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, BCD F9- radionuclide; MAb, breast cancer; BCD F9	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, bispecific F(ab')2 OC/TR; OCTR	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, bispecific hu- bsF(ab')2	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, bladder carcinoma; RG 355	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, BR 96; BR 96	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, breast cancer antigen; Pro 1.5.3	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, BW 494	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, c-Nd2; e-Nd2	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, C215-	Phase II		biotechnology; monoclonal antibody	cancer
staphylococcal enterotoxin; FAb, C215-SEA				
MAb, C242; MAb, colonic adenocarcinoma	Discontinued		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, C242-DM 1 conjugate; huC242- DM1	Preliminary		biotechnology; monoclonal antibody	cancer

MAb, C242-maytansine conjugate	Preliminary		biotechnology; monoclonal antibody
MAb, cancer	Phase III		cancer
MAb, cancer; MAb, EpCAM	Preliminary		biotechnology; monoclonal antibody
MAb, cancer; BW 1209w95	Preliminary		biotechnology; monoclonal antibody
MAb, cancer; hybrid antibody, anti-Her-2, anti-CD3	Preliminary		biotechnology; monoclonal antibody
MAb, cancer and Fc, bispecific antibody, melanoma, glioma, neuroblastoma; MDX 260	Preliminary		biotechnology; monoclonal antibody
MAb, cancer, Biolivent	Preliminary		biotechnology; monoclonal antibody
MAb, cancer, PPL	Preliminary		biotechnology; monoclonal antibody
MAb, cancer, XTL Biopharmaceuticals; MAb, cancer; Neoprobe	Preliminary		biotechnology; monoclonal antibody
MAb, carcinoembryonic antigen; MAb, CEA	Preliminary		biotechnology; monoclonal antibody
MAb, carcinoembryonic antigen; MAb, CEA	Preliminary		cancer

MAb, carcinoma; MAb, SK-1; MAb, cancer;	Phase I		biotechnology; monoclonal antibody	cancer
MONOPHARM C MAb, CC49; MAb, TAG B723; MAb, B723 second generation	Phase II		biotechnology; monoclonal antibody	cancer
MAb, CC49-interleukin-2; fusion protein, CC49-IL-2	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CC49-lutetium 177; MAb, anti-TAG-72-lutetium 177	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CC83; MAb, TAG B723; MAb, B723 second generation	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CD19/CD3; bispecific antibody, cancer	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, CD28/CD30; Bi-MoAb	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, CD3/CD30; Bi-MoAb; bispecific antibody, CD3, CD30	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, CD34; anti-CD34	Phase I		biotechnology; monoclonal antibody	cancer
MAb, CD67; MAb, cancer, Wilx Biotechnology	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, ch14.18	Phase II		biotechnology; monoclonal antibody	cancer

MAb, chemotherapeutic conjugates, IDEC	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, chimeric CC49; MAb, chimeric TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAb, chimeric CC83; MAb, TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAb, chimeric IgG1 anti CD20	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, colon-DM1	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, colorectal cancer	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, CYT 372 humanized; MAb, C46 humanized; MAb, humanized panadeno carcinoma MAb, directed enzyme prodrug therapy; ADEPT, cancer therapy	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, directed enzyme prodrug therapy + CMDA; ADEPT + CMDA; ZD 2767	Phase II		biotechnology; monoclonal antibody	cancer
MAb, EGFR and Fc; Phase II bispecific antibody, cancer; MDX 447; H 447; EMD 82633	Phase II		biotechnology; monoclonal antibody	cancer

MAb, epidermal growth factor receptor; MAb, EGF receptor; EMD 55900	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, epidermal growth factor receptor; MAb, EGF receptor; MAb, 528; MoAb528	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, epidermal growth factor receptor; MAb, EGFR; C 225	Phase III		biotechnology; monoclonal antibody	cancer
MAb, epidermal growth factor receptor; MAb, EGFR; ICR 62	Phase I		biotechnology; monoclonal antibody	cancer
MAb, epidermal growth factor, humanized; MAb, EGF, humanized; EMD 72000	Phase I		biotechnology; monoclonal antibody	cancer
MAb, erbB-2; MAb, cancer	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, erbB2	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, F(ab)2 NRC002-tienium 186; MAb, antiCEA	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, F4	Preliminary		biotechnology; monoclonal antibody	cancer

MAb, FAb NRU10- radionuclide; MAb, lung cancer; MAb, prostate cancer	Precinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, fas; MAb, bladder cancer	Phase II		biotechnology; monoclonal antibody	cancer
MAb, FC-2.15	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, fibroblast growth factor receptor; MAb, FGFR	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, germ cell cancer; ImmuRAID-HCG	Precinical		biotechnology; monoclonal antibody	cancer
MAb, gp75; MELVAX II	Precinical		biotechnology; monoclonal antibody	cancer
MAb, heparanase	Precinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, HER-2 immunoliposome	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, HER2/neu20 immunoliposomes, breast cancer; C 6.5	Precinical		biotechnology; monoclonal antibody	cancer
MAb, Hodgkin's lymphoma	Precinical		biotechnology; monoclonal antibody	cancer
MAb, human antiganglioside	Phase II		biotechnology; monoclonal antibody	cancer
MAb, human chorionic gonadotropin; MAb, hCG; CTP 103	Precinical		biotechnology; monoclonal antibody	cancer

MAb, human chorionic gonadotropin, human; MAb, hCG, human	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, human EpCAM; UBS 54	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, humanized LL2; MAb, B cell Lymphoma; LymphoCide	Phase II		biotechnology; monoclonal antibody	cancer
MAb, humanized N901-DC1	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, humanized, cancer; MAb, cancer humanized	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, IgG1 fragment	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, IgX	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, ING-1; MAb, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, interleukin-6; MAb, IL-6	Phase I		biotechnology; monoclonal antibody	cancer
MAb, KAII; MAb, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, KM641; KM 64I	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, L 6; L 6	Discontinued		biotechnology; monoclonal antibody	cancer

MAb, L6 alkaline phosphatase conjugate; L6 alkaline phosphatase MAb conjugate; MAb, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, Lewis Y; ABL 364; SDZ ABL 364	Phase I		biotechnology; monoclonal antibody	cancer
MAb, Lewis Y, humanized; HuABL 364; SMART ABL 364; BR 55-2	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, LL2-rhenium 188; Re-188-LL2	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, MAb fragment, Discontinued REC A33-nuclide	Phase II		biotechnology; monoclonal antibody	cancer
MAb, mB43-technetium 99m; Tru-Scint OV	Phase II		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, MDX 11; MAb, myeloid leukemia; MAb, CD15; MDX 11; PM 81	Phase II		biotechnology; monoclonal antibody	cancer
MAb, melanoma; MAb, cancer; MONOPHARM M	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, melanoma, Novartis; CGP 62360	Phase I		biotechnology; monoclonal antibody	cancer
MAb, MN-14 carcinoembryonic antigen; MAb, MN-14 CEA; CEA-Cide	Phase II		biotechnology; diagnosis; cancer	diagnosis; cancer

MAb, MRK 20; MRK 20	Preliminary		biotechnology; monoclonal antibody; biotechnology;	cancer
MAb, multiple myeloma, U-BiSsys	Preliminary		monoclonal antibody; biotechnology;	cancer
MAb, oncology, Glaxo Wellcome	Preliminary		monoclonal antibody; biotechnology;	cancer
MAb, ONS M21; ONS M21	Preliminary		monoclonal antibody; biotechnology;	cancer
MAb, P-67; MAb, acute myelogenous leukemia	Preliminary		monoclonal antibody; biotechnology;	cancer
MAb, PAM4	Phase I		biotechnology; monoclonal antibody; biotechnology;	cancer
MAb, polymorphic epithelial mucin; MAb, PEM, AS 125	Discontinued		monoclonal antibody; monoclonal antibody	cancer
MAb, prostate cancer	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, prostate cancer	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, prostate cancer	Preliminary		biotechnology; monoclonal antibody	cancer
MAb, SM3	Discontinued		biotechnology; monoclonal antibody	cancer
phosphorus 32			biotechnology;	
MAb, TAG-72	Preliminary		biotechnology;	cancer
MAb, TAG-72 and Fc, bispecific antibody, cancer; MDX 220	Phase II		monoclonal antibody; biotechnology; monoclonal antibody	cancer

MAb, TB94, human; MAb, TB94, IgA1k; MAb, small cell lung cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, TH69	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, transobalamin II; MAb, vitamin B12 carrier protein, Receptagen	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, transferrin receptor targeted immunotoxin; MAb, tfrR targeted immunotoxin; tfrR-CRM107	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, tumor necrosis factor; MAb, TNF; SMA TNF	Preclinical		biotechnology; monoclonal antibody	Crohn disease; cancer; septic shock
MAb, tumor necrosis factor alpha; MAb, TNF-alpha; MAAb32	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, U36/E48	Discontinued		biotechnology; monoclonal antibody	cancer
MAbs, cancer, human, Medarex	Preclinical		biotechnology; monoclonal antibody	cancer
MAbs, chimeric, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAbs, pancreaticoma, B-cell tumor; bispecific antibody, cancer	Preclinical		biotechnology; monoclonal antibody	cancer

prostate carcinoma tumor antigens rituximab; MAb, CD20; MA, pan-B; IDECK 2B8; Ro 425294; IDEC 102; RITUXAN; MabThera	Discontinued Marketed	immunoglobulin G1 (human-mouse monoclonal IDEC- C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer	biotechnology; monoclonal antibody biotechnology; monoclonal antibody	cancer, diagnosis cancer
SDZ MMA 383; MMA 383	Phase I		biotechnology; monoclonal antibody	cancer
trastuzumab; HERCEPTIN	Marketed	immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer	biotechnology; monoclonal antibody	cancer
MAb, KDR; MA, b vascular endothelial growth factor receptor; DC 101	Preliminary		biotechnology; monoclonal antibody; angiogenesis inhibitor	
MAb, KDR; MA, b vascular endothelial growth factor receptor; CP1C11	Preliminary		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer

Mab, VNR integrin; LM 609; VITAXIN	Phase II		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
Mab, CEA and doxorubicin; MAb, 26-61-10; bispecific antibody, CEA and doxorubicin	Preliminary		biotechnology; monoclonal antibody; anthracycline; DNA intercalator; antibiotic	cancer
Mab, antilaminin gamma2 chain; BST 1004	Preliminary		biotechnology; monoclonal antibody; contrast medium	cancer; diagnosis
Mab, cancer; MAb, tumor necrosis technology; MAb, INT	Preliminary		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer
Mab, cancer, radioiodinated; NOVOMAb-G2	Phase I		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
Mab, epidermal growth factor receptor; MAb, EGFr; DiaCIM; TheraCIM; RadioTheraCIM	Phase I		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis
MAb, TC5-Au198	Preliminary		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis

MAb, B cell cytokine fusion protein	Preclinical		biotechnology; monoclonal antibody; cytokine	cancer
Interleukin-2, antigen-ganglioside chimeric protein; G2-IL2 fusion protein; MAb-G2 IL-2 fusion protein; ch14.18-IL2	Preclinical		biotechnology; monoclonal antibody; cytokine; growth factor	cancer
MAb, L49-sFv-beta-lactamase	Preclinical		biotechnology; monoclonal antibody; enzyme	cancer
MAb, 2C11.F(ab')2 + microbeads; MAbs, anti-CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer
MAb, c-erbB-2 and CD16; bispecific antibody, c-erbB-2 and CD16; 2B1	Phase I		biotechnology; monoclonal antibody; immunostimulant	cancer
MAb, c-Mpl; MAbs, thrombocytopenia; BAH 1	Preclinical		biotechnology; monoclonal antibody; immunostimulant	thrombocytopenia; cancer
MAb, CD3 F(ab')2 + microbeads; MAbs, CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer

MAb, HER-2 and Fc; bispecific antibody, ovarian and breast cancer; bispecific antibody 520C9x22; MDX 210	Phase II		biotechnology; monoclonal antibody; immunostimulant	cancer
dacuzumab; daciximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	Marketed	immunoglobulin G1 (human-mouse monoclonal clone IH4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone IH4 light chain, dimer	biotechnology; monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
MAb, alpha-tubulin	Preliminary		biotechnology; monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAb, T cell antigen receptor; TM 29	Preliminary		biotechnology; monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAbs, B cells; migis	Discontinued		biotechnology; monoclonal antibody; immunosuppressant	autoimmune disease; cancer
MAb, MHC class II	Preliminary		biotechnology; monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer

MAb, 791T/36-ricin A immunotoxin; immunotoxin; colorectal cancer; XOMAZYME 791	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, A7 milomycin C-dextran conjugate; MAb, A7-MMCd; MAb, colon cancer milomycin C-dextran conjugate	Preliminary		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, alpha CD80- gelonin	Preliminary		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, alphaCD86- gelonin	Preliminary		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Anti-Tac Pseudomonas exotoxin; immunotoxin, T cell cancers	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, B3- Pseudomonas exotoxin; immunotoxin B3-PE 38-LMB 1	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, B4-blocked ricin; MAb, B4-blR; ONCOLYSIN B	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, B7- immunotoxin	Preliminary		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, BACH 250-gelonin conjugate; immunotoxin, BACH 250-gelonin	Precinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, basic fibroblast growth factor receptor-saporin; MAb, bFGF receptor-SAP; 11A8	Precinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CD33-calicheamicin; CMA 676; CDP 771	Phase III		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CMB 401-calicheamicin; MAb, ovarian cancer; CMB 401; CDP 671	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CYT 103-aminopterin; MAb, B72.3-aminopterin; ONCOOTHER 130 MAb, epidermal growth factor receptor immunotoxin	Precinical		biotechnology; monoclonal antibody; immunotoxin	cancer
OLX 103; TP 40; L 691912	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, erbB-2-Pseudomonas exotoxin; immunotoxin, single chain erbB-2-Pseudomonas exotoxin; OLX 209; AR 209	Precinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, F(ab)2 HRS-3 deglycosylated ricin A; MAb, HRS-3 deglycosylated ricin A; MAb, F(ab)2 HRS-3 dgA; MAb, HRS-3 dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, F(ab)2 IRac deglycosylated ricin A; MAb, IRac deglycosylated ricin A; MAb, F(ab)2 IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Fv B3-Pseudomonas exotoxin; immunotoxin Fv B3-PE 38; LMB 7; NSC 658931	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, FvB1-Pseudomonas exotoxin; immunotoxin FvB1-PE33	Precclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, LL2-Pseudomonas exotoxin	Precclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, ME20-Pseudomonas exotoxin; immunotoxin ME20-LysPE40	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, N901-blocked ricin; immunotoxin, N901-hR; ONCOLYSIN S	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, N901-DM1; immunotoxin, N901-DM1	Precclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, OVB3-Pseudomonas exotoxin conjugate; immunotoxin OVB3-PE	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, RFB4(dsFv)-PE38; immunotoxin, RFB4(dsFv)-PE38; BL 22; NSC 691237	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, RFT5-ricin A (CD25) immunotoxin; RFT5.dgA	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, ricin A immunocoujugate; immunotoxin; melanoma; XOMAZYME-MEL	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, SN7-ricin A; immunotoxin SN7-ricin A; SN7-RA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Tac(Fv)-PE38; Phase I immunotoxin Tac(Fv)-PE38; LMB 2	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Tac(Fv)-PE40 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, transferrin receptor targeted immunotoxin; MAb, ffnR targeted immunotoxin; 454A12-rRA	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, tumor immunotoxins, Menarini	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, UV72 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, VEGF receptor/ligand complex-dgA; immunotoxin VEGF receptor/ligand complex-dgA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer

MAbs, CD22-saporin; Phase II immunotoxin, bispecific, cancer; ITF 1265 + ITF 1269	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, doxorubicin conjugates; MAb, CC49-doxorubicin			biotechnology; monoclonal antibody; immunotoxin; anthracycline; antibiotic; DNA intercalator	cancer
MAb, antiharracine amine derivative	Precclinical		biotechnology; monoclonal antibody; immunotoxin; antibiotic	cancer
MAb, CD5- monordin; immunotoxin CD5- monordin; ITF 1532	Phase II		biotechnology; monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection
Mab, humanized, MRK 16; MRK 16	Precclinical		biotechnology; monoclonal antibody; MDR inhibitor	cancer
Mab, MRK 17; MRK 17	Discontinued		biotechnology; monoclonal antibody; MDR inhibitor	cancer
Mab, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Phase II		biotechnology; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
Iodine 131 isotumomab; MAb, CD20-iodine 131; BEXXAR	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer

Mab, 16.88-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
Mab, 35-67Cu; Mab, murine colon carcinoma; MAb, cancer	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
Mab, 88BV59- yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, B3- <sup>90</sup> yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CC49- <sup>90</sup> yttrium	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CD20-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CD20- streptavidin + biotin- yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CEA rhenium-188; MAb, colorectal cancer; IMMURAIT-Rhenium	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CG250-Iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, chimeric L6- iodine 131; BMS 180548	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAb, CYT 103- yttrium 90; MAb, B72.3-yttrium 90; ONCORAD OV103; ONCORAD CR103	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, ERIC1 yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, F(ab)2	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
NRLU10-rhenium 186; MAb, F(ab)2 pancarcinoma; RHENEX			biotechnology; monoclonal antibody; radiotherapeutic	
MAb, G250-iodine [31]	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, humanized MN-14; MAb, humanized carinoembryonic antigen; MN 14; CEA-Cide	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, iodine-131, DNA-associated antigen; 131I- chTNT-1/B; COTARA; Tumor Necrosis Therapy; INT	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, LL2-iodine [31]; LymphoCide; ImmuRAIT-LL2	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAb, LYM-1-iodine [31]; LYM 1; ONCOLYM	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, MAb fragment, Discontinued REC A33-ITM-mucide; CDP 833			biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, NRU13-streptavidin + biotin-yttrium 90; AVICIDIN	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, OKB7-iodine [31]; OKB7	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, pan-B-yttrium; MAb, B-cell radiation therapy; IDEC Y2B8	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, PEM-antisense oligonucleotide-radioisotope; AS 102	Preliminary		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, PFL-1-A; MAb, squamous cell carcinoma; AS 114	Preliminary		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, UJ13A yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
Yttrium 90 capromab; MAb, CYT 356-yttrium 90; MAb, 7E11C5; yttrium 90; MAb, prostate cancer; OncoRad PR	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAb, 4B5; MAb, anti-GD2 anti-idiotypic; NOVOVAC-M1	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAb, BEC-2; vaccine, BEC-2; EMD 60205; BEC2	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAb, CA 125; vaccine, cancer; B43.13; OvaRex	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAb, CA199; AR 44.6; GivaxRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAb, idiotypic CEA; Phase II vaccine, cancer; cancer vaccine; CeaVac	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAb, idiotypic GD; Phase II vaccine, cancer; cancer vaccine; TriGem	Phase II		biotechnology; monoclonal antibody; vaccine	cancer, psoriasis
MAb, idiotypic, MUC1; vaccine, cancer; cancer vaccine, TriAb	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAb, MUC1; vaccine, cancer; AR 20.5; Brevarex	Phase I		biotechnology; monoclonal antibody; vaccine	cancer
MAb, PSA; ProstaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer

monoclonal antibody, anti-idiotypic, cancer	Clinical		biotechnology; monoclonal antibody; vaccine	cancer
antisense oligonucleotide, B cell lymphoma	Preliminary		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-myc	Preliminary		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer; mRNA translation inhibitor, cancer	Preliminary		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Ha-ras; ISIS 2503	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Kaposi's sarcoma	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer

antisense oligonucleotide, Philadelphia chromosome; antisense oligonucleotide, chronic myelogenous leukemia; G 1128	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotides, Kras	Precclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
GPS 0193; NAVIN	Discontinued		biotechnology; mRNA HIV infection; translation inhibitor; antisense; oligonucleotide	cancer
LR 3523	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
BCG A4	Precclinical		biotechnology; mRNA oligonucleotide	cancer
LR 5165	Discontinued		biotechnology; oligonucleotide	cancer
oligonucleotide directed DNA therapy	Discontinued		biotechnology; oligonucleotide	cancer; genetic disorder; viral infection; bacterial infection
oligonucleotide, cancer, Kimeragen	Precclinical		biotechnology; oligonucleotide	cancer
oligonucleotide, chronic myelogenous leukemia, Kimeragen	Precclinical		biotechnology; oligonucleotide	cancer

antisense oligonucleotide, bcl-2; ODN 2009	Preliminary		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, Genesense Technologies; GTI 2040	Preliminary		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, Genesense Technologies; GTI 2501	Preliminary		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, Isis/AstraZeneca	Preliminary		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, raf kinase; antisense oligonucleotide, cancer; ISIS 5132; CGP 69846A; CGP 69846A; ODN 698	Phase II	d(P-thio) (T-C-C-C-G-C-C-T-G-T-G-A-C-A-T-G-C-A-T-T-)	biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, TAG 6; TAG 6	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotides, non-Hodgkins lymphoma, Fox Chase Cancer Center	Preclinical		biotechnology; oligonucleotide; antisense	cancer

oligonucleotides, VimRx	Precinical		biotechnology; oligonucleotide; ribozyme	cancer; psoriasis
ribozyme, bcl-2, Ribozyme	Precinical		biotechnology; oligonucleotide; ribozyme	cancer
ribozyme, eupropium- texaphyrin, cancer; ribozyme, eupropium texaphyrin, viral infection	Precinical		biotechnology; oligonucleotide; ribozyme	cancer; viral infection
ribozyme, K-ras	Precinical		biotechnology; oligonucleotide; ribozyme	
sense oligonucleotides, GenSet; transcription factor decoys, GenSet	Discontinued		biotechnology; oligonucleotide; transcription factor	
polyethylene glycol uricase; PEG-uricase; uricase macrogol	Discontinued		regulator biotechnology; oxidoreductase; uricase	
class II restricted melanoma antigens, National Institutes of Health	Precinical		biotechnology; peptide;cancer	
urokinase receptor antagonists, Chiron	Precinical			biotechnology; peptide;cancer; inflammation
interferon-inducible protein-10; IP-10	Precinical			biotechnology; peptide; chemokine
interferon-inducible protein-10; IP-10	Precinical			cancer; eye disease biotechnology; peptide; chemokine

antibody-derived anticancer peptides, Antisoma	Discontinued		biotechnology; peptide; contrast medium	cancer; diagnosis
RecepTox-GnRH	Preliminary		biotechnology; peptide; fusion toxin	cancer
chimeric peptides, National Institutes of Health	Preliminary		biotechnology; peptide; vaccine	cancer; viral infection
plasminogen activator/Phase II inhibitor, PAI-2	Phase II		biotechnology; plasminogen activator inhibitor; cicatrizant	cancer; inflammation; skin ulcer
matrix metalloproteinase inhibitor	Discontinued		biotechnology; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis; cancer; arthritis
maspin; mammary serine proteinase inhibitor, LXR 023; METAREX	Preliminary		biotechnology; proteinase inhibitor; serine proteinase inhibitor	cancer
neutral endopeptidase; NEP	Discontinued		biotechnology; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
oligonucleotides, acute promyelocytic leukemia	Preliminary		biotechnology; ribozyme; oligonucleotide	cancer
oligonucleotides, multiple drug resistance	Preliminary		biotechnology; ribozyme; oligonucleotide	cancer

ribozyme, BCR-ABL	Preliminary		biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, ras, Ribozyme	Preliminary		biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, vascular endothelial growth factor receptor; ribozyme, VEGF receptor; RPI 4610; ANGIOZYME	Phase I		biotechnology; ribozyme; oligonucleotide	retinopathy; cancer
screening technology, growth regulatory compounds	Preliminary		biotechnology; target based screening	drug design technology; cancer
drug delivery system, verotoxin fusion protein cancer vaccine; vaccine, cancer	Preliminary		biotechnology; vaccine	cancer
epidermal growth factor, EGF	Phase I		biotechnology; vaccine	cancer
MEDI 501	Phase I		biotechnology; vaccine	cancer
MEDI 503	Preliminary		biotechnology; viral infection	
MEDI 504	Preliminary		biotechnology; vaccine	cancer
tumor associated antigen, PP <sub>X</sub> X	Preliminary		biotechnology; vaccine	cancer
tumor associated antigen; CTA A 79	Preliminary		biotechnology; vaccine	cancer
AV1017				

vaccine, B cell lymphoma specific idiotype-granulocyte macrophage colony stimulating factor; vaccine, id/MoGMI-CSF	Preclinical		biotechnology; vaccine;cancer
vaccine, breast cancer; immunotherapy, breast cancer; MUVAC	Preclinical		biotechnology; vaccine;cancer
vaccine, breast cancer, CelSci	Preclinical		biotechnology; vaccine;cancer
vaccine, canarypox ALVAC-CEA	Phase I		biotechnology; vaccine;cancer
vaccine, cancer CEA; vaccine, cancer; ALVAC-CEA	Preclinical		biotechnology; vaccine;cancer
vaccine, cancer	Preclinical		biotechnology; vaccine;cancer
vaccine, cancer, Medimmune	Discontinued		biotechnology; vaccine;cancer
vaccine, cervical cancer; vaccine, Hsp65-HPV E7 fusion protein; Hsp65E7, HspE7; ONCOCINE	Phase I		biotechnology; vaccine;cancer
vaccine, colorectal and lung cancers; colorectal and lung cancers vaccine; Onco Vax-CL	Phase II		biotechnology; vaccine;cancer

vaccine, colorectal cancer	Preliminary		biotechnology; vaccine;cancer
vaccine, Epstein Barr viral coat protein; EBV vaccine, EBV	Preliminary		biotechnology; vaccine;glandular fever; cancer
vaccine, Epstein-Barr virus gp 220-240; vaccine, EBV	Clinical		biotechnology; vaccine;cancer
vaccine, gp 75 antigen; vaccine, cancer	Preliminary		biotechnology; vaccine;cancer
vaccine, hepatitis B core antigen fusion proteins, National Institutes of Health; vaccine, cancer	Preliminary		biotechnology; vaccine;cancer
vaccine, HER/neu-2 oncogene; vaccine, breast cancer	Preliminary		biotechnology; vaccine;cancer
vaccine, human papilloma virus; vaccine, cervical cancer; vaccine, HPV	Phase I		biotechnology; vaccine;cancer
vaccine, human papillomavirus; therapeutic antigen, cervical cancer; vaccine, HPV, TA-HPV	Phase II		biotechnology; vaccine;cancer; viral infection

vaccine, human papillomavirus; therapeutic antigen, genital warts; vaccine, HPV, TA-GW	Phase II		biotechnology; vaccineviral infection; cancer
vaccine, mage-1; vaccine, melanoma; TBC-Mage-1; MAGEVAC	Discontinued		biotechnology; vaccinecancer
vaccine, MART-1; vaccine, melanoma	Phase I		biotechnology; vaccinecancer
vaccine, mutant p53 and ras peptide activated monocytes	Phase I		biotechnology; vaccinecancer
vaccine, neu; vaccine, breast and ovarian cancer; TBC-NEU	Preliminary		biotechnology; vaccinecancer
vaccine, papilloma virus HPV 16; vaccine, cervical cancer	Discontinued		biotechnology; vaccinecancer
vaccine, prostate cancer; immunotherapy, prostate cancer; PROSTVAC	Phase I		biotechnology; vaccinecancer
vaccine, prostate cancer	Preclinical		biotechnology; vaccinecancer
vaccine, prostate cancer; prostate cancer vaccine; NORELIN	Phase II		biotechnology; vaccinecancer

vaccine, prostate cancer, CelSci vaccine, ras; vaccine, colorectal cancer; TBC-RAS, RASVAC vaccine, recombinant dendritic cells, Duke University vaccine, IBC-CEA; vaccine, cancer; TBC-CEA	Preclinical Discontinued Phase I		biotechnology; vaccine;cancer
vaccine, tumor; tumor vaccine	Discontinued	biotechnology; vaccine;cancer	
virus derived particles, human papillomavirus; VDPs, HPV thymfasin; thymosin alpha-1; Ta-1; ZADAXIN	Discontinued	biotechnology; vaccine;cancer	
	Marketed	(N-acetyl)-ser-aspartala-alal-val-aspartyl-ser-ser-glu-ile-thr-thr-lys-asp-leu-lys-glutamyl-lys-glu-val-val-glu-glutala-glu-aspartyl-OH	biotechnology; vaccine;cancer; viral infection adjuvant; immunostimulant; peptide
vaccine, human papilloma E7 antigen; vaccine, HPV; vaccine, cervical cancer	Preclinical		biotechnology; vaccine; biotechnology
vaccine, gene-based, cancer	Preclinical		biotechnology; vaccine; gene therapy

vaccine, gene-based, non-Hodgkin's B cell lymphoma; VAXID	Phase II		biotechnology; vaccine; gene therapy	cancer
vaccine, gene-based, T cell lymphoma; API 400020; GENEVAX	Preclinical		biotechnology; vaccine; gene therapy	cancer
vaccine, ALVAC-hB7.1; vaccine, ovarian carcinoma; AUT-OV-ALVAC-hB7.1	Phase I		biotechnology; vaccine; immunostimulant	cancer
vaccine, cervical intraepithelial neoplasia; TA-CTN; TA-CIN	Preclinical		biotechnology; vaccine; immunostimulant	cancer
MAb, L-Mel-1; L-Mel-1; MELIMMUNE-1	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, L-Mel-1 + MAb, L-Mel-2 + MAb, L-Mel-2 + MAb, L-Mel-1; MELIMMUNE	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, idiotypic 105AD7; MAb, anti-idiotypic gp72; 105AD7	Phase III		biotechnology; vaccine; monoclonal antibody	cancer
MAb, neuroblastoma/glioma; MAb, NG 1; MAb, cancer; NG 1; MONOPHARM G	Preclinical		biotechnology; vaccine; monoclonal antibody	cancer

vaccine, MAb, anti-idiotype, cancer; vaccine, cancer; MAb, cancer	Preliminary		biotechnology; vaccine; monoclonal antibody	cancer
vaccine, melanoma; MAb, MK223	Phase II		biotechnology; vaccine; monoclonal antibody	cancer
minodronic acid; YM 529; YH 529	Phase II	(1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene)bispophonic acid	bisphosphonate	osteoporosis; hypercalcemia; cancer
nenidronic acid; amino hexane diprophosphate; AHDP Na	Discontinued	(6-amino-1-hydroxyhexylidene)diphosphonic acid	bisphosphonate	Paget disease; osteoporosis; cancer
panidronate disodium; APD; CGP 2339AE; AREDIA; OSTEOKIT	Marketed	(3-amino-1-hydroxypropylidene)bispophonic acid	bisphosphonate	osteoporosis; cancer
ibandronate sodium; BM 210955; BONDRONA[T]	Marketed	[1-hydroxy-3-(methylpentylamino)propylidene]bispophonic acid	bisphosphonate; bisphosphonate; posteoanagenetic	osteoporosis; cancer; hypercalcemia

RC 3095	Phase I	[3R]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-glutaminyL-L-tryptophyl-L-alanyl-L-valylglycyl-N-[[(S)-1-[(S)-1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide	bombesin antagonist cancer
D 22213	Phase I	[1(R),6(S)-(R*,R*)]-N2-[2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl-L-L-glutaminyL-L-tryptophyl-L-L-alanyl-L-valylglycyl-N-[1-[[1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide monoacetate	bombesin antagonist; peptide cancer

PAK 200	Discontinued	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-1-[2-(4-morpholinyl)ethyl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid 2-[phenyl](phenylmethyl)amino]ethyl ester, P-oxide	calcium antagonist	cancer
dilazep; ANGOSIR IS	Marketed	tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropano 3,4,5-trimethoxybenzoate (diester)	calcium channel blocker; hematoprotectant; chemoprotectant	cancer; cardiac therapy
D 1465	Discontinued		calcium channel blocker; MDR inhibitor	cancer
CP 55940	Preliminary	(1alpha,2beta,5alpha,Salpha) cannabinoïd (-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol	cannabinoïd	cancer
casein kinase inhibitors, ICOS	Preliminary		casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
aragasterol A; YTA 0040	Preliminary		Cdk/cyclin inhibitor	cancer
ONCONEX	Preliminary		chelating agent	cancer

glucarolactam; ND 2001	Discontinued	5-amino-5-deoxy-D-glucosaccharic acid-delta-lactam	chemoprotectant	cancer
myeloid progenitor inhibitory factor; MPIF-1; HG 00300	Phase II		chemoprotectant; biotechnology; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor; chemokine	cancer; heart failure
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	Marketed	(+)(S)-4,4'-propylenedi-2,6-piperazine dione	chemoprotectant; cytoprotectant	cancer; heart failure
gamma linolenic acid + eicosapentaenoic acid; EF 27; AMELORAD; TARAGAM	Discontinued		chemoprotectant; cytoprotectant	cancer
ICRF 197	Preliminary		chemoprotectant; cytoprotectant	cancer; heart failure
MGI 136	Discontinued	diethyl dithiocarbamate	chemoprotectant; cytoprotectant	cancer

WR 151327; NSC 335662	Preliminary	3-[3-(methylamino)propyl]cytoprotectant	chemoprotectant; cancer; HIV infection
amifostine; ethiofos; gammaphos; WR 2721; NSC 206961; YM 08310; WR 2721C; ETHEOL	Marketed	2-[(3-amino-propyl)amino] cytoprotectant; thianethiol dihydrogen radioprotectant phosphate	cancer
hematopoietic growth factor inhibitors, Ligand	Preliminary	chemoprotectant; hematopoiesis inhibitor	cancer
hematopoietic progenitor cell inhibitor, University of Indiana	Preliminary	chemoprotectant; hematopoiesis inhibitor; stem cell division inhibitor	cancer
stem-cell division inhibitors, Terry Fox Laboratory	Discontinued	chemoprotectant; stem cell division inhibitor; hematopoiesis inhibitor	cancer
stem cell inhibitory factor, natural; SCIF	Discontinued	chemoprotectant; stem cell division inhibitor; hematopoiesis inhibitor	cancer
CRL 1095	Discontinued	chemosensitizer	cancer
CRL 1605	Preclinical	chemosensitizer	cancer
glutathione-S-transferase inhibitors, Telik	Preclinical	chemosensitizer	cancer

napavin	Preliminary	3-[[2-[(4-azido-2-nitrophenyl)amino]ethyl]amino]carbonyl]-O4-deacetyl-3-de(methoxycarbonyl)-vincalukoblastine	chemosensitizer	cancer
TER 199	Preliminary	(2R)-L-gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine	chemosensitizer	cancer
declopramide; OXI 104	Phase II			
CMDA; CIS 8	Preliminary	N-[4-[(2-chloroethyl)[2-[methylsulfonyloxy]ethyl]amino]benzoyl]-L-glutamic acid	chemosensitizer; apoptosis inducer; radiosensitizer	cancer
galamustine; galactose-6-mustard; C6 GLM; G 6 M	Discontinued	6-[bis(2-chloroethyl)amino]-6-deoxy-D-galactopyranose	chloromethine derivative; alkylating agent	cancer
SN 23862	Preliminary	5-[bis(2-chloroethyl)amino]-2,4-dinitrobenzanilide	chloromethine derivative; alkylating agent	cancer
spironutostatin; spirohydantoin mustard; SHM; speratine; NSC 172112	Phase II	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decano-2,4-dione	chloromethine derivative; alkylating agent	cancer

tallimusine; FCE 24517	Discontinued	N-[5-[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chlorethyl)amino]benzoyl]amino]1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide	chlormethine derivative; alkylating agent	cancer
veramine; RL 0017	Preliminary	(3beta,16beta,17beta,22S,25S)-17-methyl-18-norspirosta-5,12-dien-3-ol	chlormethine derivative; alkylating agent	cancer
limiapt; SR 27897; SR 27897B	Phase II	2-[[4-(2-chlorophenyl)-2-thiazoyl]amino]carbocyclicstokinin antagonist	cholecystokinin A antagonist; carbocyclicstokinin antagonist	eating disorder; cancer
docosanol n-; docosanol 1-; behenyl alcohol; LIDAKOL	Pre-registration	1-docosanoic acid	cicatrizant	viral infection; skin ulcer; cancer
Myc/Max inhibitors, Apoptosis Technology; Myc/Max inhibitors, ICRF	Discontinued	I-docosano 1	cicatrizant	cancer; skin ulcer
OLX 501	Discontinued		collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer; vascular leakage

OLX 514	Discontinued		collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer
Mab, carcinomaembryonic antigen; PR1/A3	Phase I		contrast medium; monoclonal antibody; biotechnology; radiotherapeutic; radiodiagnostic	cancer; diagnosis
NLCQ 1	Preliminary	4-[3-(2-nitroimidazolyl)propyl]imidazole	contrast medium; MRI agent; imidazole	diagnosis; cancer
vasoactive intestinal peptide-iodine 123; VIP-1123	Phase II	-laminol-7-trifluoromethyl-quinoline hydrochloride	contrast medium; peptide	diagnosis; cancer
cancer therapy, Angstrom/Diaotide	Preliminary		contrast medium; radiotherapeutic; radiodiagnostic	cancer
fludarabine + prednisone; prednisone + fludarabine	Discontinued		corticosteroid	cancer
ORG 6632	Discontinued	21-chloro-9alpha-fluoro-11beta-hydroxy-17alpha-dimethylpregna-1,4-diene-3,20-dione	corticosteroid; immunosuppressant	cancer; rheumatoid arthritis

SD-14410.1

HX 0836	Preliminary	(E)-3-(3,4-dihydroxyphenyl)-1-(2,5-dimethoxyphenyl)-2-propen-1-one	COX inhibitor; 5-lipoxygenase inhibitor	cancer
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	Marketed	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
cyclocreatine; AM 285	Discontinued	2-amino-4,5-dihydro-1H-imidazole-1-acetic acid	creatine kinase modulator	cancer; viral infection
cdk2 inhibitors, Moleculnetics	Preliminary		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase inhibitor, Agouron; cancer therapy, Agouron	Preliminary		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase/cyclin inhibitors, Mitotix; Cdk/cyclin inhibitors, Mitotix	Preliminary		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase4 modulators, Pharmacopeia; cdk4 modulator, Pharmacopeia	Preliminary		cyclin dependent kinase inhibitor	cancer

flavopiridol; NSC 649890; HMR 1275	Phase II	cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one hydrochloride	cyclin dependent kinase inhibitor	cancer
CYC 202	Preliminary		cyclin dependent kinase inhibitor; apoptosis inducer cytokine	cancer
tumor necrosis factor alpha, natural; TNF alpha, natural; Interleukin; MHR 24	Pre-registration			cancer
granulocyte-colony stimulating factor agonists, Pharmacopeia; granulocyte-colony stimulating factor agonists, Regeneron Interferon agonists, Ligand	Preliminary		cytokine agonist	cancer
Cytokine trap, Regeneron	Preliminary		cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
IL-6 receptor antagonist, Peptor	Preliminary		cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
			cytokine antagonist; peptide; NSAID	cancer

CNI 1493	Phase I Preclinical IL-2, Biovector Therapeutics	$N,N'$ -bis[3,5-bis(1-[aminoinomethyl]hydrazinoethyl)phenyl]-decanediaminide tetrahydrochloride	cytokine synthesis inhibitor	cancer
drug delivery system, IL-2, Biovector Therapeutics	delivery system, gene therapy, IL-2, Biovector Therapeutics; gene therapy, IL-2, Biovector Therapeutics		cytokine; biotechnology	cancer
LY 295501; II,X	cytotoxic lymphocyte maturation factor, CLMF	Discontinued	cytokine; biotechnology; gene therapy; immunostimulant	cancer
AN 9; PIVANEX				

CBHA	Preliminary	N-hydroxy-3-[3-(hydroxymethyl)-1-oxo-1-propenyl]-benzamide	differentiation inducer	cancer
EMBA	Preliminary	diethyl bis-(penamethylene-N,N-dimethylcarboxamide)malonate	differentiation inducer	cancer
hexamethylene bisacetamide; HMBA; NSC 95580; HEXABID	Phase II	N,N'-1,6-hexamethylenebisacetamide	differentiation inducer	cancer
NF 036	Preliminary	8-[(7-chloro-4-quinolonyl)amino]-1,3,5-naphthalenetrisulfonic acid trisodium salt	differentiation inducer	cancer
SAHA; SW 064652	Preliminary	suberoylanilide hydroxamic acid	differentiation inducer	cancer
TI 66	Preliminary	6-fluoro-7,7,8,8-tetramethyl-2,4-bis(phenylmethyl)-2,4-diazabicyclo[4.2.0]octane-3,5-dione	differentiation inducer	cancer
CDDO	Preliminary	2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid	differentiation inducer; antiproliferative agent	cancer

alitretinoin; LGD 1057; LG 1057; ALR 1057; NSC 659772; PANRETIN AG 187	Marketed	9-cis-retinoic acid	differentiation inducer; cancer; psoriasis retinoid agonist; RAR agonist; RXR agonist
	Discontinued	2,4-diamino-6-(N-(4-phenylsulfonyl)benzyl)methylamino)quinalizoline	dihydrofolate reductase inhibitor cancer
LY 298207	Preliminary	N-[4-(2,4-diamino-dihydrofolate reductase inhibitor 5-pyrimidinyl)butyl]benzoyl-L-glutamic acid	cancer
LY 316373	Preliminary	N-[4-[3-(2,4-diamino-dihydrofolate reductase inhibitor 5-pyrimidinyl)propyl]benzoyl]-L-glutamic acid	cancer
trinetrexate; trinetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	Marketed	5-methyl-6-[(3,4,5-trimethoxyphenyl)amino]dihydrofolate antifolate; NSAID quinazolinedianine	cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, methotrexate; methotrexate Therapeutic Implant; MPI 5004; IntraDose-MTX; INTRADOSE-MTX	Discontinued	dihydrofolate reductase inhibitor; antimetabolite	cancer

MDAM	Phase I	N-[4-[2-(2,4-diamino-6-pyridinyl)ethyl]benzo[y][1,4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
	Phase III	5-ethyl-2,4([H,3H]-pyrimidinedione	dihydropyrimidine dehydrogenase inhibitor; antimetabolite	cancer
eniluracil; 5-ethynyluracil; 5-EU; 776C85; BW 776C85	Discontinued	8,8-diethyl-N,N-dimethyl-1,2-azza-8-gemaspino[4,5]decan e-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
spirogermanium; NSC 192965; SPIRO-32	Preliminary		DNA intercalator	cancer
acridine-derived bisintercalators, NIH anticancer agents, Kyowa Hakko	Discontinued		DNA intercalator	cancer
BBR 2778	Phase I	6,9-bis[(2-aminoethyl)amino]benz[e]isoquinoline-5,10-dione (Z)-2-butenedioate (1:2)	DNA intercalator	cancer
bisnafide; DMP 840	Phase II	[R-(R*,R*)-2,2'-[1,2'-ethanediylbisfimino(1-methyl-2,1-ethanediyl)]bis[5-nitro-1H-benz[e]isoquinoline-1,3-(2H)dione]] dimethanesulfonate	DNA intercalator	cancer
BW 7U85	Discontinued		DNA intercalator	cancer
BW A502U; BW 502U83	Discontinued		DNA intercalator	cancer

SD-14410.1

crisnatol; crisnatol mesilate; BW 770U82; BWA 770U	D1411	Discontinued Preclinical	2-[(6-chrysinylmethyl)amino]-2-anethyl-1,3-propanediol [R-(R*,R*)]-5-[1-methyl-2-[2-[2-(5-nitro-1,3-dioxo-1H-benz[d]isoquinolin-2(3H)-y)propyl]amino]ethyl]-2-aminoethyl-4H-benz[d]pyrido[3,4-g]isoquinoline-4,6(5H)dione dimethanesulfonate	DNA intercalator	cancer
ledoxantrone; CI 958 isomer; PD 121373	Phase II	5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2H-[1]benzothiopyrano[4,3,2-ed]indazo-8-ol	DNA intercalator	cancer	
mitomafide; NSC 3002888	Phase II	2-[2-(dimethylamino)ethyl]-5-nitro-1H-benz[d]isoquinoline-1,3(2H)-dione	DNA intercalator	cancer	

S 160202; S 16020-2; NSC S 16020; NSC 659687; NSC D639687	Phase II  N-[2-(dimethylamino)ethyl]-[9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide dihydrochloride	DNA intercalator  cancer
cyclopentanthraquinone, Sloan Kettering Institute	Preliminary	DNA intercalator; anthraquinone  cancer
OC 4845	Preclinical  1,1a,2,2a,5,10-hexahydro-3[[[(methoxyimino)carbonyl]oxy]methyl]-azirino[2'3';3,4]cyclopeptan[1,2-a]anthracene-5,10-dione	DNA intercalator; anthraquinone  cancer
C 1311	Phase I  5-[[2-(diethylamino)ethyl]amino]-3-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one	DNA intercalator; DNA topoisomerase inhibitor  cancer
NLP 1	Preclinical  5-[3-(2-nitro-1H-imidazo[1,2-yl]propyl)phenanthridinium bromide	DNA intercalator; radiosensitizer  cancer

aphidicolin glycinate; Precinical NSC 303812	glycine, (3alpha,4alpha,5alpha,17alpha)-3,17-dihydroxy-4- methyl-9,15-cyclo- C,18-dinor-14,15- secostrostone-4,17- dimethanol ester hydrochloride	DNA polymerase inhibitor	DNA polymerase cancer
DNA polymerase beta; Discontinued inhibitors, Agouron NU/ICRF 505		DNA polymerase inhibitor; radiosensitizer; chemosensitizer	cancer
UCT 4B; UCTB 4	Discontinued	DNA topoisomerase inducer	bacterial infection; cancer
9-	[2-[1-hydroxy-2-[ [1,2,3,4,4a,7,8,8a- octahydro-3-hydroxy- 5-(hydroxymethyl)- 1,2,4a-trimethyl-4- oxo-1- naphthalenyl]ethyl]- alpha-oxo- oxiranacetalddehyde (S)-10-amino-4-ethyl- 4-hydroxy-1H- pyran-3',4',6,7-tindoli- zino[1,2-b]quinoline- 3,14(4H,12H)-dione AMP 53; azonafide 53	(S)-10-amino-4-ethyl-DNA topoisomerase inhibitor	cancer
		DNA topoisomerase inhibitor	cancer

azasclarine; amsalog; CI 921; NSC 343499; SN 21407	Phase I	9-[[2-methoxy-4-[(methylsilyfonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer
azatoxin; NSC 640737	Preclinical	(SR-cis)-5,6,11,11a-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-1H,3H-oxazolo[3,4;1,6]pyrido[3,4-b]indol-3-one	DNA topoisomerase inhibitor	cancer
BE 10988	Discontinued	2-(5-amino-4,7-dihydro-1-methyl-4,7-dioxo-1H-indol-3-yl)-4-thiazolecarboxamide	DNA topoisomerase inhibitor	cancer
BE 13793C	Discontinued	12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	DNA topoisomerase inhibitor	cancer
BE 22179	Discontinued		DNA topoisomerase inhibitor	cancer
BN 80915	Phase I		DNA topoisomerase inhibitor	cancer
BNP 1350	Phase I		DNA topoisomerase inhibitor	cancer
BNP1 1100	Preclinical		DNA topoisomerase inhibitor	cancer

BO 2367	Discontinued	( $\rightarrow$ 7-[IR*,2R*,6R*]-2-amino-8-azabicyclo[4.3.0]non-3-en-8-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolincarboxylic acid	DNA topoisomerase inhibitor	cancer
camptothecin analogues, Research Triangle Institute	Preliminary		DNA topoisomerase inhibitor	cancer
camptothecin derivatives, Daichi	Discontinued		DNA topoisomerase inhibitor	cancer
CKD 602	Phase I	4-ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]pyranol[3',4',6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
DM II 33	Preliminary		DNA topoisomerase inhibitor	cancer
DNA topoisomerase inhibitor, second generation, Xenova; XR 5942 series; XR 5942	Preliminary		DNA topoisomerase inhibitor	cancer
DRF 1042	Preliminary		DNA topoisomerase inhibitor	cancer

drug delivery system, Preclinical camptothecin; camptothecin delivery system; MPI 5019		DNA topoisomerase inhibitor	cancer
drug delivery system, Phase I liposome lurtotecan; lurtotecan liposome; NX 211		DNA topoisomerase inhibitor	cancer
drug delivery system, Preclinical microsphere 10- hydroxycamptothecin ; 10- hydroxycamptothecin microsphere		DNA topoisomerase inhibitor	cancer
DX 8951; DX 8951f	Phase II  (1S-trans)-1-amino-9-DNA topoisomerase inhibitor	cancer	e

ED 110	Discontinued	[2-beta-D-glucopyranosyl-12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrol[3,4-c]carbazole-5,7(6H)-dione	DNA topoisomerase inhibitor	cancer
ER 37328	Preliminary	12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzol[c]pyrimido[5,6-1-j][carbazole-4,6,10(5H,11H)-trione	DNA topoisomerase inhibitor	cancer
F 11782; F 1267; L 0084	Preliminary	[5R-[5alpha,5beta,8alpha]-5-[3,5-dimethoxy-4-(phosphenoxy)phenyl]-9-[4,6-O-ethylen-2,3-bis-O-[pentfluorophenoxy]acetyl]-beta-D-glucopyranosyl]oxy]-5,8,9,7-naphthol[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

fostriecin; NSC 339638; C1920; CL 1565A	Phase I	5,6-dihydro-6-[3,6,1-trihydroxy-3-methyl-4-(phosphonoxy)-1,7,9,11-tridecatetraenyl]-2H-pyran-2-one monosodium salt	DNA topoisomerase inhibitor	cancer
HAR 7	Preliminary		DNA topoisomerase inhibitor	cancer
intiplichine; RP 60475; NSC D645008	Phase I	11-[(3-(dimethylamino)propyl)amino]-8-methyl-7H-benzof[e]pyrido[4,3-b]indol-3-ol	DNA topoisomerase inhibitor	cancer
irinotecan; irinotecan hydrochloride; camptothecin 11; CPT 11; DQ 2805; SN 3811; UJ 101440E; CPT 11; CAMPTO; TOPOTECIN; CAMPTOSAR; IRKAN	Marketed	(1,4'-bipiperidine)-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyran(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, monohydrochloride	DNA topoisomerase inhibitor	cancer

Urtofecan; urtotecan dihydrochloride; GG 21; GI 147211; GI 147211A; GI 147211C	Suspended	(S)-8-ethyl-2,3- dihydro-8-hydroxy- 15-[4-methyl-1- piperazinyl]methyl]- 11H-1,4-dioxinol[2,3- g]pyranol[3,4;6,7]ind- olizino[1,2- b]quinoline- 9,12(8H,14H)-dione	DNA topoisomerase inhibitor	cancer
MPI 6003	Discontinued		DNA topoisomerase inhibitor	cancer
NB 506	Phase I	N-(12-beta-D- glucopyranosyl- 5,7,12,13-tetrahydro- 1,11-dihydroxy-5,7- dioxo-6H-indolo[2,3- a]pyrrolol[3,4- c]carbazol-6-yl)- formamide	DNA topoisomerase inhibitor	cancer
NCI 190; NCU 190	Discontinued	6-[[2- (dimethylamino)ethyl] laminol]carbonyl]-5- hydroxy-10- methoxybenzo[a]phen- azine-9-carboxylic acid monosodium salt	DNA topoisomerase inhibitor	cancer
NCA 0465	Preclinical		DNA topoisomerase inhibitor	cancer
NK 109; NK 106	Phase I	1-Hydroxy-2- methoxy-12-methyl- [1,3]benzodioxolol[5,6- c]phenanthridinium, sulfate (1:1) (salt)	DNA topoisomerase inhibitor	cancer

NU/JICRF 500	Discontinued		DNA topoisomerase inhibitor	cancer
NU/JICRF 506	Discontinued		DNA topoisomerase inhibitor	cancer
polyethylene glycol-camptothecin; camptothecin macrogol; PROTHECAN	Preliminary		DNA topoisomerase inhibitor	cancer
rubitecan; 9-nitrocamplothecin; RFS 2000	Phase III		DNA topoisomerase inhibitor	cancer
sobuzoxane; MST 16; PERAZOLIN	Marketed	1,2-ethanediylbis[(2,6-dioxo-4,1-piperazinediy) methylene]bis(2-methylpropyl) carbonic acid ester	DNA topoisomerase inhibitor	cancer
TAN 1496	Discontinued		DNA topoisomerase inhibitor	cancer

TAN 1518A	Discontinued	2-hydroxybenzoic acid 3-(aminocarbonyl)-8-[2,6-dideoxy-4-O-(2-methyl-1-oxo-2-butene)hexopyranosylyl]-1,4,4a,6,11,11a,12,12-a-octahydro-2,4a,5,7-tetrahydroxy-11-methoxy-11-methyl-4,6-dioxo-1-naphthalenyl ester	DNA topoisomerase inhibitor	cancer
TAS 103	Phase I	6-[[2-(dimethylamino)ethyl]amino]3-hydroxy-7H-indeno[2,1-c]quinolin-7-one	DNA topoisomerase inhibitor	cancer

TOP 53	Phase I	[5R,5alpha,5beta,8alpha]-9-[2-[2-(dimethylamino)ethyl]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furan[3',4':6,7]heptahydro[2,3-d]-1,3-dioxol-6(5aH)-one]	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota topotecan;	Preliminary		DNA topoisomerase inhibitor	cancer
hycamptamine; SKF 104864; SKF 104864A; HYCAMTIN	Marketed	(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyran[3',4':6,7]indolizino[1,2-b]quoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

AD 312	Precinical	(8S-eis)-8-acetyl-10-[3-[[[2-chloroethyl]nitrosoanthracycline; imo[carbonyl]janino]-alkylating agent; 2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	DNA topoisomerase inhibitor; antibiotic	cancer
	Discontinued	10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzo[h][1]benzopyran[5,4,3-ed][1]benzopyran-5,12-dione	DNA topoisomerase inhibitor; antibiotic	cancer
	Precinical	DNA topoisomerase inhibitor; antifungal	DNA topoisomerase inhibitor; DNA intercalator	cancer

LU 55446	Discontinued	DNA topoisomerase inhibitor; DNA intercalator	cancer
dosereside; AF 1	Discontinued	[8beta(1S,2R,3E)]-N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-6-methylergoline-8-carboxamide	dopamine agonist cancer; infertility
drug delivery system, Pre-bromocriptine; bromocriptine delivery system; ERGOSET	Pre-registration		dopamine agonist diabetes; obesity; cancer
ST 557	Discontinued		dopamine agonist; immunostimulant
ST 570	Discontinued		dopamine agonist; immunostimulant
Pan-Her inhibitors, SUGEN; Her2 inhibitors, SUGEN	Preliminary		EGF receptor inhibitor
LFM A12	Preliminary	(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethoxy)phenyl]-2-butanimide	cancer

ABT 627; A 127722; A 147627	Phase II [2S-(2alpha,3beta,4alpha)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxethyl]-2-(4-methoxyphenyl)-3-pyridinecarboxylic acid]	[2S-(2alpha,3beta,4alpha)-endothelin A antagonist]	endothelin antagonist; cancer; restenosis; myocardial infarction
BE 14348B	Discontinued 2(S)-3(S)-3-methyl-4',5,7-trihydroxyflavanone	estrogen agonist	cancer
GW 5638	Preliminary [E,Z]-3-[4-(1,2-diphenyl-1-propenoic acid	estrogen agonist; antiestrogen	osteoporosis; cancer; coronary artery disease
CP 336156	Phase II [5R,6S]-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)	estrogen partial agonist	osteoporosis; cancer
2-methoxyestradiol; 2-ME	Preliminary	estrogen; angiogenesis inhibitor	
estrogen receptor therapy, Ligand/Wyeth Ayerst EMATE	Preliminary Discontinued 3-[(aminosulfonyloxy)oxy]estra-1,3,5(10)trien-17-one	estrogen; hormone replacement therapy estrone sulfatase inhibitor	hormone deficiency; contraception; cancer; osteoporosis cancer

ara-CDP-DL-PTBA; CYTOROS	Preliminary	4-amino-1-[5-O-[1,3-dihydroxy-6-[(1-oxohexadecyl)oxy]-2,4-dioxa-8-thia-1,3-diphosphahexacos-1-yl]beta-D-arabinofuranosyl]-2(1H)-pyrimidinone P,P'-dioxide	ether lipid	cancer
edelfosine; ET 18-OGH3; ALP	Pre-registration	(+,-)4-hydroxy-7-methoxy-N,N,N-trimethyl-3,5,9-trioxa-4-phosphahexacosan-1-aminium hydroxide inner salt, 4-oxide	ether lipid	cancer
EG 6	Preliminary	1-[4-[2-(octadecyloxy)ethoxy]ethoxy]butylpyridinium methanesulfonate	ether lipid	cancer
ether lipid, Roswell Park	Preliminary	ara-CDP-rac-1-S-tetradecyl-2-O-palmitoyl-1-thioglycerol	ether lipid	cancer
ether lipid, Vancouver University	Preliminary	4-(hexadecyloxy)-3-(S-methoxybutyl)phosphorylcholine	ether lipid	cancer

imofosine; BM 41440; BM 21440	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-3,5-dioxa-9-thia-4-phosphapentacosan-1-aminium hydroxide, inner salt, 4-oxide	ether lipid	cancer
miltefosine; hexadecylphosphorylcholi ne; HPC; D 18506; MILTEX	Marketed	2-[[(hexadecyloxy)hydr oxyphosphinyl]oxy]- N,N,N-trimethyllethanaminiu m, hydroxide, inner salt	ether lipid	cancer; leishmaniasis
perifosine; D 21266; NKA 17	Phase I	4- [[hydroxy(octadecyo xy)phosphinyl]oxy]- 1,1,- dimethylpiperidinium inner salt	ether lipid	cancer
SRI 34234	Discontinued	(+,-)-2- [[hydroxy][tetrahydro -2- [(octadecyloxy)meth yl]-2-furyl]methoxy]phos phinyl]oxy]-N,N,N, trimethyl- ethanaminium, inner salt.	ether lipid	cancer; multiple sclerosis
TLC ELL 12; ELL 12	Phase I		ether lipid	cancer

SDZ 62826	Discontinued	ether lipid; immunostimulant	cancer
etoposide phosphate; BMY 40481; ETOPOPHOS	Marketed	(5R,5aR,8aR,9S)-5-[3,5-dimethoxy-4-phosphonoxy]phenyl-9-[(4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue cancer
GT 13	Preliminary Phase II	5R-[5a- alpha, beta,8a- [[2-deoxy-2- (dimethylamino)-4,6-O-ethylidene-beta-D- glucopyranosyl]oxy]- 5,8,8a,9-tetrahydro-5- (4-hydroxy-3,5-dimethoxyphenyl)furan- 3-dl-1,3-dioxol-6(5aH)-one	etoposide analogue cancer
NK 611; VP 19; 2- (dimethylamino)etopo- side		hydrochloride	

GI-331	Phase II	[5R-(5alpha,5beta,8alpha,8beta)-5,8,8a,9-a,9beta]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[(4-nitrophenyl)amino]furan[3',4',6,7]naphtho[2,3-d]-1,3-dioxol-6(SH)-one	etoposide analogue; etoposide DNA topoisomerase inhibitor	cancer
ARGLABIN	Registered		farnesyl protein transferase inhibitor	cancer
B 956	Preliminary	[2S-(2R*,3Z,5R*,6E,8S*)]-N-[8-amino-9-mercapto-5-(1-methylethyl)-1-oxo-2-(phenylmethyl)-3,6-nonadienyl]-L-methionine	farnesyl protein transferase inhibitor	cancer
farnesyl transferase inhibitors	Discontinued		farnesyl protein transferase inhibitor	cancer
L 639749	Preliminary		farnesyl protein transferase inhibitor	cancer

L 744832	Preliminary	[2S-[1R*(R*)]2R*(S,3R*)]-2-[2-[[2-amino-3-mercaptopropyl]amino]-3-methylpentyl]oxy]-1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid, 1-methylethyl ester	farnesyl protein transferase inhibitor	cancer
L 778123	Phase I		farnesyl protein transferase inhibitor	cancer
PD 169451	Preliminary		farnesyl protein transferase inhibitor	cancer
perillyl alcohol; NSC 641066	Phase II	4-(1-methylethethyl)-1-cyclohexene-1-methanol	farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, Parke Davis	Preliminary		farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, University of Pittsburgh	Preliminary		farnesyl protein transferase inhibitor	cancer
RPR 115135	Preliminary		farnesyl protein transferase inhibitor	cancer

SD-144110 1

SCH 59228	Preliminary	$\text{[}-\text{3-primo-8-chloro-6,11-dihydro-5H-benz}[5,6]\text{cycloheptal}[1,2,\text{b}]\text{pyridin-11-yl}-4-(\text{1-oxido-4-pyridinylacetyl})\text{piperazine}$	farnesyl protein transferase inhibitor	cancer
L 731734	Discontinued	$\text{[3S}-\text{[}3\text{R*}\text{][}2\text{R*}\text{][}2\text{R*}\text{[S*}\text{]}\text{]}\text{3S*}\text{[}3\text{R*}\text{][}2\text{]-[}2\text{-(2-amino-3-mercaptopropyl)aminol-3-methylpentyl]amino]-3-methyl-N-(tetrahydro-2-oxo-3-furyl)pentanamide}$	farnesyl protein transferase inhibitor; peptide	cancer
L 731735	Discontinued	$\text{[2S}-\text{[}2\text{R*}\text{[S*}\text{][}3\text{S*}\text{][}]-\text{N-[}2\text{-(2-amino-3-mercaptopropyl)aminol-3-methylpentyl]L-isoleucyl]-L-homoserine}$	farnesyl protein transferase inhibitor; peptide	cancer
R 115777	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer
SCH 66336	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer

TOP 53	Phase I topoisomerase inhibitor, Biota	[5R-(5alpha,5abeta,8alphaH,9beta)-9-{2-[[2-(dimethylamino)ethyl][methylamino]ethyl]jethyl}-5,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furan[3',4';6,7]naphtho[2,3-d]-1,3-dioxol-6(5arF)-one]	DNA topoisomerase inhibitor	cancer
	Preliminary topotecan; Marketed	(S)-10-(dimethylalanino)methylhydrazine; SKF 104864; SKF 104864A; HYCAMTIN	DNA topoisomerase inhibitor	cancer
	Discontinued		DNA topoisomerase inhibitor	cancer
	Discontinued		DNA topoisomerase inhibitor	cancer
	Phase I XR 5000; NSC 601316; DACA	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

BIM 26028	Discontinued		gastrin antagonist; bombesin antagonist; gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer; cachexia; respiratory disease
CDP 845	Discontinued			cancer
CT 1746	Discontinued		gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
gelatinase inhibitors, Celltech	Preliminary		gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
basal cell carcinoma therapy, Oncogeny; patched gene, ptc gene	Preliminary		gene	cancer, skin disease
bcl-6-based non-Hodgkin's lymphoma therapy	Preliminary		gene	cancer
cancer therapy, cancer cell growth genes	Preliminary		gene	cancer
CDK4 based therapy, Axs, melanoma therapy, Axs	Preliminary		gene	cancer
HFE-based therapies, Progenitor	Preliminary		gene	iron overload; cancer

immune system modulators, Chiroscience	Precinical		gene	autoimmune disease; rheumatoid arthritis; cancer; HIV infection
melanoma differentiation-associated genes	Discontinued		gene	cancer
MMAC1 based therapy, Myriad	Precinical		gene	cancer
MTS2 based therapy, Myriad	Precinical		gene	cancer
MTS3 based therapy, Myriad; cancer therapy, Myriad	Precinical		gene	cancer
num-1-based cancer therapy	Precinical		gene	cancer
P-TEF-based cancer therapy, Amplicon	Precinical		gene	cancer
prostate tumor-inducing genes	Discontinued		gene	cancer; diagnosis
gene therapy, ATase	Precinical		gene therapy;	biotechnology
gene therapy, C-CAM, Introgen; adenoviral C-CAM, Introgen; INGN 231	Precinical		gene therapy;	biotechnology
gene therapy, cancer	Precinical		gene therapy;	biotechnology
gene therapy, cancer; SMART GENETIC CONSTRUCTS	Precinical		gene therapy;	biotechnology
gene therapy, cancer	Precinical		gene therapy;	biotechnology

gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, Cobra Therapeutics; CTL 102; TXS 0202	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, pulmonary disease	Preclinical		gene therapy; biotechnology	cancer, respiratory disease
gene therapy, hepatocellular carcinoma; HepXia	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian and pancreatic cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian cancer, gene therapy, bical, MB 700	Preclinical		gene therapy; biotechnology	cancer
gene therapy, p16, p27; gene therapy, restenosis; gene therapy, cancer	Preclinical		gene therapy; biotechnology	restenosis; cancer
gene therapy, p53; gene therapy, cancer	Phase I		gene therapy; biotechnology	cancer
gene therapy, scFV/gamma G250;	Precinical		gene therapy; biotechnology	cancer
gene therapy, renal carcinoma				
gene therapy, stress proteins	Preclinical		gene therapy; biotechnology	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk	Phase I		gene therapy; biotechnology	cancer

gene therapy, thymidine kinase; gene therapy, glioma	Preliminary		gene therapy; biotechnology	cancer
gene therapy, tumor antigens; gene therapy, cancer	Preliminary		gene therapy; biotechnology	cancer
gene therapy, ATF B1P1; gene therapy, cancer	Preliminary		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, colorectal cancer, Oxford BioMedica; CoRecoGen	Preliminary		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, glioma, Oxford Biomedica; GlioStat	Preliminary		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, ovarian cancer, Oxford BioMedica; BelOvaC	Preliminary		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, prostate cancer, ProCaStat	Preliminary		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, interleukin-2; Transgene; gene therapy, cancer	Phase I		gene therapy; biotechnology; cytokine;	cancer
gene therapy, wt p53; gene therapy, cancer	Preliminary		immunostimulant gene therapy; biotechnology; radiosensitizer; chemosensitizer	cancer

vaccine, gene-based, colorectal cancer; vaccine, gene-based, CO17-A/GA733; AV GA 7332	Phase I		gene therapy; biotechnology; vaccine	cancer
vaccine, gene-based, human papilloma virus	Preliminary		gene therapy; biotechnology; vaccine	cancer
progression elevated genes glutathione inhibitors, Telik	Discontinued		gene; angiogenesis inhibitor glutathione inhibitor	cancer
AG 2026	Discontinued		glycaminide ribotide formyltransferase inhibitor	cancer
AG 2032	Discontinued		glycaminide ribotide formyltransferase inhibitor	cancer
AG 2034	Phase I	(S)-N-[15-[2-(2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-y)ethyl]-2-thienyl]carbonyl]-L-glutamic acid	glycaminide ribotide formyltransferase inhibitor	cancer
AG 2037	Preliminary		glycaminide ribotide formyltransferase inhibitor	cancer
contortrostatin; CN	Preliminary		glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

mannostatin A	Preliminary	[1R-[1alpha,2alpha,3alpha,4alpha,5beta]-4-amino-5-(methylthio)-1,2,3-cyclopentanetriol	glycosidase inhibitor	cancer
glycosidase inhibitor, Oxford GlycoSciences	Preliminary		glycosidase inhibitor, NSAID	cancer; rheumatoid arthritis
leuprorelin A TRIGEL drug delivery system, GlycoSciences	Preliminary	ATRIGEL sustained release leuprorelin; leuprorelin A TRIGEL drug delivery system.	gonadorelin agonist	cancer
microparticle buserelin; buserelin microparticle delivery system	Phase III		gonadorelin agonist	cancer; endometriosis
drug delivery system, sustained release LHRH analogue; LHRH analogue delivery system; ProMaxx, LHRH analogue; ProMaxx 100	Clinicals		gonadorelin agonist	cancer

goserelin; goserelin acetate; ICI 118630; ZOLADEX	Marketed	$\delta$ -(D-[1,1-dimethylethyl]-D-serine-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide	gonadorelin agonist cancer; endometriosis; infertility
leuprorelin; leuprorelin acetate; leuprorelin prootide; TAP 144; TAP 144SR; ABBOTT 43818; LUPRON; CARCIN; LEUPLON; LUPRON DEPOT; PROSTAP SR; ST; PROSTAP SR; ENANTONE	Marketed	6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (swine)	gonadorelin agonist cancer; endometriosis
naftarelin; naftarelin acetate; D-Nal(26 LHRH; RS 94991; RS 94991 298; SAMYNAREL; SYNAREL; NASANYL	Marketed	6-[3-(2-naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine)	gonadorelin agonist cancer; endometriosis; infertility
RL 0903	Phase II		
triptorelin; BN 52014; BIM 21003; AY 25650; CL 118532; WY 42462; ARVECAP, DECAPEPTYL	Marketed	6-D-tryptophan-luteinizing hormone-releasing factor (swine)	gonadorelin agonist gonadorelin agonist cancer; precocious puberty; endometriosis

+ cuproliide + estrogen + progesterone gonadotropin releasing hormone analogue, conjugated; GnRH analogue copolymer conjugate avorelin	Phase I  Preclinical	gonadorelin agonist; estrogen; progestogen gonadorelin agonist; gonadorelin antagonist	contraception; cancer cancer
	Phase II	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-2-methyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin agonist; peptide cancer; precocious puberty; endometriosis
drug delivery system, histrelin hydrogel implant; histrelin hydrogel implant	Phase I		gonadorelin agonist; peptide precocious puberty; cancer
A. 84861 abarelix; PPI 149; R 3827	Phase III	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alanamide	gonadorelin antagonist gonadorelin antagonist cancer; benign prostate hypertrophy; endometriosis

cetrorelix; SB 75; SB 075; CETROTIDE	Registered	[N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide]	gonadorelin antagonist infertility, cancer; endometriosis; benign prostate hypertrophy; contraception
D 20453	Discontinued	[N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[N-acetyl-3-(acetylamino)-L-alanyl]-D-lysyl-L-leucyl-L-arginy-L-prolyl-D-alaninamide]	gonadorelin antagonist cancer
D 21775; T 148	Discontinued	[Unspecified]	gonadorelin antagonist cancer
D 23487	Discontinued	[Unspecified]	gonadorelin antagonist cancer
D 26344	Preclinical		gonadorelin antagonist cancer, infertility

deutrelix; RS 68439	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-Phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylidene]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist; contraception; cancer
	Drug delivery system, ATRIGEL sustained release ganirelix; ganirelix ATRIGEL	Discontinued	gonadorelin antagonist; endometriosis; cancer
	Drug delivery system, ATRIGEL sustained release GnRH antagonists	Discontinued	gonadorelin antagonist; endometriosis; cancer
	Drug delivery system, microcapsule SB 75; SB 75 microcapsule	Preliminary	gonadorelin antagonist; contraception; cancer
	Gonadotropin releasing hormone antagonists, Alanex	Preliminary	gonadorelin antagonist; cancer
	Gonadotropin-releasing hormone antagonist, Aguron; GnRH antagonist, Aeguron	Preliminary	gonadorelin antagonist; cancer
	HOE 2013	Suspended	gonadorelin antagonist; endometriosis

ranorelix; HOE 013	Phase II	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-trityptophyl-L-seryl-L-tyrosyl-O-(6-deoxy-alpha-L-mannopyranosyl)-D-seryl-L-leucyl-L-arginyl-L-proline, 2-(aminocarbonyl)hydrazide	gonadorelin antagonist/cancer
A 76154	Preliminary	N-[3-(4-fluorophenyl)-1-oxopropyl]-3-(1-naphthalenyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alanamide	cancer; endometriosis; precocious puberty

everelix; ANTARELIX	Phase I  deslorelin; BACHEM 9022; SOMAGARD	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-L-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alanamide  deslorelin implant; deslorelin implant	gonadorelin antagonist; peptide superagonist  discontinued	cancer; endometriosis; infertility  cancer; precocious puberty  cancer
deslorelin; BACHEM 9022; SOMAGARD	Marketed	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin superagonist	cancer; precocious puberty
drug delivery system, Preclinical deslorelin implant;			gonadorelin superagonist	cancer; gynecological; infertility
hematology	Discontinued		growth factor	cancer
cytokines, AMRAD; cytokines, Clugui				
hematopoietic growth factor mimetics, Ligand	Preclinical		growth factor	cancer; bacterial infection; anemia
GM 1306	Preclinical		growth factor modulator	diabetes; neuropathy; cancer
GM 1474	Preclinical	Unspecified	growth factor modulator	cancer
keratinocyte growth factor antagonist	Preclinical		growth factor modulator; peptide	cancer

hepatocyte growth factor related proteins; HGF-related proteins CMI SAF9	Preliminary		growth factor; biotechnology; chemoprotectant; cytoprotectant	cancer
thrombopoietin; TPO Phase II	Preliminary		growth factor; hematopoietic factor	cancer; cancer; thrombocytopenia
Tie-2 ligands; Regeneron; angiogenesis ligands, Regeneron	Preliminary		growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
SB 251353	Preliminary		growth factor; hematopoietic factor; immunostimulant	cancer
goralatide; seraspenuide; BN 52040; BIM 32001	Phase II	I-[N2-[N-(N-acetyl-L-seryl)-L-alphasparyl]-L-lysyl]-L-proline	hematoprotectant; chemoprotectant; peptide	cancer
pentosan polysulfate sodium; SP 54-PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE MAXAMINE	Marketed	(1-4)-beta-D-xyran 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
	Phase III		histamine agonist; histamine H2 agonist	cancer; viral infection; hepatitis

MAP 30	Precclinical	N2-[N-(N-[N-(N-[L-threonyl-L-isoleucyl]-L-lysyl]-L-threonyl)-L-threonyl]-L-lysine	HIV integrase inhibitor	HIV infection; cancer
	Marketed	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydrono-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer
lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVYLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	cancer therapy, Oxis drug delivery system, PEPTITROL calcitonin; calcitonin PEPTITROL	hormone	cancer	osteoporosis; Paget disease; cancer
	Preclinical	hormone	hormone	precocious puberty; endometriosis; cancer; contraception
	Preclinical	hormone	hormone	infertility; cancer

human chorionic gonadotropin beta; beta hCG NV 06	Preliminary		hormone	cancer
galium nitrate; NSC 15200; CALSTAT; GANITE AS 101; IVXQ 101; OSSIRENE	Marketed	galium nitrate monohydrate	hormone; apoptosis inhibitor; antiproliferative agent; differentiation inducer hypocalcemic; nitric oxide synthase inhibitor	cancer
BCH 1393	Phase II  Suspended	(SP-5-22)-ammonium trichloro[1,2- ethandiolato(2-)- 0,0]-tellurate  N2-[{[5-[6- (dimethylamino)-9H- purin-9- yl]pentyl}oxy]carbon yle-D-arginine  beta-alethine; BETATHINE	immunostimulant  immunostimulant  immunostimulant  immunostimulant	HIV infection; cancer  cancer  cancer
CL 870420	Discontinued	propirimine; ABPP; U 54461; U 54461S; NSC 149027; REMISAR	Pre- registration  2-amino-5-bromo-6- phenyl-4(1H)- pyrimidinone	cancer; viral infection
conagenin	Preliminary	CL 246738	Phase II  3,6-bis(2- piperidinoethoxy)aci- dine trihydrochloride  N-(3,5-dideoxy-3- methyl-D-xylofuranoyl)- 2-methyl-L-serine	viral infection; HIV infection; cancer  cancer cancer

DNA repair enhancers, OXIGENE drug delivery system, liposome muramyl tripeptide-phosphatidylethanolamine; drug delivery system, liposome MTP-PE; MTP-PE liposome	Precinical Phase III		immunostimulant	cancer
FCE 24578	Discontinued	alpha-cyano-1,4-dihydro-beta-oxo-N-(1-diphenyl[1]benzothiophenyl)[4,3-c]pyrazole-3-propanamide	immunostimulant	cancer; bacterial infection
FCE 25276	Suspended		immunostimulant	cancer; bacterial infection
FCE 25648	Suspended		immunostimulant	cancer; bacterial infection
FCE 25651	Suspended		immunostimulant	cancer; bacterial infection
FR 901235	Discontinued	(-)-2,4,9-trihydroxy-6-methoxy-7-methyl-2-(2-oxopropyl)-1H-phenalenene-1,3(2H)-dione	immunostimulant	cancer
HAB 439	Discontinued	(4,5-dihydro-3-phenyl-5-isoxazolyl)phosphonic acid	immunostimulant	cancer, bacterial infection

icadamines, Cornell Research Foundation	Precinical		immunostimulant	viral infection; cancer
idramantone; kemantane	Phase I	5-hydroxytricyclo[3.3.1.1(3,7)]decanone	immunostimulant	cancer
iniquimod; R 837; S 26308; DZ 2636; ALDARA; ZARTRA	Marketed	[1-(2-methylpropyl)-1H-imadazo[4,5-c]quinolin-4-amine	immunostimulant	viral infection; cancer
immunostimulant, Repigen; immunostimulant, Pfizer	Precinical		immunostimulant	cancer; infectious disease
immunostimulanis, Massachusetts General Hospital	Precinical		immunostimulant	cancer; autoimmune disease
JT 3002; CGP 40774	Precinical	[1S-(R* 2R*,3S*)]-N-[1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]hexacosanamide	immunostimulant	cancer
large multivalent immunogen; LMI	Precinical		immunostimulant	cancer
LC 9018; YIT 9018; DP 2202; PS PG; LIMONAL; LEMONAL	Pre-registration		immunostimulant	cancer; HIV infection
lentinan sulfate; lentinan; LENTINAN	Marketed		immunostimulant	HIV infection; cancer
LK 409	Precinical	N-(1,7-dioxooctyl)-L-alanyl-D-alpha-glutamine	immunostimulant	cancer

loxoridine; RWJ 21757	Discontinued	7-allyl-8-oxoguanosine	immunostimulant	cancer
miniristim; human urine derived stimulating factor inducer; CSF-HU; P100; LEUKOPROL; COSTILATE	Marketed	1-214-colony-stimulating factor 1 (human clone p3ACSF-69 protein moiety reduced)	immunostimulant	cancer
MMS 2	Preliminary Discontinued		immunostimulant	cancer
Noocardia-CWS; N-CWS; rubratine; RUBRATIN	Preliminary Phase I	Unspecified	immunostimulant	cancer
OM 163	Preliminary Phase I		immunostimulant	cancer
OM 174	Discontinued		immunostimulant	HIV infection; cancer
RG 003; RG 136			immunostimulant	cancer; transplant rejection
RM 06	Discontinued	N-[N-[[5-(1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]oxy]carbon-yl]-L-leucyl]-L-methionine	immunostimulant	
romurtide; muroclasin; MDP-Lys (L18); MDP-Lys; DJ 7041; NOPIA	Marketed	2-acetamido-3-O-[(R)-1-[[S]-1-[(R)-1-carbamoyl-3-[(S)-1-carboxy-5-stearamidopentyl]carbamoyl]propyl]carbamoyl]-2-deoxy-D-glucopyranose	immunostimulant	cancer; bacterial infection

RS 0481; S 0481	Discontinued	[R-(R*,R*)]-3-benzoyl-N-(1-phenylethyl)-4-thiazolidinecarboxamide	immunostimulant	cancer
S 27609	Discontinued	4-amino-alpha alpha-2-trimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol	immunostimulant	cancer
SRL 172	Phase III		immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis
ST 789; PCF 39	Phase I	N-[5-(hypoxanthin-9-ylpentyloxycarbonyl)]-L-arginine	immunostimulant	cancer; bacterial infection
RGH 0205; TP3	Suspended	N-(N2-L-arginy-L-lysyl) L-aspartic acid	immunostimulant	cancer
vaccine, malignant melanoma; LP 2307	Phase II		immunostimulant	cancer
vaccine, Maruyama; Pre-Registration	Pre-registration		immunostimulant	cancer
SSM			immunostimulant	cancer
vaccine, melanoma, University of Pittsburgh; melanoma vaccine	Phase I		immunostimulant	cancer
tipronimod; HBW 538	Discontinued	2-[3-carboxypropyl]thio-4-methyl-5-thiazoleacetic acid	immunostimulant; antifungal	mycosis; cancer

MGN 3	Phase I	Unspecified	immunostimulant; biological response modifier	cancer
NSC 631570; E 09/029; NSC B238865; UKSR 222; W 122; UKRAIN	Pre-registration	5,5'-[phosphinothioylidyn esterimino-2,1-ethanediyl)tris[5-methylchelidoninium]] triyodoxide	immunostimulant; biological response modifier	cancer
CD40 ligand, Immunex; CD40LT prolactin	Phase I preclinical		immunostimulant; biotechnology	cancer
penoxifloxine : ciprofloxacin; ciprofloxacin : penoxifloxine; CT 1500	Discontinued		immunostimulant; biotechnology; hormone; vaccine adjuvant	cancer; infectious disease
acemannan; CARN 1000; CARN 750; CARRASYN; ALGINASE; VORALEX; CARRAVEX	Marketed	(1->4),(1->6)-alpha-D-galacto-beta-D-mannan acetate	immunostimulant; chemoprotectant; cytoprotectant	cancer
tetrachlorodecaoxide; TCDO; WF 10; OXOFERIN	Marketed		immunostimulant; cicatrizant	skin ulcer; HIV infection; cancer

granulocyte colony stimulating factor mimetic, Ligand/SmithKline Beecham; G-CSF mimetic, Ligand/SmithKline Beecham	Preliminary		immunostimulant, cytokine agonist	cancer; viral infection; bacterial infection
thiethazole	Preliminary	2-[1-(1,1-dioxoethoxy-3)-benzimidazolyl]-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
tabilautide; RP 56142	Discontinued	dihydro-6-carbamoyl-N2-[N-(tauroyl-L-alanyl)-D-gamma-glutamyl]-L-lysine	immunostimulant; lipopeptide	bacterial infection; cancer
hemoregulatory peptide, Nycomed	Preliminary		immunostimulant; peptide	bacterial infection; cancer
immunostimulant peptides, BioChem Pharma	Discontinued		immunostimulant; peptide	cancer; viral infection
interleukin-2 receptor agonist; IL-2R	Preliminary		immunostimulant; peptide	cancer; HIV infection
SUIS-gonadorelin; SUIS-LHRH	Phase I		immunostimulant; peptide	cancer
thymopoietin receptor agonist	Preliminary		immunostimulant; peptide	cancer; HIV infection
ubenimex; bestatin; NK 421; BESTATIN	Marketed	(-)-N-[ZS(3R)-3-amino-2-hydroxy-4-phenylbutyryl)]-L-leucine	immunostimulant; peptide	cancer

THERAMIDE	Suspended		immunostimulant; peptide; oligosaccharide	cancer; infectious disease
monophosphoryl lipid A + myobacterium cell wall sk; myobacterium cell wall skeleton + monophosphoryl; MPL + CWS; DETOX	Phase III		immunostimulant; vaccine adjuvant	cancer
D5; PM 92114	Discontinued			
dehydrodidermin B; DDB	Preliminary	N-[1-(1,2-dioxopropyl)-L-propyl]didermin A	immunosuppressant	cancer
dinaline; GOE 1734; NSC 328786; AAPBA	Discontinued	4-amino-N-(2-aminophenyl)benzamide	immunosuppressant	viral infection; cancer
fluasterone	Phase I		immunosuppressant	cancer
gusperimus; gusperimus hydrochloride; deoxyspergualin, 15; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215-1; SPANIDIN; SUPANIDIN; promedulan; TERICIMUS	Marketed	(+,-)-7-[(aminoiminomethyl)(amino)-N-[2-[4-(3-aminopropyl)amino]-butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide	immunosuppressant	cancer; diabetes; systemic lupus erythematosus; transplant rejection; multiple sclerosis; cancer
	Discontinued			

XENOJECT	Preliminary		immunosuppressant	cancer; autoimmune disease
protein A-based immune modulator	Preliminary		immunosuppressant; immunostimulant	autoimmune disease; cancer
signal transduction modulators, National Jewish Center for Immunology and Respiratory Medicine	Preliminary		immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
CI 972	Discontinued	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrol[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
cladribine; 2-CIA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	Marketed	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
T cell peptide, University of Illinois	Preliminary		immunosuppressant; peptide	autoimmune disease; cancer, bacterial infection
Mab, BR96 Fv-PE40; SGN 10; BMS 191352	Phase I		immunotoxin; biotechnology	cancer
Mab, TES-23-neocarzinostatin; TES-23-NCS	Discontinued		immunotoxin; biotechnology	cancer

MAb, TP3-pokeweed viral protein conjugate; immunotoxin, TP3-pokeweed viral protein conjugate; TP3-PAP	Preliminary		immunotoxin; biotechnology; monoclonal antibody	cancer
MAb, doxorubicin-CEA; DOX-CEA	Preliminary		immunotoxin; biotechnology; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
drug delivery system, ANCHOR angiostatic agent S 836	Preliminary	Discontinued	integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor	cancer
CDP 850	Preliminary		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	cancer

cytostatin, MJ 654NF4	Preliminary	5,6-dihydro-6-[6-hydroxy-1,5-dimethyl-4-(phosphonoxy)-7,9,11-tridecatrienyl]-5-methyl-2H-pyran-2-one	integrin antagonist; cell adhesion inhibitor	cancer
SB 223245	Preliminary	(S)-7-[(1H-benzimidazol-2-ylmethyl)methyl]anilino[carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists, DuPont	Preliminary		integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis

[C 101]	Precinical	(alphaS,2R,5S,6R)-6-integrin antagonist; ethyltetrahydro-alpha-cell adhesion inhibitor; immunostimulant; peptide; antibiotic	cancer; bacterial infection
		methy l-5-(3-methylbutyl)-2H-pyran-2-acetyl-L-(3S)-3-hydroxy-L-leucyl-hexahydro-3-pyridazinecarbonyl-N-hydroxy-L-alanylglucyl-L-(3S)-hexahydro-3-pyridazinecarbonyl-N-hydroxy-D-Alanine (7->2)-lactone	
	Precinical	anti-inflammatory agents, Chiroscience/Trega	integrin antagonist; cell adhesion inhibitor; NSAID
	Precinical	cell adhesion inhibitor, GlycoTech/Novartis	integrin antagonist; cell adhesion inhibitor; NSAID
	Precinical	drug delivery system, STEALTH cell adhesion inhibitors GM 7050	integrin antagonist; cell adhesion inhibitor; NSAID
	Discontinued		integrin antagonist; cell adhesion inhibitor; NSAID
	Precinical	RGD-based angiogenesis antagonists	integrin antagonist; NSAID; cell adhesion inhibitor

SD-14410.1

drug delivery system, Discontinued interferon alfa; interferon alfa depot delivery; MPI 7057		interferon	cancer
drug delivery system, Preclinical transdermal BIPHASIC interferon alfa; interferon alfa transdermal		interferon	cancer; viral infection
interferon alfa; BALL-1; MR 22; BALL-1; OIF; IFN ALPHA MOCHIDA	Marketed	interferon	cancer; viral infection; mucositis; musculoskeletal disorder
interferon alfa;	Marketed	interferon	cancer; viral infection
interferon Alfanate interferon alfa-n3; KEMRON; ALFERON; ALFERON N; ALFERON LDO; ALTEMOL; REFERON	Marketed	interferon	viral infection; cancer
interferon beta; FRONE	Marketed	interferon	multiple sclerosis; cancer; eye disease
interferon gamma, natural; IFN gamma, natural; OH 6000; OGAMMA 100	Marketed	interferon	cancer
interferon-alpha; IFN alpha	Preclinical		interferon; biotechnology
interferon, modified, Tanox	Preclinical		interferon; biotechnology; immunosuppressant

leukocyte alpha interferon; ALFAFERONE; CILIFERON dorelief; BASF 4701; RWJ 20257; ORF 20257	Marketed		interferon; immunostimulant	viral infection; cancer
	Discontinued	(E)-1,2,3,4-tetrahydro-7-[2-[4-(hydroxymethyl)phenyl]-1-methylethoxy]-1,1,4,4-tetramethylnaphthalenol	keratolytic	cancer
U 74389	Preliminary	Unspecified	lazaroid	cancer
U 74500A	Preliminary	21-[4-[3,6-bis(diethylamino)-2-pyridinyl]-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione hydrochloride	lazaroid	cerebrovascular disease; cancer
lysopholine; isosolylene; CT 1501R; ProTec preflate; NSC 656202; NAS 656202	Phase II	(R)-1-(5-hydroxyhexyl)-3,7-dimethylxanthine	lysophosphatidic acid transferase inhibitor; xanthine macrolide; antibiotic	cancer; cardiovascular disease; respiratory disease; mucositis
	Preliminary	N,N-dimethylglycine, [1R-(1R*,2E,6S*,10E,11aS*,13S*,14aR*)]-1,6,7,8,11a,12,13,14,14a-decahydro-1-hydroxy-6-methyl-4-oxo-4H-cyclopent[fl]oxacyclofridein-13-yl ester		cancer

duocarmycin SA; DC 113	Discontinued [7bR]-1,2,4,5,8a-hexahydro-4-oxo-2-[5,6,7-trimethoxy-1H-indol-2-yl]carbonyl]cyclopropa[c]pyrrol[3,2-e]indole-6-carboxylic acid methyl ester	Phase II	macrolide; antibiotic macrophage stimulator; immunostimulant	macrolide; antibiotic macrophage stimulator; immunostimulant	bacterial infection; cancer
rhizoxin; lizoxine drug delivery system, liposome CGP 31362; CGP 31362 liposome; MLV-CGP 31362 GPX 325	Discontinued Drug delivery system, liposome CGP 31362; CGP 31362 liposome; MLV-CGP 31362 GPX 325	Precclinical	MAO inhibitor; chemoprotectant; cytoprotectant; radioprotectant	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrilysins inhibitors, Affymax	Precclinical	Discontinued	matrix metalloproteinase inhibitor; proteinase inhibitor	matrix metalloproteinase inhibitor; cicatrizant; proteinase inhibitor; NSAID	arthritis; periodontal disease; skin ulcer; cancer

anticancer matrix metalloproteinase inhibitors	Preliminary		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
CMT 3; COL 3; NSC [Phase I 683551; METASTAT]	(4aS,5aR,12aS)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
D 1927	Preliminary		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
D 2163	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	Phase III	N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(methylpropyl)-butanediamide	matrix metalloproteinase inhibitor; proteinase inhibitor	retinopathy; diabetes; cancer

marimastat; BB 2516; Phase III TA 2516	[2S,3R]-N4-[(IR)- 2,2-dimethyl-1- [(methylamino)carbo- nyl]propyl]-N1,(2- dihydroxy-3-(2- methylpropyl)butanedi- amide]	Precinical	matrix metalloproteinase inhibitor, Agouron	matrix metalloproteinase inhibitor; protease inhibitor	cancer
S 3304	Phase I			matrix metalloproteinase inhibitor; protease inhibitor	cancer; inflammation
prinomastat; AG 3340; Phase III	Unspecified			matrix metalloproteinase inhibitor; protease inhibitor; angiogenesis inhibitor	cancer; retinopathy
CH 104	Discontinued			matrix metalloproteinase inhibitor; protease inhibitor; NSAID	cancer; inflammation
CH 715	Discontinued			matrix metalloproteinase inhibitor; protease inhibitor; NSAID	cancer; inflammation
matrix metalloproteinase inhibitor, State University of New York	Preclinical			matrix metalloproteinase inhibitor; protease inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis

matrix metalloproteinase inhibitors, ProScript	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
PI 88	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation; cancer
solimastat; BB 3644	Phase I	(2S,3R)-3-[{[O1S]-2,2-dimethyl-1-(2-pyridylcarbamoyl)propanoyl]carbamoyl}-2-methoxy-5-methylhexanoxyhydroxamic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
BIBW 22; BIBW 22BS	Discontinued		MDR inhibitor	cancer
biricodar, biricodar dicistrate; VX 710; INCEL	Phase II	(S)-1-[oxo(3,4,5-trimethoxyphenyl)ace tyl]-2-piperidinecarboxylic acid 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]buty Lester	MDR inhibitor	cancer
duthionine sulfroxime; BSO; NSC 326231	Phase I	(2S)-2-amino-4-(S-butylsulfonimidoyl)b utanoic acid	MDR inhibitor	cancer

dexniguldipine; (+)- niguldipine; (R)- niguldipine; niguldipine, (R); B 8509035; BY 935	Discontinued niguldipine, B 8509035; BY 935	(R)-1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinecarboxylic acid 3-(4-(4-di phenyl- 1-piperidinyl)propyl methyl ester	MDR inhibitor	cancer
drug delivery system, liposome cyclosporin; cyclosporin liposome; CYCLOXOME flezelastine; D 18024	Discontinued flezelastine; D 18024	4-(4-(4- fluorophenyl)methyl) 2-(hexahydro-1- (phenylethyl)-1H- azepin-4-yl)-1(2H)- phthalazinone monohydrochloride	MDR inhibitor	cancer
H 85	Precclinical H 85	N-[2-[3-(4- chlorophenyl)-2- propenyl]formylamino ethyl]-5- isoquinolinesulfonam ide	MDR inhibitor	cancer
LU 49667	Discontinued LU 49667		MDR inhibitor	cancer
LU 51903	Discontinued LU 51903		MDR inhibitor	cancer
MDR inhibitor, BioNumerik	Precclinical MDR inhibitor, BioNumerik		MDR inhibitor	cancer
Xenova	Precclinical MDR inhibitors, Fox Chase Cancer Center		MDR inhibitor	cancer

MS 209	Phase II	4-(diphenylacetyl)- alpha-[5- quinolinyloxy]methyl J-1-piperazineethanol, (E)-2-butenedioate (2:3)	MDR inhibitor	cancer
NA 382	Precclinical	N-(ethoxycarbonyl)- 7-oxostauroporine	MDR inhibitor	cancer
PAK 104P	Precclinical	trans-5-(4,6-dimethyl-1- 2-oxido-1,3,2- dioxaphosphorinan-2- yl)-2,6-dimethyl-4-(3- nitrophenyl)-3- pyridinecarboxylic acid 2-[4- (diphenylmethyl)-1- piperazinyl]ethyl ester trihydrochloride	MDR inhibitor	cancer
propyl bis-acridone	Precclinical	1,3-bis(9-oxoacridin- 10-yl)propane	MDR inhibitor	cancer
R 101933	Phase I	Discontinued	MDR inhibitor	cancer
Ro 112933	Phase I	N-[2-(3,4- dimethoxyphenyl)ethyl yl]-N-methyl-2-(2- naphthalenyl)-1,3- dithiane-2- propanamine hydrochloride	MDR inhibitor	cancer

S 16209	Preliminary	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[(4-nitrophenyl)methyl][amino]ethoxy]ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16317	Preliminary	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[(4-pyridinylmethyl)amino]ethoxy]ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16324	Preliminary	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[(3-thienylmethyl)amino]ethoxy]ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer

S 9788	Discontinued	6-[4-[2,2-bis(4-fluorophenyl)ethyl][amino]-1-piperidinyl]-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine	MDR inhibitor	cancer
SB RA 31012	Preliminary			
SDZ 214103	Discontinued	2-(3-methyl-D-2-hydroxybutanoic acid)-4-L-leucine-7-L-threonine-10-L-leucinecyclosporin A	MDR inhibitor MDR inhibitor	cancer cancer
XR 1500	Suspended			
CRL 1336	Discontinued		MDR inhibitor MDR inhibitor; chemosensitizer	cancer cancer
valsotdar; SDZ PSC333; PSC 833; SDZ PSC 833; AMDRAY	Phase III	6-[[R-(E)]-6,7-didehydro-N,4-dimethyl-3-oxo-L-2-aminoctanoic acid]-7-L-valine-cyclosporin A	MDR inhibitor; chemosensitizer; P glycoprotein inhibitor	cancer
elacridar; GF 120918; GG 918	Suspended	N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(H)-isoquinoliny)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide	MDR inhibitor; P glycoprotein inhibitor	cancer

timcedar; timcodar dimesylate; VX 853	Phase II  [alphaS)-4-chloro-alpha-[methyl[oxo(3,4,5-trimethoxyphenyl)acetyl]amino]-N-(phenylmethyl)-N-[3-(4-pyridinyl)-1-[2-(4-pyridinyl)ethyl]propyl]benzenepropanamide	(Z,Z)-N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(H)-isoquinoliny)ethyl]phenyl]-4-[4-methyl-3,6-dioxo-5-(phenylmethylethylene)pyrerazinglidene]methyl]benzamide	MDR inhibitor; P glycoprotein inhibitor	cancer; neuropathy
XR 9051	Suspended		MDR inhibitor; P glycoprotein inhibitor	cancer
SDZ 280446	Discontinued	cyclo[N-methyl-L-alpha-Asp-N-methyl-L-Ile-L-Ile-N-methyl-L-Ile-Gly-N-methyl-L-Val-O-methyl-L-Tyr-(2S)-2-hydroxypropanoyl-(2S)-2-piperidinecarbonyl-N-methyl-L-Val-L-Val], 1,1-dimethyllethyl ester	MDR inhibitor, peptide	cancer

melanostatin; BMY 2856; BU 3619E	Discontinued gammaaminolevate; EF 13; GLAMOLEC PGE 2946979	(S)-3-[1-(1-carboxy-2-(1H-imidazol-4-yl)ethyl)amino]-N-(N-methyl-L-phenylalanyl)-L-alanine  lithium	(S)-3-[1-(1-carboxy-2-(1H-imidazol-4-yl)ethyl)amino]-N-(N-methyl-L-phenylalanyl)-L-alanine  Discontinued	melanin synthesis inhibitor  metalloproteinase inhibitor; proteinase inhibitor	melanin synthesis inhibitor  cancer; HIV infection
metalloproteinase inhibitors, Syntex	Precclinical	3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester		metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
BW 1069C85	Suspended			metalloproteinase inhibitor; proteinase inhibitor; NSAID microtubule assembly inhibitor	cancer; arthritis
cryptophycin 52; LY 355703	Phase I	(2S)-3-chloro-N-[(2E,5S,6S)-5-hydroxy-1-oxo-6-[(2R,3R)-3-phenylxiranyl]-2-heptyl]-O-methyl-tyrosyl-2,2-dimethyl-beta-alanyl-2-hydroxy-4-methylpentanoic acid (3fwdrw)-lactone		microtubule assembly inhibitor	cancer

cryptophycin 8	Preliminary	(2S)-3-chloro-N-[(2E,5S,6R,7R,8S)-8-chloro-5,7-dihydroxy-6-methyl-1-oxo-8-phenyl-2-octenyl]-O-methyl-D-trosyl-(2R)-2-methyl-beta-alanyl-2-hydroxy-4-methylpentanoic acid (3->15)-lactone	microtubule assembly inhibitor	cancer
cryptophycin A derivatives, Wayne State University D 24851	Preliminary	1-[(4-chlorophenyl)methyl]-alpha-oxo-N-(pyridinyl-1H-indole-3-acetamide)	microtubule assembly inhibitor	cancer
epothilone	Preliminary		microtubule assembly inhibitor	cancer

maitansine; maytansine; NSC 153858	Precinical	N-acetyl-N-methyl-L-alanine [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1].11.0,14.0,3.5]hexacos-a-10,12,14(26),16,18-pentaen-6-yl ester	microtubule assembly inhibitor	cancer
T 138067	Phase I	2-fluoro-1-methyl-4-pentylfluorophenylsulfonamidobenzene	microtubule assembly inhibitor	cancer
T 900607	Precinical		microtubule assembly inhibitor	cancer
AC 7700	Precinical		microtubule assembly inhibitor	cancer
epothilones, Society for Biotechnology Research	Precinical		microtubule assembly inhibitor; antibiotic	cancer
cemadotin; LU 103793	Phase II	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-N-(phenylmethyl)-L-prolinamide	microtubule assembly inhibitor; peptide	cancer

[LU 2233651]	Preliminary	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolin-Tert-butylamide	microtubule assembly inhibitor; peptide	cancer
epithilones	Preliminary	[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazoly)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (B is [1S, 16-methyl])	microtubule assembly promoter	cancer
antimitotics, Nanodesign	Preliminary		mitosis inhibitor	cancer
TZT 1027	Phase I	[2S, N,N-dimethyl-L-valyl-L-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-1,3-oxo-3-[(2-phenethylamino)propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-L-valinamide	mitosis inhibitor	cancer
mivobulin; Cl 980; NSC 613862(-)	Phase II	(S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-y)carbamic acid ethyl ester	mitosis inhibitor; tubulin polymerase inhibitor	cancer

MAb, 81C6; MAb, cancer	Phase II		monoclonal antibody; biotechnology	cancer
MAb, alpha 5 beta 3 integrin	Discontinued		monoclonal antibody; biotechnology	cancer
MAb, boron complex, Preclinical Straticycle Institute for Drug Research			monoclonal antibody; biotechnology	cancer
MAb, cancer-beta glucosidase; AGENT	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, epidermal growth factor receptor; MAb, EGFR; MAb, E7.6.3; ABX EGF	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, HMFG-1	Phase I		monoclonal antibody; biotechnology	cancer
MAb, platelet derived growth factor/basic fibroblast growth factor; MAb PDGF/bFGF; SMA PDGF/bFGF	Preclinical		monoclonal antibody; biotechnology	cancer; restenosis
MAb, tissue factor/factor VII; MAb, T/F/factor VII; SMA T/F/factor VII	Preliminary		monoclonal antibody; biotechnology	cancer
MAbs, folate receptors & immune effector cells; bispecific monoclonal antibodies; folate receptors & immune effector cells	Preliminary		monoclonal antibody; biotechnology	cancer

tumor stroma specific antibody	Preliminary		monoclonal antibody; biotechnology	cancer
MAb, vascular endothelium growth factor; MAb, vEGF; SMA vEGF	Preliminary		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer
MAb, VEGF; MAb, vascular epithelial growth factor	Phase II		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer; retinopathy
MAb, endoglin-Tf; immunotoxin, endoglin-Tf	Preliminary		monoclonal antibody; biotechnology; coagulation factor; immunotoxin	cancer
MAb, endoglin-dgA; immunotoxin endoglin-dgA	Preliminary		monoclonal antibody; biotechnology; immunotoxin	cancer
MAb, HMFG-1 fragment-yttrium 90; TheraFab	Preliminary		monoclonal antibody; biotechnology; radiotherapeutic	cancer
MAb, L1.2-yttrium-90; yttrium-90-L1.2; LymphoCide	Phase I		monoclonal antibody; biotechnology; radiotherapeutic	cancer
MAb, polymorphic epithelial mucin-yttrium 90; MAb, human-milk fat globulin-1 (HMFG1); THERAGYN	Phase III		monoclonal antibody; biotechnology; radiotherapeutic	cancer

N 3554S; N 1554	Preliminary	[S-(all E)]-[3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracontanonaen-1-ol, dihydrogen phosphate]	N Glycosylation stimulator	cancer
SR 48692	Phase II	2-[[1-(7-chloro-4-quinolonyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.13.7]tetradeca-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
NS 521	Discontinued		neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes
sodium borocapate [10B; borocapate sodium B 10; NASH; BSH; BOROLIFE	Suspended	1,2,3,4,5,6,7,8,9,10,11-undecylidro-12-mercaptoodecaborat e(2-)10B12 disodium	neutron capture agent	cancer
nitric oxide-releasing anticancer agents, National Institutes of Health	Preliminary		nitric oxide donor	cancer
NCX 1101	Preliminary		nitric oxide donor; NSAID	cancer
hemoglobin-based scavenger, ENDOGLOBIN-HT; ENDOGLOBIN-CT	Discontinued		nitric oxide scavenger	hypotension; cancer

hemoglobin-based therapy, Apex NOX 100	Precclinical Precclinical		nitric oxide scavenger	cancer; hypotension; septic shock
NOX 101	Discontinued Unspecified		nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	Precclinical		nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	Phase II		nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
tolemustine; S 10036; MUPHORAN	Marketed	(+/-)-diethyl [1-[3-(2-chloroethyl)-3-nitrosuccido]ethyl]p phosphonate	nitrosourea; alkylating agent	cancer
nitrovin; CRC 7805068	Phase II		nitrosourea; alkylating agent	cancer

SarCNU; NSC 364/432	Precinical	2-[(2-chloroethyl)nitrosoamino]carbonylmethylacetamide	nitrosurea; alkylating agent	cancer
semustine; methyl CCNU; WR 220076; NSC 95441; ICG 1110	Phase I	N-(2-chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea	nitrosurea; alkylating agent	cancer
TA 077	Phase III	N-(2-chloroethyl)-N-(4-O-alfa-D-glucopyranosyl-beta-D-glucopyranosyl)-N-(2-methylpropyl)-N-nitrosourea	nitrosurea; alkylating agent	cancer
Tauromustine; TENU; LS 2667; TAURICYT	Phase III	2(((2-chloroethyl)nitrosoamino)carbonyl)amino)-N,N-dimethylethanesulfonamide	nitrosurea; alkylating agent	cancer
cell adhesion molecules intracellular inhibitors, ICOS/Abbott	Precinical		NSAID	cancer; inflammation
drug discovery, Trega Biosciences; drug discovery, Chugai	Precinical		NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
G-protein therapy, Cadus/Bristol-Myers Squibb	Precinical		NSAID	inflammation; cardiovascular disease; cancer

kinase modulators, ICOS	Preliminary		NSAID	cancer; inflammation
nitric oxide modulators, Duke University	Preliminary		NSAID	hypotension; cancer; rheumatoid arthritis
signal transduction modulators, Cancer Research Campaign	Preliminary		NSAID	cancer; inflammation; neurological
synthetic glycosaminoglycans drug delivery system, Registered HIT diclofenac; diclofenac HIT; HYAL CT1101; HYAL AV2201; HYAL AT1201; HY ANALGEESE; HYANALGEESE-D; SOLARASE; ORALEASE P 54	Preliminary		NSAID; analgesic	pain; cancer; inflammation; skin disease; mucositis
apoptosis modulators, IDUN	Phase II		NSAID; analgesic	osteoarthritis; Crohn disease; cancer
MDR inhibitors, BioResearch Ireland proteasome inhibitors; ProScript	Preliminary		NSAID; apoptosis inhibitor; caspase inhibitor	cancer; neuropathy; inflammation
EP1163; Epicyte	Preliminary		NSAID; MDR inhibitor	cancer
			NSAID; transcription factor regulator	inflammation; cancer
			nucleoside analogue	cancer

OGT 719	Phase I Preclinical	5-fluoro-1-beta-L-galactopyranosyl-2,4(1H,3H)-pyrimidinedione	nucleoside analogue	cancer
thio-cytarabine derivatives; Southern Research Institute; thio-arac derivatives; Southern Research Institute				
yunamycin	Preclinical Discontinued	8-chloro-cyclic adenosine 3',5'-monophosphate	nucleoside analogue; nucleoside analogue; antimetabolite	cancer cancer
8-chloro-cAMP; 8-Cl-cyclic adenosine monophosphate; 8-Cl-cAMP				
anticancer, Camerino University	Preclinical	1-beta-D-ribofuranosyl-1H-pyrol[3,2-c]pyridine-4,6-diamine	nucleoside analogue; antimetabolite	cancer
CNDAC	Preclinical	4-amino-1-(2-cyano-2-deoxy-beta-D-arabinosyl)furanosyl)-2(1H)-pyrimidinone	nucleoside analogue; antimetabolite	cancer
DMDC	Phase II	2'-deoxy-2'-methylencytidine	nucleoside analogue; antimetabolite	cancer
drug delivery system; Phase I 5 fluoropyrimidine; 5 fluoropyrimidine delivery system	Phase I		nucleoside analogue; antimetabolite	cancer; viral infection

fludarabine; F-araAMP; fludarabine phosphate; SH 573; SH 584; SH 586; NSC 312887; NSC 3289002; 2'-F araAMP; NSC 118218; NSC 118218-H; 2'-F-araA; ZK 153851; FLUDARA	Marketed	9-beta-D-arabinofuranosyl-2-fluoroadenine-5-(dihydrogen phosphate)	nucleoside analogue; antimetabolite	cancer
gemcitabine; dFdC; difluorodeoxycytidine; LY 188011; DDFC; GEMZAR	Marketed	2'-deoxy-2',2'-difluorocytidine	nucleoside analogue; antimetabolite	cancer
CYT OVERT sulfinosine; fin; SULFINOSINE	Preclinical	2-amino-9-beta-ribofuranosyl-9H-purine-6-sulfonamide	nucleoside analogue; antimetabolite	cancer
UK 25	Preclinical	5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[[[(1-oxo-2-propylpentyl)amino]acetyl]amino]hexyl]-[1(2H)-pyrimidinecarbonyl]de	nucleoside analogue; antimetabolite	cancer
IPdR	Preclinical	5-iodo-pyrimidinone-2-deoxyribose	nucleoside analogue; antimetabolite; radiosensitizer	cancer

troxacitabine; BCH 4556	Phase II	(2S-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2(1H)-pyrimidinone	nucleoside analogue; DNA polymerase inhibitor	cancer
N 10146	Phase I	5-amino-3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,4H)-dione	nucleoside analogue; immunostimulant; biological response modifier	cancer; viral infection
nucleoside analogues, Nabi; nucleotide analogues, Nabi	Precclinical		nucleoside analogue; nucleotide analogue	viral infection; HIV infection; cancer
TAS 106	Precclinical		nucleoside analogue; RNA polymerase inhibitor, antimetabolite	cancer
FES 12	Precclinical		nucleoside; antimetabolite	cancer
CS 682	Phase I	N-[1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]hexadecaamide	nucleoside; DNA polymerase inhibitor	cancer
adenosine triphosphate; ATP	Discontinued	adenosine 5'- (tetrahydro triphosphate)	nucleotide	cancer, cachexia
oligonucleotide, cancer immunotherapy	Precclinical		oligonucleotide; biotechnology; immunostimulant	cancer
ribozyme, dysprostium-texaphyrin, cancer; Dy-Tex	Precclinical		oligonucleotide; biotechnology; ribozyme	cancer

drug delivery system, Phase II sustained release DepoFoam morphine; morphine DepoFoam; C 0401;		opiate agonist; mu agonist; analgesic	pain; cancer
DepoMorphine haloxone + pentazocine; pentazocine + haloxone	Pre-registration	opiate agonist; opiate antagonist; analgesic	pain; cancer
CP 100356	Preclinical	4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinamine	P glycoprotein inhibitor cancer
LY 335979; RS 33295 33295198; RS 33295	Phase II	[6(R)-[a alpha,6alpha,10b alpha]]-4-(1,1-difluoro-1,1a,6,10b-tetrahydrotetra[b][a,c]cyclopropa[c]cyclohexen-6-y])-alpha-[(5-quinolinyloxy)methyl]-1-piperazineethanol, trihydrochloride	P glycoprotein inhibitor cancer

N 1379; L 623	Discontinued	hydroxybutanedioic acid cmpd with N,N'-bis[3-(4-dimethoxyphenyl)methyl]-N-[3(7,11,15,19,23,27,3,135-nonanethyl)-2,6,10,14,18,22,26,30,34hexatriacontanonaenyl]-1,2-ethanediamine (1:1)	P glycoprotein inhibitor	cancer
XR 9576	Phase II	N-[2-[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-[4,5-dimethoxyphenyl]-3-quinolinescarboxamide	P glycoprotein inhibitor; MDR inhibitor	cancer
toritukine; L 868275	Preclinical	cis-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-2-methyl-4H-1-benzopyran-4-one	p34 kinase inhibitor	cancer
SDZ 62434; SDZ 62-434	Discontinued	2,3-dihydro-5-[4-(1-piperidinylmethyl)phenoxy]imidazo[2,1-a]isoquinoline dihydrochloride	PAF antagonist	cancer
plasminogen activator inhibitor antagonists, Corvas	Preclinical		PAI inhibitor	cancer

plasminogen activator inhibitor-1 inhibitor, Xenova; PAI-1 inhibitor, Xenova	Preliminary		PAI inhibitor	cancer
BIM 44002	Phase I		parathyroid hormone antagonist peptide	hypercalcemia; cancer
antifreeze protein, cancer cryosurgery, A F Protein	Preliminary		peptide	cancer
axinastatin 1; malaysianin; pseudoxinellin	Preliminary	axinastatin 1	peptide	cancer
axinastatin 2	Preliminary	5-L-leucine-axinastatin 1	peptide	cancer
axinastatin 3	Preliminary	4-L-isoleucine-5-L-leucine-axinastatin 1	peptide	cancer
BST 1002	Preliminary		peptide	cancer
BST 1003; COLLAGER	Preliminary		peptide	cancer
cancer therapy, Aptein	Preliminary		peptide	cancer
cancer therapy, Magainin	Preliminary		peptide	cancer
cancer therapy, PSP 94, Procyon	Preliminary	Delta-Inhibin (human reduced)	peptide	cancer
cell permeable peptides	Preliminary		peptide	cancer
corticotropin-releasing factor; corticotropin-releasing hormone; CRF; XERECPT CYC 100	Phase II		peptide	cancer; stroke; trauma
	Preliminary		peptide	cancer.

CYC 101	Precinical		peptide	cancer
CYC 102	Precinical		peptide	cancer
CYC 103	Precinical		peptide	cancer
D 22631	Discontinued		peptide	cancer
drug delivery system, anticancer peptide	Precinical		peptide	cancer
GPX 200	Phase I		peptide	cancer
GW 395058	Precinical		peptide	cancer, thrombocytopenia
insulin-like growth factor-1 receptor inhibitor; IGF-1 receptor inhibitor; IGF-1 B3	Precinical		peptide	restenosis; cancer
laminin peptides, National Institutes of Health	Precinical		peptide	cancer
MF 13	Precinical	[L-prolyl-3-[bis(2-chloroethyl)amino]-L-phenylalanyl-L-norvaline ethyl ester monohydrochloride]	peptide	cancer
monocyte attracting peptide	Precinical		peptide	cancer; bacterial infection
MSI 103	Discontinued	Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Alannamide	peptide	cancer
MSI 500	Discontinued		peptide	cancer

NA 22598; NA 22598A1	Preliminary	N-[2,3-diamino-8-[2- amino-1-(aminocarbonyl)-4,5- dihydro-1H-imidaz- ol-5-yl]-2,3,4,5,8- pentadecyloxotonyl]- L-alanyl-L-valine	peptide	cancer
NSC 630176; FR 901228	Phase I	N-[3S,4E]-3- hydroxy-7-mercapto- 1-oxo-4-heptenyl]-D- (2Z)-2-amino-2- butenoyl-L-valine (4- 1)-actone cyclic (1- 2)disulfide	peptide	cancer
p16 analogue	Preliminary		peptide	cancer
prohibitin	Preliminary		peptide	cancer
PTL 03001	Preliminary		peptide	cancer
sonaloprin; PTR 3046	Preliminary	cyclo[Phe-N2-Tyr-D- Itp-Lys-Val-Phe- C3]Thr-NH2	peptide	pancreatitis; cancer; restenosis
thiocoraline	Preliminary		peptide	cancer
urokinase receptor antagonist	Preliminary		peptide	cancer
cyclopentapeptide, Wilex Biotechnology IM 862	Phase II		peptide; angiogenesis inhibitor	cancer
D2A721	Preliminary		peptide; antibiotic	bacterial infection; trichomoniasis;
breast cancer therapy, Cytoclonal	Preliminary		peptide; antiestrogen	cancer

BRCA1, recombinant transducin factor, vascular endothelial growth factor gene alpha-conopeptides	Precclinical Preclinical		peptide; biotechnology peptide; biotechnology cancer
fibroblast growth factor, basic, antagonists, NIH fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	Precclinical Preclinical	peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
splenopentin, diacetyl-splenopentin; beropentin; DA-SP5; DA-SP 5, BCH 069	Precclinical	peptide; FGF antagonist; angiogenesis inhibitor	restenosis; cancer
integrin-specific peptides, Integra LifeSciences	Precclinical	N2-acetyl-L-arginyl-N6-acetyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-tyrosine	peptide; immunostimulant
antagonist D	Precclinical		cancer
auristatin PE	Precclinical		osteoporosis; cancer; restenosis
C3B Cdc25 inhibitors, Mitox	Precclinical Preclinical	Unspecified	peptide; substance P antagonist; cell adhesion inhibitor; angiogenesis inhibitor
			peptide; tubulin polymerase inhibitor
			phosphatase inhibitor
			cardiovascular disease; cancer

CT 2584; APRA	Phase II	I-[1-(dodecylamino)-10-hydroxyundecyl]-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione	phosphatidic acid inhibitor	cancer
benzochlorin	Preclinical	photosensitizer	cancer	
benzophenothiazines, Rowland Institute; benzophenothiazines, Ergo Science	Preclinical	photosensitizer	cancer	
benzoporphyrin derivatives, third generation; OL-T 0074;	Preclinical	photosensitizer	cancer	
boronated porphyrin compounds; BOPP	Phase I	photosensitizer	cancer	
chlorins	Preclinical	photosensitizer	cancer	
cis-porphyrin	Preclinical	cis-meso-bis(N-methyl)-4-(pyridinium)diphenylporphyrin	photosensitizer	cancer
drug delivery system, liposome zinc phthalocyanine; zinc phthalocyanine liposome; CGP 55847	Discontinued		photosensitizer	cancer
drug delivery system, RFS aminolevulinic acid; 5-ALA RFS; aminolevulinic acid, RFS	Preclinical		photosensitizer	cancer

drug delivery system, transdermal 5- aminolevulinic acid; 5-aminolevulinic acid transdermal; drug delivery system, transdermal ALA PDT	Discontinued		photosensitizer	cancer
ER 470	Discontinued		photosensitizer	cancer
HAT D01	Preliminary		photosensitizer	cancer; diagnosis
HPHH	Phase I		photosensitizer	cancer
hypericin; VIMRxyn; CYCLO-WEROI; CYCLOSAN	Phase II	1,3,4,6,8,13- hexahydroxy-10,11- dimethylphenanthro[1- 10,9-8- optra]perylene-7,14- dione	photosensitizer	psoriasis; cancer
JM 2929	Discontinued	(OC-6-12)-bis[3- (diphenylphosphino- kappa)benzenesulfo- nato][29H,31H- phthalocyaninato(2-) kappa]29,kappaN30, kappaN31,kappaN32] ruthenate(2-), dipotassium	photosensitizer	cancer
Iutetium texaphyrin, Lu Tex; PC1 0123; LUTRIN; Lu-Tex; OPTRIN; ANTRIN	Phase II		photosensitizer	cancer; atherosclerosis; eye disease; skin disease

NPe 6; NP e6; ME 2906	Phase II photodynamic immunotherapy, Pacific; PDT	N-[3-[2S,3S]-18-carboxy-20-(carboxymethyl)-8-ethoxy-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21H,23H-porphin-2-yl]-1-oxopropyl-L-aspartic acid tetrasodium salt	photosensitizer	cancer
photodynamic phototherapy, Anutech; drug delivery system, photosensitizer	Precclinical		photosensitizer	cancer
photodynamic therapy, plant-derived, Sieba Beher	Precclinical		photosensitizer	cancer, bacterial infection
porfimer sodium; polyporphyrin; CL 184116; PHOTOFRIN; PHOTOFRIN II	Marketed	photofrin porfimer sodium	photosensitizer	cancer
purpurins	Precclinical		photosensitizer	cancer
SC 102	Precclinical		photosensitizer	cancer
SQN 400; SQ 400	Precclinical		photosensitizer	cancer
tellurapyrylum; USB 006	Discontinued		photosensitizer	cancer
temoporfin, m-THPC; EF 9; FOSCAN	Phase III	3,3",3'''(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetraakis phenol	photosensitizer	cancer

tin ethyl etiopurpurin; SnEt12; PURLYTIN	Phase III tin [ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)]-kappa,N23,kappa.N24,kappa.N25,kappa.N26]-[SP-4-2]-verdins	photosensitizer prostate hypertrophy; retinopathy	cancer; benign
zinc phthalocyanine	Preclinical Discontinued	photosensitizer cancer	cancer
aminolevulinic acid, photodynamic therapy; 5-ALA PDT; LEVULAN	Pre-registration	photosensitizer contrast medium	psoriasis; skin disease; endometriosis; cancer; diagnosis
verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	Phase III Marketed	trans-18-ethenyl-4,4a-photosensitizer; NSAID bistimethoxy carbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzof[b]porphine-9,13-dipropionic acid monomethyl ester	cancer; psoriasis; arthritis; retinopathy
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN AP 5070	Precinical	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinalolin-2(3H)-one	platelet antiaggregant thrombosis; cancer
		platinum complex	cancer

B 850040	Discontinued	1,3-diamino-2-methoxymethyl-2-methyl-propan-N,N-platin (II)-0,0-cyclobutan-1,1-dicarboxylate	platinum complex	cancer
BBR 2207	Discontinued	hydrogen [mu-benzenepentacarboxylato(5-)O1,O2,O4,O5]bis(1,2-cyclohexanediamine-N,N')diplatinate (1-), stereoisomer	platinum complex	cancer
BBR 3464	Phase I	cisplatin analogue, II	platinum complex	cancer
Yang	Preliminary	cycloplatam	platinum complex	cancer
	Phase I	drug delivery system, ATRIGEL sustained release cisplatin; cisplatin ATRIGEL	platinum complex	cancer
	Phase III	drug delivery system, cisplatin; cisplatin Therapeutic Implant; MPI 5010; IntraDose INJECTABLE GEL; IntraDose-CDDP; INTRADOSE-CDDP; IntraDose	platinum complex	cancer

drug delivery system, Preclinical cisplatin biodegradable polymer implant; cisplatin biodegradable polymer implant		platinum complex	cancer
drug delivery system, Phase II liposomal L-NDDP; L-NDDP liposomes; AR 726; PLATAR		platinum complex	cancer
drug delivery system, Preclinical liposome carboplatin; carboplatin liposome		platinum complex	cancer
drug delivery system, Preclinical liposome carboplatin; carboplatin liposome		platinum complex	cancer
drug delivery system, Preclinical microsphere cisplatin; cisplatin microsphere		platinum complex	cancer
drug delivery system, Phase I NDDP liposome; NDDP liposome		platinum complex	cancer
drug delivery system, Phase II STEALTH cisplatin; cisplatin STEALTH delivery system; SPI 77; SPI 077		platinum complex	cancer
GB 21; W 16d; E 92/114	Preclinical	poly-[(trans-1,2- diamino- cyclohexane)platinum ]-carboxyamyllose	cancer

JM 221	Discontinued	(OC-6-43)-amminabis(putanoato)O dichloro(cyclohexanamine)platinum	platinum complex	cancer
JM 335	Discontinued	(OC-6-12)-amminedichloro(cyclodexanamine)dihydroxy platinum	platinum complex	cancer
JM 473	Precinical	(SP-4-3)-amminedichloro(2-methylpyridine)platinum	platinum complex	cancer
KHPC 001	Phase I	[SP-4-2-(1R-trans)-1,2-cyclohexanediamine-kappaN,kappaN][1,3-propandiylibis(diphenylphosphine-kappaP)]-platinum(2+),dinitrate	platinum complex	cancer
KHPC 002	Phase I	poly[[(+/-)-trans-1,2-diaminocyclohexane][1,3-dicarboxylatopropylamido(nitrido)phosphoric acid]platinum (II)]	platinum complex	cancer
KI 30606	Precinical		platinum complex	cancer

KP 1250	Precclinical compounds, Aroxex loboplatin; D 19466	(SP-4-2)- dichloro[5,7,8,10,11,1 3,14,16,17,19,20,22, dodecahydro[1,4,7,1 0,1,3,6]- hexaoxacyclodocosin o[19,18-b:20,21- b]dipyridine- N1,N2b]platinum	Discontinued	platinum complex	cancer
	Registered	cis-(trans-1,2- cyclobutanethiomethan amine N,N')[(2- hydroxypropionato(2- )-O1,O2)platinum		platinum complex	cancer
	Discontinued	[SP-4-3-(1R-cis)]- [1,1'- cyclobutanedicarboxy lato(2')][2- pyrrolidinemethanami ne- N]alpha N1]platinum		platinum complex	cancer
	Marketed	(SP-4-3)- diammine[(hydroxy- kappa.O)acetato(2-) kappa.O]platinum		platinum complex	cancer

SD-144110.1

oxaliplatin; oxalatoplatin; L- OHP; ACT 078; ELOXATINE; L- OHP; TRANSPLATIN; ELOXATIN PADP	Marketed	[SP-4-2-(IR-trans)]- (1,2- cyclohexanediamine)- N,N')ethanediato(2- )O,O'platinum	platinum complex	cancer
	Phase I	phosphonoacetato-1, 2-diaminocyclohexane platinum (II)	platinum complex	cancer
platinum complex, Cancer Research Center	Precclinical	cis-diamine(nitrilotri(methoxy)phosphonato)(2-) O1,N1)platinum II	platinum complex	cancer
platinum compounds, Georgetown University	Discontinued		platinum complex	cancer
platinum-triamine complex; DRR	Precclinical	(SP-4-3)- diamminechloro[2- (diethylamino)ethyl]- 4-aminobenzoate- N4]platinum(+)chloride monohydrochloride	platinum complex	cancer
polymer platinum compounds, London School of Pharmacy	Precclinical		platinum complex	cancer

RL 0013; NSC 328005; Pt 268; CYPLATATE	Preliminary	(SP-4-3)-(1,2-cyclohexanediamine-N,N')[(N-(phosphonoacetyl)-L-asparto(4-O,1,O4)platinato(2-)dihydrogen	platinum complex	cancer
satraplatin; JM 216; BMS 182751; BMY 45594	Phase III	(OC-6-43)-bis(acetato-O)amminedichloro(cyclotripanamine)platin	platinum complex	cancer
sebriplatin; NR 121; CI 973; SEVRUPLATIN	Discontinued	[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)][2-(methyl-1,4-butanediamine-N,N')platinum	platinum complex	cancer
SKI 2034R	Discontinued	[SP-4-2-[4R-(2[alpha],4[alpha],5[beta],5[alpha])-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)kappa01,kappa03]platin	platinum complex	cancer
SKI 2053R; SK 12035R	Phase II	[SP-4-2-[4R-(2[alpha],4[alpha],5[beta],5[alpha])-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)kappa01,kappa03]platin	platinum complex	cancer
SM 11355; DACHEPM	Discontinued	(trans-cyclohexane-1,2-diamine)bis(myristate)platinum (II)	platinum complex	cancer

TRK 710	Discontinued	[SP-4-3-1(S),3(I,R-trans)]-(3-acetyl-5-methyl-2,4(3H,5H)-furandionato-O3,O4)(1,2-cyclohexanediamine-N,N')-platinum(1+), salt with (S)-3-acetyl-5-methyl-2,4(3H,5H)-furandione (1:1), tetrahydrate	platinum complex	cancer
ZD 0473; AMD 473	Phase I	(SP-4-3)-amminedichloro(2-methylpyridine)platinum	platinum complex	cancer
zeniplatin; 2,2-bis(aminomethyl)-1,3-propanediol platinum complex; 1,1-cyclobutanedicarboxylic acid platinum complex; CL 285558	Phase II	(SP-4-2)-[2,2-bis(aminomethyl)-1,3-propanediol-N,N'][1,1-cyclobutanedicarboxylato(2-)platinum	platinum complex	cancer
PD 128763	Preliminary	3,4-dihydro-5-methyl-1(2H)-isoquinolinone	poly (ADP ribose) polymerase inhibitor	cancer
diethylnorspermine ; DEHOP; DE 444	Phase II	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
diethylnorspermine; DENSPM; CI 1006; DE 333	Phase II	N1,N11-diethylorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease

linear polyamine analogue; SunPharm MDL 28314	Preliminary Discontinued	N,N'-bis[3-(ethylamino)propyl]-1,7-heptane diamine	polyamine analogue	cancer; Alzheimer disease
polyamine analogues; National Institutes of Health	Preliminary Marketed	1,1'-([(methylmethacryloyloxy)methylidene]dinitro)diguanidine	polyamine analogue	cancer
mitoguzone; methylglyoxal bisguanylhydrazone; MGBG; NSC 32946;	Preliminary ZIRKAMINE		polyamine synthesis inhibitor	cancer
polyclonal antibody; complement inhibitor protein; gamma globulin, complement inhibitor protein; PASS-Cab	Preliminary actinopanone A; R 304G		polyclonal antibody; immunoglobulin	cancer
	Discontinued	[1S-(1alpha,3alpha,4beta,8alpha)-13-amino-11-chloro-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xanthenol[4'3'2'4'5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione]	polycyclic xanthone; antibiotic	bacterial infection; cancer

actinoplanone B; R 304H	Discontinued [1S-(1alpha,3alpha,4beta,8alpha)-antibiotic (3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3':2'4:5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione]	[1S-(1alpha,3alpha,4beta,8alpha)-antibiotic (3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3':2'4:5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione]	bacterial infection; cancer
actinoplanone C; R 304J	Discontinued [1S-(1alpha,3alpha,4beta,8alpha)-amino-13-amino-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3':2'4:5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione]	[1S-(1alpha,3alpha,4beta,8alpha)-amino-13-amino-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3':2'4:5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione]	bacterial infection; cancer

actinoplanone G; R 304F	Discontinued [1S-(1alfa,3alfa,4beta,8aalpha)-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-13-[(1-methyl-2-oxopropylidene)amino]-1H-xantheno[4',3':2',4:5][1,3]benzodioxinol[7,6-g]isoquinoline-14,17(2H,9H)-dione	[1S-(1alfa,3alfa,4beta,8aalpha)-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-13-[(1-methyl-2-oxopropylidene)amino]-1H-xantheno[4',3':2',4:5][1,3]benzodioxinol[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; bacterial infection; cancer
CARN 700; CARRADEX CKD 606	Phase I Unspecified	Phase I Unspecified	polysaccharide cancer
sizofiran; sizofilan; neoschizophilylan; SONIFILAN; SONIFIRAN	Preclinical Marketed	poly[3-[(O-beta-D-glucopyranosyl)-1--3]-O-[beta-D-glucopyranosyl]-1--6]-O-beta-D-glucopyranosyl-1-[(3-O-beta-D-glucopyranosyl)-1]	polysaccharide; polysaccharide; immunostimulant cancer; liver disease cancer; viral infection
CM 101; ZD 0101	Phase II Unspecified	Phase II Unspecified	polysaccharide; immunostimulant; angiogenesis inhibitor cancer
AM 5 LG 2527; LG 2716	Discontinued Preclinical		polysaccharide; radioprotectant progestogen; hormone replacement therapy cancer hormone deficiency; cancer

progesterone receptor therapy, Ligand/Wyeth Ayerst	Preclinical		progesterone; hormone replacement therapy	hormone deficiency; contraception; cancer
prolyl hydroxylase inhibitor, Cornell Research Foundation	Preliminary		prolyl hydroxylase inhibitor; angiogenesis inhibitor	retinopathy; cancer; skin disease; atherosclerosis
TEI 9826	Preliminary		prostaglandin prostanoid	cancer
OC 3186	Preliminary	(S <sub>Z</sub> ,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid (acetoxy)methyl ester homopolymer	prostanoid	cancer
prostaglandin J2; PG I <sub>2</sub>	Preclinical		prostanoid	cancer; viral infection
YM 11	Preliminary	(S <sub>S</sub> ,6 <sub>S</sub> ,7 <sub>Z</sub> ,12 <sub>alpha</sub> ,14 <sub>Z</sub> )-5,6-bis(acetoxy)-10-chloro-12-hydroxy-9-oxoprosta-7,10,14-trien-1-oic acid methyl ester	prostanoid	cancer
YM 3	Preliminary	(7 <sub>E</sub> ,12 <sub>xi</sub> )-10-chloro-12-hydroxy-9-oxoprost-7,10-dien-1-oic acid methyl ester	prostanoid	cancer

cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	Discontinued	[3aS-[2E,3alpha,4alpha(3R*)4R*)5beta,6alpha]-[2-(hexahydro-5-hydroxy-4-(3-hydroxy-4-(methyl-1,6-noradinyl)-2(1H)-pentenylidene)ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
bryostatin; bryostatin I; BMY 45618; NSC 339555	Phase II	bryostatin 1	protein kinase activator; protein kinase C activator	cancer
hexanemethylene bisacetamide derivative; HMBA derivative	Preclinical		protein kinase activator; protein kinase C activator	cancer
Y 27632	Preclinical	[4(R)-trans]-4-(1-aminoethyl)-N-(4-pyridinyl)cyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
cancer therapy, Kinetix	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
CP 564959	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
H 87	Discontinued	N-[2-[[3-(4-bromophenyl)-2-propenyl]ethylamino]-ethyl]-5-isouquinolinesulfonamide	protein kinase inhibitor; protein kinase A inhibitor; MDR inhibitor	cancer

BM 41400	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
calphostin C; calphostin; UCN 1028C; UCN 1028	Discontinued	2-[12-(2- [benzoxoxy]propyl)- 3,10-dihydro-4,9- dihydroxy-2,6,7,11- tetraethoxy-3,10- dioxo-1-perylene]-1- methyl-4- hydroxyphenyl carbonyl acid ester	protein kinase inhibitor; protein kinase C inhibitor	cancer
diacetyl glycerol analogues; National Institutes of Health midostaurin;	Preliminary		protein kinase inhibitor; protein kinase C inhibitor	cancer
benzoylstauroporine; N- benzoylstauroporin; CGP 41251; CGP 41231	Phase II	(9alpha,1,10beta,11beta,11alpha)-N- (2,3,10,12,13- hexahydro-10- methoxy-9-methyl-1- oxo-9,13-epoxy- 1H,9H- dindolol[1,2,3- gli:3'2'1'- im]pyrrol[3,4- j][1,7]benzodiazepin- 11-yl)-N- methylbenzamide	protein kinase inhibitor; protein kinase C inhibitor	cancer
NK 860276	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer

NSC 646958	Precclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer
protein kinase C inhibitor, microalgal, Martek	Precclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer, psoriasis
protein kinase C inhibitor, Xenova	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
safingol; safingol hydrochloride; SPC 100270; mSPC 100271; KYNACET; KYNACYTE SPC 100221	Phase II	(2S,3S)-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	psoriasis; dermatitis; cancer
SPC 101591	Precclinical	R-(R*,S*)]-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	cancer
RK 1409B	Precclinical	[9S-(9alpha,10alpha,11beta)-10alpha,11beta-dihydro-11H,9H-12,13-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-1,2,3-dindolo[1,2,3-gh:3'2'1'-im]pyrrol[3,4-j][1,7]benzodiazepin-1-one]	protein kinase inhibitor; protein kinase C inhibitor; antibiotic	cancer; ischemia; reperfusion injury

CGP 60474	Phase I		protein kinase inhibitor; protein kinase C inhibitor; cyclin dependent kinase inhibitor	cancer
MLR 52; (+)-MLR-52	Discontinued	[9S-(9alpha,10beta,11alpha,11alpha,13alpha)-2alpha,13alpha]-2,3,10,11,12,13-hexahydro-11,12-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-1H,9H-dindolo[1,2,3-gh]3',2',1'-impyrrol[3,4-j][1,7]benzodiazepin-1-one	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	cancer
	Precclinical	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-(4-hydroxybenzoyl)amin o]-1H-azepin-4-yl]ester	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
SPC 100840	Precclinical		protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury

UCN 01; UCN 1; KW[Phase I 240]	(3 $\alpha$ ,9 $\beta$ ,10 $\alpha$ )-11- alfa,13beta)-(+)- 2,3,10,11,12,13- hexahydro-3- hydroxy-10-methoxy- 9-methyl-11- (methylamino)-9,13- epoxy-1H,9H- dindolo[1,2,3- gh]3',2',1'- Im]pyrrol[3,4- j][1,7]benzodiazonin- 1-one	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; allergy
MDL 27032	Suspended	4-propyl-5-(4- pyridinyl)- 2(3H)oxazolone	protein kinase inhibitor; protein kinase C inhibitor;
BE 23372M	Discontinued	(E)-5-(3,4- dihydroxyphenyl)-3- [3,4- dihydroxyphenyl]met- hylene]-2(3H)- furanone	vasodilator protein kinase inhibitor; tyrosine kinase inhibitor
CGP 53716	Phase II	N-[4-nethyl-3-[(4-(3- pyridinyl)-2- pyrimidinyl)amino]phakinase enyl]benzanide	protein kinase inhibitor; tyrosine kinase inhibitor
CGP 59326B	Preliminary		EGF receptor inhibitor

KRN 5500	Phase I	4-deoxy-4-[[[(14-methyl-1-oxapentadecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptopyranosylamine	protein synthesis inhibitor	cancer
Pseudomonas exotoxin A linked to F(ab')2 fragment of MAb 1H10-PE; 1H10-PE didemnin B; NSC 325319; IND 24505	Precclinical		protein synthesis inhibitor	cancer
B 428	Phase II	(S)-N-[1-(2-hydroxy-1-oxopropyl)-L-prolyl]didemnin A	protein synthesis inhibitor; antifungal; peptide proteinase inhibitor	cancer; bacterial infection; mycosis; viral infection
Bowman Birk inhibitor concentrate; BBIC	Precclinical	4-iodobenzof[b]thiophen-e-2-carboximidamide monohydrochloride	proteinase inhibitor	cancer
KT 512	Phase II		proteinase inhibitor	benign prostate hypertrophy; cancer
P 35011	Precclinical		proteinase inhibitor	cancer
urokinase inhibitor, 3 Dimensional Pharmaceuticals	Precclinical		proteinase inhibitor	cancer
Ays urokinase inhibitors, Corvas	Precclinical		proteinase inhibitor	cancer
			proteinase inhibitor	cancer

PS 341	Phase I Preclinical	[S-(R*,S*)]-[3-methyl-1-[1-(1-oxo-3-phenyl)-2-[(pyrazinylcarbonyl)amino]propyl]laminooxy]boronic acid	proteinase inhibitor; apoptosis inducer	cancer
cathepsin B inhibitors, Arys AG 3433	Preclinical		proteinase inhibitor; cathepsin B inhibitor	cancer
CGS 27023A	Phase II Preclinical	(R)-N-hydroxy-2-[[{(4-methoxyphenyl)sulfonyl}[3-pyridinylmethyl]amino]-3-methylbutanamide	proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
CH 4815	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
metalloproteinase inhibitors, Glycomed	Preclinical		proteinase inhibitor; metalloproteinase inhibitor	cancer
cysteine proteinase inhibitor, Sympart/British Biotech	Preclinical		proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis

pelodesine; BCX 34; BCX 34B	Phase II  CI 1000; PD 141955	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrido[3,2-d]pyrimidin-4-one  Discontinued	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID  purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection  cancer; psoriasis; rheumatoid arthritis; inflammatory bowel disease; cancer
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
Helicobacter pylori therapy, RPMS Technology	Discontinued		quinoline; antibiotic	gastrointestinal ulcer; bacterial infection; cancer
A 84441	Preliminary	6-[3-{(2-amino-1-oxopropyl)amino}-1-pyridinyl]-5-fluoro-3-oxo-3H-pyrido[3,2,1-k]phenoxazine-2-carboxylic acid	quinolone; antibiotic	cancer

KB 5246	Discontinued 28662; BU 3845T	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopental(cd)phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic quinomycin; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
WR 16804; NSC 333839	Precclinical	4,4'-trihibis-1-butanesulfonic acid, disodium salt	radioprotectant	cancer
anticancer radiosensitizers; Telik AQ4N radiation enhancer; AQ4N	Precclinical	1,4-bis[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenediol	radiosensitizer	cancer
broxuridine; BuDR; BROXINE; NEOMARK CT 2412	Pre-registration		radiosensitizer	cancer; diagnosis
cupimol; RL 5077; CUPRINYL	Discontinued	(2,2'-bipyridine-N,N')propanedioato(2-)-O,O'copper	radiosensitizer	cancer
etanidazole; SR 2508; Phase III NSC 301467; RADINYL	Phase III	N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
KIN 804	Precclinical	N-methoxy-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer

KIN 831	Precclinical	N-hydroxy-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
KU 2285	Precclinical	alpha,alpha-difluoro-N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
metoclopramide; AHR 3070 C; DEL 1267; SENSAIMIDE; NEU-SENSAMIDE; AEROFLAT; ANANDA; ANAUSIN; ANTIMET; BENAGASTRON; PRIMPERRAN; DIGENOR; REGLAN	Marketed	4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide	radiosensitizer	emesis; cancer
MPI-5020	Phase II			
mirorazole	Discontinued	4-[2-(5-nitroimidazol-1-yl)-ethyl]morpholine	radiosensitizer	cancer
PD 130908	Precclinical	N-(2-bromoethyl)-2-nitro-1H-imidazole-1-propanamine monohydrobromide	radiosensitizer	cancer
radiosensitizer, NCI RK 28	Precclinical		radiosensitizer	cancer
	Discontinued	4-[2-nitro-1H-imidazol-1-yl)methoxy]-2-butene-1-ol	radiosensitizer	cancer

RP 170	Preliminary	2-[2-(2-nitro-1H-imidazol-1-yl)methoxy]-1,3-propanediol	radiosensitizer	cancer
RSU 1164	Discontinued	cis-alpha-[{(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
RSU 1165	Discontinued	trans-alpha-[{(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
SN 24699	Preliminary	N-[2-(2-methyl-5-nitro-1H-imidazolyl)ethyl]-4-(2-nitro-1H-imidazolyl)butanamide	radiosensitizer	cancer
SPI 40	Preliminary			
SR 2545	Discontinued	N-[2-(acetyl oxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
SR 2555; NSC 314-055	Discontinued	N,N-bis(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
tirapazamine; WIN 59075; SR 4233; TIRAZONE	Phase III	3-amino-1,2,4-benzotriazine-1,4-dioxide	radiosensitizer	cancer

gadolinium texaphyrin; Gd Tex; PCI 0120; Gd-Tex; XCYTRIN	Phase III  (PB-7-11-233[24]-bis(aceto-O)[9]10-diethy-20,21-bis[2-(2-methoxyethoxy)ethoxy]ethoxy-3,6:16,13-dinitrilo-1,18-benzodiazacycloeticsine-5,14-dipropanolato-N1,N18,N23,N24,N25]-gadolinium	radiosensitizer; chemosensitizer	cancer
lobenguanine; lobenguanine sulfate II23; MIBG; MIBG-I 123	Marketed  [[3-(iodo-1,3,1')phenyl)methyl]guanidine	radiosensitizer; contrast medium; radioimaging; radiotherapeutic	cancer; diagnosis
PK 110	Preliminary  N-[{4-(4-fluorophenyl)methyl}-imidazole-2-nitro-1H-imidazole-1-acetamide	radiosensitizer; imidazole	cancer
PK 130	Preliminary  N-[{2-nitro-1H-imidazol-1-yl}acetyl]-L-phenylalanine, methyl ester	radiosensitizer; imidazole	cancer
RB 6145; PD 144872; Phase I PD 144871; PD 130571; CI 1010	alpha-[(2-bromoethyl)amino]methyl-2-nitro-1H-imidazole-1-ethanolmonohydrobromide	radiosensitizer; imidazole	cancer

nitric oxide-releasing radiosensitizer, National Institutes of Health	Precclinical			radiosensitizer; nitric oxide donor	cancer
cytochlor	Precclinical	S-chloro-2'-deoxycytidine		radiosensitizer; nucleoside analogue	cancer
floranidazole; RP 343; Phase I PR 350		(R*,S*)-3-[(2-nitro-1H-imidazo[1-yl)methoxy]-1,2,4-butanetriol		radiosensitizer; nucleoside analogue; antimetabolite	cancer
117m Sn DTPA; pentaetate 117m Sn	Phase II			radiotherapeutic; analgesic	cancer; pain
thennium Re 186 citidronate; 186-Re HEDP; 186-Re	Pre-registration			radiotherapeutic; analgesic	pain; cancer
METAMET strontium-89 chloride; METASTRON	Marketed	strontium chloride (89SrCl2)		radiotherapeutic; analgesic	pain; cancer
ALRT 1455	Precclinical			RAR agonist; retinoid agonist	
AGN 192792; LG 100382	Precclinical			RAR agonist; RXR agonist; retinoid; retinoid agonist	cancer
CP 609734 ras inhibitors, Agouron	Precclinical Suspended			RAS inhibitor	cancer
Ras inhibitors, Bristol-Myers Squibb	Precclinical			RAS inhibitor	cancer
ras farnesylyl transferase inhibitor, Xenova; XR 3005 series	Discontinued			RAS inhibitor; farnesylyl protein transferase inhibitor	cancer

ras FT inhibitor, Genentech	Discontinued		RAS inhibitor; farnesyl protein transferase inhibitor	cancer
ras inhibitors, Onyx/Bayer	Preliminary		RAS inhibitor; signal transduction inhibitor	cancer
cancer therapy, retinoids, Cornell Research Foundation	Preliminary		retinoid	cancer, psoriasis
drug delivery system, Pre- liposome retinoin; tretinoin liposome; AR 623; ATRAGEN	Pre- registration	retinoid		cancer
NIK 333	Preliminary		retinoid	cancer
polyperenoic acid; E 5166	Discontinued	(all-E)-3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acid	retinoid	cancer
RII retinamide	Marketed		retinoid	cancer
tazarotene; AGN 190168; ZORAC; TAZORAC	Marketed	6-[3-(3,4-dihydro-4,4- dimethyl-2H-1- benzothiopyran-6- y)ethynyl]-3-pyrid inecarboxylic acid ethyl ester	retinoid	acne; cancer; psoriasis
tretinoin; Ro 015488/115; NSC 122758; VESANOID	Marketed	(all-E)-3,7-dimethyl- 9-(2,6,6-trimethyl-1- cyclohexen-1-y)- 2,4,6,8- nonatetraenoic acid	retinoid	acne; cancer

AM 580	Discontinued	4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]benzoic acid	retinoid agonist	psoriasis; cancer
MX 33511; MX 33511; MX 33501	Preclinical	6-(7-tricyclo[3.3.1.1,3,7]de-c-1-yl-1,3-benzodioxol-5-yl)-2-naphthalenecarboxylic acid	retinoid agonist	cancer
Iambarotene; AM 80	Discontinued	4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carboxylic acid	retinoid agonist	psoriasis; cancer
LGD 1550; ALRT 1550; LG 100550; AGN 193101; LG 1550; ALRT 550	Phase II	[all-E]-7-[3,5-bis(1,3-dimethylbutyl)phenyl]agonist	retinoid agonist; RAR agonist	cancer; skin disease
AGN 190521; LG 030106	Preliminary	5,6,7,8-tetrahydro-3,5,5,8-pentamethyl-2-naphthalenecarboxylic acid 4-carboxyphenyl ester	retinoid agonist; retinoid agonist; RAR agonist	cancer; skin disease
ER 38925	Preliminary	4-[5-(4,7-dimethyl-2-benzofuran-1-yl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RAR alpha agonist	cancer; psoriasis

ER 65250	Preliminary	4-[5-(7-ethyl-4-methyl-1- benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
ER 69029	Preliminary	4-[5-["7-fluoro-4-(trifluoromethyl)-2-benzofuranyl]-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
AGN 190121; LG 030042	Preliminary	(E)-4-[4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-1-ynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; viral infection
AGN 191379; LG 030053	Preliminary	4-[(3,4-dihydro-2,2,4,4-tetramethyl-2H-1-benzopyran-6-yl)ethynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; skin disease
bezaxotene; LGD 1069; LG 10069; LG 1069; LDG 1069; TARGETIN	Phase II	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-cthenyl]benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
LGD 1324; ALRT 324	Preliminary		retinoid antagonist; RXR agonist	diabetes; cancer
AGN 4310; ALRT 4310	Preliminary		retinoid antagonist	psoriasis; cancer
TAC 101; AM 555s	Phase I	4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid	retinoid antagonist	cancer

femreotide; HPR, 4; 4HPR; RAHA; McN R1967	Phase III	N-(4- hydroxyphenyl)retina mide	retinoid; NSAID rheumatoid arthritis; cancer
apurinic acid	Preliminary		reverse transcriptase inhibitor
P 30 protein; P 30; ONCONASE [LY 309887]	Phase III	ribonuclease (Rana pipiens reduced) (R)-N-[5-[2-(2- amino-1,4,5,6,7,8- hexahydro-4- oxopyrido[2,3- d]pyrimidin-6- y)ethyl]-2- [thienyl]carbonyl]-L- glutamic acid	HIV infection; cancer
	Phase I		ribonucleotide formyltransferase inhibitor; antifolate; antimetabolite
amidox; VF 236	Preliminary	N-[3,4- trihydroxybenzene]car boximidamide	cancer
didox; VF 147; NSC 324360	Phase II	N-[3,4- trihydroxybenzamide] reductase inhibitor	cancer; HIV infection
OCX 189; OCX 0189	Discontinued		ribonucleotide reductase inhibitor
OCX 191; OCX 0191; 3AP; TRIAPINE	Phase I	2-[(3-amino-4- methyl-2- pyridyl)methylene] hydrazinecarbothioam ide	ribonucleotide reductase inhibitor
OCX 191 prodrugs, Vion trimidox	Preliminary		ribonucleotide reductase inhibitor
	Preliminary		ribonucleotide reductase inhibitor

KW 2331	Phase II (E)-2'-fluoromethylene-2'-deoxyxytidine (FMdc)	ribonucleotide reductase inhibitor; nucleoside analogue	cancer
parabacitin	Preliminary	ribonucleotide reductase inhibitor; polyamine analogue	cancer
LGD 1268; ALRT 268	Preliminary	RXR agonist; retinoid agonist	diabetes; cancer
ALRT 620; AGN 192620; LG 100268	Preliminary	6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentanethyl-2-naphthalenyl)cyclopropyl]-3-pyridinecarboxylic acid	RXR agonist; retinoid; cancer retinoid agonist
CGP 35753	Discontinued	2-[{3-(aminoiminomethyl)phenyl}methylene]N-hydroxyhydrazinecarboximide	\$ adenosylmethionine decarboxylase inhibitor
CGP 39937	Discontinued	[2,2'-bipyridine]-6,6'-dicarboximidamide	\$ adenosylmethionine decarboxylase inhibitor
sardomozide; CGP 48664; SAM 486	Phase II	2-[4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]hydrazinecarboximide	\$ adenosylmethionine decarboxylase inhibitor
cancer therapy, Cortecs	Preliminary		signal transduction inhibitor

GW 7072	Preliminary		signal transduction inhibitor	cancer
signal transduction inhibitor, National Academy of Science	Preliminary		signal transduction inhibitor	cancer
signal transduction inhibitors, NCI	Preliminary		signal transduction inhibitor	cancer
signal transduction inhibitor, Sugen/A-Qule	Preliminary		signal transduction inhibitor	cancer; diabetes; neurological; autoimmune disease
BIBX 1382	Phase II		signal transduction inhibitor; immunosuppressant	cancer
Ianreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPtin; IPSTYL	Marketed	3-(2-naphthalenyl)-D-somatostatin analogue alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis	cancer
TT 232; TT 2-32	Preliminary	D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-L-threoninamide cyclic (2->6)-disulfide	somatostatin analogue	cancer

TT 250; TT 2-50	Preliminary	D-Phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-leucyl-L-cysteinyl-L-threoninamide cyclic (2->7)-disulfide	somatostatin analogue	cancer
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA vapreotide; octastatin; Phase II RC 160; BMY 41606	Marketed	[R-(R*,R*)]D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
stem cell inhibitor	Preliminary	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH2	somatostatin analogue; cancer; pain	cancer
BAY 129566	Phase III	(S)-4'-chloro-gamma-oxo-alpha-[(phenylthio)methyl][1,1'-biphenyl]-4-butanoic acid	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	osteoarthritis; cancer

stromelysin inhibitors, Agouron	Precclinical		stromelysin inhibitor; proteinase inhibitor, matrix metalloproteinase inhibitor, NSAID	cancer; arthritis
antagonist G; PTL 68300B	Phase I	Arg-DTrp-NMePhe-DTrp-Leu-Met-NH2	substance P antagonist; peptide; growth factor modulator	cancer
DW 2282	Precclinical		sulfonylurea; antineoplastic	cancer
LaneBase	Precclinical		target based screening	drug design technology; cancer
screening technology, Preclinical cancer, Cellomics	Precclinical		target based screening	drug design technology; cancer
screening technology, Discontinued granulocyte colony-stimulating factor mimetic	Precclinical		target based screening	drug design technology; cancer
screening technology, Preclinical human papillomavirus therapy, Harvard Medical School	Precclinical		target based screening	drug design technology; viral infection; cancer
NuMA	Precclinical		target based screening	drug design technology; cancer
screening technology, Discontinued thrombopoietin mimetic	Precclinical		target based screening	drug design technology; cancer; thrombocytopenia
screening technology, Preclinical cox-2 gene suppression	Precclinical		target based screening; biotechnology	drug design technology; inflammation; cancer

screening technology, MDR inhibitors	Preliminary	Preliminary	target based screening; drug design technology; cancer	
baccatin III derivatives, Indena	Preliminary	2aR-[2aalpha,4beta,4abeta, 9beta,9alpha,10beta,1 alpha,2aalpha,12aa pha,12balpha]-12b- (acetoxy)-12- (benzyloxy)- 1,2a,3,4,4a,6,9,10,11, 12,12a,12b- dodecahydro- 4,6,9,10,11- pentahydroxy- 4a,8,13,13- tetramethyl-7,11- methano-5H- cyclodeca[3,4]benz[1, 2-b]oxet-5-one	MDR inhibitor taxane	cancer
BMS 184476	Phase I	taxane	cancer	

BP 179	Preclinical	[2aR-[2alpha,4beta,4beta, 6beta,9,9alpha(alpha)R*, 'betaS')],11alpha,[2alpha, pha,12aalpha,[2balpha, a]]-[partial]-beta- (benzoylamino)- alpha-hydroxybenzenepropo- nic acid, 6,12b- bis(acecyloxy)-12- (benzoyloxy)-4- [[[2,3- dihydroxypropoxy)ea- phony]oxy]- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-11- hydroxy-4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodeca[3,4]hept[1,2- b]oxet-9-yl ester	taxane	cancer
--------	-------------	---	--------	--------

dihydrotaxol, 9-, 9-dihydrotaxol; TAXAN	Precinical [2aR-[2a]ph <sub>4</sub> beta, <sub>4</sub> beta, 5alpha,beta, <sub>5</sub> alpha/beta, <sub>5</sub> alphaR*, <sub>5</sub> betaS*], 11aip ha, 12alpha, [2aalpha, 11balpha]-beta-[2balpha]-beta- benzoylamino)-alpha-hydroxy- benzenepropanoic acid, 6,12b- bis(acetoxy)-12-(benzoyloxy)-12- 2a,3,4,4a,5,6,9,10,11, 12,12a,4,12b-dodecahydro-4,5,11-trihydroxy- 4a,8,13,13-tetramethyl-7,11-methano-1H-cyclohexa[3,4]benz[1,2-b]oxet-9-yl ester	[2aR- taxane cancer
drug delivery system, LDS microemulsion paclitaxel; paclitaxel	Preclinical LDS microemulsion	taxane cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Phase I IDN 5109; SB T101131	taxane cancer
paclitaxel analogues, Virginia Tech RPR 10981	Preclinical Phase I	taxane cancer

TAXOPREXIN IDX 258	Phase II		taxane	cancer
bromotaxol	Phase I		taxane	cancer
	Preclinical		taxane; microtubule assembly promoter	cancer
docetaxel; RP 56976; NSC 628503;	Marketed	beta-[[(1-dimethylethoxy)carboxyassembly promoter nylamino]-alpha-hydroxybenzenepropyl no ic acid [2aR-( [2alpha,4beta,4abeta, 6beta,9alpha[alpha]R*, betaS*)- 11alpha,12alpha,12aa [pha,12balpha]]-12b-( acetoxy)-12-( benzyloxy)- 2a,3,4a,5,6,9,10,11, 12,12a,12b-do d ecalhydro-4,6,11- trihydroxy- 4a,8,13,13-tetranethyl-5-oxo- 7,11-methano-1H-cyclodec a[3,4]benz[1,2- b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer, malaria
drug delivery system, biodegradable polymer paste	Preclinical		taxane; microtubule assembly promoter	cancer
pacitaxel; paclitaxel biodegradable polymer paste				

drug delivery system, CY TOPORTER paclitaxel	Preciinical		taxane; microtubule assembly promoter	cancer
drug delivery system, intralesional paclitaxel; paclitaxel anhydrous delivery vehicle; ADV paclitaxel; MPI 5018	Preciinical		taxane; microtubule assembly promoter	cancer
drug delivery system, Discontinued liposome paclitaxel; paclitaxel liposome			taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Preciinical		taxane; microtubule assembly promoter	cancer
drug delivery system, ONCHOLAB paclitaxel; paclitaxel ONCHOLAB	Discontinued		taxane; microtubule assembly promoter	cancer
drug delivery system, polyglutamic acid paclitaxel; paclitaxel polyglutamic acid; PG-TXL	Preciinical		taxane; microtubule assembly promoter	cancer
drug delivery system, Phase I polymer-bound paclitaxel; paclitaxel polymer-bound; PNU 166945			taxane; microtubule assembly promoter	cancer
drug delivery system, polymeric micelle paclitaxel; paclitaxel polymeric micelle	Preciinical		taxane; microtubule assembly promoter	cancer

drug delivery system, PROCYTE microsphere paclitaxel; paclitaxel PROCYTE	Preliminary		taxane; microtubule assembly promoter	cancer
drug delivery system, ReGel paclitaxel; GENEXOL	Preliminary		taxane; microtubule assembly promoter	cancer
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	Preliminary		taxane; microtubule assembly promoter	restenosis; cancer
paclitaxel; NSC 125973; BMS 181339; TAXOL; ANZATAK; YEWTAXAN	Marketed	[2aR][2aalpha,4beta,4 abeta,9beta,9alpha(al phaR*)betaS*],11beta [12alpha,12alpha,12 beta][beta- (benzoylamino)- alpha- hydroxybenzopropan oic acid 6,12b- bis(acetoxy)-12- (benzoyloxy)- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-4,11- dihydroxy- 4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodecal[3,4]benz[1, 2-b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer

paclitaxel analogue, Reading, University	Preclinical		taxane; microtubule assembly promoter	cancer
paclitaxel derivatives, EnzyMed	Preclinical		taxane; microtubule assembly promoter	cancer
polyethylene Glycol paclitaxel; PEG- paclitaxel; paclitaxel inactogol	Preclinical		taxane; microtubule assembly promoter	cancer
ZYN-LINKER conjugated paclitaxel drug delivery system, anticancer agents	Suspended		taxane; microtubule assembly promoter	restenosis; cancer
telomerase inhibitor, Telik	Preclinical		taxane; microtubule assembly promoter; DNA topoisomerase inhibitor	cancer
telomerase inhibitors, Geron	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, University of Texas Whitehead Institute for Biomedical Research	Preclinical		telomerase inhibitor	cancer
cancer therapy, Viscount Pharma	Preclinical		telomerase inhibitor;	cancer
acylfulvene, MG Pharma/Dainippon	Phase I		nucleoside analogue terpene	cancer
betaulinic acid; betulinic acid	Preclinical	(3. $\beta$ -)-3-hydroxy- lup-20(29)-en-28-oic acid	terpene	cancer
eaulerpenyne	Suspended		terpene	cancer

monoterpenes, Endorex	Precclinical		terpene	cancer
TGF beta antagonists; GLYCODesign; transforming growth factor beta antagonists	Precclinical		TGF beta antagonist; cicatrizant	cancer; viral infection; inflammation; skin ulcer
thrombospondin inhibitor, Allelix	Discontinued		thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
CV 6504	Precclinical	2,3,5-trimethyl-6-(3- pyridinylmethyl)-2,5- cyclohexadiene-1,4- dione	thromboxane antagonist; 5- lipoxygenase inhibitor	cancer
[CI] D8322; ZD 8322	Discontinued		thymidylate synthase inhibitor	cancer
ralitrexed; ralitrexed; ZD 1694; [CI] D1694; TOMIDEX	Marketed	N-[{[5-[(1,4-dihydro- 2-methyl-4-oxo-6- quinazolinyl)methyl] methylamino]-2- thienyl}carbonyl]-L- glutamic acid	thymidylate synthase inhibitor; antimetabolite	cancer
AG 250	Discontinued		thymidylate synthase inhibitor;	cancer
AG 341	Discontinued		thymidylate synthase inhibitor;	cancer
AG 394	Discontinued		thymidylate synthase inhibitor;	cancer

BW 1843U9	Suspended  Dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl]methyl)amino)-1-oxo-2-(isoindolinyl)glutaric Acid	(S)-2-(5-(((1,2-dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl]methyl)amino)-1-oxo-2-(isoindolinyl)glutaric Acid	thymidylate synthase inhibitor; antimetabolite	cancer
FTC 092	Discontinued  alpha, alpha, alpha-trifluoro-3-O-(phenylmethyl)thymidine	alpha, alpha, alpha-trifluoro-3-O-(phenylmethyl)thymidine	thymidylate synthase inhibitor; antimetabolite	cancer
metesind; AG 331	Suspended  4-[14-[[[(2-aminobenzof[cd]indol-6-yl)methylamino]methoxy]phenyl]sulfonyl]morpholine	4-[14-[[[(2-aminobenzof[cd]indol-6-yl)methylamino]methoxy]phenyl]sulfonyl]morpholine	thymidylate synthase inhibitor; antimetabolite	cancer
nolatrexed; nolatrexed dihydrochloride; AG 337; THYMITAQ	Discontinued  2-amino-6-methyl-5-(4-pyridylthio)-4(1H)-quinazolinone	2-amino-6-methyl-5-(4-pyridylthio)-4(1H)-quinazolinone	thymidylate synthase inhibitor; antimetabolite	cancer
penetrexed; penetrexed disodium; LY 231514; MTA	Phase III  N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrido[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid	N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrido[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid	thymidylate synthase inhibitor; antimetabolite	cancer

ZD 9331	Phase II Discontinued	(2S)-[4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(2-propynyl)amino]-2-fluorobenzimidol]-4-(1H-tetrazol-5-yl)butyric acid	thymidylate synthase inhibitor; antimetabolite	cancer
titanocene dichloride budotitane	Phase II Discontinued	CpTiCl <sub>2</sub> diethoxybis(1-phenyl-titanium complex); alkylating agent	titanium complex TNF inhibitor; NSAID	cancer arthritis; cancer; multiple sclerosis; retinopathy; cancer
CC 1080	Preliminary		TNF modulator; NSAID	arthritis; cancer; cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
thalidomide; BMS 205935	Phase II Marketed	N-(2,6-dioxo-3-piperidyl)phthalimide N-(2,6-dioxo-3-piperidyl)phthalimide	angiogenesis inhibitor TNF modulator; immunosuppressant	cachexia; arthritis; cancer
thalidomide; SYNOVIR; THALOMID				
CC 1069	Preliminary Discontinued	beta-(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-2H-isindole-2-propanamide	TNF modulator; NSAID	cachexia; arthritis; cancer
ERK inhibitor, Signal; fos regulating kinase inhibitor, Signal			transcription factor regulator; MAP kinase inhibitor	cancer; hypothyroidism; Paget disease; periodontal disease
NF-kappaB inhibitor, Signal	Preliminary		transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease

AP-1 inhibitor; Signal; JNK inhibitor, Signal	Preliminary		transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 104	Discontinued		triglyceride	cancer
halichondrin B	Preliminary	halichondrin B	tubulin polymerase inhibitor	cancer
NSC 654261	Preliminary		tubulin polymerase inhibitor	cancer
spongistatin 1 analogues, Hughes Institute	Preliminary		tubulin polymerase inhibitor	cancer
comfreystatin analogue	Preliminary	3,4,5-trimethoxy-N- (4-methylphenyl)benzenamine	tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
DDE 261	Preliminary	emethanamine	tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
dolastatin 10; NSC 376128	Phase I	N,N-dimethyl-L- valyl-N-[1S,2R]-2- methoxy-4-[(2S)-2- [(1R,2R)-1-methoxy- 2-methyl-3-oxo-3- [(1S)-2-phenyl-1-(2- thiazolyl)ethyl]amino [propyl]-1- pyrrolidinyl]-1-1-[1(S)- 1-methoxypropyl]-4- oxobutyl-N-methyl-L- valinamide	tubulin polymerase inhibitor; peptide	cancer

ALL-TK antagonists; acute lymphoblastic leukemia tyrosine kinase antagonists	Suspended		tyrosine kinase inhibitor	cancer
angelmixin B	Discontinued		tyrosine kinase inhibitor	cancer
BCR/ABL antagonists	Discontinued		tyrosine kinase inhibitor	cancer
CEP 2563; KT 8391	Phase I		tyrosine kinase inhibitor	cancer
CEP 701; KR 5555	Phase I		tyrosine kinase inhibitor	cancer
CEP 751; KT 6587	Suspended		tyrosine kinase inhibitor	cancer
CGP 52411	Discontinued	5,6-bis(phenylamino)-1H-isindole-1,3(2H)-dione	tyrosine kinase inhibitor	cancer
CGP 53353	Discontinued	5,6-bis[(4-fluorophenyl)amino]-1H-isindole-1,3(2H)-dione	tyrosine kinase inhibitor	cancer
CGP 57148; CGP 57148B	Phase I	4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-pyridinyl)-2-pyridinyl]amino]phenyl-benzamide	tyrosine kinase inhibitor	cancer
FGF-1 receptor inhibitors, Park Davis/Auckland University	Preclinical		tyrosine kinase inhibitor	cancer

GW 282974; GW 974	Preclinical	N6,N6-dimethyl-N4-[1-(phenylmethyl)-1H-indazol-5-yl]pyrido[3,4-d]pyrimidine-4,6-diamine monohydrochloride	tyrosine kinase inhibitor	cancer
LFM A13	Preclinical		tyrosine kinase inhibitor	cancer
Met tyrosine kinase antagonist	Preclinical		tyrosine kinase inhibitor	cancer
PD 157655	Preclinical		tyrosine kinase inhibitor	cancer
PD 158294	Preclinical		tyrosine kinase inhibitor	cancer
PD 158780	Preclinical	N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine	tyrosine kinase inhibitor	cancer
PD 164199	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer, atherosclerosis, restenosis
PD 164771	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer, atherosclerosis, restenosis

PD 166285	Preclinical	6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]phenyl]anino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 167978	Preclinical		tyrosine kinase inhibitor	cancer
PD 173956	Preclinical		tyrosine kinase inhibitor	cancer
SU 101	Phase II	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	tyrosine kinase inhibitor	cancer
SU 101 analogues	Preclinical		tyrosine kinase inhibitor	cancer
SU 102	Preclinical		tyrosine kinase inhibitor	cancer
SU 65847	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Cephalon	Discontinued		tyrosine kinase inhibitor	benign prostate hypertrophy; cancer
tyrosine kinase inhibitors, Novartis	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, XenoVa	Discontinued		tyrosine kinase inhibitor	cancer
ZD 4190	Preclinical		tyrosine kinase inhibitor	cancer

SU 1433	Discontinued	4-(6,7-dimethyl-2-quinoxaliny)-1,2-benzendiol	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
SU 1498	Discontinued	(E)-2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-2-propenamide	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
CGP 59326A	Phase I	N-(3-chlorophenyl)-5,6-dimethyl-1H-pyrrolo[2,3-d]pyrimidin-4-amine monohydrochloride	tyrosine kinase inhibitor; EGFR receptor inhibitor	cancer
CP 358774	Phase II	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinanine	tyrosine kinase inhibitor; EGFR receptor inhibitor	cancer
PD 153055	Preclinical	N-(3-bromophenyl)-6,7-dimethoxy-4-quinazolinamine	tyrosine kinase inhibitor; EGFR receptor inhibitor	cancer
PD 183805; CI 1033	Preclinical		tyrosine kinase inhibitor; EGFR receptor inhibitor	cancer
ZD 1839	Phase I		tyrosine kinase inhibitor; EGFR receptor inhibitor	cancer
tyrosine kinase inhibitors, AstraZeneca	Discontinued		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
WHIP131	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer

WHI P154	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
DAB 720	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
PD 169540	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	cancer
BML0V	Discontinued	bis(maltolato) oxovanadium	tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	cancer
	Discontinued		tyrosine phosphatase inhibitor	cancer
cancer-associated protein tyrosine phosphatase inhibitor, Ontogen			tyrosine phosphatase inhibitor	cancer
AG 213; RG 50964; RG 50864 (no stereo)	Phase I	(E)-2-cyano-3-(3,4-dihydroxyphenyl)-2-propenoic acid	tyrophostin	psoriasis; cancer; atherosclerosis
AG 555	Preclinical	(2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenoic acid	tyrophostin	psoriasis; cancer; atherosclerosis
tyrophostins	Preclinical		tyrophostin	psoriasis; cancer; atherosclerosis; septic shock
AG 490	Discontinued	(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenoic acid	tyrophostin; tyrosine kinase inhibitor	cancer

UBC inhibitors, Mitox; ubiquitin conjugating enzyme inhibitors	Preliminary		ubiquitin conjugating enzyme inhibitor;	cancer; inflammation
urate oxidase; SR 29142	Phase II			
epatoloprost; epataprost; Discontinued ZK 97959	3aS-[2E,3aalfa,4alfa(3R*, 4R*)Shea,6aalfa]-4- (2-hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-noradiynyl- 2(1H)- pentalenylidene)ethoxy- ybutanedioic acid	ureate oxidase; biotechnology; enzyme	vasodilator; prostanoid; thrombosis; peripheral vascular disease; cancer	gout; cancer
SR 49059	Phase II	[2R- 2alfa(S*),3beta]-1- [[5-chloro-3-(2- chlorophenyl)-1- [[3,4- dimethoxyphenyl]sulf- onyl]-2,3-dihydro-3- hydroxy-1H-indol-2- yl]carbonyl]-2- pyrrolidinecarboxami- de	vasopressin antagonist; gynaecological; diuretic	vasopressin antagonist; gynaecological; cancer; hypertension; heart failure; emesis
VRCIC 310 anhydrovinblastine	Preliminary Phase I	Unspecified 3',4'-dihydro-4'- deoxyvincalukoblast ine	venom vinca alkaloid	cancer cancer

drug delivery system, liposome vincristine; vincristine liposome; VincaXome	Preliminary		vinca alkaloid	cancer
drug delivery system, ONCHOLAB vincristine; vincristine	Discontinued		vinca alkaloid	cancer
drug delivery system, STEALTH liposome vincristine; vincristine STEALTH	Preliminary		vinca alkaloid	cancer
drug delivery system, vinblastine; Therapeutic Implant; MPI 5017	Discontinued		vinca alkaloid	cancer
drug delivery system, vincristine; vincristine drug delivery system; Onco TCS	Phase II		vinca alkaloid	cancer
vinflunine; F 12158; L 0070	Phase I	4'-deoxy-20'-20'-difluoro-C-norvincaleukoblastine	vinca alkaloid	cancer
vinorelbine;	Marketed	3',4'-dihydro-4'-deoxy-C-norvincaleukoblastine	vinca alkaloid	cancer
vinorelbine tartrate; PM 259; DC 1; KW 2307; BW 7Y89; KW 3407; NAVELBINE; EUNADES; NABELBIN				

vinxaline; S 12363	Phase I  superactive vasoactive intestinal peptide antagonist, NCI	[3(S)]-O4-deacetyl-3-[dimethoxycarbonyl]-microtubule assembly inhibitor  2-methyl[prolyl]amino]carbonylvincaleukoblastine	vinca alkaloid; cancer
LR 103	Precclinical  Pre-registration	VIP antagonist  vitamin D analogue  vitamin D2 analogue	cancer  osteoporosis; hyperparathyroidism cancer
HECTOROL			
CB 1267	Discontinued	[1R-[1alpha(R*)],3beta,4E(1R*,3S*,5Z),7alpha]-4-methylene-5-[octahydro-7a-methyl-1-[1-methyl-2-[[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentenyl]oxy]ethyl]-4H-inden-4-ylidene]ethyliidene]-1,3-cyclohexanediol	vitamin D3 analogue  cancer

ILX 237553; ILX 23-7553	Preliminary	1,25(OH)2-16ene-23yne 26,27-hexafluorovitamin D3	vitamin D3 analogue	cancer
seocalcitrol; EB 1089	Phase II	1(S),3(R)-dihydroxy-20(R)-[5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl]-9,10-secopregn-5(Z),7(E),10(19)-triene	vitamin D3 analogue	cancer
solverol; PRI 11901	Phase I	(IR,3S,5Z)-4-methylene-5-[{(2E)-[(1R,3S,7aR)-octahydro-1-[(1R,5E)-7-hydroxy-1,7-dimethyl-5-octenyl]-7a-methyl-4H-inden-4-ylidene]ethylidene}-1,3-cyclohexanedio]-	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

Table 25. Current Candidate Therapeutic Interventions for the Treatment of ALS

Product Name	Chemical Name	Action	Indication
EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethylbenzenesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	Neurodegeneration; depression; cancer
AMPA antagonists	Unspecified	AMPA antagonist; glutamate antagonist	Neurodegeneration; eye disease
SPD 502; NS 1209	2-[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
pirfenidone; MAR 01; AMR 69; DESKAR	5-methyl-1-phenyl-2(1H)-pyridinone	antifibrotic	skin disease; pulmonary fibrosis; neurodegeneration
dehydroascorbic acid	Unspecified	antioxidant	neurodegeneration; neurological
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues	Unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	neurodegeneration

neurodegeneration therapy	unspecified	apoptosis inhibitor	neurodegeneration; amyotrophic lateral sclerosis
apoptosis modulators	Unspecified	apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
apoptosis inhibitors	Unspecified	apoptosis inhibitor; peptide	neurodegeneration
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
cardiotrophin-1 secreting implant	Unspecified	Cardiotrophin-1 agonist	amyotrophic lateral sclerosis; neurodegeneration
caspase inhibitors	Unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
CPP32 inhibitors, caspase 3 inhibitors,	unspecified	caspase inhibitor; apoptosis inhibitor	neurodegeneration
creb gene transcription modulators, CNS disorders	Unspecified	Creb gene transcription modulation	neurodegeneration; Alzheimer disease
Neurotransmitter transporter modulators	Unspecified	Excitatory amino acids transporter function	neurodegeneration
batyl alcohol; CPR 4001	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
chimyl alcohol; CPR 4004	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
free radical scavengers	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
growth and differentiation factor-1; GDF-1	Unspecified	GDF-1 agonist	neurodegeneration
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain

Excitatory amino acid antagonists	Unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
2-PMPA; GPI 5000	Unspecified	glutamate release inhibitor	stroke; neurodegeneration
NZ 093	Unspecified	IGF-1	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor-1; IGF-1	Unspecified	IGF-1 agonist	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor binding protein ligand inhibitors	Unspecified	IGFBP ligand inhibitors	stroke; neurodegeneration
ICE inhibitors	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor	neurodegeneration
Neurodegenerative disease therapy	Unspecified	Immunomodulation, peptide mediated	neurodegeneration
MKK4 modulators	Unspecified	MAP kinase inhibitor; signal transduction inhibitor, NSAID	inflammation; neurodegeneration
Melatonin analogue	Unspecified	Melatonin agonist	neurodegeneration
Neurodegenerative disease therapy	Unspecified	monoclonal antibody immunomodulation	neurodegeneration; Alzheimer disease
neural progenitor regulatory factor	Unspecified	Neural progenitor regulation, growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
Neuroimmunophilin ligands	Unspecified	Neuroimmunophilins, growth factor; neurotrophic factor	neurodegeneration
Neuroimmunophilins	Unspecified	neurotrophic factor	neurodegeneration
nerve growth factor secreting implant	Unspecified	NGF agonist	neurodegeneration; neuropathy
nerve growth factor mimetics	Unspecified	NGF mimetics	neurodegeneration

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Telomerase activators	Unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
Neurotropin-4/5 secreting implant; NT-4/5 implant	Unspecified	NT-4/5 agonist	neurodegeneration; neuropathy; amyotrophic lateral sclerosis; eye disease
Synthetic opioid alkaloids	Unspecified	Opioid agonists	neurodegeneration
prion inhibiting peptides	Unspecified	Prion inhibition	neurodegeneration
taltirelin; TA 0910; CEREDIST	(S)-N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide	Protirelin analogue	neurodegeneration
telomere modulators	Unspecified	Telomere modulation	neurodegeneration; atherosclerosis; arthritis
NZ 097	Unspecified	TGF- $\beta$ agonist	brain ischemia; trauma; stroke; neurodegeneration
Transforming growth factor beta; TGFbeta	Unspecified	TGF- $\beta$ agonist	brain ischemia; trauma; stroke; neurodegeneration
CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease

Table 26. Current Candidate Therapeutic Interventions for the Treatment of Anxiety

Product Name	Chemical Name	Action	Indication
CGS 12066	4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)pyrrololo[1,2-a]quinoxaline	5HT agonist	anxiety
umespirone; KC 7218; KC 9172	3-butyl-7-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone	5HT agonist	anxiety
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
alnespirone; S 20499	(+)-8-[4-[(3,4-dihydro-5-methoxy-2H-1-benzopyran-3-yl)propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione	5HT agonist; 5HT1A agonist	anxiety
EMD 67478		5HT agonist; 5HT1A agonist	anxiety
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
gepirone; gepirone hydrochloride; MJ 13805; BMY 13805; BMY 138051	4,4-dimethyl-1-[4-[2-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression

ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	depression; anxiety
lesopitron; E 4424	2-[4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine dihydrochloride	5HT agonist; 5HT1A agonist	anxiety
LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
MKC 242	(S)-N-[3-(1,3-benzodioxol-5-yloxy)propyl]-2,3-dihydro-1,4-benzodioxin-2-methanamine, hydrochloride	5HT agonist; 5HT1A agonist	anxiety
S 14506	4-fluoro-N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride	5HT agonist; 5HT1A agonist	anxiety
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
SUN 8399	2,3,4,5-tetrahydro-4-(4-(4-(2-pyrimidinyl)piperazin-1-yl)butyl)-1,4-benzoxazepine-3,5-dione hydrochloride	5HT agonist; 5HT1A agonist	anxiety; emesis
Tandospirone; metanopirone; SM 3997; SEDIEL	3alpha,4beta,7beta,7aa,1fa-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-methano-1H-isoindole-1,3(2H)-dione	5HT agonist; 5HT1A agonist	anxiety
U 92016A		5HT agonist; 5HT1A agonist	anxiety; depression

U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
SL 870765		SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decaene-1-carboxamide	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
S 213571; S 21357-1	3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-6-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]-2(3H)-benzothiazolone trihydrochloride	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety
sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	SHT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
SB 236057		SHT agonist; 5HT1B agonist	anxiety
LY 293284	(R)-1-[4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indol-6-yl]ethanone	SHT agonist; 5HT1D agonist	anxiety

ICI 190622	4-amino-1-(3-pentyanyl)-N-2-propenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide	SHT antagonism	anxiety
SHT1B antagonists		SHT antagonist	depression; anxiety
BMY 7378	8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride	SHT antagonist	anxiety
DU 123015		SHT antagonist	anxiety; depression
DU 125530		SHT antagonist	depression; anxiety; psychosis
ICI 170809	N,N,2-trimethyl-1-[(3-phenyl-2-quinoliny)thio]-2-propanamine monohydrochloride	SHT antagonist	anxiety
RS 42358; RS 42358197	(S)-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1H-benz[de]isoquinolin-1-one monohydrochloride	SHT antagonist	anxiety; emesis
seganserin; R 56413	3-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one	SHT antagonist	anxiety
serazapine; CGS 15040A	1,3,4,16b-tetrahydro-2-methyl-2H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4]benzodiazepine-16-carboxylic acid methyl ester	SHT antagonist	anxiety

5-HT antagonist; pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	5HT antagonist; SHT1A antagonist	anxiety; depression
Anxiolytic	(S)-5,6,6a,7-tetrahydro-6,10-dimethyl-4H-dibenzo[de,g]quinolin-11-ol	5HT antagonist; SHT1A antagonist	anxiety
Binospirone; binospirone mesylate; MDL 73005EF	8-[2-[(2,(3-dihydro-1,4-benzodioxan-2-yl)methyl]amino]ethyl]-8-azaspiro[4.5]decan-7,9-dione	5HT antagonist; SHT1A antagonist	anxiety
F 8910RS		5HT antagonist; SHT1A antagonist	anxiety
Rabalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	5HT antagonist; SHT1A antagonist	anxiety; depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	5HT antagonist; SHT1A antagonist	anxiety; depression
SDZ 216525; SDZ 216-525	methyl 4-[4-[4-(1,1,3-trioxo-2H-1,2-benzisothiazol-2-yl)butyl]-1-piperazinyl]-1H-indole-2-carboxylate	5HT antagonist; SHT1A antagonist	anxiety
UH 301	(+,-)-7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydro-1-naphthalenol	5HT antagonist; SHT1A antagonist	anxiety

WAY 100135	N-(1,1-dimethylethyl)-4-(2-methoxyphenyl)-alpha-phenyl-1-piperazinepropanamide	SHT antagonist; SHT1A antagonist	anxiety
WAY 100635	N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexane carboxamide trihydrochloride	SHT antagonist; SHT1A antagonist	anxiety
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
drug delivery system, transdermal buspirone; buspirone transdermal		SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder
CR 1909		SHT antagonist; SHT2 antagonist	anxiety
Glemanserin; MDL 11939	(+,-)-alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol	SHT antagonist; SHT2 antagonist	anxiety
ritanserin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	SHT antagonist; SHT2 antagonist	addiction; anxiety; schizophrenia
CGS 18102	trans-10-methoxy-4-propyl-1,3,4,4a,5,10b-hexahydro-2H-(1)benzopyrano(3,4-b)pyridine	SHT antagonist; SHT2 antagonist; SHT agonist; SHT1A agonist	anxiety

HT 90B	(-)-N-[2-[[[(2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.13,7]decane-1-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety; depression
Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Deramciclane; EGIS 3886; EGYT 3886	(1R-exo)-N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo[2.2.1]hept-2-yl)oxy]-ethanamine	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	anxiety
Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
EGIS 8465		5HT antagonist; 5HT2C antagonist	anxiety
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 200646A	N-(1-methyl-1H-indol-5-yl)-N'-(3-pyridinyl)urea monohydrochloride	5HT antagonist; 5HT2C antagonist	anxiety
SB 228357	N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
ADR 851	(S)-4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-7-benzofurancarboxamide monohydrochloride	5HT antagonist; 5HT3 antagonist	anxiety; emesis

Antidepressant		5HT antagonist; SHT3 antagonist	depression; anxiety
itasetron; DAU 6215; DAU 6215CL; DA 6215; U 98079; U 98079A	endo-2,3-dihydro-N- (8-methyl-8- azabicyclo[3.2.1]oct- 3-yl)-2-oxo-1H- benzimidazole-1- carboxamide	5HT antagonist; SHT3 antagonist	emesis; anxiety
ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3- dimethyl-N-(8- methyl-8- azabicyclo[3.2.1]oct- 3-yl)-1H-indole-1- carboxamide	5HT antagonist; SHT3 antagonist	anxiety; schizophrenia; emesis
tropisetron; ICS 205930; NAVOBAN	1H-indole-3- carboxylic acid endo- 8-methyl-8- azabicyclo[3.2.1]oct- 3-yl ester	5HT antagonist; SHT3 antagonist	emesis; anxiety
VA 21B7	2-[(4-piperonyl)-1- piperazinyl]-3- indolecarboxaldehyde	5HT antagonist; SHT3 antagonist	anxiety
WAY 100289; WY 100289	(endo)-N-[[8-aza-8- methylbicyclo[3.2.1]o- ctan-3- yl)amino]carbonyl]- 2- (cyclopropylmethoxy )benzamide	5HT antagonist; SHT3 antagonist	anxiety
WAY 100579; SEC 579	endo-1-cyclohexyl- 1,4-dihydro-N-(8- methyl-8- azabicyclo[3.2.1]oct- 3-yl)-4-oxo-3- quinolinecarboxamid e (Z)-2-butenedioate	5HT antagonist; SHT3 antagonist	anxiety
zacopride; zacopride hydrochloride; ZAP; AHR 11190B; AHR 11190; MD 78027	4-amino-N-1- azabicyclo[2.2.2]oct- 3-yl-5-chloro-2- methoxy-benzamide	5HT antagonist; SHT3 antagonist	anxiety; emesis

zatosetron; LY 277359	endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide	SHT antagonist; 5HT3 antagonist	emesis; anxiety
SB 204070	8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylic acid (1-butyl-4-piperidinyl)methyl ester	SHT antagonist; 5HT4 antagonist	anxiety; irritable bowel syndrome
SC 56184		SHT antagonist; SHT4 antagonist	anxiety
THE JL3; JL 3	10-(4-methyl-1-piperazinyl)-pyrido[4,3-b][1,4]benzothiazepine	SHT antagonist; dopamine antagonist	anxiety; depression
fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMELE	5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-(2-aminoethyl)oxime	SHT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAK; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine	SHT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4- dichlorophenyl)- 1,2,3,4-tetrahydro-N- methyl-1-naphthal eneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2- (dimethylamino)-1- (4- methoxyphenyl)ethyl] cyclohexanol	5HT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
ST 1112	2-acetyl-5-(4- methoxyphenyl)-3- oxo-1,2,4-triazine	SHT1/SHT2 ligand	anxiety
L 0068; F 11440	4-methyl-2-[4-[4-(2- pyrimidinyl)-1- piperazinyl]butyl]- 1,2,4-triazine- 3,5(2H,4H)-dione	SHT1A agonist; SHT agonist	anxiety; depression
OPC 14523	1-[3-[4-(3- chlorophenyl)-1- piperazinyl]propyl]- 3,4-dihydro-5- methoxy-2(1H)- quinolinone	SHT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 92502CN	Unspecified	SHT1A ligand	anxiety
EGIS 9933	2-(2-[N-(3- trifluoromethyl- benzyl)-N- piperazinyl]ethyl)mer- capto-4,6-diamino-5- (2-methoxy-benzyl)- pyrimidine hydrochloride	SHT2C antagonist; 5HT antagonist	anxiety
SB 243213	2,3-dihydro-5- methyl-N-[(6-[(2- methyl-3- pyridinyl)oxy]-3- pyridinyl]-6- (trifluoromethyl)-1H- indole-1-carboxamide	SHT2C antagonist; 5HT antagonist	depression; anxiety

zalospirone; WY 47846	(3aalpha,4beta,4aalpha,6aalpha,7beta,7aalpha)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphoryloxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
drug delivery system; adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'- (1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia
gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
AIT 084		antispasmodic	anxiety
alpidem; SL 80034200; ANANXYL	6-chloro-2-(4-chlorophenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-acetamide (imidazopyridine)	Anxiolytic activity with unspecified mechanism of action	anxiety

Anxiolytic	Ketoisoxalidine derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
AP 521	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 181100	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 184111	Unspecified	Anxiolytic activity with unspecified mechanism of action	Anxiety
CEB 1128	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1342	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1459	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CGS 13767	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CL 870704	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CNS 3	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
Co 2-6749; Co 26749	Synthetic epalons	Anxiolytic activity with unspecified mechanism of action	anxiety
transmucosal etomidate	Etomidate derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
transdermal buspirone;	Buspirone	Anxiolytic activity with unspecified mechanism of action	anxiety
dulozafone; dicozafone; F 1933	2-[bis(2-hydroxyethyl)amino]-N-[4-chloro-2-(chlorobenzoyl)phenyl]-N-methylacetamide	Anxiolytic activity with unspecified mechanism of action	anxiety

enciprazine; D 13112; WY 48624	(+,-)-4-(2-methoxyphenyl)-alpha-[(3,4,5-trimethoxyphenoxy)methyl]-1-piperazineethanol	Anxiolytic activity with unspecified mechanism of action	anxiety
etizolam; Y 7131; DEPAS; PASADEN	4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	Anxiolytic activity with unspecified mechanism of action	anxiety
F 2692	3-amino-6-methyl-1-[3-(trifluoromethyl)phenyl]-4(1H)-pyridazinone	Anxiolytic activity with unspecified mechanism of action	anxiety
mexidol	2-ethyl-6-methyl-3-hydroxypyridine succinate	Anxiolytic activity with unspecified mechanism of action	anxiety; cognitive defect
rilapine	(Z)-2-chloro-10-(4-methyl-1-piperazinyl)-5H-dibenzo[a,d]cycloheptene-delta5,alfa-acetonitrile	Anxiolytic activity with unspecified mechanism of action	anxiety
SC 48274; BTG 1501	3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione hydrochloride	Anxiolytic activity with unspecified mechanism of action	anxiety
sultopride; sultopride hydrochloride; LIN 1418; DAN 2163; BARNETIL	N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide	Anxiolytic activity with unspecified mechanism of action	anxiety
suricline; RP 31264; RP 006; SURIL	4-methyl-1-piperazinecarboxylic acid ester with 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxy-5H-1,4-dithiino[2,3-c]pyrrol-5-yl	Anxiolytic activity with unspecified mechanism of action	anxiety

TAS 401	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine	Benzodiazepine	epilepsy; anxiety
AD 8152 adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
AHR 14749	5-chloro-N,N-dimethyl-2-(4-methylphenyl)-3H-imidazo[4,5-b]pyridine-3-acetamide	benzodiazepine	anxiety
CGS 20625	5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one	benzodiazepine	anxiety
clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
drug delivery system, intranasal benzodiazepines; benzodiazepine intranasal delivery system		benzodiazepine	anxiety; insomnia

drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
EGIS 5278	3-amino-4-ethylthio- 7-chloro-quinolone hydrochloride	benzodiazepine	anxiety
EGIS 8858	5-[2-(4- fluorophenyl)ethenyl]- 8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin e	benzodiazepine	anxiety
girisopam; EGIS 5810; GYKI 51189	1-(m-chlorophenyl)- 7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepine	benzodiazepine	anxiety
midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2- fluorophenyl)-1- methyl-4H- imidazo[1,5- a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
nerisopam; EGIS 6775; GYKI 52232	4-(7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepin-1-yl)- benzenamine	benzodiazepine	anxiety
panadiplon; U 78875; FG 10571	3-(5-cyclopropyl- 1,2,4-oxadiazol-3-yl)- 5-(1-methylethyl)- imidazo[1,5a]- quinoxalin-4(5H)-one	benzodiazepine	anxiety
RU 32759	[6-ethyl-5-methyl-7- (methylthio)imidazo[ 1,2-a]pyrimidin-2- yl]phenylmethanone	benzodiazepine	anxiety

tofisopam; EGYT 341; MER 19; MER 1961; GRANDAXIN; SERIEL; ISOTAN	1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine	benzodiazepine	anxiety; skin disease
abecarnil; ZK 112119; FG 7516; NNC 157516; SH 524; LADOTEC	4-(methoxymethyl)-6-(phenylmethoxy)-9H-pyrido[3,4-b]indole-3-carboxylic acid, 1-methylethyl ester	benzodiazepine partial agonist	anxiety
FG 8119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	anxiety
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
ICI D7569		benzodiazepine partial agonist	anxiety
imidazenil; FGIN 2073; FID 02023; Ro 231412	6-(2-bromophenyl)-8-fluoro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxamide	benzodiazepine partial agonist	anxiety
Ro 198022	(R)-1-((10-chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidine-methanol	benzodiazepine partial agonist	anxiety
saripidem; SL 850274	N-[[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-N-methylbutyramide	benzodiazepine partial agonist	anxiety

Y 23684	2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepine[5,4-c]pyridazin-3(2H)-one 7-oxide	benzodiazepine partial agonist	anxiety
5HT4 human neuroreceptor; neuroreceptor, 5HT4		biotechnology	irritable bowel syndrome; cognitive deficit; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2622	[R-(R*,S*)]-4-[[5-(8-azaspiro[4.5]dec-8-yl)-4-[(3,5-dichlorobenzoyl)amino]o]-1,5-dioxopentyl]amino]-5-(1-naphthalenylamino)-5-oxo-pentanoic acid	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
GV 150013	(R)-N-phenyl-N'-[2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]urea	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2345	N-[1-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4-(4-methyl-1-piperazinyl)-4-oxobutyl]-3,5-dichlorobenzamide monohydrochloride	cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	anxiety; gastrointestinal ulcer; bacterial infection

CR 2945		cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	gastrointestinal ulcer; anxiety
L 740093	(R)-N-[5-(3-azabicyclo[3.2.2]nona-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea monohydrochloride	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 134308; CI 988	[R-(R*,R*)]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[tricyclo[3.3.1.1sup.3,7]dec-2-yl]oxy]carbonyl]aminol]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 135158	[1S-[1alfa,2beta[S*(S*)],4alfa]]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[[(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)oxy]carbonyl]aminol]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid cmpd with meglumine (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety

PD 145942	[2-[(hexahydro-1H-azepin-1-yl)amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamic acid tricyclo[3.3.1.13,7]dec-2-yl ester	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF2 antagonists		CRF antagonist	depression; anxiety
NBI 27914	5-chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine	CRF antagonist	anxiety
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
corticotropin releasing factor analogue	Unspecified	CRF ligand	anxiety; depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
RP 60503	4-(acetylamino)butanoic acid 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl ester	Cyclic GMP modulation	anxiety
CCD 2034		GABA agonist	anxiety
GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
RWJ 38293	1,2,3,5-tetrahydro-3-oxo-N-4-pyridinylpyrido[1,2-a]benzimidazole-4-carboxamide	GABA agonist	anxiety
U 91571	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethylimidazo[1,5-a]quinoxaline-5(4H)-carboxamide	GABA antagonist	anxiety
U 94625		GABA antagonist	anxiety

ocinaplon; CL 273547	2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	GABA modulation	anxiety
pazinaclone; DN 2327; A 77000	8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-1,4-dioxa-8-azaspiro[4.5]decane	GABA modulation	anxiety
Anxiolytics		GABA modulator	anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(morpholinyl)-2H-imidazol-2-on e	GABA modulator	epilepsy; anxiety
NGD 911; CP 409092		GABA modulator	anxiety
NGD 912; NGD 91-2		GABA modulator	anxiety
NGD 913; NGD 91-3		GABA modulator	anxiety
NS 2552		GABA modulator	anxiety; epilepsy
NS 2608		GABA modulator	epilepsy; anxiety
NS 2710; ME 3127		GABA modulator	anxiety
pagoclone; IP 456; RP 62955; (+)-RP 59037	(+)-2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA modulator	anxiety
RWJ 53050		GABA partial agonist	anxiety
U 101017; PNU 101017	cis-7-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]imidazo[1,5-a]quoline-3-carboxylic acid 1,1-dimethylethyl ester	GABA partial agonist	anxiety
RP 59037	2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA partial agonist; benzodiazepine partial agonist	anxiety
SNAP 5258	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5294	Unspecified	GAT2 transporter	epilepsy; anxiety; insomnia

ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-amino-1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
HA 966	3-amino-1-hydroxy-2-pyrrolidone	glutamate antagonist; NMDA antagonist	anxiety
LY 354740	(1alpha,2beta,5alpha,6alpha)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid	glutamate release inhibitor	anxiety; nicotine withdrawal
hBGT1 transporter modulator	Unspecified	HBGT1 transporter modulator	epilepsy; anxiety; insomnia
GT 5140		histamine agonist; histamine H3 agonist	insomnia; anxiety
Methylhistamine, R-alpha; BP 2.94		histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
CNS disorder modifiers	Unspecified	Ion channel modification	anxiety; schizophrenia; depression
Befloxatone; MD 370503	(R)-5-(methoxymethyl)-3-(p-((R)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
BW 1370U87	1-ethylphenoxythiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
Co 6-0549; Co 60549		neuroactive steroid	anxiety
MEN 10376		neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CGP 60829		neurokinin antagonist; neurokinin 1 antagonist	anxiety

GR 100679	N-(cyclohexylcarbonyl)glycyl-L-alanyl-D-tryptophyl-N,N-dimethyl-L-phenylalaninamide	neurokinin antagonist; neurokinin 2 antagonist	anxiety
MEN 10207		neurokinin antagonist; neurokinin 2 antagonist	anxiety
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
Neuropeptide Y antagonists		neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
MDL 105519	(E)-3-(2-carboxy-2-phenylethethyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
SNAP 1156		peptide	anxiety; hypertension; obesity; addiction
LU 28179	1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]spiro[isobenzofuran-1(3H),4'-piperidine]	Sigma ligand	anxiety
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis

vasopressin antagonist		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
------------------------	--	----------------------------------	---

Table 27. Current Candidate Therapeutic Interventions for the Treatment of Dementia

Product Name	Chemical Name	Action	Indication
SR 57746; SR 57746A	1,2,3,6-tetrahydro-1-[2-(1-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine	SHT agonist; 5HT1A agonist; growth factor modulator	Alzheimer disease; neuropathy
AP 159	N-cyclohexyl-1,2,3,4-tetrahydro-[1]benzothieno[2,3c]pyridine-3-carboxamide monohydrochloride	SHT antagonist; 5HT1A antagonist	cognitive defect
SL 880338		SHT antagonist; 5HT1A antagonist	cognitive defect
GYKI 46903	(1R-endo)-6-(4-fluorophenyl)-1-azabicyclo[3.3.1]non-6-en-4-ol propanoate hydrochloride	SHT antagonist; 5HT3 antagonist	cognitive defect
Ondansetron; GR 38032; GR 38032F; SN 307; ZOFTRAN; ZOPHREN; ZOFRON	1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one	SHT antagonist; 5HT3 antagonist	emesis; cognitive defect
FG 7080	trans-(-)-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]piperidine hydrochloride	SHT reuptake inhibitor	cognitive defect
Fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	SHT reuptake inhibitor	migraine; cognitive defect; depression

Indeloxazine; ideloxazine; YM 08054; CI 874; ELEN; NOIN	(+,-)-2-[(indel-7- yloxy)methyl]morpho- line	5HT reuptake inhibitor	cognitive defect
NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
SM 3163	3-((1,5- diphenylpentyl)oxy)- N,N-dimethyl-1- propanamine citrate	5HT reuptake inhibitor; vasodilator	cognitive defect; cerebrovascular disease
FK 960	N-(4-acetyl-1- piperazinyl)-4- fluorobenamide	SHT, somatostatin	Alzheimer disease
SL 650102; SL 65.0102	(-)-8-amino-7-chloro- N-(1,4- diazabicyclo[2.2.2]oc- t-2-ylmethyl)-2,3- dihydro-1,4- benzodioxin-5- carboxamide dihydrochloride	SHT4 agonist; 5HT agonist	Alzheimer disease
SHT4 human neuroreceptor		SHT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2- [[hydroxy(4- phenylbutyl)phosphinyl] oxy]-1-oxohexyl]- L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
Alzheimer's disease therapy	1-[3,4- (methylenedioxy)ben- zoyl]-3-[2-(1-benzyl- 4- piperidinyl)ethyl]thio urea	Acetylcholinesterase inhibitor	Alzheimer disease
NBI 117	Extracellular portion of activin receptor (soluble)	Activin soluble portion of receptor	Alzheimer disease
AD7C-NTP modulators, Alzheimer disease		AD7C-NTP modulation	Alzheimer disease

KF 15372	8-(3-dicyclopethylmethyl)-1,3-dipropylxanthine	adenosine antagonist	cognitive defect
KFM 19	3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	Alzheimer disease
MDL 102234	(R)-3,7-dihydro-8-(1-phenylpropyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
MDL 102503	(R)-3,7-dihydro-8-(1-methyl-2-phenylethyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
apaxifylline; BIIP 20XX; U 98950; BIIP 20	(S)-3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl 1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist; xanthine	cognitive defect
MAb, adrenomedullin	Unspecified	adrenomedullin monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
Alzheimer's disease therapy		Alpha 2 macroglobulin inhibitor	Alzheimer disease
RU 49041; RU 49067	(3alpha)-(+,-)-11-methyl-20,21-dinoreburnamene	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
RU 52583	(3alpha)-11-methyl-20,21-dinoreburnamene	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
NS 1201		AMPA antagonist; glutamate antagonist	cognitive defect
NS 377	7-ethyl-1,6,7,8-tetrahydro-5-phenylbenzo[2,1-b:3,4-c']dipyrrrole-2,3-dione 3-oxime	AMPA antagonist; glutamate antagonist	cognitive defect

NS 420	4-[2,3,6,7,8,9-hexahydro-3-(hydroxyimino)-8-methyl-2-oxo-1H-pyrrolo[3,2-h]isoquinolin-5-yl]-N,N-dimethylbenzenesulfonamide	AMPA antagonist; glutamate antagonist	cognitive defect
S 18986; S 18986-1	(S)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide	AMPA antagonist; glutamate antagonist	cognitive defect
CX 691	Unspecified	AMPA glutaminergic receptor ligand	Alzheimer disease; schizophrenia
amyloid aggregation inhibitors	Unspecified	amyloid aggregation inhibitors	Alzheimer disease
antiamyloid	Unspecified	Amyloid antagonists	Alzheimer disease
GT 4001	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4002	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4003	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4011	Unspecified	Amyloid b destruction	Alzheimer disease
GT 5011	Unspecified	Amyloid b destruction	Alzheimer disease
PTI 00703	Cats claw extract	Amyloid b protein deposition inhibitor	Alzheimer disease
amyloid enzyme inhibitors,	Unspecified	amyloid enzyme inhibitors	Alzheimer disease
amyloid inhibiting peptides	Unspecified	amyloid inhibiting peptides	Alzheimer disease
amyloid neurotoxicity antagonists,	Unspecified	amyloid neurotoxicity antagonists,	Alzheimer disease
CX 423	Unspecified	Amyloid neurotoxicity antagonist	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease; diabetes

FID 072021	3-atropanyl 2-(4-chlorophenoxy)butyrate maleate	analgesic	pain; cognitive defect
galanin modulators	Unspecified	galanin modulators analgesic	obesity; diabetes; cognitive defect; pain
galanin1 antagonists	Unspecified	galanin1 antagonists analgesic	obesity; pain; cognitive defect
metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
anatoxin analogue, prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	Unspecified (3beta)-3-hydroxyandrost-5-en-17-one	Anatoxin androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	Alzheimer disease systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
nootropic,	2-(4-allyl-1-piperazinyl)-4-pentyloxyquinazoline	antihypoxic	cognitive defect
RU 35929	(+,-)-5-ethoxy-1-(phenylsulfonyl)-2-pyrrolidinone	antihypoxic	cognitive defect
tenilsetam; tenimal; PAS 997; CAS 997; HR 029	(+/-)-3-(2-thienyl)-2-piperazinone	antihypoxic	cognitive defect
RGH 5279	(3alpha)-eburnamine-14-carboxylic acid 2-(acetoxyethyl ester monohydrochloride	anti-ischemic	cognitive defect; brain ischemia
CPG 607	Unspecified	antioxidant	cognitive defect
Neurodegenerative disease therapy, antioxidant,	Unspecified	antioxidant	stroke; Alzheimer disease
VANTOX	Unspecified	antioxidant; free radical scavenger	Alzheimer disease
		antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke

antisense oligonucleotides, amyloid precursor/beta amyloid proteins; antisense oligonucleotides, Alzheimer's disease	Unspecified	antisense; oligonucleotide amyloid precursor/beta amyloid	Alzheimer disease
antisense oligonucleotide, APO-E4; antisense oligonucleotide, Alzheimer's disease	Unspecified	antisense; oligonucleotide APO-E4;	Alzheimer disease
Alzheimer's disease therapy	Unspecified	ApoE	Alzheimer disease
RU 34332	3-(cyclopropylcarbonyl)-7-fluoro-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine	cognitive defect
S 8510	1,6,7,9-tetrahydro-2-(3-isoxazolyl)imidazo[4,5-d]pyran[4,3-b]pyridine phosphate (1:1)	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
SX 3933	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one monohydrochloride	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
RU 33965	3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine partial agonist	cognitive defect
terbequinil; SR 25776	1,4-dihydro-1-(methoxymethyl)-4-oxo-N-propyl-3-quinolinecarboxamide	benzodiazepine partial agonist	cognitive defect

nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
RGH 2716; TDN 345	8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diazaspiro[4.5]decan-2-one	calcium antagonist	cognitive defect
voltage-dependent calcium channel antagonists, VDCC antagonists	Unspecified	calcium antagonist	Alzheimer disease; neurological
sabeluzole; R 58735; JK 601	(+,-)-4-(2-benzothiazolylmethylamino)-alfa-[(4-fluorophenoxy)methyl]-1-piperidineethanol	calcium antagonist; antihypoxic	Alzheimer disease
Tamolarizine; tamolaridine hydrochloride; NC 1100; ZC 110	(+,-)-alfa-(3,4-dimethoxyphenyl)-2-(4-diphenylmethyl)-1-piperazineethanol	calcium antagonist; vasodilator	cognitive defect; cerebrovascular disease
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
NS 649	1-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine	calcium channel blocker	cognitive defect
elziverine; Ro 224839	1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-4-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]isouquinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect

drug delivery system; CDS sinnabidol; sinnabidol CDS	Unspecified	cannabinoid; glutamate antagonist; NMDA antagonist	cognitive defect; glaucoma
SK 067	Unspecified	Cerebral metabolic agent	cognitive defect
SNK 882	2-oxo-N-[(tetrahydro-1H-pyrolizin-7a(5H)-yl)methyl]-1-pyrrolidin eacetamide, monohydrochloride	Cerebral metabolic agent	cognitive defect
vinconate; vincantenate; vintenate; OM 853; OC 340; OC 34; BRENAL	(+,-)-methyl 3-ethyl-2,3,3a,4-tetrahydro-1H-indolo[3,2,1-de][1,5]naphthyridine-6-carboxylate	Cerebral metabolite enhancer	cognitive defect
SUT 8701	N-[(1,1-dimethylethoxy)carbo nyl]-O-(dimethylphosinyl)-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-alfa-aspartyl-L-phenylalaninamide	cholecystokinin antagonist	Alzheimer disease
sibopirdine; DUP 921; X 9121; EXP 9121; EXP921	5,5-bis(4-pyridinylmethyl)-5H-cyclopenta-[2,1-b;3,4-b']dipyridine	Choline release stimulator	cognitive defect
choline alphoscerate; choline glycerophosphate; GLIATILIN; DELECIT; BREZAL	L-alpha-glycerylphosphorylcholine	Choline releasing agent	cognitive defect
MKC 231	2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)-1-pyrrolidineacetamide	Choline uptake stimulation	cognitive defect; Alzheimer disease

bifemelane; bifemelane hydrochloride; MCI 2016; E 0687; CELEPORT; ALNERT; NEUROCINE; SURTOMIL; CORDINAL	N-methyl-4-[2-(phenylmethyl)phenoxy]-1-butanamine	Cholinergic agent	cognitive defect
ABT 089	(R)-2-methyl-3-(2-pyrrolidinylmethoxy)pyridine	Cholinergic channel modifier	Alzheimer disease
stacofylline; S 9977; S 99772; SE 9977	N,N-diethyl-4-[3-(2,3,6,7-tetrahydriodioxy-1,3,7-trimethyl-2,6-dioxo-1H-purin-8-yl)propyl]-1-piperazinecarboxamide monohydrochloride	Cholinergic stimulation, 5HT uptake stimulation	Alzheimer disease
NS 2330	Unspecified	Cholinergic, adrenergic, noradrenergic	cognitive defect
choline derivatives,	Choline derivatives	Cholinomimetic	cognitive defect
HOE 065	[2S-[1[R*(R*)],2alpha,3alpha,6beta]-1-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (Z)-2-butenedioate	Cholinomimetic	cognitive defect
acetyl-L-carnitine; acetyl carnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinomimetic, stimulation of neuron growth and repair	Alzheimer disease; stroke; diabetes; neuropathy
Alzheimer's therapy,	Unspecified	Complement activation by b-amyloid	Alzheimer disease

complement activation inhibitors	Unspecified	complement activation inhibitors	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Complex IV cytochrome oxidase function	Alzheimer disease
ebiratide; ACTH (4-9) analogue; corticotropin (4-9) analogue; HOE 427	4-(methylsulfonyl)-L-2-aminobutanoyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-N-alpha-(8-aminoctyl)-L-phenylalaninamide	corticotropin analogue	Alzheimer disease
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
creb gene transcription modulators, CNS disorders,	Unspecified	creb gene transcription modulators	neurodegeneration; Alzheimer disease
CRF1 partial agonist	Unspecified	CRF1 partial agonist	Alzheimer disease; Crohn disease
differentiation-inducing factor; DIF	Unspecified	differentiation-inducing factor; DIF; growth factor; neurotrophic factor	cognitive defect
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
NDD 094; SDZ NDD094	Unspecified	Disease specific targets	Alzheimer disease
alapotide; VUFB 15754	8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione	dopamine agonist; cicatrizant; peptide	Alzheimer disease; skin ulcer; gastrointestinal ulcer
dihydrexidine; IP 202	trans-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease

voxergolide; RU 41656	(8beta)-(+,-)-6-methyl-8-[(methylthio)methyl]-9-oxaergoline	dopamine agonist; dopamine D2 agonist	cognitive defect
estrogens,	Estrogens	estrogen	Alzheimer disease
estrogens,	Estrogens	estrogen	neuropathy; Alzheimer disease
ABPI 124	Unspecified	estrogen agonist	Alzheimer disease
17alpha estradiol	estr-1,3,5(10)-triene-3,17alpha-diol	estrogen; hormone replacement therapy	hormone deficiency; cognitive defect
estrogen,	Estrogen	estrogen; neuroactive steroid	Alzheimer disease
estrogen + medroxyprogesterone acetate; PREMPRO; PREMPHASE; PREMARIN MPA; PREMIQUE; PREMIQUE CYCLE	estrogen + medroxyprogesterone acetate	estrogen; progestogen; hormone replacement therapy	hormone deficiency; Alzheimer disease
excitatory amino acid antagonists,	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
carboxylated buckminsterfullerenes ; carboxyfullerenes	Carboxylated buckminsterfullerenes ; carboxyfullerenes	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
nefiracetam; feniracetam; DM 9384; DMPPA; TRANSLON	N-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineacetamide	GABA agonist	cognitive defect
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
cognition enhancer,	Unspecified	GABA inverse agonist	Alzheimer disease
NGD 971; NGD 97-1	Unspecified	GABA inverse agonist	cognitive defect
suritozole; MDL 26479	2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione	GABA inverse agonist	depression; cognitive defect

valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release enhancer	Alzheimer disease; epilepsy
siagoside; AGF 2	[R-[R*,S*-(E)]]-N-[1-[[[O-[1',2'-anhydro]-N-acetyl-alpha-neuraminosyl-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside	cognitive defect; stroke
Dimethylhomospermine; DMHSPM	Dimethylhomospermine	gastroprokinetic; polyamine analogue	gastrointestinal motility disease; Alzheimer disease
Alzheimer disease therapy,	Unspecified	gene	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Gene transcription based drugs	Alzheimer disease
ALT 766	Unspecified	Glucose derived cross-link breaker	diabetes; cardiovascular disease; Alzheimer disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma

LY 341495	[1S-[1alpha(R*),2beta]]-alpha-amino-alpha-(2-carboxycyclopropyl)-9H-xanthene-9-propanoic acid	glutamate antagonist; mGluR antagonist	psychosis; cognitive defect
PD 129653; SC 46643	(+)-alpha-amino-4-(phosphonomethyl)benzenoacetic acid	glutamate antagonist; NMDA antagonist	cognitive defect
PD 130527	3-(phosphonomethyl)phenylalanine	glutamate antagonist; NMDA antagonist	cognitive defect
dimiracetam; ISF 4185	dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione	Glutaminergic, cholinergic pathways, inhibition of hippocampal serotonergic activity	cognitive defect
glycine transporter modulator,	Unspecified	glycine antagonist	epilepsy; cognitive defect
gene therapy, nerve growth factor	Unspecified	growth factor	Alzheimer disease
BU 4514N	Unspecified	growth factor	cognitive defect
CX 438	Unspecified	growth factor	Alzheimer disease
nerve growth factor inducer, NGF inducer,	Unspecified	growth factor	Alzheimer disease
drug delivery system, polymer pellet nerve growth factor; NGF polymer pellet	NGF polymer pellet	growth factor;	Alzheimer disease
neurodegenerative disease therapy,	Unspecified	growth factor; growth factor modulator	cognitive defect; Alzheimer disease; neuropathy
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neurotrophin agonist,	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy

drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	NT-3	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
ciproxifan; compound 359; BP 2359	Cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenylm ethanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
GR 175737	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; cognitive defect
GT 2016	1-(5-cyclohexyl-1-oxepentyl)-4-(1H-imidazol-4-yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
GT 2227	1-[1H-imidazol-4-yl]-6-cyclohexyl-cis-hex-3-ene	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder
GT 2331	4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]-1H-imidazole	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder; Alzheimer disease
thioperamide; MR 12842	N-cyclohexyl-4-(1H-imidazol-4-yl)-1-piperidincarbothioamide	histamine antagonist; histamine H3 antagonist	cognitive defect
drug delivery system, thyrotropin releasing hormone; TRH-SR; HILTONIN SR	Unspecified	hormone	cognitive defect
ICE inhibitors,	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	endotoxic shock; rheumatoid arthritis; Alzheimer disease
AIT 083	Unspecified	immunostimulant	cognitive defect

CEP 1347; KT 7515	[9S-(9alpha,10beta,12alpha-a)]-5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo [1,2,3-fg;3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester	Kinase inhibitor, jnk inhibitor	Alzheimer disease
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
Maillard reaction inhibitors	Unspecified	Maillard reaction ; blocks glycated proteins	atherosclerosis; Alzheimer disease
drug delivery system, transdermal selegiline; selegiline transdermal	Selgiline	MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
SL 251188	Unspecified	MAO inhibitor; MAO B inhibitor	Alzheimer disease; nicotine withdrawal
neurodegenerative disease therapy	Unspecified	monoclonal antibody; biotechnology	neurodegeneration; Alzheimer disease
BY 1949	3-methoxy-11-methyl-dibenzo(b,f)(1,4)oxazepine-8-carboxylic acid	Na+, K+ ATPase activation	cerebrovascular disease; cognitive defect
SR 57667	Unspecified	Neurodegeneration protection agent	Alzheimer disease; Parkinson disease

memory enhancer,	Unspecified	Neuron enhancement at hippocampus	cognitive defect
neurophilins	Neurophilins	Neurophilin receptor ligand	Alzheimer disease; Parkinson disease; neuropathy
jubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethylamino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
CX 417	Unspecified	Neurotransmitter retro modulator	Alzheimer disease
DMP 543	10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone	Neurotransmitter release	Alzheimer disease
leteprinim; leteprinim potassium; AIT 082; NEOTROFIN	4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]benzoic acid	Neurotrophic factor production stimulation	cognitive defect; Alzheimer disease
CEP 427	Unspecified	neurotrophic factor; growth factor	Alzheimer disease
K 252a derivative	[9S-(9alpha,10beta,12alpha)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-j][1,6]benzodiazocine-10-carboxylic acid methyl ester]	neurotrophic factor; growth factor	neuropathy; Alzheimer disease
NS 506	Unspecified	neurotrophic factor; growth factor	cognitive defect
NS 521	Unspecified	neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes

ST 857	[R-(R*,S*)]-2-(acetoxy)-4-[(4-[aminoiminomethyl]amino)-1-carboxybutyl]amino]-N,N,N-trimethyl-4-oxo-1-butanaminium chloride	neurotrophic factor; growth factor	cognitive defect
eurystatin A; Bu 4164EA	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotridec-10-yl]-2-heptenamide	neutral endopeptidase inhibitor	Alzheimer disease
eurystatin B; Bu 4164EB	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotidec-10-yl]-2-octenamide	neutral endopeptidase inhibitor	Alzheimer disease
Y 29794	[2-[[8-(dimethylamino)octyl]thio]-6-(1-methylethyl)-3-pyridinyl]-2-thienylmethanone	neutral endopeptidase inhibitor	cognitive defect; Alzheimer disease
neurodegeneration therapy	Unspecified	Nicotinic compounds	Alzheimer disease; Parkinson disease
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
CR 2249	(S)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid	NMDA modulator	Alzheimer disease
GVS 111	l-(phenylacetyl)-L-prolylglycine ethyl ester	NMDA modulator	cognitive defect

adafenoxate; WON 150	4-chlorophenoxyacetic acid 2-(1-adamantylamino)ethyl ester	Nootropic agent	cognitive defect
ALE 26015	Unspecified	Nootropic agent	cognitive defect; Alzheimer disease
aloracetam; CAS 493	N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide	Nootropic agent	cognitive defect
Alzheimer's disease therapy,	Unspecified	Nootropic agent	Alzheimer disease
AWD 5239	9,10-dihydrolysergic acid bis-(beta-acetoxyethyl)amide monutartrate	Nootropic agent	cognitive defect
bacoside A	3-[(O-alfa-L-arabinosyl-beta-D-glucosyl)oxy]-19,20-dihydroxydammaram-24-en-16-one	Nootropic agent	cognitive defect
bacoside A + bacoside B	Unspecified	Nootropic agent	cognitive defect
bacoside B	3-[(O-L-arabinosyl-D-glucosyl)oxy]-19,20-dihydroxydammaram-24-en-16-one	Nootropic agent	cognitive defect
BDP	(11beta,16beta)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione	Nootropic agent	Alzheimer disease
BMY 21502; BMS 181168	1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone	Nootropic agent	cognitive defect
BR 16A	Unspecified	Nootropic agent	cognitive defect
CGP 34735	Unspecified	Nootropic agent	cognitive defect
CGP 50068A	Unspecified	Nootropic agent	cognitive defect

CL 275838	4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)pyrazolo(1,5-a)pyrimidine-3-carbonitrile	Nootropic agent	cognitive defect
CX 516; AMPALEX	1-(6-quinoxalinylcarbonyl)piperidine	Nootropic agent	Alzheimer disease; schizophrenia
cycloserine-D; cycloserine; SC 49088	4-amino-3-isoxazolidinone	Nootropic agent	Alzheimer disease
dabelotine; S 12024; S 120242	(S)-1,2,3,4-tetrahydro-1-methyl-8-(2-morpholinylmethoxy)quinolinenomonethanesulfonate	Nootropic agent	Alzheimer disease
exifone; ADLONE	2,3,3',4,4',5'-hexahydroxybenzophenone	Nootropic agent	cognitive defect
fasoracetam; NS 105; LAM 105	(R)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine	Nootropic agent	cerebrovascular disease; cognitive defect
FR 121196	1-acetyl-4-[[4-fluorophenyl)sulfonylamino]piperazine	Nootropic agent	cognitive defect; sexual dysfunction
gedocarnil; SH 530; ZK 113315	5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylic acid 1-methylethyl ester	Nootropic agent	cognitive defect
idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect

IDRA 21	7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide	Nootropic agent	cognitive defect
KI 711	Sialic acid derivative	Nootropic agent	Alzheimer disease
KW 6055	N-[3-nitro-4-(2-pyridinylmethyl)phenyl]butanamide	Nootropic agent	cognitive defect
mexidol	2-ethyl-6-methyl-3-hydroxypyridine succinate	Nootropic agent	anxiety; cognitive defect
oxiracetam; ISF 2522; CT 848; CGP 21690; NEUROMET; NEURACTIV; SENEX	4-hydroxy-2-oxo-1-pyrrolidineacetamide	Nootropic agent	cognitive defect
P 128	Unspecified	Nootropic agent	cognitive defect
P 58	Unspecified	Nootropic agent	Alzheimer disease; cognitive defect
P 867493	Unspecified	Nootropic agent	cognitive defect
P 878184	Unspecified	Nootropic agent	cognitive defect
PPRT 424	Ginko bilboa extract	Nootropic agent	cognitive defect
pramiracetam; amacetam; CI 879; CNS 1879; ECTAPRAM; NEUPRAMIR; REMEM	N-[2-[bis-(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide	Nootropic agent	Alzheimer disease
prisotinol; prisotinal; CGS 5649B	(+,-)-6-[2-(isopropylamino)propyl]-3-pyridinol	Nootropic agent	cognitive defect
RU 47067	5-(1-methylethoxy)-1-3-(trifluoromethyl)phenylsulfonyl-2-pyrrolidinone	Nootropic agent	cognitive defect
SC 110	Unspecified	Nootropic agent	Alzheimer disease
SEE 405	Unspecified	Nootropic agent	Alzheimer disease
South American frog toxins	Histrionicotoxin	Nootropic agent	Alzheimer disease
UCB 11056	Unspecified	Nootropic agent	Alzheimer disease
UCB 29427	Unspecified	Nootropic agent	cognitive defect
UCB 29536	Unspecified	Nootropic agent	cognitive defect

Z 4105	N-(3-carboxypropyl)-3-methylisoxazole-5-carboxamide	Nootropic agent	cognitive defect
T 588	(R)-1-alfa-[(2-(diethylamino)ethoxy)methyl]benzo[b]thiophene-5-methanol hydrochloride	Nootropic agent, neurodegeneration protection	cognitive defect
VA 045	(3alpha,16alpha)-eburnamenine-14-carboxylic acid 2-(nitrooxy)ethylene ester, apovincaminic acid derivative	Nootropic agent, neuroprotective agent	cognitive defect
nebracetam; WEB 1881; WEB 1881FU; MEMOLOG	4-aminomethyl-1-benzylpyrrolidin-2-one hemifumarate	Nootropic agent, unknown mechanism	Alzheimer disease
DQ-CER	des-Gln2-[Leu5,Nle8]-cerulein	Nootropic agnet	cognitive defect
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazine-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Noradrenergic, serotonergic reuptake inhibitors	cognitive defect; depression
notch signalling pathway modulators	Unspecified	notch signalling pathway modulators	stroke; cognitive defect; cancer
CPH 82; REUMACON; COMIHOG	Unspecified	NSAID	inflammation; Alzheimer disease
HCT 1026	Unspecified	NSAID; nitric oxide donor	urinary incontinence; Alzheimer disease; osteoporosis
quadazocine; WIN 444413; WIN 44441	(-)-(2R,6S,11S)-1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-tromethyl-2,6-methano-3-benzazocin-11-yl)-3-pentanone	opiate antagonist; kappa antagonist	cognitive defect
MAb, OX 26-nerve growth factor conjugate; MAb, OX 26-NGF conjugate; OX 26-NGF	Unspecified	OX 26-nerve growth factor conjugate monoclonal antibody	cognitive defect

ACTH (4-10); SEMAX	Unspecified	peptide	cognitive defect; trauma; stroke
Alzheimer disease therapy;	Unspecified	peptide	Alzheimer disease
beta-sheet breaker,	Unspecified	peptide	Alzheimer disease
Transglutaminase inhibitor	Unspecified	peptide; transglutaminase inhibitor	psoriasis; Alzheimer disease
KS 505a	2,3,4,4a,4b,5,6,6a,6b, 7,8,8a,8b,9,10,10a,16, 16a,16b,17,18,18a,18b,19,2 0,20a,20b,21,22,22a,- triacontahydro- 8a,10a- bis(hydroxymethyl)- 14-(4-methoxy-1,4-dioxobutyl)1,4,4a,6,6a,16b,18b,20b-octamethyl-2-((2-O-methyl-beta-D-glucopyranuronosyl)oxy)-1H-benzo(9,10)piceno(3,4-a)xanthene-1,15-dicarboxylic acid	phosphodiesterase inhibitor	cognitive defect
Ropipram; ZK 62711; ME 3167; ADEO	4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
Propentofylline; HWA 285; HEXTOL; BRAINORM; VIVIQ	3-methyl-1-(5-oxohexyl)-7-propylxanthine	phosphodiesterase inhibitor; xanthine	Alzheimer disease
Diethylnorspermine; DENSPM; CI 1006; DE 333	N1,N11-diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease
Dipropylnorspermine; DPNSPM	Dipropylnorspermine	polyamine analogue	diarrhea; Alzheimer disease
linear polyamine analogue	linear polyamine analogue	polyamine analogue	cancer; Alzheimer disease
Polymerization inhibitor	Unspecified	polymerization inhibitor	Alzheimer disease

Clausenamide	(3R,4S,5S)-rel-3-hydroxy-5-[[(R)-hydroxyphenylmethyl]-1-methyl-4-phenyl-2-pyrrolidinone]	potassium channel blocker	cognitive defect
Potassium channel modulators,	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
Alzheimer's disease therapy	Unspecified	Presenilins	Alzheimer disease
JTP 3399	Unspecified	prolyl endopeptidase inhibitor	cognitive defect
JTP 4819	[S-(R*,R*)]-2-[[2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-1-pyrrolidinecarboxamide	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
ONO 1603	(S)-N-[(4-chlorophenyl)methyl]-2-formyl-gamma-oxo-1-pyrrolidinebutanamide	prolyl endopeptidase inhibitor	Alzheimer disease
S 17092	Unspecified	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
Z 321	(4R)-3-(2-indanyl-2-ylacetyl)-4-(1-pyrrolidinylcarbonyl)-1,3-thiazolidine	prolyl endopeptidase inhibitor	cerebrovascular disease; cognitive defect; Alzheimer disease
CEP 431 proteinase inhibitors,	Unspecified	proteinase inhibitor	Alzheimer disease
SIB T1980	Unspecified	proteinase inhibitor	cognitive defect
azetirelin; YM 14673	(S)-N-[(4-oxo-2-azetidinyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect
JTP 2942	(1S-cis)-N-[(2-methyl-4-oxocyclopentyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect

posatirelin; RGH 2202	(S)-N-[(6-oxo-2-piperidinyl)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
Alzheimer's disease therapy,	Unspecified	Serum amyloid p component	Alzheimer disease
igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteaminide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
NX D2858; NXD 2858	Unspecified	Spherons, inhibition of spherons into plaques	Alzheimer disease
screening technology, ADAP	Unspecified	target based screening	drug design technology; Alzheimer disease
drug delivery system, thyroid stimulating hormone;	Unspecified	thyroid stimulating hormone delivery system	cognitive defect
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

CEP 3265; CB 1093 ademetionine; FO 1561; GUMBARAL; DONAMET; TRANSMETIL; CERITAN; ERGEN; TWIN; SAMY R	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease
AIT 034; AIT 34	(3S)-5'-(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine hydroxide inner salt	transmethylator; NSAID	inflammation; cognitive defect; cholestasis
BTG 1640	1,6-dihydro-6-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]9H-purine-9-propanamide	Unknown	cognitive defect
cebaracetam; ZY 15119	Heterocyclic compound	unknown	cognitive defect; Alzheimer disease
fatty acids, microalgal	(+,-)-4-[[4-(p-chlorophenyl)-2-oxo-1-pyrrolidinyl]acetyl]-2-piperazinone	Unknown	cognitive defect
NBI 107	Unspecified	Unknown	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease
pregnenolone; NBI 113	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	multiple sclerosis
			infectious disease; Alzheimer disease

vinpocetine; AY 27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3alpha,16alpha)-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
vasoactive intestinal peptide analogue; [stearyl norleucine17]VIP; [St-Nle17]VIP	Unspecified	VIP agonist	Alzheimer disease

Table 28. Current Candidate Therapeutic Interventions for the Treatment of Depression

Product Name	Chemical Name	Action	Indication
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
F 12439		SHT agonist; SHT1A agonist	depression; anxiety
Flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	SHT agonist; 5HT1A agonist	anxiety; depression
Gepirone; gepirone hydrochloride; MJ 13805; BMY 13805; BMY 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression
Ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	SHT agonist; 5HT1A agonist	depression; anxiety

LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
ORG 13011		5HT agonist; 5HT1A agonist	depression
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
U 92016A		5HT agonist; 5HT1A agonist	anxiety; depression
U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
WY 48723	octahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-a]azepin-2,4(3H,5H)-dione dihydrochloride	5HT agonist; 5HT1A agonist	depression
SL 870765		5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
Adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decane-1-carboxamide	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression

AF 2968	(S)-[R-(R*,R*)]-2,3-2-[3-[4-(3-chlorophenyl)-2-methyl-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one dihydroxybutanedioate (1:1)	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2A antagonist; 5HT2C antagonist	depression
Sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	SHT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
Aromatic triflates,		SHT agonist; 5HT1D agonist	depression; migraine
GMC 2020		SHT agonist; 5HT1D agonist	depression; migraine
GMC 2021	trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	SHT agonist; 5HT1D agonist	depression; migraine
ORG 12962		SHT agonist; 5HT2C agonist	depression
ORG 37684		SHT agonist; 5HT2C agonist	depression
Ro 600175; Ro 60-0175	(alphaS)-6-chloro-5-fluoro-alpha-methyl-1H-indole-1-ethanamine (2E)-2-butenedioate (1:1)	SHT agonist; 5HT2C agonist	depression; obsessive compulsive disorder
SR 57227; CM 57277	1-(6-chloro-2-pyridinyl)-4-piperidinamine	SHT agonist; 5HT3 agonist	depression
SHT1B antagonists,		SHT antagonist	depression; anxiety
BN 50156	3-(4-chlorophenyl)-alpha-[3-(dimethylamino)-1-propenyl]-1,3-dihydro-7-hydroxyfuro[3,4-c]pyridine-6-methanol	SHT antagonist	depression
DU 123015		SHT antagonist	anxiety; depression

DU 125530		SHT antagonist	depression; anxiety; psychosis
Moxyfetin		SHT antagonist	depression
SB 245570		SHT antagonist	depression
5-HT antagonist, pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	SHT antagonist; SHT1A antagonist	anxiety; depression
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	SHT antagonist; SHT1A antagonist	anxiety; depression
S 14063	1-(2-benzothiazolyl)-N-[2-(2-methoxyphenoxy)ethyl]-4-piperidinemethamine dihydrochloride	SHT antagonist; SHT1A antagonist	depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	SHT antagonist; SHT1A antagonist	anxiety; depression
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride	SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
Drug delivery system, transdermal buspirone; buspirone transdermal		SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder

EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	SHT antagonist; SHT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
L 694247	N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide	SHT antagonist; SHT1D antagonist	depression
GR 127935	N-(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-5-yl)-1H-indole-3-yl)ethylamine	SHT antagonist; SHT1Dbeta antagonist	depression
Flibanserin; BIMT 17	1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one	SHT antagonist; SHT2 antagonist; SHT agonist; SHT1A agonist	depression
HT 90B	(-)-N-[2-[[2,(3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.13,7]decane-1-carboxamide	SHT antagonist; SHT2 antagonist; SHT agonist; SHT1A agonist	anxiety; depression
Nefazodone; MJ 13754; MS 13754; BMY 13754; BMY 137541; SERZONE; DUTONIN; RESERIL; NEFADAR; NIFEREL; MENFAZONA; RULIVAN; DEPREFAX; SERZONIL	2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one	SHT antagonist; SHT2 antagonist; SHT reuptake inhibitor; alpha adrenergic antagonist; alpha1 adrenergic antagonist	depression

Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Mirtazapine; mepirzipine; azamianserin; ORG 3770; REMERON; ZISPIN	1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	5HT antagonist; 5HT2 antagonist; 5HT3 antagonist; alpha2 adrenergic antagonist; alpha adrenergic antagonist	depression
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEPK	2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 228357	N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
Antidepressant		5HT antagonist; 5HT3 antagonist	depression; anxiety
SHT7 receptor antagonists,		5HT antagonist; 5HT7 antagonist	depression; insomnia; schizophrenia
DR 4004		5HT antagonist; 5HT7 antagonist	depression; insomnia
THE JL3; JL 3	10-(4-methyl-1-piperazinyl)-pyrido[4,3-b][1,4]benzothiazepine	5HT antagonist; dopamine antagonist	anxiety; depression
BMS 181101; BMY 42569	5-fluoro-3-[3-[4-(1,4,5,6-tetrahydropyrimidin-4-yl)-2,3-dihydropyrazin-1-yl]propyl]-2,3-dihydro-1H-indole	5HT reuptake inhibitor	depression

Cericlamine; JO 1017(+,-); JO 1239(-); JO 1240(+)	(+,-)-3,4-dichloro-beta-(dimethylamino)-beta-methylbenzenepropanol	5HT reuptake inhibitor	depression
CGP 6085A	4-(5,6-dimethyl-2-benzofuranyl)piperidine hydrochloride	5HT reuptake inhibitor	depression
Citalopram; nitalopram; nitalapram; ZD 211; LU 10171; CIPRAMIL; SEROPRAM; CIPRAM; ELOPRAM; CELEXA	1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Citalopram, (S); (+)-citalopram	(S)-1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Dapoxetine; LY 210448	(S)-N,N-dimethyl-alpha-[2-(1-naphthalenyl)ethoxy]benzenemethanamine	5HT reuptake inhibitor	depression
Depression therapy,		5HT reuptake inhibitor	depression
Dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal

Drug delivery system, controlled release GEOMATRIX paroxetine; paroxetine GEOMATRIX; PAXIL CR		SHT reuptake inhibitor	depression
FCE 25876	(E)-N-methyl-3-phenyl-3-(4-trifluoromethylphenoxy)-2-propen-1-amine	SHT reuptake inhibitor	depression
FI 4500		SHT reuptake inhibitor	depression
FI 4501		SHT reuptake inhibitor	depression
FI 4503		SHT reuptake inhibitor	depression
Fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	SHT reuptake inhibitor	migraine; cognitive defect; depression
Fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-(2-aminoethyl)oxime	SHT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
Litoxetine; SL 810385	4-(2-naphthalenylmethoxy)piperidine	SHT reuptake inhibitor	depression
LY 280253	Unspecified	SHT reuptake inhibitor	depression
LY 285974	Unspecified	SHT reuptake inhibitor	depression

Paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAK; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety
Sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
Tianeptine; S 1574; STABLON	7-[(3-chloro-6,11-dihydro-6-methyldibenz[b,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide	5HT reuptake inhibitor	depression
EMD 68843	5-[4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl]benzofuran-2-carboxamide hydrochloride	5HT reuptake inhibitor; 5HT agonist; 5HT1A agonist	depression
YM 992; YM 35992	(S)-2-[[[7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy]methyl]morpholine hydrochloride	5HT reuptake inhibitor; 5HT antagonist; 5HT2A antagonist	depression
A 80426	(R)-N-methyl-N-[(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)methyl]-6-benzofuranethanamine	5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Antidepressants		5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression

NS 2347		SHT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
NS 2389		SHT reuptake inhibitor; dopamine reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Drug delivery system, OROS oral controlled release venlafaxine; venlafaxine OROS; EFFEXOR XL		SHT reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Duloxetine; LY 248686	(S)-N-methyl-gamma-(1-naphthalenylxyloxy)-2-thiophenepropanamine	SHT reuptake inhibitor; noradrenalin reuptake inhibitor	depression; urinary incontinence
Venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	SHT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
Ebalzotan; NAE 086	(R)-3,4-dihydro-N-(1-methylethyl)-3-[(1-methylethyl)propylamino]-2H-1-benzopyran-5-carboxamide	SHT1A agonist; SHT agonist	depression
L 0068; F 11440	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2H,4H)-dione	SHT1A agonist; SHT agonist	anxiety; depression
LY 274600	(S)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamine hydrochloride	SHT1A agonist; SHT agonist	sexual dysfunction; depression; irritable bowel syndrome
LY 274601	(R)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamoine hydrochloride	SHT1A agonist; SHT agonist	sexual dysfunction; depression; irritable bowel syndrome

OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	5HT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 12682; F 14258	N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-phenylethyl)-1-piperazinecarboxamide	5HT1B/5HT1D inverse agonist	depression
GMC 5036	Mirtazepine analogue	5HT2, 5HT3 antagonist; alpha 2 adrenergic antagonist; histaminergic antagonism;	depression
Levopropertiline; levo-oxaprotiline; oxaprotiline, R-(-) enantiomer; CGP 12103A; CONSONAR	(R)-alpha-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol	5HT2A, 5HT2C 5HT1A agonist alpha adrenergic agonist; 5HT1D and histaminergic antagonist	depression
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT2C antagonist; 5HT antagonist	depression; anxiety
Zalospirone; WY 47846	(3aalpha,4beta,4alpha,6alpha,7beta,7aalpha)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
Drug delivery system, adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonalinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression

Midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Adrenergic and serotonergic reuptake inhibitor	cognitive defect; depression
Adrafinil; adrafinal; CRL 40028; OLMIFON	2-[(diphenylmethyl)sulfonyl]N-hydroxyacetamide	alpha adrenergic agonist	neurological depression
Modafinil; CRL 40476; CEP 1538; MODIODAL; PROVIGIL; ALERTEC; MODASOMIL	2-[(diphenylmethyl)sulfonyl]acetamide	alpha adrenergic agonist	neurological depression
SDZ NVI085	(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3,b]-1,4-oxazine	alpha adrenergic agonist; alpha1 adrenergic agonist	neurological depression; depression
Imiloxan; RS 21361	2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-ethyl-1H-imidazole	alpha adrenergic antagonist	depression
ORG 6906		alpha adrenergic antagonist	depression
Setiptiline; teciptiline; MO 8282; ORG 8282; TECIPUL	2,3,4,9-tetrahydro-2-methyl-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine	alpha adrenergic antagonist	depression
Atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety

CH 38083	[8aS-(8aalpha,11alpha,12a alpha,13alpha)]-5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-11-ol hydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
MK 912; L 657743	(2S-trans)-1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethylspiro[2H-benzofuro[2,3-a]quinolizine-2,4'(1'H)-pyrimidin]-2'(3'H)-one monohydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Napitane; ABT 200; A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
ORG 9768		alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Reboxetine; FCE 20124; FCE 21684; EDRONAX; PROLIFT	(R*,S*)-2-[(2-ethoxyphenoxy)phenylmethyl]morpholine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
AMPA receptor modulators,		AMPA receptor modulators	schizophrenia; depression

Dehydroepiandrosterone analogues; DHEA analogues,		androgen	atherosclerosis; depression
Drug delivery system; dehydroepiandrostone; dehydroepiandrostone delivery system; drug delivery system, DHEA		androgen	atherosclerosis; depression
Adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
Flumazenil; flumazepil; flumenazil; Ro 151788; ANEXATE; MAZICON; LANEXAT; ROMAZICON	8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester	benzodiazepine antagonist	neurological depression; liver disease
Flerobuterol	alpha-[(1,1,dimethylethyl)amino]methyl]-2-fluorobenzene methanol	beta adrenergic agonist	depression
SR 56811; SR 58611A; SR 58611; ME 3411	[R-(R*,S*)]-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]acetic acid ethyl ester hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	irritable bowel syndrome; obesity; depression
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3-ethynyl phenyl)-3,5-pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression

CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
Corticotropin releasing factor analogue		CRF analogue	anxiety; depression
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist,		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF receptor antagonist; corticotropin releasing factor antagonist		CRF antagonist	depression
CRF2 antagonists,		CRF antagonist	depression; anxiety
NBI 103		CRF antagonist	depression; eating disorder
NBI 104		CRF antagonist	depression; stroke
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
Pivagabine; PG 2; TONERG	4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid	CRF modulation	depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
Etrabamine; JL 14839	4,5,6,7-tetrahydro-N-methyl-6-benzothiazolamine	dopamine agonist	depression
MR 708	N-acetyl-DL-phenylalanine with tricyclo[3.3.1.13,7]decane-1-amine (1:1)	dopamine agonist	depression
Roxindole; EMD 62100; EMD 49980; EMD 62080	3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridyl)butyl)indol-5-ol	dopamine agonist; 5HT reuptake inhibitor	depression
Amisulpride; aminosultopride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
Pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
GYKI 52895	4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzodiazepine	dopamine reuptake inhibitor	depression
HOE 249	(+)-2-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]tricyclo[3.3.1.1(3,7)]decan-2-ol]	dopamine reuptake inhibitor	depression
NS 2200		dopamine reuptake inhibitor	Parkinson disease; depression; addiction
OPC 14117	N-(2,3-dihydro-7-hydroxy-2,2,4,6-tetramethyl-1H-inden-1-yl)-4-(3-methoxyphenyl)-1-piperazineacetamide	free radical scavenger	neurological depression
GABA-based depression therapy,		GABA agonist	depression
CGP 35348	(3-aminopropyl)(diethoxymethyl)phosphinic acid	GABA antagonist	depression
Suritozole; MDL 26479	2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione	GABA inverse agonist	depression; cognitive defect
Valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA receptor	epilepsy; migraine; schizophrenia; depression

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	I-(aminomethyl)cyclohexaneacetic acid	GABA release; analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	I-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
BN 50043	N-allyl N-isopropyl (p-chlorophenyl-4-piperidino)-2-acetamide hydrochloride	Imipramine binding site	depression
L 671776	3',4',4'a,5',6',7',8',8'a-octahydro-4,6'-dihydroxy-6-(hydroxymethyl)-2',5',5',8'a-tetramethylspiro[benzofuran-2(3H),1'(2'H)-naphthalene]-5-carboxaldehyde	inositol monophosphatase inhibitor	depression
Befloxitone; MD 370503	(R)-5-(methoxymethyl)-3-(p-((R)-4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
Brofaromine; CGP 11305A; CONSONAR	4-(7-bromo-5-methoxy-2-benzofuranyl)piperidine	MAO A inhibitor; MAO inhibitor	depression
BW 1370U87	1-ethylphenoxythiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
CS 8359; RS 8359	(+,-)-4-[(6,7-dihydro-7-hydroxy-5H-cyclopentapyrimidin-4-yl)amino]benzonitrile	MAO A inhibitor; MAO inhibitor	depression
E 2011	[R-(R*,S*)]-gamma-hydroxy-6-[5-(methoxymethyl)-2-oxo-3-oxazolidinyl]-2-benzothiazolebutanenitrile	MAO A inhibitor; MAO inhibitor	depression

Esuprone; LU 43839	ethanesulfonic acid 3,4-dimethyl-2-oxo- 2H-1-benzopyran-7- yl ester	MAO A inhibitor; MAO inhibitor	depression
Moclobemide; Ro 111163; Ro 111163/000; AURORIX; MANERIX; ACUILIX; MOCLAMINE	4-chloro-N-[2-(4- morpholinyl)ethyl]benzamide	MAO A inhibitor; MAO inhibitor	depression
Pirlindole; pyrasidol; pyrazidol; pyrazidole; LIFRIL; PYRAZIDOL; EUTHYM	2,3,3a,4,5,6- hexahydro-8-methyl- 1H-pyrazino[3,2- jk]carbazole	MAO A inhibitor; MAO inhibitor	depression
Drug delivery system, controlled release selegiline; selegiline		MAO B inhibitor; MAO inhibitor	depression
Drug delivery system, transdermal selegiline; selegiline transdermal		MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
MDL 72145	(E)-(beta- fluoromethylene)-3,4- dimethoxybenzeneeth anamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
KP 157		MAO inhibitor; MAO A inhibitor	depression
KP 9		MAO inhibitor; MAO A inhibitor	depression
T 794	(R)-3-[6- (cyclopropylmethoxy )-2-naphthalenyl]-5- (methoxymethyl)-2- oxazolidinone	MAO inhibitor; MAO A inhibitor	depression
SL 650477; SL 65.0477	[R-(R*,R*)]-5- (methoxymethyl)-3- [6-(4,4,4-trifluoro-3- hydroxybutoxy)-3- benzofuranyl]-2- oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
Agomelatine; S 20098	N-[2-(7-methoxy-1- naphthalenyl)ethyl]acetamide	melatonin agonist	depression; insomnia

Melatonin modulators; melatonin analogues		Melatonin analogues	depression; infertility
Neuropeptide Y antagonists		neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
RB 101	N-[2-[[[2-amino-4-(methylthio)butyl]dithio)methyl]-1-oxo-3-phenylpropyl]-L-phenylalanine phenylmethyl ester	neutral endopeptidase inhibitor	addiction; depression
EGYT 4201	ethanesulfonic acid compd. with 5-chloro-2-(2-imino-3-thiazolidinyl)benzamine (2:1)	Nonmonoaminergic action	depression
COR 3224	4,5-dihydro-5-((4-phenyl-1-piperazinyl)methyl)-2-oxazolamine	Nontricyclic action	depression
Minaprine; minaprine hydrochloride; minaprina; CB 30038; 30038 CB; AGR 1240; CANTOR; KANTOR; ALCAS; NORTIMIC; BRANTUR; ISOPULSAN	4-[2-[(4-methyl-6-phenyl-3-pyridazinyl)amino]ethyl]morpholine	Nontricyclic action	depression
Amfebutamone; bupropion hydrochloride; bupropion; bupropin; BW 323U; WELLBUTRIN; ZYBAN	(+,-)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone	noradrenalin reuptake inhibitor	depression; nicotine withdrawal; obesity
Beloxyepin; ORG 4428	cis-2,10-dimethyl-1,2,3,4,4a,13b-hexahydrodibenzo-[2,3:6,7]oxepino [4,5-c]pyridin-4a-ol	noradrenalin reuptake inhibitor	depression

Dexnafenodone; LU 43706	(S)-2-[2-(dimethylamino)ethyl]-3,4-dihydro-2-phenyl-1(2H)-naphthalenone	noradrenalin reuptake inhibitor	depression
Hydroxynortriptyline	(E)-10-11-dihydro-5-[3-(methylamino)propylidene]-5H-dibenzo[a,d]cyclohepten-10-ol	noradrenalin reuptake inhibitor	depression
Drug delivery system, sustained release milnacipran; milnacipran sustained release		noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
Milnacipran; midalcipran; midacipran; F 2207; TN 912; DALCIPRAN; IXEL	cis-(+,-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide	noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
1555; 1555U88; BW 1555U88	[2S-(2alpha,3alpha,5alpha)-J-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrochloride	noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	attention deficit disorder; nicotine withdrawal; depression; psychosis
Nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
NS 1546		potassium channel modulator	depression
Potassium channel modulators		potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes

Igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
GW 273293		sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
Sifaprazine; FI 4303	1-(2-(phenylmethyl)phenyl)-4-methylpiperazine hydrochloride	Tricyclic antidepressant activity	depression
Antidepressant	N'-[5-[(2-chlorophenyl)methylen]-4,5-dihydro-6-methyl-3-pyridazinyl]-N,N-dimethyl-1,2-ethanediamine	Unknown	depression
Antidepressant, PPRT 152	St. John's Wort herbal remedy extract	Unknown	depression
ATX 70	(SP-4-2)-[[N,N'-[17,12-bis[1-(decyloxy)ethyl]-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-kappaN21,kappaN22, kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)]bis[L-aspartato]](6-)gallate (3-) trihydrogen	Unknown	depression; cancer
Bipenamol; BW 647U	2-[(2-(aminomethyl)phenyl]thio]benzenemethanol	Unknown	depression

BW 403U76		Unknown	depression
CGP 25454		Unknown	depression
CS 2232		Unknown	depression
Delfaprazine; FI 4310	1-(alpha2-phenyl-2,5-dimethyl)-piperazine	Unknown	depression
Depression therapy		Unknown	depression
E 5505		Unknown	depression
ORG 12437		Unknown	depression
ORG 20091	5-chloro-4-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-2-thiazolamine (Z)-2-butenedioate (2:1)	Unknown	depression
YKP 10A		Unknown	depression
DGAVP; ORG 5667	8-L-arginine-9-deglycinamidevasopressin	Vasopressin	depression
Vasopressin antagonist,		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 29. Current Candidate Therapeutic Interventions for the Treatment of Epilepsy

Product Name	Chemical Name	Action	Indication
MMPQ; SRC 820; SRC 820R	2-methyl-3-(3-methyl-2-pyridinyl)-4(3H)-quinazolinone	5HT neuromodulation	epilepsy
Adenosine regulating agents, epilepsy	Unspecified	adenosine regulating agent	epilepsy
Adenosine utilization inhibitors, epilepsy	Unspecified	adenosine regulating agent	epilepsy
GP 3269; GP 13269	7-(5-deoxy-beta-D-ribofuranosyl)-N-(4-fluorophenyl)-5-phenyl-7H-pyrido[2,3-d]pyrimidin-4-amine	adenosine regulating agent	epilepsy
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia

LY 215490	(3alpha,4alpha,6beta,8alpha)-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	epilepsy
LY 293558	[3S-(3alpha,4alpha,6beta,8alpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
SYM 2189	Unspecified	AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5-methyl-N-propyl-1,3-dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
Pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
mu-conopeptides	Unspecified	analgesic; peptide; sodium channel blocker	pain; epilepsy
ADD 196022	4-[(4-chlorophenyl)amino]-6-methyl-2-oxo-3-cyclohexene-1-carboxylic acid methyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
ADD 55051	4-chlorobenzenesulfonamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
AHN 649	(9alpha,13alpha,14alpha)-17-methylmorphinan-3-amine	Antiepileptic agent with unspecified mechanism of action	epilepsy; neuropathy
Ameltolide; LY 201116; ADD 75073	4-amino-N-(2,6-dimethylphenyl)benzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
Anticonvulsant	(R)-7-[1-(4-chlorophenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine	Antiepileptic agent with unspecified mechanism of action	epilepsy

Anticonvulsants	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	4-phenoxy-2-(4-propyl-1-piperazinyl)quinazoline	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	(S)-2-amino-4,5-dihydro-5-(2-methylpropyl)-4-oxo-1H-imidazole-1-carboxylic acid phenylmethyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptics	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
B 974	N-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazine-2-acetamido-4-methylthiazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
Benzoidazoxan	6,7-benzoidazoxan	Antiepileptic agent with unspecified mechanism of action	epilepsy
Carabersat; SB 204269; SB 204269EO	(3R-trans)-N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluorobenzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
CGS 18416	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 2993	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 3381	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
D 20443	[2-amino-4-[[[4-fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester dihydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy

D 2624	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Endixaprine; SR 41378	1-[6-(2,4-dichlorophenyl)-3-pyridazinyl]-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
F 721	5-[4-(trifluoromethyl)phenyl]-3-(diethylamino)-2,2-dimethylpropyl 2-furancarboxylic acid ester hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
FCE 23819	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Harkoseride; ADD 234037	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Lodaxaprine; CM 40907	1-(6-(2-chlorophenyl)-3-pyridazinyl)-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
Loreclezole; R 72063	(Z)-1-[2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1H-1,2,4-triazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 193453	Amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 228721	Bentamide amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 274959	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
MS 16056	1-(3-phenyl-5-isoxazolyl)-3-(1-imidazolyl)-methylindole hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
NPS 1776	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy

Oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide	Antiepileptic agent with unspecified mechanism of action	epilepsy; diabetes; neuropathy
Ro 70213	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
RWJ 37868	2-(4-chlorobenzoyl)-4-[(1-piperidinyl)acetyl]-1,3,5-trimethylpyrrole	Antiepileptic agent with unspecified mechanism of action	epilepsy
RX 751067	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
SL 900571	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Soretolide; D 2916	2,6-dimethyl-N-(5-methyl-3-isoxazolyl)benzamide ; aryl-isoxazole carboxamide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
Stiripentol; BCX 2600	4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 141	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 1901	Unspecified	Antiepileptic agent with unspecified mechanism of action	Epilepsy
Clobazam; HR 376; H 4723; LM 2717; NH 15; FRISUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
GYKI 52466	1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine	benzodiazepine	epilepsy

Midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
Ro 417812	Unspecified	benzodiazepine	epilepsy
Ro 428773	Unspecified	benzodiazepine	epilepsy
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
CNS 1067	Unspecified	calcium antagonist	epilepsy
U 54494A	cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamide monohydrochloride	calcium antagonist	epilepsy
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
CNS 2103	Unspecified	calcium antagonist; venom	epilepsy
CPC 8027	Unspecified	calcium channel blocker	stroke; epilepsy
CPC 8029	Unspecified	calcium channel blocker	stroke; epilepsy
NS 696	Unspecified	calcium channel blocker	epilepsy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia

DP 16	Acylglycerol derivative of BAPTA	Calcium chelation	epilepsy; stroke; heart ischemia
AO 78	Tetronic acid derivative, unspecified	Calcium ion modulator	epilepsy
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3,4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression
Losigamone; AO 33	5-[(2-chlorophenyl)hydroxymethyl]-4-methoxy-2(5H)-furanon; tetronic acid derivative	Chloride ion influx by GABA sensitive mechanism at a site distant from GABA	epilepsy
Levetiracetam; etiracetam, (S); UCB L059 (S); SIB S1 (S); UCB L060 (R); UCB 6474 (no stereo, etiracetam)	(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide	cholinergic agonist	epilepsy
Dopamine D4 receptor ligands	Unspecified	dopamine antagonist; dopamine D4 antagonist	attention deficit disorder; epilepsy; addiction
ADD 17014	4-[(4-chlorophenyl)-4,5-dihydro-1H-1,2,3-triazol-5-yl]pyridine	excitatory amino acid antagonist	epilepsy
Excitatory amino acid antagonists	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123	Unspecified	excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
Dezinamide; AN 051; AHR 11748; ADD 94057	3-[(3-trifluoromethyl)phenoxyl]-1-azetidinecarboxamide (desmethyl metabolite of fluzinamide)	Fluzinamide derivative	epilepsy
1-decylpyrrolidinone	1-decanoyl-2-pyrrolidinone	GABA agonist	epilepsy
1-dodecylpyrrolidinone	1-dodecanoyl-2-pyrrolidinone	GABA agonist	epilepsy

GABA agonist; XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
Ganaxolone; CCD 1042	(3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one	GABA agonist	epilepsy; migraine
MDL 27192	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	GABA agonist	epilepsy
PD 144550	(R)-3-(aminomethyl)-5-methylhexanoic acid	GABA agonist	epilepsy
R 7621	N1-(3-trifluoromethylphenyl)N2-nicotinoyl piperazine hydrochloride	GABA agonist	epilepsy
Vigabatrin; gamma vinyl GABA; GVG; RMI 71754; MDL 71754; RMI 71890; RMI 71894; SABRIL; SABRILEX	4-amino-5-hexenoic acid	GABA agonist	epilepsy; addiction
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
Rufinamide; CGP 33101; RUF 331	1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide	GABA antagonist	epilepsy

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	[1-(aminomethyl)cyclohexaneacetic acid]	GABA modulation	epilepsy; anxiety; pain; neuropathy; psychosis; depression
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a](1,4)benzodiazepine; benzodiazepine derivative	GABA modulation	epilepsy; anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
Co 21068	(3alpha,5beta)-3-[(4-acetylphenyl)ethynyl]-21-(3-carboxy-1-oxopropoxy)-3-hydroxypregn-20-one sodium salt	GABA modulator	epilepsy
NNC 140189	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-5-(4-methyl-1-piperazinyl)-imidazo[1,5-a]quinoxaline	GABA modulator	epilepsy
NS 2552	Unspecified	GABA modulator	anxiety; epilepsy
NS 2608	Unspecified	GABA modulator	epilepsy; anxiety
NS 2664	Unspecified	GABA modulator	epilepsy
Retigabine; D 23129; GKE 841	[2-amino-4-[[4-(fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester	GABA modulator; potassium channel activator	epilepsy
Co 21970	(3alpha,5alpha)-3-hydroxy-3-(trifluoromethyl)-pregnan-20-one	GABA partial agonist; neuroactive steroid	epilepsy
Valproate magnesium; magnesium valproate; DEPAMAG; VALPAMAG	2-propylpentanoic acid magnesium salt	GABA release	epilepsy

Valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA release	epilepsy; migraine; schizophrenia; depression
Valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release	Alzheimer disease; epilepsy
Cl 966	1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid	GABA uptake inhibitor	epilepsy
NNC 711	1,2,5,6-tetrahydro-1-[2-[[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid monohydrochloride	GABA uptake inhibitor	epilepsy
Tiagabine; tiagabine hydrochloride; NO 050328; A 70569; NO 328; NNC 050328; NNC 328; NN 301; ABT 569; GABITRIL; TIABIX	(R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinocarboxylic acid	GABA uptake inhibitor	epilepsy
3-isobutyl GABA	3-(aminoethyl)-5-methylhexanoic acid	GAD modulation, L-glutamic acid decarboxylase	Epilepsy
SNAP 5294	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5258	Unspecified	GAT3 transporter	epilepsy; anxiety; insomnia
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke

Talampanel; LY 300164	(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	glutamate antagonist; AMPA antagonist	epilepsy; amyotrophic lateral sclerosis
Excitatory amino acid antagonists	Unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
CNS 2	Unspecified	glutamate antagonist; mGluR antagonist	epilepsy
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-amino cyclopentane carboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
Dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
drug delivery system, felbamate; felbamate drug delivery system	unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Felbamate; W 554; ADD 03055; FELBATOL; FELBAMYL; TALOXA	2-phenyl-1,3-propanediol dicarbamate	glutamate antagonist; NMDA antagonist	epilepsy
GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MDL 27266	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-2-methyl-3H-1,2,4-triazol-3-one	glutamate antagonist; NMDA antagonist	epilepsy
RPR 118723	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy

YKP 509	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Metabotropic glutamate receptor modulators	Unspecified	Glutamate receptor modulation	pain; cognitive defect; schizophrenia; epilepsy
CNS 1145	N,N'-bisacenaphth-5-ylguanidine	glutamate release inhibitor	epilepsy
glycine transporter modulator	Unspecified	glycine antagonist	epilepsy; cognitive defect
MDL 100458	3-(benzoylmethylamino)-6-chloro-1H-indole-2-carboxylic acid	glycine antagonist	epilepsy
L 687414	(3R-cis)-3-amino-1-hydroxy-4-methyl-2-pyrrolidone	glycine partial agonist	epilepsy
hBGT1 transporter modulator	Unspecified	hBGT1 transporter modulator	epilepsy; anxiety; insomnia
AQ 0145	4-[1-[(adamant-3-yl)iminomethyl]piperidin-4-yl]imidazole	histamine antagonist; histamine H3 antagonist	epilepsy
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
FCE 26743	(S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide	MAO B inhibitor; MAO inhibitor	epilepsy
Remacemide, (-); FPL 14145; PR 1032646; PR 1032-646	(-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist	epilepsy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
ACEA 1011	Unspecified	NMDA antagonist; glutamate antagonist	ischemia; epilepsy
CGP 37849	(E)-(+,-)-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy
CGP 39551	(E)-(+,-)-2-amino-4-methyl-5-phosphono-3-pentenoic acid 1-ethyl ester	NMDA antagonist; glutamate antagonist	epilepsy

CGP 40116	[R-(E)]-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
D-CPP	(R)-4-(3-phosphonopropyl)-2-piperazinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
FR 115427	(+)-1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride	NMDA antagonist; glutamate antagonist	epilepsy
L 701252	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methyl]phenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke
LY 233536	(3R-(3alpha,4alpha,6beta,8alpha)-decahydro-6-(1H-tetrazol-5-ylmethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 235723	(2R-cis)-4-(1H-tetrazol-5-ylmethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 274614	(3alpha,4alpha,6beta,8alpha)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
MDL 104653	7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy

MDL 105519	(E)-3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
MDL 29814	5,7 dichlorokynurenic acid	NMDA antagonist; glutamate antagonist	epilepsy
NMDA antagonist	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NPS 1387	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
RPR 104632; RPR 110754	2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-3-carboxylic acid 1,1-dioxide	NMDA antagonist; glutamate antagonist	epilepsy
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
Conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
Conantokin G	Unspecified	peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

Fosphenytoin; fosphenytoin sodium; prophenytoin; ACC 9653; CI 982; PD 135711-15B; CEREBYX; PRO-EPA-NUTIN	5,5-diphenyl-3-[(phosphonoxy)methyl]-2,4-imidazolidinedione	Phenytoin prodrug; fosphenytoin converted to phenytoin by endogenous phosphatases	epilepsy
proline transport inhibitors	Unspecified	Proline transporter inhibitor	epilepsy; stroke
JNK 3 inhibitors	Unspecified	signal transduction inhibitor	epilepsy
Zonisamide; fenisoxine; AD 810; CI 912; PD 110843; EXCEGRAN; EXEGRAN; ZONEGRAN	1,2-benzisoxazole-3-methansulfonamide	Sodium and calcium voltage sensitive channel blockade	epilepsy
534U87; BW 534U87	Unspecified	sodium channel blocker	epilepsy
AWD 140190	4-(4-bromophenyl)-3-(4-morpholinyl)-1H-pyrrole-2-carboxylic acid, methyl ester	sodium channel blocker	epilepsy
Co 102862	2-[[4-(4-fluorophenoxy)phenyl]methylene]hydrazinecarboxamide	sodium channel blocker	epilepsy
GW 273293	Unspecified	sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
taurine transporter modulator	Unspecified	Taurine transporter inhibitor	epilepsy; brain ischemia
MDL 27531	4-methyl-3-(methylsulphonyl)-5-phenyl-4H-1,2,4-triazole	triazole	epilepsy

A 76895; ABBOTT 76895	Unspecified	Valproic acid derivative	epilepsy
Anticonvulsants	Unspecified	Valproic acid derivative	epilepsy
Antiepileptics	Unspecified	Valproic acid derivative	epilepsy
CHF 1504	Unspecified	Valproic acid derivative	epilepsy
RAP-valproic acid; DP VPA	Unspecified	Valproic acid derivative	epilepsy
ABS 103; ABS-103R	Unspecified	Valproic acid derivative	epilepsy
CHF 1355	Unspecified	Valproic acid derivative	epilepsy
Vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 30. Current Candidate Therapeutic Interventions for the Treatment of Huntington's Disease.

Product Name	Chemical Name	Action	Indication
Neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	Neurodegeneration
Brain-derived neurotrophic factor; BDNF;	BDNF, and derivatives	BDNF, growth factor; neurotrophic factor	amyotrophic lateral sclerosis; neuropathy
Dopamine release inhibitor	Unspecified	Calcium antagonist	schizophrenia
Cardiotrophin-1 secreting implant; cardiotrophin-1 secreting implant	Cardiotrophin-1 and derivatives	Cardiotrophin-1; growth factor	amyotrophic lateral sclerosis; neurodegeneration
Tacrine; THA; tetrahydroaminacrine; CI 970; COGNEX	1,2,3,4-tetrahydro-9-acridinamine	cholinesterase inhibitor	Alzheimer disease
AXOKINE	Ciliary neurotrophic factor derivative	CNTF, growth factor	amyotrophic lateral sclerosis; obesity; eye disease
Ciliary neurotrophic factor; CNTF; CNTF delivery system	CNTF and derivatives	CNTF, growth factor	amyotrophic lateral sclerosis; neuropathy

Estrogens	Estrogen and derivatives	estrogen	neuropathy; Alzheimer disease
SYM 2101	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2250	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2007	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 2192	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 1010	Unspecified	glutamate agonist; NMDA partial agonist	neurological
SYM 2315	Unspecified	glutamate agonist; NMDA partial agonist	neurological
Riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
MAb, major histocompatibility complex I; F(ab') <sup>2</sup> , MHC I	Monoclonal antibody fragment	Immunomodulation	transplant rejection
Nerve growth factor secreting implant	NGF and derivatives	NGF, growth factor	Neurodegeneration; neuropathy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect
Neurotrophin-3 secreting implant	NT-3 and derivatives	NT-3, growth factor	Alzheimer disease; Parkinson disease; neuropathy
Neurotrophin-4; NT-4	NT-4 and derivatives	NT-4, growth factor	neuropathy; diabetes

Naimefene; nalmetrene; JF 1; INCYSTEINE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Synthetic opioid alkaloids	Unspecified	Opioid ligand	Neurodegeneration

Table 31. Current Candidate Therapeutic Interventions for the Treatment of Migraine

Product Name	Chemical Name	Action	Indication
ALX 0646	Unspecified	5HT agonist	migraine
CP 122288	(R)-N-methyl-3-[(1-methyl-2-pyrrolidinyl)methyl]-1H-indole-5-methanesulfonamide	5HT agonist	migraine
IS 159	Unspecified	5HT agonist	migraine
avitiptan; avitriptan fumarate; BMS 180048; BMS 18004802	3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
BW 324C91	Unspecified	5HT agonist; 5HT1 agonist	migraine
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
D 1997	2-quinolineethanamine	5HT agonist; 5HT1 agonist	migraine
GR 127607	Unspecified	5HT agonist; 5HT1 agonist	migraine
GR 40370	Unspecified	5HT agonist; 5HT1 agonist	migraine

Naratriptan; naratriptan hydrochloride; GR 85548; GR 85548A; GR 85548X; NARAMIG; AMERGE	N-methyl-3-(1- methyl-4- piperidinyl)-1H- indole-5- ethanesulfonamide	SHT agonist; 5HT1 agonist	migraine
Sumatriptan; GR 43175; GR 43175X; GR 43175A; GR 43175C; SN 308; GW 102; IMIGRAN; IMITREX; SUMADOL; IMIJECT; ARCOIRAN	3-[2- (dimethylamino)ethyl] 1-N-methyl-1H- indole-5- methanesulfonamide	SHT agonist; 5HT1 agonist	migraine
tonabersat; SB 220453	(3S-cis)-N-(6-acetyl- 3,4-dihydro-3- hydroxy-2,2- dimethyl-2H-1-benz pyran-4-yl)-3-chloro- 4-fluorobenzamide	SHT agonist; 5HT1 agonist	migraine
CP 93129	1,4-dihydro-3- (1,2,3,6-tetrahydro-4- pyridinyl)-5H- pyrrolo[3,2-b]pyridin- 5-one	SHT agonist; 5HT1B agonist	migraine
Frovatriptan; VML 251; SB 209509; MIGUARD	(R)-2,3,4,9- tetrahydro-3- (methylamino)-1H- carbazole-6- carboxamide	SHT agonist; 5HT1B agonist; 5HT1D agonist	migraine
rizatriptan; rizatriptan benzoate; rizatriptan sulfate; MK 462; MAXALT	N,N-dimethyl-5-(1H- 1,2,4-triazol-1- ylmethyl)-1H-indole- 3-ethanamine	SHT agonist; 5HT1B agonist; 5HT1D agonist	migraine
Almotriptan; LAS 31416	1-[[3-[2- (dimethylamino)ethyl] 1-H-indol-5- yl]methyl]sulfonyl]py- rolidine	SHT agonist; 5HT1D agonist	migraine

almiditan; R 91274; PASMIGREN; PASMIGRINE	(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine	SHT agonist; SHT1D agonist	migraine
ALX 1323	Unspecified	SHT agonist; SHT1D agonist	migraine
aromatic triflates,	Unspecified	SHT agonist; SHT1D agonist	depression; migraine
eletriptan; UK 116044; RELPAX	(R)-3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole	SHT agonist; SHT1D agonist	migraine
GMC 2020	Unspecified	SHT agonist; SHT1D agonist	depression; migraine
GMC 2021	Trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	SHT agonist; SHT1D agonist	depression; migraine
L 741519	3-(1-methyl-4-piperidinyl)-5-(4H-1,2,4-triazol-4-yl)-1H-indole	SHT agonist; SHT1D agonist	migraine
L 741604	N,N-dimethyl-5-(4H-1,2,4-triazol-4-yl)-1H-indole-3-ethanamine	SHT agonist; SHT1D agonist	migraine
LAS 31727	Unspecified	SHT agonist; SHT1D agonist	migraine
VS 395	3-[3-[4-(5,6-dimethoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	SHT agonist; SHT1D agonist	migraine

F 11356; L 0076	1-[[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-4-(4-cyanophenyl)piperazine monohydrochloride	SHT agonist; SHT1D agonist; SHT1B agonist	migraine
Zolmitriptan; 311C90; BW 311C90; ZOMIG	(S)-4-[[3-[2-(dimethylamino)ethyl]1H-indol-5-yl]methyl]-2-oxazolidinone	SHT agonist; SHT1Dalpha agonist; SHT1Dbeta agonist; SHT1B agonist	migraine
LY 334370	4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide	SHT agonist; SHT1F agonist	migraine
selective serotonin 1F receptor agonists,	Unspecified	SHT agonist; SHT1F agonist	migraine
Sergolexole; LY281067	trans-4-methoxycyclohexyl 1-isopropyl-6-methylergoline-8beta-carboxylate	SHT antagonist; SHT2 antagonist	migraine
tropoxin	O-(3,4,5-trimethoxybenzoyl)oxime-8-methyl-8-azabicyclo[3.2.1]octan-3-one monohydrochloride	SHT antagonist; SHT2 antagonist	migraine
dotarizine; FI 6026	1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine	SHT antagonist; SHT2 antagonist; SHT1C antagonist; calcium antagonist	migraine
Bemesetron; MDL 72222	3,5-dichlorobenzoic acid, endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester	SHT antagonist; SHT3 antagonist	emesis; migraine
LY 53857	(8beta)-6-methyl-1-(1-methylethyl)ergoline-8-carboxylic acid 2-hydroxy-1-methylpropyl ester,(Z)-2-butenedioate (1:1)	SHT antagonist; vasodilator	migraine

fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression
fluoxetine, (S)-; (S)-fluoxetine	(S)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine
5HT4 human neuroreceptor; neuroreceptor, 5HT4	Unspecified	5HT4 human neuroreceptor;	Irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
drug delivery system, transdermal lidocaine; PAINTROL TW; PAINTROL HM; PAINTROL TV	unspecified	analgesic	pain; migraine
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	analgesic; NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha, alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
drug delivery system, intranasal propranolol; propranolol intranasal; MIGRASTAT	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	migraine
Bradykinin antagonist/mu agonist,	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	Inflammation; pain; migraine

calcitonin gene-related peptide (CGRP) receptor modulators,	Unspecified	Calcitonin gene related peptide modulation	migraine; diabetes
Nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
Lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
BIBN 4096	Unspecified	CGRP antagonist	migraine
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
Ganaxolone; CCD 1042	(3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one	GABA agonist	epilepsy; migraine
valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA releasing agent	epilepsy; migraine; schizophrenia; depression

4991W93	Unspecified	Inflammation inhibitor	migraine
FK 888	trans-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N- methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
GR 205171	(2S-cis)-N-[(2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist	emesis; migraine
neutral endopeptidase; NEP	Unspecified	neutral endopeptidase; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
nitric oxide inhibitor;	unspecified	nitric oxide inhibitor	migraine
diclofenac potassium; CGP 45840B; CATAFLAM; CATAFLAN; DICLOFEN; VOLTAREN	potassium (o-(2,6-dichloroanilino)-phenyl)acetate	NSAID	Inflammation; migraine; surgery
dipitant; RPR 100893	[3aS-[2(R*),3alpha,4beta,7alpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoiindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine

BMS 182246	Unspecified	Sumitriptan-like activity	migraine
ALX 0625	Unspecified	Unspecified	migraine
BMS 181885	3-[[3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-1H-indol-5-yl]amino]-4-methyl-3-cyclobutene-1,2-dione	Unspecified	migraine
drug delivery system, solid liquid polymer, migraine therapy	Unspecified	Unspecified	migraine
migraine therapy	Unspecified	Unspecified	migraine
Parthenolide	Unspecified	Unspecified	migraine
SB 218842	Unspecified	unspecified	migraine

Table 32. Current Candidate Therapeutic Interventions for the Treatment of Multiple Sclerosis

Product Name	Chemical Name	Action	Indication
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
VLA4 integrin antagonist,	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, corticotropin; corticotropin delivery system; drug delivery system, ACTH	Unspecified	Corticotropin; hormone	multiple sclerosis
interferon agonists,	Unspecified	cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
gene therapy, cytokines,	Unspecified	cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis

Interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
Spirogermanium; NSC 192965; SPIRO-32	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
SRI 62834	(+,-)-2-[[hydroxy[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphoryloxy]-N,N,N-trimethyl-ethanamium, inner salt.	ether lipid	cancer; multiple sclerosis
Transforming growth factor beta 2; TGF beta2; FOVALIN; BetaKine	Unspecified	growth factor; cicatrizant	retinopathy; osteoporosis; skin ulcer; multiple sclerosis
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neural progenitor regulatory factor	Unspecified	growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
AG 284	MHC molecule with myelin basic protein	Immunomodulation	multiple sclerosis
Multiple sclerosis therapy	Chimeric virus particles	Immunomodulation	multiple sclerosis
Oligodendroglial trophic factor; OTF	Peptide	Immunomodulation	multiple sclerosis
RecepTox-MBP	peptide; fusion toxin	Immunomodulation	multiple sclerosis

MAb, 23F2G; MAb, leukointegrin; Hu 23F2G; Leuk Arrest	23F2G; MAb, leukointegrin monoclonal antibody	Immunomodulation;	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
MAb, OX40-ricin A; immunotoxin OX40-ricin A	Immunotoxin monoclonal antibody;	Immunomodulation;	multiple sclerosis
MAb, alpha4beta1 integrin; AN 100226; ANTEGREEN	Unspecified	Immunomodulation; monoclonal antibody	multiple sclerosis; Crohn disease; ulcerative colitis
MAb, M1	Unspecified	Immunomodulation; monoclonal antibody	trauma; multiple sclerosis
MAb, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Unspecified	Immunomodulation; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
ABR 215062	Unspecified	Immunomodulator	multiple sclerosis
Glatiramer acetate; copolymer 1; COP 1; COPAXONE	L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)	Immunomodulator	multiple sclerosis
PA 1093	Herpes virus 6 protein derivative	Immunomodulator	multiple sclerosis
Roquinimex; LS 2616; FCF 89; LINOMIDE	1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide	immunostimulant	multiple sclerosis
AI 101	Unspecified	immunosuppressant	multiple sclerosis
AI 102	Unspecified	immunosuppressant	multiple sclerosis
Galaptin L-14-1; immunomodulatory lectin-1; IML-1	Unspecified	immunosuppressant	transplant rejection; multiple sclerosis
PEPTIMER	Unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
AI 100; MYLORAL	Unspecified	immunosuppressant	multiple sclerosis

Gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxysspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215-1; SPANIDIN; SUPANIDIN	(+,-)-7-[(aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
MAb, gamma interferon, humanized; SMART anti-gamma interferon	Unspecified	immunosuppressant monoclonal antibody;	systemic lupus erythematosus; multiple sclerosis
Lymphocyte activation gene 3 protein; LAG 3 protein	Unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MP 4	Unspecified	immunosuppressant; biotechnology; apoptosis inducer	multiple sclerosis
ATP 012; TP 12	Unspecified	immunosuppressant; biotechnology; peptide	multiple sclerosis
MAb, T cell antigen receptor; ATM 027; TM 27	Unspecified	Immunosuppressant; monoclonal antibody;	multiple sclerosis
Priliximab; MAb, humanized CD4; cM-T412; CEN 000029; CENTARA	Immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412 kappa-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
Lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis

MAb, CD40 ligand; 5C8; ANTOVA	Unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
Autoimmune disease therapy,	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
Cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
alpha4beta1 integrin antagonist	Unspecified	integrin antagonist; cell adhesion inhibitor; alpha4 beta1 integrin antagonist	multiple sclerosis
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl-L-alpha-aspartyl-L-valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
Interferon beta-1a; IFN beta; AVONEX	interferon beta-1a	interferon	viral infection; multiple sclerosis; cancer
Interferon beta-1a; interferon beta; IFN-beta; REBIF	Unspecified	interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
Interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETAFERON	2-166-interferon beta 1 (human fibroblast reduced)	interferon	multiple sclerosis; cancer; viral infection
Interferon tau	Unspecified	interferon	multiple sclerosis

alpha interferon, natural; OMNIFERON	Unspecified	interferon	multiple sclerosis; viral infection
Interferon beta; FRONE	Unspecified	interferon	multiple sclerosis; cancer; eye disease
Solimastat; BB 3644	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl]-2-methoxy-5-methylhexanohydroxamic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
LG 21101	Unspecified	NSAID	inflammation; multiple sclerosis
NBI 116	Unspecified	NSAID	multiple sclerosis; rheumatoid arthritis
PKC-RACK interaction inhibitors, white blood cell migration inhibitors,	Unspecified	NSAID, PKC-RACK interaction inhibitors	arthritis; multiple sclerosis; asthma
Neurotactin blockers	Unspecified	NSAID, white blood cell migration inhibitors,	inflammation; multiple sclerosis
Lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N{[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl}sulfonyl}-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
Ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
CGP 77116	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
NBI 114	Unspecified	peptide	multiple sclerosis
NBI 115	Unspecified	peptide	multiple sclerosis

NBI 5788; MSP 771	D-al-a-L-lys-L-pro-L-val-L-val-L-his-L-leu-L-phe-L-al-a-L-as-p-L-ile-L-val-L-thr-L-pro-L-arg-L-thr-L-pro	peptide	multiple sclerosis
rD-mPGtide	Unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
TNF receptor antagonist; TNF receptor antagonist, rolipram; ZK 62711; ME 3167; ADEO	Unspecified	peptide; NSAID	rheumatoid arthritis; multiple sclerosis
	4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
SH 636	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	multiple sclerosis
drug delivery system, IPDAS fampridine; fampridine IPDAS	Unspecified	potassium channel blocker	multiple sclerosis; neuropathy
Fampridine; EL 970; AVITROL	4-pyridinamine	potassium channel blocker	multiple sclerosis
adapalene; CD 271; DIFFERINE; DIFFERIN	6-(4-methoxy-3-tricyclo[3.3.1.1(3,7)]dec-1-ylphenyl)-2-naphthalenecarboxylic acid	retinoid agonist; retinoid; RAR agonist; RARbeta agonist	acne; multiple sclerosis
drug delivery system, biodegradable micellar paclitaxel; paclitaxel micellar	Unspecified	Taxane; DMARD; NSAID; microtubule inhibitor	rheumatoid arthritis; multiple sclerosis
CC 1080	Unspecified	TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis
Thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

Mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHAQ; DHAD; NOVANTRONE; NOVATRON	1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione	Topoisomerase inhibitor	cancer; multiple sclerosis
TCR peptide, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, activated T cells; vaccine, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, multiple sclerosis; vaccine, Vbeta6.2/6.5 T cell receptor; AI 208; IR 208	Vaccine	vaccine	multiple sclerosis
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
VCAM antagonists	Unspecified	vascular cell adhesion molecule inhibitor; NSAID	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 609	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 772	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
ZD 7349	Unspecified	VLA 4 antagonist; integrin antagonist; NSAID; cell adhesion inhibitor	multiple sclerosis; arthritis

Table 33. Current Candidate Therapeutic Interventions for the Treatment of Pain

Product Name	Chemical Name	Action	Indication
anpirtoline	4-[(6-chloro-2-pyridyl)thio]piperidine	5HT agonist; 5HT1B agonist; analgesic	pain
SHT antagonists	Unspecified	5HT antagonist; 5HT1A antagonist; analgesic	pain
SP 186	Unspecified	SHT reuptake inhibitor; analgesic	pain

AAL 13	2-[4-(3-chloropropyl)-1-piperazinyl]quinoline	SHT reuptake inhibitor; analgesic; NSAID	inflammation; pain
GR 79236	(1S-trans)-N-(2-hydroxycyclopentyl)adenosine	adenosine agonist; adenosine A1 agonist	pain; coronary artery disease
UP 20232	Unspecified	adenosine agonist; analgesic	pain; neuropathy
adenosine analogues	Unspecified	adenosine analogues analgesic	pain
analgesic adenosine regulating agents	Unspecified	adenosine regulating agent	pain
GP 1683	Unspecified	adenosine regulating agent; analgesic	pain
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	adrenergic alpha2 human neuroreceptors analgesic	research tool; pain; hypertension; glaucoma
S 18616	8-chloro-3,4-dihydrospiro[naphthalene-2(1H),4'(5'H)-oxazol]-2'-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain
SNAP 5143	Unspecified	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain; glaucoma
RWJ 52807	Unspecified	alpha2 adrenergic agonist; alpha adrenergic agonist; analgesic	pain
ABT 594	(R)-2-chloro-5-(2-azetidinylmethoxy)pyridine	analgesic	pain
analben	Unspecified	analgesic	rheumatoid arthritis; pain
analgesic,	2-phenylimidazo[2,1-b]benzothiazole-3-propanoic acid 9,9-dioxide	analgesic	pain
analgesic,	9-phenyl-9H-thioxanthen-9-ol propanoate	analgesic	pain

analgesic	N-[4-(4-methyl-2-thiazolyl)-1-[2-(1H-pyrazol-1-yl)ethyl]-4-piperidinyl]N-phenylpropanamide	analgesic	pain; anesthesia
analgesic,	Unspecified	analgesic	pain
analgesic	(R)-3-amino-2,3,4,9-tetrahydrothiopyran(2,3-b)indole	analgesic	pain
analgesic	(R)-3-methylamino-2,3,4,9-tetrahydrothiopyran(2,3-b)indole	analgesic	pain
analgesic	(R)-3-dimethylamino-2,3,4,9-tetrahydrothiopyran(2,3-b)indole	analgesic	pain
analgesic,	Unspecified	analgesic	pain
analgesic	5-(4-methylbenzoyl)-6-(methylthio)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1-carboxylic acid	analgesic	pain
analgesics	Unspecified	analgesic	pain
Analgesics	Unspecified	analgesic	pain; neuropathy
BCH 1788	Unspecified	analgesic	pain
buprenorphine + naloxone; naloxone + buprenorphine	Unspecified	analgesic	pain
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL;	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide	analgesic	pain; neuropathy; diabetes
cizolirtine; E 4018	N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylimethoxy]ethanamine	analgesic	pain
D 20450	Unspecified	analgesic	pain
D 21151	1-phenoxyphthalazine	analgesic	pain
dexpemedolac; PEM 420; WAY PEM 420	(1S-cis)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran of[3,4-b]indole-1-acetic acid	analgesic	pain

dezocine; WY 16225; DALGAN	[5R-(5'alfa,11'alfa,13S*)]-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-11-methanobenzocyclodeen-3-ol	analgesic	pain
F 9004T	Unspecified	analgesic	pain
FID 072021	3-atropanyl 2-(4-chlorophenoxy)butyrate maleate	analgesic	pain; cognitive defect
filenadol; FI 2024	(R*,S*)(+,-)-beta-1,3-benzodioxol-5-yl-alpha-methyl-4-morpholineethanol	analgesic	pain
flubichin	Unspecified	analgesic	pain
flupirtine; D 998; W 2964M; KATADOLON	[2-amino-6-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl], ethyl ester, carbamic acid	analgesic	pain; neurological
gapxavanyl; DA 5018; DA 50018; KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
GW 275919	Unspecified	analgesic	pain
JTC 801	Unspecified	analgesic	pain
KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pemedolac; AY 30715	cis-(+,-)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran o[3,4-b]indole-1-acetic acid	analgesic	pain
peripheral nervous system therapy	Unspecified	analgesic	pain; urinary tract disorder

phenaridine; fenaridin	N-[2,5-dimethyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide	analgesic	pain
pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
Ro 158081	Unspecified	analgesic	pain
ruzadolane; UP 2691	3-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]thio]-1,2,4-triazolo[4,3-a]pyridine	analgesic	pain
S 01	5,6-dihydro-9,10,14-trimethoxy-8H-1,3-dioxolo[4,5-h]isoindolo[1,2-b][3]benzazepine-8-one	analgesic	pain
S 14080	benzoyl-6 dihydro-2,3-benzothiazole	analgesic	pain
S 8117	Unspecified	analgesic	pain
sameridine; LPB 139	N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidinecarboxamide	analgesic	local anesthesia; pain
SJ 2321	Unspecified	analgesic	pain
SYM 2081	(4R)-4-methyl-L-glutamic acid	analgesic	pain
tramadol analogues	Unspecified	analgesic	pain
UP 52204	Unspecified	analgesic	pain
V 2	Unspecified	analgesic	pain
NC 164	Unspecified	analgesic	pain
dynorphin A; dynorphin A (1-13)	Unspecified	analgesic; peptide	pain
bradykinin antagonists	Unspecified	bradykinin antagonist; analgesic; NSAID	pain; inflammation; septic shock
bradykinin antagonist/mu agonist, Cortech	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain; migraine

CP 0880; CP 880	N-[[3-[[1-oxo-3-[4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-3-piperidinyl]propyl]amino]phenyl]acetyl]-beta-alanyl-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain
FR 173657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamin o]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
AM 336	Unspecified	calcium channel blocker; analgesic	pain
calcium channel blockers,	Unspecified	calcium channel blocker; analgesic	pain
SNX 239	Unspecified	calcium channel blocker; analgesic	pain; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
NE 21610	(Z)-N-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-9-octadecenamide	capsaicin analogue; analgesic	pain

L 365031	4-bromo-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)benzamide	cholecystokinin A antagonist; cholecystokinin antagonist	pain
L 156586	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156587	14,15-didehydro-14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156588	14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156906	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
devazepide; L 364718; MK 329	(S)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide	cholecystokinin antagonist; cholecystokinin A antagonist; analgesic	pain
L 365260	(R)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea	cholecystokinin B antagonist; cholecystokinin antagonist; analgesic	pain
vedaclidine; NNC 111053; LY 297802	(S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane	cholinergic agonist; muscarinic agonist; analgesic	pain
CMI 980	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	pain
nicotinic agonists	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	cognitive defect; pain; nicotine withdrawal
SIB T1887	Unspecified	cholinergic antagonist; nicotinic antagonist; analgesic	pain
RU 54808	Unspecified	COX inhibitor; 5 lipoxygenase inhibitor	pain

drug delivery system, transdermal ketorolac; ketorolac transdermal	Unspecified	COX inhibitor; analgesic	pain
ketorolac; ketorolac trometamol; BPPC; RS 37619; RS 3761900313; TORADOL; TARASYN; TORATEX; ACULAR; LIDIXOL; TORA DOL; TORA-DO; TONUM; KETRODOL	(+,-)-5-benzoyl-2,3- dihydro-1H- pyrrolizine-1- carboxylic acid	COX inhibitor; analgesic	pain
meloxicam; UH AC62; UH AC26XX; MOB1C; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl- N-(5-methyl-2- thiazolyl)-2H-1,2- benzothiazine-3-car- boxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
AHR 10037	2-amino-3-(4- chlorobenzoyl)benzen- acetamide	COX inhibitor; analgesic; NSAID	inflammation; pain
D 1367	Unspecified	COX inhibitor; analgesic; NSAID	pain; inflammation
T 614	N-[3-(formylamino)- 4-oxo-6-phenoxy-4H- 1-benzopyran-7-yl]- methanesulfonamide	COX inhibitor; analgesic; NSAID; DMARD	inflammation; pain
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
L 783003	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain
parecoxib; SC 69124A	N-[[4-(5-methyl-3- phenyl-4- isoxazolyl)phenyl]sul- fonyl]propanamide	COX inhibitor; COX 2 inhibitor; analgesic	pain
celecoxib; SC 58635; YM 177	4-[5-(4- methylphenyl)-3- (trifluoromethyl)-1H- pyrazol-1- yl]benzenesulfo- namide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer

CT 3	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
JTE 522	4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
L 745337	N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 752860	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
MK 663	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
NS 398	N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
Rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
Valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
COX 2 inhibitors,	Unspecified	COX inhibitor; COX 2 inhibitor; NSAID; analgesic	inflammation; osteoarthritis; pain
Lornoxicam; chlortenoxicam; Ro 139297; TS 110; CTX; SAFEM; XEFO; LORCAM	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazin e-3-carboxamide 1,1-dioxide	COX inhibitor; NSAID; analgesic	inflammation; pain
E 5090	(Z)-3-[4-(acetoxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid	cytokine inhibitor; analgesic; NSAID	inflammation; pain

TAN 67	trans-3-(1,3,4,5,12,12a-hexahydro-2-methylpyrido[3,4-b]acridin-4a(2H)-yl)phenol	delta agonist; opiate agonist; analgesic	pain
Prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino- 2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
FR 64822	N-(3,6-dihydro-1(2H)-pyridinyl)-N'-4-pyridinylurea	dopamine agonist; dopamine D2 agonist; analgesic	pain
BW 443C	L-tyrosyl-D-arginylglycyl-4-nitro-L-phenylalanyl-L-prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
KK 3	[S-(R*,R*)]-alfa-amino-4-hydroxy-N-[4-[[1-(hydroxymethyl)-2-phenylethyl]amino]-4-oxobutyl]-N-methylbenzenepropanamide	enkephalinase inhibitor; analgesic	pain
ONO 9902	[1S-[1R*[R*(R*)]]]-4-[[2-[(1,3-dihydro-3-oxo-1-isobenzofuranyl)thio]methyl]-1-oxo-3-phenylpropyl]amino]-5-oxo-5-(phenylamino)pentanoic acid	enkephalinase inhibitor; analgesic	pain
Excitatory amino acid antagonist	Unspecified	excitatory amino acid antagonist; analgesic	pain
CGP 29030A	1-[2-(4-chlorophenyl)ethyl]-4-(3,5-dimethoxybenzoyl)-piperazine, monohydrochloride	GABA agonist; analgesic	pain

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA release analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
galanin1 antagonists,	Unspecified	Galanin 1 antagonists	obesity; pain; cognitive defect
galanin modulators,	Unspecified	Galanin modulation analgesic	obesity; diabetes; cognitive defect; pain
Mipragoside; AGF 44	[R-[R*,S*-(E)]]-N-[1-[[O-[N-acetyl-1-(1-methylethyl)-alpha-neuraminosyl]-2-(3-O-[O-beta-D-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside analogue; analgesic; NSAID	inflammation; pain
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain
BW 524C79	Unspecified	glutamate antagonist; analgesic	pain
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
GV 196771; GV 196771A	E-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid monosodium salt	glutamate antagonist; NMDA antagonist; analgesic	pain

CP 331; CP 6	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[[2-oxo-2-[(3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]ethyl]thio]ethyl ester	histamine antagonist; histamine H2 antagonist; analgesic; NSAID	inflammation; pain
Melanocortin receptor-1 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
Metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
remifentanil; GI 87084; GI 87084B; GI 87084X; ULTIVA	4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid methyl ester	mu agonist; opiate agonist; analgesic	pain
trefentanil; trefentanil hydrochloride; A 3665	N-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl)-4-phenyl-4-piperadinyl)-N-(2-fluorophenyl)propanamide monohydrochloride	mu agonist; opiate agonist; analgesic	pain
BCH 150	Unspecified	mu agonist; opiate agonist; peptide; analgesic	pain
mirfentanil; mirfentanil hydrochloride; A 3508	N-[1-(2-phenethyl)-4-piperidinyl]-N-pyrazinyl-2-furancarboxamide	mu antagonist; opiate antagonist; analgesic	anesthesia; pain
Narcotics	Unspecified	Narcotics analgesic	pain; addiction; intoxication
WIN 64821	(2alpha,2'beta,5beta,5'alpha)-2,5:2',5'-dide(epidithio)-3,3'-dimethyl-19,19'-dideoxy-19,19'-diphenylchaetocin	neurokinin antagonist; analgesic	pain

GR 82334	9-deglycine-10-[(5S)-6-oxo-L-alfa-(2-methylpropyl)-1,7-diazaspiro[4.4]nonane-7-acetic acid]-11-L-tryptophanamide physalemin	neurokinin antagonist; analgesic; neurokinin 1 antagonist	pain
Ianepitant; LY 303870	(R)-N-[2-acetyl][(2-methoxyphenyl)methyl]amino]-1(1H-indol-3-yl)methyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
CP 96345	(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octa-n-3-amine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID; substance P antagonist	inflammation; pruritis; pain
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence
neurokinin antagonists	Unspecified	neurokinin antagonist; analgesic; NSAID	pain; inflammation
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain

neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
JMV 449	(S)-1-de-L-lysine-2-[N2-(2,6-diaminoethyl)-L-lysine]neuromedin N (pig spinal cord)	neurotensin analogue; analgesic	pain
nitroglycerin; glyceryl trinitrate; trinitrin; ANOGESIC	Unspecified	nitrate; cicatrizant; analgesic	skin ulcer; angina; pain
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
ACEA 1328	5-nitro-6,7-dimethyl-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	pain
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
NMDA antagonists,	Unspecified	NMDA antagonist; glutamate antagonist; analgesic	pain
conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
nociceptor blockers, NB 1	Unspecified	nociceptor blockers analgesic	pain
non-narcotic analgesic	Unspecified	non-narcotic analgesic analgesic	pain

2-halopyridine	Unspecified	NSAID	inflammation; pain; insomnia
Analgesic	3-methyl-5-oxobenzo(b)thieno(2,3-d)thiazolo(3,2-a)pyrimidine-2-carboxylic acid ethyl ester	NSAID	pain; inflammation; gastrointestinal ulcer
BN 50370	1,3-dihydro-3,6-dimethyl-7-hydroxy-furo(3,4)pyridine hydrochloride	NSAID	inflammation; pain
Diaveridine; EGIS 5645	5-[(3,4-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine	NSAID	inflammation; pain
drug delivery system, hydrogel diclofenac; diclofenac hydrogel; DICLOFENAC HYCORE-R	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT diclofenac; diclofenac sustained release	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	Unspecified	NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
drug delivery system, sustained release microsphere flurbiprofen; flurbiprofen, sustained release	Unspecified	NSAID	pain; inflammation
DTA	4'-methyl-[1,1':3',1"-terphenyl]-5'-acetic acid	NSAID	inflammation; pain
FA 401	1-(4-fluorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester	NSAID	pain; inflammation

Flurbiprofen axetil; LFP 83; ROPION; LIPFEN	2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid, 1-(acetoxy)ethyl ester	NSAID	pain; inflammation
HU 239	(6aR-trans)-3-(1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid	NSAID	inflammation; pain
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	NSAID	inflammation; pain; asthma
M 5011; T 3788	alpha-2-[4-(3-methylthienyl)phenyl]propionic acid	NSAID	inflammation; pain
Proglumetacin; protacetin; CR 604; IMPETIN; PROXIL; PROXATIL; AFLOXAN; TOLINDOL; BRUXEL; MIRIDACIN	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[4-[3-[(4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester, (+,-)-	NSAID	inflammation; pain
RP 67580	(3aR-cis)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol-4-one	NSAID	pain; inflammation
SC 107	Unspecified	NSAID	arthritis; pain
TZI 41078	Unspecified	NSAID	inflammation; pain
Acceclofenac; YT 919; AIRTAL; GERBIN; FALCOL; BRISTAFLAM; PRESERVEV; BIOFENAC; BARRACAN	2-[(2,6-dichlorophenyl)amino]benzenoacetic acid, carboxymethyl ester	NSAID; analgesic	pain; inflammation

Amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
bromfenac; bromfenac sodium; AHR 10282; DURACT	2-amino-3-(4-bromobenzoyl)benzenoic acid	NSAID; analgesic	inflammation; pain
CHF 2003	Unspecified	NSAID; analgesic	pain; inflammation
Dexketoprofen trometamol; LM 1158; TRIS; D 1158; ENANTYUM; QUIRALAM; KETESSE	(S)-3-benzoyl-alpha-methylbenzeneacetic acid cpd with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)	NSAID; analgesic	pain; inflammation
Esfibruprofen; flurbiprofen, (S)-; (S)-flurbiprofen; BTS 24332	(S)-2-fluoro-alpha-methyl-4-biphenylacetic acid	NSAID; analgesic	pain
florifanine; FI 2522	2-(1-pyrrolidinyl)ethyl-N-[7-(trifluoromethyl)-4-quinolyl]anthranilate	NSAID; analgesic	inflammation; pain
flosulide; ZK 38997; CGP 28238; CGS 28238; SH 459	N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	NSAID; analgesic	inflammation; pain
FS 205397	6-ethoxy-2,3-dihydro-3,3-dimethyl-1H-indole methanesulfonate	NSAID; analgesic	pain
HAI 105	6,11-dihydro-2-methoxy-alpha-methyl-11-oxodibenzo[b,e]oxepin-3-acetic acid	NSAID; analgesic	pain; inflammation
HN 3392	N-(4-(4-methoxyphenyl)-5-phenylthiazolyl)	NSAID; analgesic	inflammation; pain
mofezolac; N 22; DISOPAIN	3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid	NSAID; analgesic	inflammation; pain

Nabumetone; BRL 14777; RELIFEN; RELIFEX; LISTRAN; PRODAG; BALMOX; NABUMETON; RELAFEN	4-(6-methoxy-2-naphthyl)-2-butanone	NSAID; analgesic	pain; inflammation
olvanil; oluvanil; NE 19550	N-vanillyloleamide	NSAID; analgesic	pain; inflammation; viral infection
Pelubiprofen; CS 670; RS 2131	alpha-methyl-4-[(2-oxocyclohexylidene)methyl]benzenoacetic acid	NSAID; analgesic	inflammation; pain
piroxicam betadex; piroxicam cyclodextrin; CHF 1194; BREXIN; BREXINE; BREXIDOL; CYCLADOL; BREXICAM; BREXINIL	4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound with beta-cyclodextrin	NSAID; analgesic	pain; inflammation
Polyunsaturated fatty acids, PUFA	Unspecified	NSAID; analgesic	inflammation; pain
Tenosal; MR Y 134	2-thiophenecarboxylic acid, ester with salicylic acid	NSAID; analgesic	pain
Tifurac; RS 82917; RS 82917030	7-[4-(methylthio)benzoyl]-5-benzofuranacetic acid	NSAID; analgesic	inflammation; pain
Tilnoprofen arbame; Y 23023	(+/-)-alpha-2-methyl-5H-[1]benzopyran[2,3-b]pyridine-7-acetic acid, 2-(dimethylamino)-2-oxoethyl ester	NSAID; analgesic	inflammation; pain
HCT 3012	Unspecified	NSAID; nitric oxide donor	pain; inflammation
HCT 6015	Unspecified	NSAID; nitric oxide donor	pain

NCX 4016	2-(acetyloxy)benzoic acid, 2-[(nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
Samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424;	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis[phosphonato]](8-)[N,N',OP,OP',OP'',OP'']-]samarate(5)-153Sm	NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
Analgesic, human serum albumin conjugated opioid peptide	Unspecified	opiate agonist	pain
AXC 3742	Unspecified	opiate agonist	pain
AXC 3943	Unspecified	opiate agonist	pain
drug delivery system, hydrogel pethidine; pethidine hydrogel	Unspecified	opiate agonist	pain
Oxycodone + ibuprofen; ibuprofen + oxycodone	Unspecified	opiate agonist	pain
ADL 21294	Unspecified	opiate agonist; analgesic	pain; corneal abrasion
Analgesic	Unspecified	opiate agonist; analgesic	pain
Brifentanil; A 3331	(+,-)-cis-N-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide	opiate agonist; analgesic	
drug delivery system, ANCHOR opioid agonist	Unspecified	opiate agonist; analgesic	pain

drug delivery system, transdermal fentanyl; TTS-fentanyl; fentanyl transdermal; KJK 4263; SUBLIMAZE; DURAGESIC; DUROGESIC	Unspecified	opiate agonist; analgesic	pain
LEF 576; BCH 3963	Unspecified	opiate agonist; analgesic	pain
ocfentanil; A 3217	N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide	opiate agonist; analgesic	pain
TRK 820	(2E)-N-[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide monohydrochloride	opiate agonist; analgesic; kappa agonist	pain
BW 373U86	[1(S*),2alfa,5beta]-(+,-)-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N,N-diethylbenzamide	opiate agonist; delta agonist; analgesic	pain
SB 235863	Unspecified	opiate agonist; delta agonist; analgesic	pain
SNF 8912	(H2N-(CH2)7-CO-NH)Asp-Tyr-(N-Me)Nle-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2	opiate agonist; delta agonist; analgesic	pain
SNF 9007	L-alpha-aspartyl-L-tyrosyl-D-phenylalanylglycyl-L-tryptophyl-N-methyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	opiate agonist; delta agonist; analgesic	pain

opioid mimetic peptides	Unspecified	opiate agonist; delta agonist; analgesic; peptide	pain; addiction
Apadoline; RP 60180; RP 60180A; RPR 60180	(R)-10-[1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-10H-phenothiazine-2-carboxamide	opiate agonist; kappa agonist; analgesic	pain
BRL 53001A	(2S)-1-(1-oxo-3,4-dihydro-(2H)-naphth-6-yl)acetyl-2-dimethylaminomethyl piperidine hydrochloride	opiate agonist; kappa agonist; analgesic	pain
CL 891601	Unspecified	opiate agonist; kappa agonist; analgesic	pain
DUP 747	trans-(+,-)-3,4-dichloro-N-methyl-N-[1,2,3,4-tetrahydro-5-methoxy-2-(1-pyrrolidinyl)-1-naphthalenyl]benzene acetamide	opiate agonist; kappa agonist; analgesic	pain
E 2078; 66A078	N-methyl-L-tyrosylglycylglycyl-L-phenylalanyl-L-leucyl-L-arginyl-N2-methyl-L-arginyl-N-ethyl-D-leucinamide	opiate agonist; kappa agonist; analgesic	pain
EMD 60400	N-methyl-N((1S))-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl-2-amino-phenylacetamide	opiate agonist; kappa agonist; analgesic	pain
GR 102908	Unspecified	opiate agonist; kappa agonist; analgesic	pain
GR 107537	[S-(R*,R*)]-5-[(3,4-dichlorophenyl)acetyl]-4,5,6,7-tetrahydro-4-[(3-hydroxy-1-pyrrolidinyl)methyl]furo[3,2-c]pyridine	opiate agonist; kappa agonist; analgesic	pain

ICI 197067	(S)-3,4-dichloro-N-methyl-N-[2-methyl-1-(1-pyrrolidinylmethyl)propyl]benzeneacetamide monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
ICI 204448	(+,-)-[3-[1-[(3,4-dichlorophenyl)acetyl]methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxy]acetic acid monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
R 84760	(3R)-4-[(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]carbonyl]-3-(1-pyrrolidinylmethyl)thiomorpholine monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
Asimadoline; EMD 61753	[S-(R*,R*)]-N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-alpha-phenyl-, benzeneacetamide	opiate agonist; kappa agonist; analgesic; NSAID	pain
opiate analgesic,	Unspecified	opiate agonist; mu agonist	pain
BCH 2687; LEF 553	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, hydrogel morphine; morphine hydrogel; MORAXEN; MORPHINE HYCORE-R	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, oral sustained release morphine; morphine sustained release; KAPANOL; KADIAN; MORCAP SR	Unspecified	opiate agonist; mu agonist; analgesic	pain

drug delivery system, oral transmucosal fentanyl; fentanyl OTFC; ACTIQ; FENTANYL ORALET	Unspecified	opiate agonist; mu agonist; analgesic	anesthesia; pain
drug delivery system, OROS oral controlled release hydrocodone; hydrocodone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release hydromorphone; hydromorphone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release morphine; morphine OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OSAT morphine; morphine sustained release	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, subcutaneous hydromorphone; hydromorphone subcutaneous implant	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Unspecified	opiate agonist; mu agonist; analgesic	pain; cancer
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, transdermal fentanyl; fentanyl transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain

HP 736	cis-7-bromo-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol (E)-2-butenedioate (1:1) (salt)	opiate agonist; mu agonist; analgesic	pain
morphine-6-glucuronide; CEE 04410; HN 33169; CAP	morphine-6-glucuronide	opiate agonist; mu agonist; analgesic	pain
pentamorphone; RX 77989; A 4492	7,8-didehydro-4,5a-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-6-one	opiate agonist; mu agonist; analgesic	pain
DPI 3290	[2S-[1(S*),2alpha,5beta]]-3-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide monohydrochloride	opiate agonist; mu agonist; delta agonist; analgesic	pain
OHM 3295; ANQ 3295	Unspecified	opiate agonist; mu agonist; kappa agonist; analgesic	pain
SK 9709	Tyr-D-Ala-Phe-Leu-Arg (CH <sub>2</sub> NH) Arg-NH <sub>2</sub>	opiate agonist; mu agonist; kappa agonist; peptide	pain
naloxone + pentazocine; pentazocine + naloxone	Unspecified	opiate agonist; opiate antagonist; analgesic	pain; cancer
tonazocine; WIN 42156; WIN 42156 2	(+,-)-(2alpha,6alpha,11S*)-1-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-octanone	opiate agonist; opiate antagonist; mu agonist; delta agonist; analgesic	pain

picenadol; LY 150720	trans-(+,-)-3-(1,3-dimethyl-4-propyl-4-piperidinyl)phenol	opiate agonist; opiate antagonist; mu agonist; mu antagonist; analgesic	pain
acetylmethadol; levomethadyl acetate hydrochloride; L-alpha acetylmethadol; LAAM; methadyl acetate; LAAM; MK 790; ORLAAM	beta-[2-(dimethylamino)propyl]-alfa-ethyl-beta-phenylbenzeneethanol acetate (ester)	opiate antagonist; analgesic	pain; addiction
SNC 80	[2S-[1(S*),2alpha,5beta]]-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethyl-benzamide	opiate antagonist; delta antagonist; analgesic	pain
ibuprofen + propiram; propiram + ibuprofen; DIRATAB	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram; propiram fumarate; BAY 4503; FBA 4503; DIRAME; ALGERIL fumarate	N-(1-methyl-2-piperidinoethyl)-N-2-pyridyl-propionamide	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram + paracetamol; propiram + acetaminophen; paracetamol + propiram; acetaminophen + propiram; DIRAMAX	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate partial agonist; analgesic	pain
MR 2264	Unspecified	opiate partial agonist; analgesic	pain
analgesics,	Unspecified	peptide	pain
CEE 04420	Unspecified	peptide	pain
CEE 04421	Unspecified	peptide	pain

drug delivery system, analgesic, oral transmucosal	Unspecified	peptide	pain
drug delivery system, Polyfunctional Molecular Modification, enkephalin; enkephalin Polyfunctional Molecular Modification	Unspecified	peptide; analgesic	pain
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	Unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
ZD 4953	Unspecified	prostaglandin antagonist; prostaglandin endoperoxide 1 antagonist	pain
ZD 6416	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
ZD 6804	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
limaprost; limeprost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain
SC 42867	8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide	prostanoid; analgesic	pain

SCH 34826	N-[N-[2-[(2,2-dimethyl-1-3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension
117m Sn DTPA; pentetate 117m Sn	Unspecified	radiotherapeutic; analgesic	cancer; pain
rhenium Re 186 etidronate; 186-Re HEDP; 186-Re HEDP; BETAMET	Unspecified	radiotherapeutic; analgesic	pain; cancer
Sm 153 hydroxyapatite; Sm 153 HA; samarium 153 hydroxyapatite	Unspecified	radiotherapeutic; analgesic	pain
strontium-89 chloride; METASTRON	strontium chloride (89SrCl <sub>2</sub> )	radiotherapeutic; analgesic	pain; cancer
PD 144418	1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine	sigma antagonist; analgesic	pain
mu-conopeptides	Unspecified	sodium channel blocker	pain; epilepsy
4030W92; BW 4030W92	(5R)-5-(2,3-dichlorophenyl)-6-(fluoromethyl)-2,4-pyrimidinediamine	sodium channel blocker	pain
GW 286103	Unspecified	sodium channel blocker; analgesic	pain
LTA	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain

Octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinateamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
Vapreotide; octastatin; RC 160; BMY 41606	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH2	somatostatin analogue; analgesic	cancer; pain
NKT 343; SDZ NKT 343	1-[[(2-nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	substance P antagonist; analgesic	pain
Etanercept; tumor necrosis factor receptor; TNFr; TNR 001;	Unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease

Table 34: Current Candidate Therapeutic Interventions for the Treatment of Parkinson's Disease

Product Name	Chemical Name	Action	Indication
KF 17837	(E)-8-[2-(3,4-dimethoxyphenyl)ethyl]-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist	Parkinson disease
KW 6002	Unspecified	adenosine antagonist	Parkinson disease
Parkinson's disease therapy	Unspecified	adenosine antagonist	Parkinson disease
SCH 58261	2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine	adenosine antagonist; adenosine A2 antagonist	Parkinson disease

Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
alpha2 adrenoceptor antagonists,	Unspecified	alpha2 adrenergic antagonist; alpha adrenergic antagonist	Parkinson disease
SR 57667	Unspecified	Antineurodegenerative	Alzheimer disease; Parkinson disease
Parkinson's disease therapy.	Unspecified	antioxidant	Parkinson disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
CNS therapy, IDUN; CNS therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
CNS 1237	N-5-acenaphthylene-N'-(4-methoxy-1-naphthalenyl)-guanidine	Calcium channel blocker; glutamate release inhibitor	brain ischemia; Parkinson disease; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
SIB 1508Y	(S)-3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine	cholinergic agonist; nicotinic agonist	Parkinson disease
SIB S1663; S 1663	2,3,3a,4,5,9b-hexahydro-7-methoxy-1-methyl-1H-pyrrolo[3,2-h]isoquinoline	cholinergic agonist; nicotinic agonist	Parkinson disease
CGP 28014	N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimide	COMT inhibitor	Parkinson disease
Entacapone; OR 611; COMTAN; COMTESS	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide	COMT inhibitor	Parkinson disease

Tolcapone; Ro 407592; TASMAR	(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone	COMT inhibitor	Parkinson disease
drug delivery system, controlled release carbidopa + levodopa; carbidopa + levodopa	Unspecified	decarboxylase inhibitor; dopamine agonist	Parkinson disease
Dopaminergic neurotrophic factor; DNTF	Unspecified	DNTF growth factor	Parkinson disease
JA 116a; JA 116	1,2,6,7,8,8a-hexahydro-1-acenaphthyleneamine hydrochloride	dopamine agonist	Parkinson disease
levodopa methyl; CHF 1301	Unspecified	dopamine agonist	Parkinson disease
levodopa methyl + carbidopa; carbidopa + levodopa methyl; CHF 1512	Unspecified	dopamine agonist	Parkinson disease
Moxiraprine; 4-hydroxyminaprine; CM 30366	p-[5-methyl-6-[(2-morpholinoethyl)amino]-3-pyridazinyl]phenol	dopamine agonist	Parkinson disease
naxagolid; PHNO; dopazinol; MK 458; L 647339	(4aR-trans)-3,4,4a,5,6,10b-hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol	dopamine agonist	Parkinson disease
U 86170F	(R)-5-(dipropylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrobromide	dopamine agonist	Parkinson disease
WAY 124486	(S)-3-[[3-(3-aminophenoxy)propyl]amino]methyl]-2,3-dihydro-1,4-benzodioxin-6-ol	dopamine agonist	Parkinson disease

Quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)-5,5a,6,7,8,9,9a,10-octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
HW 165	trans-(+/-)-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Apomorphine; apomorphine hydrochloride; UPRIMA	(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinolin- e-10,11- diol hydrochloride hydrate (2:1)	dopamine agonist	sexual dysfunction; Parkinson disease
talipexole; BHT 920; DOMINE; DOMIN	6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine	dopamine agonist; alpha adrenergic agonist; alpha2 adrenergic agonist	Parkinson disease; glaucoma
drug delivery system, benserazide + levodopa; benserazide + levodopa, levodopa + benserazide; MADOPAR DR	Unspecified	dopamine agonist; decarboxylase inhibitor	Parkinson disease
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
A 77636	(1R-cis)-1-(aminomethyl)-3,4-dihydro-3-tricyclo[3.3.1.13,7]dec-1-yl-1H-2-benzopyran-5,6-diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
A 86929	trans-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3-c]quinoline-9,10-diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease

ABT 431	(5aR-trans)-4,5,5a,6,7,11b-hexahydro-2-benzo[f]thieno[2,3-c]quinoline-9,10-diol, diacetate (ester), hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine agonist	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine-D1 agonists, BLSI	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dihydrexidine; IP 202	trans-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease
BAM 1110	(8 beta)-6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)ergoline (Z)-2-butenedioate	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal pergolide; pergolide transdermal	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression
CQA 206291	Unspecified	dopamine agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal N 0923; N 0923 transdermal delivery system; N 0923; SPM 962	(S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol	dopamine agonist; dopamine D2 agonist	Parkinson disease
ropinirole; ropinirole hydrochloride; ropinerole; SKF 101468; SKF 101468A;	(4-2-(dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease

U 91356A	(R)-5,6-dihydro-5-(propylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease
Cabergoline; FCE 21336; CG 101; DOSTINEX; SOGILEN; CABASER	(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide	dopamine agonist; dopamine D2 agonist	Parkinson disease; hyperprolactinemia
PNU 95666; U 95666A	(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one	dopamine agonist; dopamine D2 agonist; 5HT agonist; 5HT1A agonist	Parkinson disease
Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
LEK 8829	(8beta)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
Brasofensine; NS 2214; BMS 204756	[1R-[1alpha,2beta(E),3alpha,5alpha]-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxaldehyde O-methyloxime	dopamine reuptake inhibitor	Parkinson disease
NS 2141	Unspecified	dopamine reuptake inhibitor	Parkinson disease
NS 2200	Unspecified	dopamine reuptake inhibitor	Parkinson disease; depression; addiction

drug delivery system, dopamine secreting implant; dopamine secreting implant; NeuroCRIB	Unspecified	Dopaminergic agonist	Parkinson disease
drug delivery system, dopamine secreting implants, Parkinson's disease; SPHERAMINE	Unspecified	Dopaminergic agonist	Parkinson disease
NB 355	3-hydroxy-L-tyrosine, 4-(2,2,-dimethylpropanoate)	Dopaminergic agonist, L-dopa prodrug	Parkinson disease
epidermal growth factor; EGF	epidermal growth factor	EGF growth factor	eye disease; Parkinson disease
Carboxylated buckminsterfullerenes; carboxyfullerenes	Unspecified	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
glial cell line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
glial-cell-line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
drug delivery system, neurturin secreting implant; neurturin secreting implant; GDNF secreting implant	Unspecified	GDNF; neurotrophic factor; growth factor	Parkinson disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
NS 072	Unspecified	glutamate antagonist	Parkinson disease
MRZ 2579; MRZ 2/579	Unspecified	glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
CNS 5065	N-(2-chloro-5-ethylphenyl)-N'-(3-ethylphenyl)-N'-methylguanidine	glutamate antagonist; NMDA antagonist	Parkinson disease; neuropathy; brain ischemia

CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
Neurotrophin agonist	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
V 10367; VA 10367	Unspecified	growth factor; neurotrophic factor	Parkinson disease
drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	Unspecified	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
MDL 72145	(E)-(beta-fluoromethylene)-3,4-dimethoxybenzenethanamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
2 HxMP	N-(2-hexyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
drug delivery system, transdermal selegiline; selegiline transdermal	Unspecified	MAO B inhibitor; MAO inhibitor	Parkinson disease
M 2 PP	N-(2-pentyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
mofegilime; MDL 72974A; MDL 72974	(E)-4-fluoro-beta-(fluoromethylene)benzenebutanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease

selegiline; selegiline hydrochloride; deprenyl; E 250; FPF 1100; ELDEPRYL; DEPRENYL; JULAP; NIAR; SELEDAT; DEPRILAN; SELEPARKIN; KINABIDE; NOVO-SELEGILINE; MOVERDIN	(R)-N,alpha-dimethyl-N-2-propynylbenzeneethanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
SL 650477; SL 65.0477	[R-(R*,R*)]-5-(methoxymethyl)-3-[6-(4,4,4-trifluoro-3-hydroxybutoxy)-3-benzofuranyl]-2-oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
SL 340026; SL 34.0026	3-(2-methoxyethyl)-5-[4-(4,4,4-trifluorobutoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one	MAO inhibitor; MAO B inhibitor	Parkinson disease
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
fatty acids, microalgal,	Unspecified	Microalgal extracts	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
Neurophilins	Unspecified	Neurophilins	Alzheimer disease; Parkinson disease; neuropathy

LIGA 20; FID 012020	[R-[R*,S*-(E)]]-N-[1-[[[O-(N-acetyl-alpha-neuraminosyl)-2->3]-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)]-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy)methyl]-2-hydroxy-3-heptadecenyl]-2,2-dichloroacetamide	Neuroprotectant	Parkinson disease
neurturin	Unspecified	Neurturin; growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
SIB 1765F; SIB 1765	3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine, (E)-2-butenedioate (1:1)	nicotinic agonist; cholinergic agonist	Parkinson disease
neurodegeneration therapy	Unspecified	Nicotinic cholinergic receptor ligands	Alzheimer disease; Parkinson disease
nitric oxide synthase inhibitors,	Unspecified	nitric oxide synthase inhibitor	Parkinson disease; stroke
remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
CO 101244	1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol hydrochloride	NMDA antagonist; glutamate antagonist	Parkinson disease
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke

budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
antisense oligonucleotide, p75	Unspecified	P75 transcriptional coactivator antisense; oligonucleotide	Parkinson disease
alpha-conopeptides	Unspecified	peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
CEB 1097	Unspecified	Unknown	Parkinson disease
TV 1203	Unspecified	Unknown	Parkinson disease

Table 35. Current Candidate Therapeutic Interventions for the Treatment of Schizophrenia (and Other Psychoses)

Product Name	Chemical Name	Action	Indication
BW 1192U90; 1192U90	2-amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]benzamide	5HT agonist; 5HT1A agonist; dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Ritanserin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methoxy]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	5HT antagonist; 5HT2 antagonist	addiction; anxiety; schizophrenia

Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one	5HT antagonist; 5HT2 antagonist; SHT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
Ocaperidone; R 79598	3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEPK	2-methyl-1-(piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
Perospirone; SM 9018; LULLAN	cis-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-hexahydro-1H-isoindole-1,3(2H)-dione	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Risperidone; R 64766; RISPERDAL; BELIVON	3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Eplivanserin; SR 46349; SR 46349B	(1Z,2E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (2E)-2-butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
M 100907; MDL 100907	(R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol	5HT antagonist; 5HT2A antagonist	schizophrenia
Sertindole; LU 23174; S 1991; SERDOLECT	1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-2-imidazolidinone	5HT antagonist; 5HT2A antagonist; 5HT2C antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia

AS 5370	N-[hexahydro-1-methyl-4-[(3-methylphenyl)methyl]-1H-1,4-diazepin-6-yl]-1H-indazole-3-carboxamide dihydrochloride	SHT antagonist; SHT3 antagonist	emesis; schizophrenia
BMY 33426		SHT antagonist; SHT3 antagonist	schizophrenia
BMY 33462	(4-amino-N-(1-azabicyclo-[2.2.2]oct-3-yl)-2-(butan-2-one-3-yl)oxy-5-chlorobenzamine 1.25 fumerate hydrate	SHT antagonist; SHT3 antagonist	schizophrenia
Ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indole-1-carboxamide	SHT antagonist; SHT3 antagonist	anxiety; schizophrenia; emesis
SHT7 receptor antagonists		SHT antagonist; SHT7 antagonist	depression; insomnia; schizophrenia
BTS 79018		SHT antagonist; dopamine antagonist	schizophrenia
Schizophrenia therapy,		AMPA receptor modulators	schizophrenia; depression
bretazenil; Ro 166028; Ro 166028001	(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid 1,1-dimethylethyl ester	benzodiazepine partial agonist	schizophrenia
dopamine release inhibitor.		calcium antagonist; dopamine release inhibitor	schizophrenia
SR 141716; SR 141716A	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide	cannabinoid antagonist	schizophrenia

Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 262691	trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide	cholecystokinin B antagonist; cholecystokinin antagonist	schizophrenia
Alentemol; alentemol hydrobromide; U 68553B	(+)-2-(dipropylamino)-2,3-dihydrophenalen-5-ol	dopamine agonist	schizophrenia
CGS 15873A	trans-(+,-)-1,3,4,4a,5,10b-hexahydro-4-propyl-2H-[1]benzopyrano[3,4-b]pyridin-7-ol hydrochloride	dopamine agonist	schizophrenia
HW 165	trans-(+/-)-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Amisulpride; aminosulpride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
terguride; TDHL; VUFL 6638; ZK 31224; SH 406; DIRONYL; TELURON; TERULON	1,1-diethyl-3-(6-methylergolin-8alpha-yl)urea	dopamine agonist; dopamine antagonist	schizophrenia; hyperprolactinemia

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6-( propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
PD 158771	trans-N-[4-[2-(4- phenyl-1- piperazinyl)ethyl]cyclohexyl]-2- pyrimidinamine	dopamine agonist; dopamine D2 partial agonist; 5HT1A partial agonist; 5HT agonist	schizophrenia
CI 1007; PD 143188	(R)-1,2,3,6- tetrahydro-4-phenyl- 1-[(3-phenyl-3- cyclohexen-1-yl)methyl]pyridine	dopamine agonist; dopamine D2 partial agonist; dopamine D3 partial agonist	schizophrenia
GYKI 22441; BRENFUMOD	2-(4-chlorophenoxy)- 2-methylpropanoic acid 2-[4-[3-[2- (trifluoromethyl)- 10H-phenothiazin-10- yl]propyl]-1- piperazinyl]ethyl ester	Dopamine antagonist Phenothiazine ester	schizophrenia
Isofloxythepin; VUFB 10662	4-[3-fluoro-10,11- dihydro-8-(1- methyl ethyl)dibenzo[ b,f]thiepin-10-yl]-1- piperazineethanol	Dopamine antagonist	schizophrenia
Bromperidol; R 11333; IMPROMEN; BRIDOL; IMPROMEN DECANOAS; ERODIUM; LUNAPRON; PRINDRIL; ROPEL	4-[4-(4- bromophenyl)-4- hydroxy-1- piperidinyl]-1-(4- fluorophenyl)-1- butanone	dopamine antagonist	schizophrenia
dopamine D4 antagonists, Taisho		dopamine antagonist	schizophrenia

Nemonapride; emonapride; YM 09151; YM 091512; EMILACE; SEPAN; NEPONID	cis-5-chloro-2-methoxy-4-(methylamino)-N-[2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]benzamide	dopamine antagonist	schizophrenia
Savoxepin; cipazoxapine; CGP 19486	3-(cyclopentylmethyl)-2,3,4,5-tetrahydro-1H-dibenz[2,3:6,7]oxepin o[4,5-d]azepine-7-carbonitrile	dopamine antagonist	schizophrenia
NGD 931; NGB 566		dopamine antagonist, SHT agonist, adrenergic agonist; Atypical neuroleptic.	schizophrenia
Quetiapine; quetiapine fumarate; ZD 5077; Zeneca 204636; ICI 204636; SEROQUEL	2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol	dopamine antagonist; SHT antagonist; SHT2 antagonist	schizophrenia
Berupipam; NNC 220010	(S)-8-chloro-5(5-bromo-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine	dopamine antagonist; dopamine D1 antagonist	schizophrenia
CEE 03310; NNC 010687; NNC 687; NO 687; NNC 01-0687	(S)-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-8-nitro-1H-3-benzazepin-7-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia; insomnia
CEE 03320; NNC 220215	Unspecified	dopamine antagonist; dopamine D1 antagonist	schizophrenia
ecopipam; SCH 39166	(6aS-trans)-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia

ZD 3638; M 275562	4-[2-(ethylsulfinyl)-3-pyridinyl]-1-(9,10-methanoanthracen-9(10H)-ylmethyl)-4-piperidinol	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
zotepine; LODOPIN; NIPOLEPT; ZOLEPTIL; ZOPITE; SETOUS; MAJORPIN	2-[8-chlorodibenzo[b,f]thiophen-10-yl)oxy]-N,N-dimethylethylamine	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist; noradrenalin reuptake inhibitor	schizophrenia
Mosapramine; clobipramine; Y 516; CREMIN	(+,-)-1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydrospiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one	dopamine antagonist; dopamine D2 antagonist	schizophrenia
Remoxipride; remoxipride hydrochloride; FLA 731; A 33547; ROXIAM	(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide	dopamine antagonist; dopamine D2 antagonist	schizophrenia
RWJ 25730	1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-1H-pyrrol-2-yl]methyl-2-piperidinone	dopamine antagonist; dopamine D2 antagonist	schizophrenia
DU 29894		dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT1A antagonist	schizophrenia
Blonanserin; AD 5423	2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia

ORG 5222	trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepin o[4,5-c]pyrrole maleate (1:1)	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Amisulpride, (S); (-)-amisulpride	(S)-4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide	dopamine antagonist; dopamine D2 antagonist; dopamine D3 antagonist	schizophrenia
RGH 1756	6-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butoxy]phenyl]imidazo[2,1-b]thiazole	dopamine antagonist; dopamine D3 antagonist	schizophrenia; psychosis
YM 43611	(S)-5-chloro-4-[(cyclopropylcarbonyl)amino]-2-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]benzamide	dopamine antagonist; dopamine D3 antagonist; dopamine D4 antagonist	schizophrenia
CP 293019	7-[(4-fluorophenoxy)methyl]-2-(5-fluoro-2-pyrimidinyl)octahydro-2H-pyrido[1,2-al]pyrazine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
L 745870	3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-1H-pyrrolo[2,3-b]pyridine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 941	2-[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]pyrimidine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 944; NGD 94-4		dopamine antagonist; dopamine D4 antagonist	schizophrenia

PD 172760	7-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-2H-1,4-benzoxazin-3(4H)-one	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Sonepiprazole; PNU 101387; U 101387G	(S)-4-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinylbenzenesulfonamide	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Belaperidone; LU 111995	(1alpha,5alpha,6alpha)-3-[2-[6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-2,4(1H,3H)-quinazolinidine	dopamine antagonist; dopamine D4 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
dopamine antagonist		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist	schizophrenia; psychosis
HMR 2934		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist; 5HT antagonist	schizophrenia
LEK 8829	(8beta)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
levosulpiride; LEVOPRAID	(S)-5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide	dopamine D2 antagonist; dopamine antagonist	emesis; schizophrenia
LU 201640		dopamine D3 antagonist; dopamine antagonist	schizophrenia

fananserin; RP 62203	2-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-2H-naphth[1,8-cd]isothiazole, 1,1-dioxide	dopamine D4 antagonist; dopamine antagonist; 5HT antagonist; 5HT2A antagonist	schizophrenia
valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABAergic agonist	epilepsy; migraine; schizophrenia; depression
glycine reuptake inhibitors,		Glycine reuptake inhibitors, GlyT-1	schizophrenia
ciproxifan; compound 359; BP 2359	cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenylm ethanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421		histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
metabotropic glutamate receptor modulators		metabotropic glutamate receptor modulators , analgesic	pain; cognitive defect; schizophrenia; epilepsy
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
SR 48692	2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.13,7]deca ne-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia

alpha-conopeptides		peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
lithium gamolenic acid; SC 111	(Z,Z,Z)-6,9,12-octadecatrienoic acid lithium salt	phospholipase inhibitor	schizophrenia
panamesine; EMD 57445	(S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinyl]methyl]-3-(4-methoxyphenyl)-2-oxazolidinone	sigma agonist; dopamine antagonist	schizophrenia
BMY 14802; BMY 148021	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol	sigma antagonist	schizophrenia
CNS 1044		sigma antagonist	schizophrenia
CNS 1169		sigma antagonist	schizophrenia
CNS 1307		sigma antagonist	schizophrenia
CNS 3040		sigma antagonist	schizophrenia
MS 355		sigma antagonist	schizophrenia
NPC 16316		sigma antagonist	schizophrenia
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
CX 516; AMPALEX	1-(6-quinoxalinylcarbonyl)piperidine	Unknown	Alzheimer disease; schizophrenia
Maroxepine; CGP 13442A	2,3,4,5-tetrahydro-3-methyl-1H-dibenz[2,3:6,7]oxepin or [4,5-d]azepine	Unknown	schizophrenia

Table 36. Current Candidate Therapeutic Interventions for the Treatment of Spasticity

Product Name	Chemical Name	Action	Indication
Tizanidine; tizanidine hydrochloride; AN 021A; DS 103 282 CH; SIRDALUD; ZANAFLEX; TEMELIN	5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; antispasmodic; muscle relaxant	muscle spasm

botulinum A toxin; Clostridium botulinum toxin type A; DYSPORT	Botulinum toxin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	Botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)- 2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
GRI 2	Unspecified	Glycine reuptake inhibitors	muscle spasm
afloqualone; HQ 495; AROFUTO; ALOFT; PLENCO; AFROBARON	6-amino-2- (fluoromethyl)-3-o- tolyl-4(3H)- quinazolinone	muscle relaxant	surgery
lanperisone; lanperisone hydrochloride; NK 433	2-methyl-3-(1- pyrrolidinyl)-1-[4- (trifluoromethyl)phen yl]-1-propa none	muscle relaxant	muscle spasm; urinary incontinence
MS 322	(R)-(+)-3-phenyl-5- (2-(1- pyrrolidinylmethyl)buc tyryl)isoxazole hydrochloride	muscle relaxant	muscle spasm
threonine, L-; L- threonine; IP 204	L-threonine	unknown	muscle spasm

Table 37. Current Candidate Therapeutic Interventions for the Treatment of Stroke

Product Name	Chemical Name	Action	Indication
repinotan; BAY x 3702	(R)-2-[4-[(3,4- dihydro-2H-1- benzopyran-2- yl)methyl]amino]buty l]-1,2-benzothiazol- 3(2H)-one 1,1- dioxide	5HT agonist; 5HT1A agonist	stroke; trauma
Levemopamil; emopamil, (S)	(2S)-2-isopropyl-5- (methylphenethylamini no)-2- phenylvaleronitrile	SHT antagonist; SHT2 antagonist; calcium antagonist; antihypoxic	stroke

5HT4 human neuroreceptor; neuroreceptor, 5HT4		5HT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
A3 receptor regulator		Adenosine 3 receptor ligand	stroke
Adenosine A1 agonists		adenosine A1 agonist	stroke
AMP 579		adenosine agonist; adenosine A1 agonist; adenosine A2 agonist	myocardial infarction; stroke
GP 04012		adenosine antagonist; adenosine A1 antagonist	stroke; trauma
Adenosine allosteric modulators		adenosine regulating agent	cardiovascular disease; cancer; stroke
Adenosine regulating agents, stroke		adenosine regulating agent	stroke
CPC 407		adenosine regulating agent	stroke
GP 1668; GP 668	5-amino-1-[beta-D-5-phosphoribofuranosyl]-imidazole-1-N-[(4-nitrophenyl)methyl]carboxamide)	adenosine regulating agent	angina; stroke
NS 257		AMPA antagonist; glutamate antagonist	stroke
NS 479		AMPA antagonist; glutamate antagonist	stroke; neuropathy
S 176252; S 17625	(6,7-dichloro-1,2-dihydro-2-oxo-3-quinolinyl)phosphonic acid	AMPA antagonist; glutamate antagonist	stroke
SH 608		AMPA antagonist; glutamate antagonist	stroke

SPD 502; NS 1209	2-[[[5-[4-((dimethylamino)sulfonyl)phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
SYM 2189		AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5-methyl-N-propyl-1,3-dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
YM 872	3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-1(2H)-quinoxalineacetic acid	AMPA antagonist; glutamate antagonist	stroke
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
TN 871	1-(6-butyl-6,7-dihydro-5H-indeno[5,6-d]-1,3-dioxol-5-yl)-4-methyl piperazine dihydrochloride	Anoxia protection	stroke
apocuanzine; IDB 1057	(3alpha,16alpha,17alpha)-17,21-epoxy-12-methoxy-eburnamenine-14-carboxylic acid methyl ester	antihypoxic	stroke
hypoxia therapy		antihypoxic	heart ischemia; stroke
KF 17329		antihypoxic	stroke; brain ischemia
KF 19863		antihypoxic	stroke

MS 153	(-)-1-nicotinoyl-5-methyl-2-pyrazoline	anti-ischemic	stroke
YM 737	N-(N-L-gamma-glutamyl-L-cysteinyl)-glycine, 1-(1-methyl)ester	anti-ischemic	stroke
BXT 51072	3,4-dihydro-4,4-dimethyl-2H-1,2-benzoselenazine	antioxidant	stroke; inflammatory bowel disease
CEB 1370		antioxidant	stroke
LY 231617	2,6-bis(1,1-dimethylethyl)-4-[(ethylamino)methyl]phenol hydrochloride	antioxidant	stroke
Neurodegenerative disease therapy		antioxidant	stroke; Alzheimer disease
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-SH-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues		antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX		antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
secreted apoptosis related proteins; SARPs		apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
CNS therapy, IDUN; CNS therapy		apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
VM 201		blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor Xa inhibitor		blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction

JTV 803		blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
deltibant; CP 0127; SB 238592; BRADYCOR	hexamethylene-bis-(succinimido-Cys(Leu)-Phe-Gly-Hyp-Pro-Arg)	bradykinin antagonist; cicatrizant	trauma; stroke
AJ 3941	11-(4-cinnamyl-1-piperazyl)-3-fluoro-6,11-dihydrodibenzo[6,e]oxepine-2 maleate	calcium antagonist	stroke
calcium antagonist		calcium antagonist	stroke
lifarizine; RS 87476; RS 87476000	1-(diphenylmethyl)-4-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]piperazine	calcium antagonist	stroke; brain ischemia
NCC 161; LY 042826		calcium antagonist	ischemia; stroke
S 830256	3-cyclo-pentyl-5-cyclopentyloxyethoxycarbonyl-4,7-dihydro-1,6-di methyl-4-(2-nitro-phenyl)pyrazolo-(3,4-b)pyridine hydrochloride	calcium antagonist	stroke
S 830327	methyl-4,7-dihydro-3-n-butyl-6-methyl-4-(3-nitrophenyl)thieno(2,3-b)pyridine-5-carboxylate	calcium antagonist	stroke
NPS 846		calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
rumbrin	(1Z,3E,5E,7E)-6-(8-(3-chloro-1H-pyrrrol-2-yl)-1-methyl-1,3,5,7-octatetraenyl)-4-methoxy-3-methyl-2H-pyran-2-one	calcium antagonist; free radical scavenger	stroke

F 0401; D 31D	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenyl-methyl-1,4-dro-2,6-dimethyl-4-(3-nitrophenyl) 3,5-pyridinedicarboxylate	calcium antagonist; PAF antagonist; thromboxane synthetase inhibitor; vasodilator	stroke
S 312; S 312d; S 830312	4,7-dihydro-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-thieno[2,3-b]pyridine-5-carboxylic acid methyl ester	calcium antagonist; vasodilator	stroke
U 92032	7-[[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-2-[(2-hydroxyethyl)amino]-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one	calcium antagonist; vasodilator	stroke
calcium channel blocker		calcium channel blocker	stroke
Calcium channel blockers		calcium channel blocker	stroke
calcium channel blockers		calcium channel blocker	stroke
CPC 301		calcium channel blocker	stroke
CPC 304		calcium channel blocker	stroke
CPC 317		calcium channel blocker	stroke
CPC 8027		calcium channel blocker	stroke; epilepsy
CPC 8029		calcium channel blocker	stroke; epilepsy
NS 3034		calcium channel blocker	stroke
NS 638		calcium channel blocker	stroke

SB 201823A	4-[2(3,4-dichlorophenoxy)ethyl]-1-pentyl piperidine hydrochloride	calcium channel blocker	stroke
drug delivery system, conopeptides		calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
stroke therapy	N-1-naphthalenyl-1-(3-phenoxypropyl)-4-piperidinamine	Calcium lowering agent	stroke
DY 9760	3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy-1H-indazole	calmodulin antagonist	brain ischemia; stroke
calpain inhibitors		calpastatin	stroke
calpain inhibitors,		calpastatin; proteinase inhibitor	stroke
caspase antagonists		caspase inhibitor; apoptosis inhibitor	stroke; myocardial infarction
KF 10632; IKY 432	2-methyl-1-[1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propenyl]piperidine	Cerebroprotectant	stroke
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinergic agonist stimulation of nerve growth	Alzheimer disease; stroke; diabetes; neuropathy
Aniracetam; Ro 135057; SARPUL; DRAGANON; APAMET; RESET	1-(4-methoxybenzoyl)-2-pyrrolidinone	cholinergic antagonist	cognitive defect; stroke

Citicoline; citicoline sodium; cytidil diphosphocholine; CDP choline; IP 302; NEUROX; ALPHCOLIN; HIPERCOL; NEUREX; SOMAZINA; TRAUSAN	P'-[2-(trimethylammonio)ethyl] citidine 5'-(trihydrogen diphosphate)	cholinesterase inhibitor	stroke
Fibroblast growth factor agonist; MAB, C5 single chain; Mab, complement C5; 5G1.1-SC		cicatrizant; FGF agonist complement inhibitor; monoclonal antibody; NSAID	skin ulcer; stroke inflammation; myocardial infarction; stroke; ischemia.
NBI 102		CRF antagonist	stroke
NBI 104		CRF antagonist	depression; stroke
interleukin-8 antagonists; IL-8 antagonists		cytokine antagonist	myocardial infarction; stroke; respiratory distress syndrome
endothelin B antagonist,		endothelin B antagonist; endothelin antagonist	stroke
Endothelium-associated disease therapy,		Endothelin receptor ligand	stroke; asthma
ABPI 126		estrogen agonist	stroke
ABPI 127		estrogen agonist	stroke
excitatory amino acid antagonists		excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123		excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
excitatory amino acid receptor modulators		Excitatory amino acid receptor ligand	stroke
APO 99		free radical scavenger	stroke; ischemia; reperfusion injury
K 7259	hexahydro-1,4-bis[4-(3,4,5-trimethoxyphenyl)butyl]-1H-1,4-diazepine dihydrochloride	free radical scavenger	stroke
NXY 059		free radical scavenger	stroke

Pyrrolostatin	4-geranylpyrrole-2-carboxylic acid	free radical scavenger	stroke
resorstatin stobadine; DH 1101; DP 1031	(4aR,9bS)- 2,3,4,4a,5,9b- hexahydro-2,8- dimethyl-1H- pyrido[4,3-b]indole dihydrochloride	free radical scavenger	stroke ischemia; stroke
TAK 218	(S)-2,3-dihydro- 2,4,6,7-tetramethyl-2- [(4-phenyl-1- piperidinyl)methyl]- 5-benzofuranamine dihydrochloride	free radical scavenger	stroke; trauma
EUK 134	(SP-5-13)- chloro[[2,2'-[1,2- ethanediyl]bis([nitrilo- kappa N)methylidyne] ]bis[6- methoxyphenolato- kappa O1]]]- manganese	free radical scavenger; antioxidant	stroke
free radical scavengers		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
EPC K1; CHX 3107	[2R-[2R*(4R*,8R*)]-2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] L-ascorbic acid esters, monopotassium salt	free radical scavenger; phospholipase inhibitor; cytokine antagonist; NSAID	stroke

OC 5186	(5Z,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid, homopolymer, ester with L-ascorbic acid	free radical scavenger; prostanoid	cancer; stroke; malaria
BMS 183729; BMY 20862	5,6-dihydro-11-methyl-11H-pyrimido[4,5-6][1,4]benzodiazepine	GABA agonist	neuropathy; stroke
clomethiazole; CMZ; HEMINEVRIN; ZENDRA		GABA modulator	insomnia; stroke
GM-1; ganglioside GM-1;	monosialotetrahexosyl ganglioside	ganglioside	stroke
siagoside; AGF 2	[R-[R*,S*-(E)]]-N-[1-[[[O-[1',2-anhydro]-N-acetyl-alpha-neuraminosyl-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside	cognitive defect; stroke
stroke therapy		glutamate agonist; mGluR agonist	stroke
HF 7		glutamate antagonist	stroke
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke
NS 409; PD 152247; PNQX	1,4,7,8,9,10-hexahydro-9-methyl-6-nitro-pyrido[3,4-f]quinoxaline-2,3-dione	glutamate antagonist	stroke
AMPA antagonist		glutamate antagonist; AMPA antagonist	stroke

CP 465022	3-(2-chlorophenyl)-2-[2-[6-[(diethylamino)methyl]-2-pyridinyl]ethenyl]-6-fluoro-4(3H)-quinazolinone (Z)-2-butenedioate (1:1)	glutamate antagonist; AMPA antagonist	stroke
NNC 070775		glutamate antagonist; AMPA antagonist	stroke
YM 90K; YM 900	1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride	glutamate antagonist; AMPA antagonist	stroke
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
EAA 090	[2-(8,9-dioxa-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid	glutamate antagonist; NMDA antagonist	stroke

GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid]	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MRZ 2579; MRZ 2/579		glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
2-PMPA; GPI 5000		glutamate release inhibitor	stroke; neurodegeneration
BW 1003C87	Ethanesulfonic acid cmpd. with 5-(2,3,5-trichlorophenyl)-2,4-pyrimidinediamine (1:1)	glutamate release inhibitor	stroke
sipatrigine; BW 619C89; BW 619C	2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinediamine	glutamate release inhibitor	stroke
ACEA 1031		glycine antagonist	stroke
gavestinel; GV 150526; GV 150526A; GV 150526X; GG 526; GV 526A	(E)-4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid	glycine antagonist	stroke
HMR 2371		glycine antagonist	stroke
M 241247		glycine antagonist	stroke
M 244249		glycine antagonist	stroke
ZD 9379	7-chloro-3,5-dihydro-2-(4-methoxy-2-methylphenyl)-pyridazino[4,5-b]quinoline-1,4-10(5H)-trione, base and salts	glycine antagonist	stroke
glycoprotein IIb/IIIa antagonist; P246		glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
cromafiban		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

EMD 122347; YM 028		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginyl-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine	Glycosylation end-product inhibitor	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
fibroblast growth factor-10		Growth factor, fibroblast growth factor-10	stroke; trauma
insulin-like growth factor-1; IGF-1		Growth factor, IGF-1	brain ischemia; trauma; stroke; neurodegeneration
transforming growth factor beta; TGFbeta		Growth factor, TGF-beta	brain ischemia; trauma; stroke; neurodegeneration
erofermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; TROFAK	N-(N-glycyl-L-threonyl)-basic fibroblast growth factor (human clone lambdaKB7/lambdaH FL1 precursor reduced)	growth factor; cicatrizant	stroke
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trafermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

drug delivery system, proteinase inhibitor and trophic factor secreting implant; proteinase inhibitor secreting implant; trophic factor secreting implant		growth factor; neurotrophic factor; proteinase inhibitor	stroke
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer		heat shock transcription factor modulators	stroke; ischemia; reperfusion injury; cancer
RSR 13	2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin, allosteric modification	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
JP 7		Hemoglobin, synthetic allosteric modifiers of	cancer; surgery; heart ischemia; stroke
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GT 2016	1-(5-cyclohexyl-1-oxopentyl)-4-(1H-imidazol-4-yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
MAb, 1A29; MAb, ICAM-1		ICAM monoclonal antibody	stroke

NZ 097		IGF-1 ligand	brain ischemia; trauma; stroke; neurodegeneration
antibody-mediated stroke inhibitor		immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
insulin-like growth factor binding protein ligand inhibitors, IGFBP ligand inhibitors		insulin-like growth factor binding protein ligand inhibitors	stroke; neurodegeneration
neutrophil inhibitory factor; NIF; CORLEUKIN NIF		integrin antagonist; cell adhesion inhibitor; NSAID	reperfusion injury; inflammation; stroke
AM 36		Ion channel blocker	stroke; trauma
cation channel blocker		Ion channel blocker, cation channel blocker	stroke
Tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1- pyrrolidinyl-4- pyrimidinyl)-1- piperazinyl]-16- alpha-me thyl-pregn- 1,4,9-(11)-triene- 3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
MAbs, leukocytes		Leukocytes monoclonal antibody	stroke
MAb, 23F2G; MAb, leukointegrin; Hu 23F2G		leukointegrin monoclonal antibody	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
stroke and trauma therapy, morphogenic proteins,		morphogenic proteins	trauma; stroke
Lubeluzole; R 87926; PROSYNAP	(S)-4-(2- benzothiazolylmethyl amino)-alpha-[(3,4- difluorophenoxy)m ethyl]-1- piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
drug delivery system, neurotrophic peptide; neurotrophic peptide delivery system; TROFEXIN-A	Trofexin-A	Neurotrophic factor	stroke

Neurotrophic peptide; TROFEXIN		neurotrophic factor; peptide; growth factor	stroke
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 151		nitric oxide scavenger	stroke
A 84643	[S-(E)]-N-(4-amino-5-hydroxy-2-pentenyl)-N'-nitroguanidine	nitric oxide synthase inhibitor	stroke; ischemia
Neuronal nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	stroke; trauma
nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	Parkinson disease; stroke
nitric oxide inhibitors,		nitric oxide synthetase inhibitor; NSAID	stroke; rheumatoid arthritis
ARL 15896; FPL 15896; ARL 15896AR; FPL15896AR	(S)-alpha-phenyl-2-pyridineethanamine	NMDA antagonist; glutamate antagonist	stroke
BIII 277; BIII 277CL	[2R-[2alpha,3(R*)],6alpha-[1,2,3,4,5,6-hexahydro-3-(methoxypropyl)-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol hydrochloride]	NMDA antagonist; glutamate antagonist	stroke
CGP 40116	[R-(E)]-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
CNS 1118	N,N'-dimethyl-N,N'-bis(1-naphthyl)guanidine	NMDA antagonist; glutamate antagonist	stroke
CNS 1531	(+)-3-fluoro-10,5-iminomethano-10,11-dihydro-5H-dibenzo(a,d)cycloheptane	NMDA antagonist; glutamate antagonist	stroke

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
eliprodil; SL 820715	(+,-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol	NMDA antagonist; glutamate antagonist	neuropathy; stroke; trauma
ES 2421		NMDA antagonist; glutamate antagonist	stroke
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methyl]phenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541		NMDA antagonist; glutamate antagonist	epilepsy; stroke
licostinel; ACEA 1021; CGP 63446	6,7-dichloro-5-nitro-1,4-dihydro-2,3-quinoxalidinedione	NMDA antagonist; glutamate antagonist	stroke; trauma
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
NMDA antagonist		NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NMDA antagonist, subtype specific, SSNRA		NMDA antagonist; glutamate antagonist	stroke; trauma
NPS 1506		NMDA antagonist; glutamate antagonist	stroke; trauma
P 7189	2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzenethanamine hydrochloride	NMDA antagonist; glutamate antagonist	stroke; neuropathy
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
selfotel; CCG 19755	cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	stroke; trauma

SM 18400		NMDA antagonist; glutamate antagonist	stroke
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
ABS 401		Nonglutaminergic neuromodulators	neuropathy; stroke
notch signalling pathway modulators		notch signalling pathway modulators	stroke; cognitive defect; cancer
PS 519		NSAID; anti-ischemic; proteinase inhibitor	inflammation; stroke
BB 823		PAF antagonist	septic shock; stroke
BN 50739	6-(2-chlorophenyl)-9-[2-[(3,4-dimethoxyphenyl)thio]-1-thioxoethyl]-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	hypotension; septic shock; stroke
ACTH (4-10); SEMAX		peptide	cognitive defect; trauma; stroke
corticotropin-releasing factor; corticotropin-releasing hormone; CRF; XERECEPT		peptide	cancer; stroke; trauma
pituitary adenylate cyclase activating polypeptide; PACAP	Unspecified	peptide	stroke
conantokin G		peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

denbufylline; BRL 30892	1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-1H-purine-2,6-dione	phosphodiesterase inhibitor; vasodilator; xanthine	stroke
coronary artery disease therapy,		platelet antiaggregant	stroke; coronary artery disease
clopidogrel; clopidogrel bisulfate; SR 25990; SR 25990C; DV 7314; PCR 4099; SR 25990B; SR 25990A; SR 25990D; SR 25990E; PLAVIX; ISCOVER	(S)-alfa-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester	platelet antiaggregant	thrombosis; stroke; ischemia
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
abciximab; abciximab; MAb, F(ab')2 fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.a.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
GPI 6000		poly (ADP ribose) polymerase inhibitor	stroke
GPI 6150		poly (ADP ribose) polymerase inhibitor	stroke; myocardial infarction

KC 399	[N-(2-cyanoethyl)-2,2-bisfluoromethyl-6-nitro-2H-1-benzopyran-4-carbothioamide]	potassium channel activator	angina; stroke
LOE 908	3,4-dihydro-6,7-dimethoxy-alpha-phenyl-N,N-bis[2-(2,3,4-trimethoxyphenyl)ethyl]-1-isoquinolineacetamide	potassium channel blocker	stroke
BMS 204352		potassium channel modulator	stroke
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
proline transport inhibitors		Proline transport inhibitor	epilepsy; stroke
drug delivery system, lipid microsphere, clinprost; clinprost lipid microsphere; TTC 909; ARTEON	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6alpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	prostanoid; platelet antiaggregant	thrombosis; stroke
fasudil; fasudil hydrochloride; AT 877; HA 1077; HA 004; ERIL	hexahydro-1-(5-isoquinolysulfonyl)-1H-1,4-diazepine	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	brain ischemia; stroke; angina; HIV infection
CPC 211; CERESINE		Pyruvate dehydrogenase activation to reduce lactic acid	stroke; trauma
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke

BIII 890		sodium channel blocker	stroke
sodium channel blocker		sodium channel blocker	stroke
SL 34082908; SL 34.0829-08; SL 34.0829		sodium channel blocker; calcium channel blocker	stroke; brain ischemia
BLIR 561		sodium channel blocker; glutamate antagonist; AMPA antagonist	stroke
BM 27	4-(cycloheptylamino)-N-[ (cycloheptylamino)carbonyl]-3-pyridinesulfonamide	sulfonylurea	stroke
SNO-tissue plasminogen activator; NMI 106		thrombolytic	stroke; myocardial infarction
Tisokinase; tissue plasminogen activator, natural; tPA, natural; AK 124; PLASVATA; HAPASE		thrombolytic	thrombosis; stroke
Prourokinase; PUK; rProUK; A 74187; PROLYSE		thrombolytic; plasminogen activator	thrombosis; stroke
Alteplase; tissue plasminogen activator; tPA; ACTIVASE; ACTILYSE; ACTIVACIN; GRTPA		thrombolytic; plasminogen activator; cicatrizant	thrombosis; skin ulcer; stroke
KT 2962; KT 2-962	3-[4-[[4-chlorophenyl]sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
Isbogrel; CV 4151; A 66900; ANTEXAN	(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; stroke

Ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethylbenzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
NZ 093		Undisclosed receptor ligand	brain ischemia; trauma; stroke; neurodegeneration
CNS 1		Unknown	stroke
EAB 318		Unknown	stroke
ONO 2506		unknown	stroke
SB 221420		Unknown	stroke
SPI 29		Unknown	myocardial infarction; stroke
SPI 42		Unknown	myocardial infarction; stroke
ST 765		Unknown	stroke
stroke therapy		Unknown	stroke; trauma
TV 2711; 2711	Polyamine	Unknown	stroke; trauma
Pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL	3,7-dimethyl-1-(5-oxo-hexyl)xanthine	xanthine; vasodilator	peripheral vascular disease; stroke; atherosclerosis

Table 38. Current Candidate Therapeutic Interventions for the Treatment of Arthritis.

Product Name	Chemical Name	Action	Indication
BW 4C; BW A4C; BW 4C86	N-(3-phenoxy-phenyl-2-propenyl)acetohydroxamic acid	5 lipoxygenase inhibitor; chelating agent; NSAID	arthritis; psoriasis
tenidap; tenidap sodium; CP 66248; CP 6624842; KENIDA; ENABLE; ENABLEX; REUMATEN	(Z)-5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide	5 lipoxygenase inhibitor; COX inhibitor; NSAID	rheumatoid arthritis; arthritis
flobufen; VUFB 16066	2',4'-difluoro-alpha-methyl-gamma-oxo-[1,1'-biphenyl]-4-butanoic acid	5 lipoxygenase inhibitor; COX inhibitor; NSAID	rheumatoid arthritis
ZD 2138; ICI D2138	6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
AKI 1	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
AKI 2	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
analben	unspecified	analgesic	rheumatoid arthritis; pain
drug delivery system; OSAT ibuprofen; ibuprofen sustained release	unspecified	analgesic; NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
SC 107	unspecified	analgesic; NSAID	arthritis; pain
samarium 153 Sm lexitronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424; QUADRAMET	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis[phosphonato]](8-)-N,N',OP,OP',OP'',OP'']-]samarate(5-)-153Sm	analgesic; NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	unspecified	angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy

FR 111142; WF 2015A	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenoil)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester	angiogenesis inhibitor; NSAID	cancer; rheumatoid arthritis; retinopathy
troponin I; cartilage derived inhibitor	unspecified	angiogenesis inhibitor; NSAID; biotechnology	cancer; rheumatoid arthritis; eye disease
MHC II peptidomimetic, rheumatoid arthritis	unspecified	Antagonists of MHC	rheumatoid arthritis
SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
ZYN-LINKER conjugated methotrexate	unspecified	antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
TRK 530	[[[4-(methylthio)phenyl]thio]methylene]bisphosphonic acid disodiumsalt	antioxidant; bisphosphonate	rheumatoid arthritis
LY 221068	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylen]-3-(dimethylamino)-4-thiazolidinone	antioxidant; NSAID	arthritis
LY 269415	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylen]-3-(dimethylamino)-4-thiazolidinone	antioxidant; NSAID	arthritis
AHR 15010	1-[(2-methoxyphenoxy)methyl]-1,2-ethanediyl ester of sulfamic acid	carbonate dehydratase inhibitor; NSAID	arthritis

caspase inhibitors, Cytovia	unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
VLA4 integrin antagonist, Cytel	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, somatomedin C; drug delivery system, insulin-like growth factor-1; somatomedin C DepoFoam; Depo IGF-1	unspecified	cicatrizant; hormone; NSAID; growth factor	rheumatoid arthritis; osteoporosis
fibroblast ant collagenase; FIBAC; ant collagenase fibroblast	unspecified	cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis
BB 926	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; eye disease
collagenase inhibitors, Affymax	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammation
collagenase inhibitors, Xenova; XR 168 series	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis

Ro 319790	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; arthritis
GR 129574A	(R)-N-[1-carboxy-3-(1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)propyl]-L-leucyl-N-methyl-L-phenylalaninamide mono(trifluoroacetate)	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
Ro 323555; TROCADE	beta-(cyclopentylmethyl)-N-hydroxy-gamma-oxo-alfa-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-L-1-piperidinebutanamide	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
WY 46135	N-[(5-chloro-2-benzothiazolyl)thio]phenylacetyl-L-cysteine	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
MAb, C5; MAb, complement C5; SG1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
hyaluronic acid 6-alpha-methylprednisolone ester; HYC 141	unspecified	corticosteroid	rheumatoid arthritis
MYC 2095	unspecified	corticosteroid	arthritis
rimexolone; trimexolone; ORG 6216; RIMEXEL; VEXOL	(11beta,16alpha,17beta)-11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)androsta-1,4-dien-3-one	corticosteroid	rheumatoid arthritis; inflammation; eye disease

deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFFLAMON; PRANDIN	(11beta,16beta)-21-(acetoxy)-11-hydroxy-2'-methyl-5H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma
prednisolone farnesylate; PNF 21; FARNESONE; FARNERATE GEL; FARNEZONE GEL	[11.beta.,21(2E,6E)]-11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-pregna-1,4-diene-3,20-dione	corticosteroid	rheumatoid arthritis; osteoarthritis
ORG 6632	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione	corticosteroid; immunosuppressant	cancer; rheumatoid arthritis
RU 46057	2-[2-bis(1-oxopropoxy)ethyl]-4-hydroxy-N-2-thiazolyl-8-(trifluoromethyl)-3-quinolinecarboxamide	COX inhibitor; 5 lipoxygenase inhibitor; NSAID	arthritis; psoriasis
meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
SD 8381	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis
SC 57666	1-(4-fluorophenyl)-2-(4-methylsulphonylphenyl)cyclopentene	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis

valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
LAS 33826	unspecified	COX inhibitor; COX 2 inhibitor; NSAID	rheumatoid arthritis
pranoprofen; Y 8004; ITEOPAN; NIEFTOP; NIFLAN; CESFLAN; ELICAPRIL; MABUL; FLANIN; PRAFEN; PRANOX; DIFEN	alpha-methyl-5H[1]benzopyrano[2,3-b]pyridine-7-acetic acid	COX inhibitor; NSAID	rheumatoid arthritis; eye disease
lipophosphoglycan analogue	unspecified	Cytokine antagonist	atherosclerosis; arthritis; septic shock; HIV infection
cytokine trap, Regeneron	unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID	psoriasis; rheumatoid arthritis; respiratory distress syndrome; septic shock